<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">The present document is a summary of the European Public Health Administration report (EPAR) in which explains how the Committee for Humanitarian Sciences (CHMP) has been judged to make recommendations concerning the application of drug.</seg>
<seg id="2">"if you need more information about your disease or its treatment, please read the package (also component of the EPAR) or contact your doctor or a pharmacist."</seg>
<seg id="3">"if you would like more information on the basis of the recommendations of CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="4">"it is available as a 5 mg, 10 mg, 15 mg and 30 mg tablets, as 10 mg, 15 mg and 30 mg of melting (tablets, which dissolve in the mouth), as a solution for insertion (1 mg / ml) and as injection solution (7,5 mg / ml)."</seg>
<seg id="5">"B. wirres thinking and speaking, hallucinations (hearing or seeing of things that are not present), mistrust and insisting; • Bipolar-I disorder, a mental disorder, in which the patients have manic episodes (periods abnormal upsurge) alternately with periods of normal mood."</seg>
<seg id="6">"Abilify will be applied to the treatment of moderate to severe Manical episodes and the prevention of Manical episodes in patients, who have addressed the drug in the past."</seg>
<seg id="7">The injection solution is applied to fast control of tapped anxiety or behavioural disturbances when the orale intake of the drug is not possible.</seg>
<seg id="8">"both diseases can take the solution to the insertion, or the melting pot in patients may be prepared, causing tablets trouble."</seg>
<seg id="9">"in patients who are taking other medicines at the same time, the same as Abilify, should be adapted to the dose of Abilify."</seg>
<seg id="10">"this affects the signal transmission between brain cells through" neurotransmitters ", i.e. chemical substances that enable communication of nerve cells each other."</seg>
<seg id="11">Aripiprazole seems probably mainly as a "partial agonist for the receptors for the neurotransmitters dopamine and 5-hydroxyloyptamin (also known serotonin).</seg>
<seg id="12">"this means that Aripiprazole like 5-hydroxyloyptamin and dopamine, but in less dimensions than the neurotransmitters affect to activate the receptors."</seg>
<seg id="13">"da dopamine and 5-hydroxyloyptamin at schizophrenia and bipolar disorder, carries Aripiprazole to normalize the activity of the brain, thus reducing psychotic or manic symptoms."</seg>
<seg id="14">"the effectiveness of Abilify, to prevent reactivity of symptoms, was investigated in three studies over up to a year."</seg>
<seg id="15">The effectiveness of the injection solution was compared to two studies in 805 patients with schizophrenia or similar diseases which were compared to a placebo over a period of two hours.</seg>
<seg id="16">"in another study, Abilify was tested over twelve weeks to 347 patients with poperated dol, in another study the effectiveness of Abilify and placebo, in another study the effectiveness of Abilify and placebo, in which the Ottoman symptoms have already been stabilised with Abilify."</seg>
<seg id="17">The effectiveness of Abilify injection solution was compared to a study of 301 patients with bipolar disorder that were raised by Lorazepam (another antipsychotic medication) and placebo over a period of two hours.</seg>
<seg id="18">"in all studies, the changes in the symptoms of the patients were examined using a standard scala for bipolar disorder or the number of patients studied in the treatment of treatment."</seg>
<seg id="19">The company also conducted studies in order to examine how the body absorbs the melting pot and the solution for insertion.</seg>
<seg id="20">"in both studies with the injection solution patients showed Abilify in doses of 5,25 mg, 9.5 mg or 15 mg, a significantly stronger reduction in symptoms impaired as the patients who received a placebo."</seg>
<seg id="21">When used to treat the bipolar disorder decreased Abilify in four of the five short-time studies of manic symptoms more effectively than placebo.</seg>
<seg id="22">"Abilify prevented also up to 74 weeks of effective, up to 74 weeks more effective than placebo the reacting of Manischer episodes before previously treated patients and if it has been administered in addition to an existing treatment."</seg>
<seg id="23">Abilify injections in 10- or 15-mg doses decreased also more effective than placebo the symptoms stricken and were similar to Lorazepam.</seg>
<seg id="24">"the most common side-effects of Abilify to take (observed from 1 to 10 of 100 patients) are extrappyramid, acistipation (impregnation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (trepation), granary (tremor), granary (</seg>
<seg id="25">"to conclude that the benefits of Abilify in the treatment of schizophrenia, from mediums to severe German episode in Bipolar-I disorder and in the prevention of a new German episode in Patients, who had mainly manic episodes and in which the joint episodes of the treatment with Aripiprazantics said to be overlapped towards the risks."</seg>
<seg id="26">"moreover, the committee came to the result that the benefits of the injection solution in patients with schizophrenia or in patients with the German episodes of Bipolar-I disorder, when an orale therapy is not suitable to override the risks."</seg>
<seg id="27">June 2004 the European Commission submitted to the company Otsuka Pharmaceutical Europe Ltd. an approval for the transport of Abilify in the entire European Union.</seg>
<seg id="28">"ABILIFY is indicated for the treatment of moderate to severe German episodes of the bipolar-I- disorder and for the prevention of a new German episode in patients, which had overwhelmingly manic episodes and their manic episodes of the treatment with Aripiprazole (see section 5.1)."</seg>
<seg id="29">The recommended starting dose for ABILIFY is 10 or 15 mg / day at a contraction of 15 mg / day once daily independently of the meals.</seg>
<seg id="30">"an increased effectiveness in doses about a daily dose of 15 mg was not proven, although individual patients can benefit from a higher dose."</seg>
<seg id="31">"the recommended starting dose for ABILIFY is 15 mg once daily, regardless of meals as monotherapy or combination therapy (see section 5.1)."</seg>
<seg id="32">The efficacy of ABILIFY in the treatment of schizophrenia and Bipolar-I- disorder in patients ≥ 65 years have not been proven.</seg>
<seg id="33">"with regard to the greater sensitivity of these patients, a lower initialdosis should be considered, when clinical factors justify this (see Section 4.4)."</seg>
<seg id="34">"if the CYP3A4 induction is derived from the combination therapy, the Aripierzole-dose should be reduced to the recommended dose (see Section 4.5)."</seg>
<seg id="35">The occurrence of suicide behaviour belongs to psychotic diseases and affective disorders and was reported in some cases after the beginning or after changing an anti-psychotic therapy (see Section 4.8).</seg>
<seg id="36">Results of an epidemiological study showed that it was not increased in patients with bipolar disorder.</seg>
<seg id="37">"Aripiprazole should be applied with caution in patients with known cardiovascular disease (elyocardiac disease, hypovolanaemia, treatment for hypotony, hypovolaemia, treatment with hemacular drugs) or hypertonie (including acute and malignant form)."</seg>
<seg id="38">"3 Spätdyskinesia: in clinical trials, one year or less, there were occasional reports over during treatment with Aripiprazole Dyskinesia."</seg>
<seg id="39">"if in one with ABILIFY, the patient treated signs and symptoms of a late dynasty, should be considered to reduce the dose or break the treatment."</seg>
<seg id="40">"when a patient develops signs and symptoms which pointed to a mns, or unclear high fever without an additional clinical manifestation of mns, all antipsychotic, including ABILIFY, must be abused."</seg>
<seg id="41">"therefore, Aripiprazole should be applied in the anamnese or in case of cases which are applied with clamps, with caution."</seg>
<seg id="42">56 - 99 years) with Aripiprazole in patients with psychosis associated with Alzheimer's disease had patients who were treated with Aripiprazole in comparison to placebo.</seg>
<seg id="43">"there were, however, in one of these studies, a study with fixed dosage, a significant relationship between the dosage and the contact for unwanted zerebrovascular events with Aripiprazole patients."</seg>
<seg id="44">"hyperglycaemia, in some cases extremely and associated with Ketoazide or death, was reported in patients who were treated with atypical anti-psychotic agents, including ABILIFY."</seg>
<seg id="45">There are no precise risk estimates for hyperglycaemia-related unwanted events with ABILIFY and other atypical antipsychotic agents treated to patients who allow direct comparisons.</seg>
<seg id="46">"Polydipes, polyurry, polyphagie and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be regularly monitored in terms of deterioration of the glucose levels."</seg>
<seg id="47">"a weight gain is generally observed in a schizophrenic patient and in patients with bipolar mania, due to comorbious Mania, in which weight gain is known as a side effect, or may lead to severe complications as well."</seg>
<seg id="48">"due to the primary effect of Aripiprazole on the central nervous system, caution is advisable when Aripiprazole is taken in combination with alcohol or other centrally effective medicines with incontinous side effects such as sedation (see Section 4.8)."</seg>
<seg id="49">"the H2-Antler Famotidin, a stomach acid blocker, reduces the remnant rate of Aripiprazole, but this effect is not relevant as clinically."</seg>
<seg id="50">In a clinical study with healthy probands a highly effective CYP2D6-Inhibitor (Chinidin) increased the Auc from Aripiprazum 107% while the Cmax remained unchanged.</seg>
<seg id="51">"it is expected that other highly effective inhibitors of CYP2D6, like fluoxetine and paroxetine, similar effects, and therefore should be made similar dosages reduction."</seg>
<seg id="52">"at CYP2D6 'bad' (=" "poor" ") Metabolisians may result in higher plasma bitors by CYP3A4 in higher plasmaconcentric compared to CYP2D6 extensive Metabolisians."</seg>
<seg id="53">"if you consider the common usage of Ketoconazol or other highly effective CYP3A4 inhibitors, with ABILIFY, the potential benefits should override the potential risks to the patient."</seg>
<seg id="54">"other highly effective Inhibitors from CYP3A4, such as Itraconazol and HIV-inflammatory, should have similar effects and therefore should be made similar dosages reduction."</seg>
<seg id="55">"after receipt of the CYP2D6- or 3A4-Inhibitors, the dosage of ABILIFY should be raised to the Dosage levels before the beginning of the companion therapy."</seg>
<seg id="56">"diltiazem or Escital opram) or CYP2D6, together with ABILIFY, can be calculated with a moderate increase in the Aripierzol- concentrations."</seg>
<seg id="57">"in clinical studies, doses of 10-30 mg Aripiprazole per day does not have any significant effect on the metadata of CYP2D6 (Dextromethorphan / 3-methodology xymorphinat-ratio), 2C9 (warcolor), and 3A4 (Dextromethoran)."</seg>
<seg id="58">The patients should be advised to notify their doctor if they are pregnant or planning a pregnancy during treatment with Aripiprazole.</seg>
<seg id="59">"due to the insufficient data base for the safety of the people and due to the concerns in the animal studies, this medicine may not be applied in pregnancy unless the potential benefits are clearly made to the potential risk of foetus."</seg>
<seg id="60">"however, as well as in other antipsychotic medication, the patients should be warned of dangerous machinery, including power vehicles, including power vehicles, until they are sure that Aripizzole has no negative influence on it."</seg>
<seg id="61">The following side effects are more common (≥ 1 / 100) than under placebo or were classified as possible medically relevant side effects (*):</seg>
<seg id="62">"the frequency of the side listed below is defined by the following criteria: frequently (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="63">"schizophrenia - In a controlled long-term study conducted over 52 weeks in patients who were treated with Aripiprasonism, Akathar, Dystonie and Dyskinesia, compared to patients who were treated with Haloperdol (57.3%)."</seg>
<seg id="64">"in a placebo-controlled long-term study, over 26 weeks, the incidence of EPS 19% in patients were under Aripiprazole treatment and 13.1% in patients under placebo."</seg>
<seg id="65">"in another controlled long-term study, over 26 weeks the incidence of EPS 14,8% were treated with patients who were treated with Aripiprazole, and 15.1% in patients under Olanzapin therapy."</seg>
<seg id="66">Manic episodes in Bipolar-I disorder - In a controlled study about 12 weeks was the incidence of EPS 23.5% in patients suffering from Arpierzol- treatment and 53.3% in patients under neck dol treatment.</seg>
<seg id="67">"in another study over 12 weeks, the incidence of EPS 26.6% was charged with patients under Aripiprazole treatment and 17.6% for those under lithium treatment."</seg>
<seg id="68">During the long-term experience period over 26 weeks at a placebo-controlled study the incidence of EPS 18.2% for patients under Aripierzol- treatment and 15.7% for patients with placebo treated patients.</seg>
<seg id="69">"a comparison between the patient groups under Aripiprazole and placebo, during which potentially clinically significant changes in routinely controlled laboratories, revealed no medically significant differences."</seg>
<seg id="70">"increases the CPK (Krematin-phosphokinase), generally temporarily and asymptomatic, were observed in 3.5% of the patients treated with Aripiprazole patients, compared to 2.0% of patients treated with placebo."</seg>
<seg id="71">"on the side effects that has been reported in connection with an anti-psychotic therapy, the malignant neuroleptic syndrome, spätdyskinesia and increased mortality in older dementia patients, hyperglycaemia and diabetes mellitus (see Section 4.4)."</seg>
<seg id="72">"in clinical trials and since the market launch, unintended or intentional acute overdose with Aripiprazations were observed alone in adult patients with estimated doses of up to 1260 mg and without death succession."</seg>
<seg id="73">"although there is no information about the effectiveness of an immodifying treatment with Aripiprazole before; however, it is unlikely that hamodialysis is in the treatment of an overdose of benefit, since Aripiprazole has a high plastic rotary."</seg>
<seg id="74">It is thought that the effectiveness of Aripiprazole at Schizophrenia and Bipolar-I disorder on the combination of a partial agonal effect on dopamine D2- and serotonin 5HT1- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="75">"Aripiprazole showed in vitro a high affinity to dopamine D2- and D3 receptor, and 5HT2a receptor, and 5HT2a, to the serotonin 5HT2c- and 5HT7-, to the alpha-1 insoles and to the histamine H1receptor."</seg>
<seg id="76">"at the gift of Aripiprazole of 0,5 to 30 mg once daily over 2 weeks of healthy probanden showed the Positching-Emissions tomato, a D2 / D3 receptor-ligands, at the Nucleus caudatus and the coup."</seg>
<seg id="77">In three placebo-controlled short-term studies (4 to 6 weeks) at 1.228 schizophrenia in comparison to placebo a statistically significant improvement of psychotic symptoms.</seg>
<seg id="78">"in a Half dol-controlled study, 52 percent of the share of respondents who have a reference to the study of study, in both groups (Aripiprazole 77% and Half dol 73%)."</seg>
<seg id="79">"current values of measuring instruments defined as secondary studies, including PANSS and the Montgomery-Asberg- depressants scale, showed a significant stronger better than with Half dol."</seg>
<seg id="80">"in a placebo-controlled study on 26 weeks of stabilised patients with chronic schizophrenia, for Aripiprazole showed a significantly higher reduction in return rates, which was at 34% in the Aripiprazole group and at 57% of placebo."</seg>
<seg id="81">"in an ox-controlled, multinational double-blind study conducted at schizophrenia over 26 weeks, the 314 patients involved in schizophrenia (N = 18 or 13% of the value of cost-value patient) in significantly less patients (i.e. an increase of at least 5,6 kg at an average weight of ca."</seg>
<seg id="82">In two placebo-controlled monotherapy studies with flexible dosage with flexible dosage with flexible dosage over 3 weeks with patients with a manic or mixed episode of the Bipolar-I disorder showed Aripiprazole a compared to placebo over placebo over 3 weeks.</seg>
<seg id="83">In a placebo-controlled monotherapy study over 3 weeks with fixed dosage with a fixed dosage with a fixed or mixed episode of the Bipolar-I disorder showed Aripiprazole towards placebo no exaggerated effectiveness.</seg>
<seg id="84">"in two placements and active monotherapy studies over 12 weeks in patients with a German or mixed episode of a bipolar-I disorder, with or without psychotic characteristics, Aripiprazene showed a placebo over placebo over a week 3 and a consumer effect, which was comparable to that of lithium or neck dol in week 12."</seg>
<seg id="85">"Aripiprazole also pointed out a comparable share of patients with symptomatic remission of the Mania, such as lithium or neck dol."</seg>
<seg id="86">"in a placebo-controlled study about 6 weeks with patients with a German or mixed episode of a bipolar-I disorder, which in part 2 weeks not to reflect on lithium- or Valproat monotherapy in therapeutical serum, revealed the companion therapy with Aripiprazole in comparison to monotherapy with lithium or Valproat."</seg>
<seg id="87">"10 In a placebo-controlled study over 26 weeks followed by a long-term extension phase over 74 weeks in German patients, with regard to the prevention of a bipolar retrospect, predominantly in the prevention of a relapse in the Mania."</seg>
<seg id="88">"based on vitro studies, the enzymes CYP3A4 and CYP2D6 are responsible for stretching the N-depletion by CYP3A4 catalytic."</seg>
<seg id="89">"the mean Elimination period is nearly 75 hours for Aripiprazag at nearly 75 hours for Aripipraising via CYP2D6 and at nearly 146 hours at 'bad' (=" "poor" ") Metabolisiers over CYP2D6."</seg>
<seg id="90">"at Aripiprazole there are no differences in the pharmakokinetics between male and female healthy probands, as well as showed no gender-dependent patient in a pharmacocular study."</seg>
<seg id="91">A clear evaluation of Pharmakokinetics revealed no indication of clinically significant differences in ethnic affiliation or the impact of smoking on the Pharmokinetics of Aripiprazole.</seg>
<seg id="92">The pharmacocular properties of Aripiprazole and elhydro-Aripiprazole were similar in patients with severe kidney failure compared to young healthy progangs.</seg>
<seg id="93">"a single dose study at Probanden with a multi-radiger liver cirrhosis (Child-Pugh Class A, B and C) showed no significant effect regarding the impairment of the liver function to the Pharmokinetics of the class C, which is not enough to draw conclusions on their metabolic capacity."</seg>
<seg id="94">"based on conventional studies on the safety of security, reproductive retention, genotoxicity and Cancerogenic potential, the preclinical data cannot recognize any particular dangers to the human being."</seg>
<seg id="95">"toxicology significant effects have only been observed in doses or externalities, which have clearly exceeded the maximum dosage or exposure to humans, that they have limited to the clinical use only limited or no meaning."</seg>
<seg id="96">The effects diverted a dosages-infrared-pigment-accumulation and / or parenchant-state exposure in rats with €20 to 60 mg / kg / day (the 10X of the mid Steady-State exposure (Auc) at recommended Maximaldosis in humans).</seg>
<seg id="97">"in addition, a cholelithiasis has been determined as a result of the failure of sulphate-conjujugation of Aripiprazole (Auc) at the recommended clinical dose of 25 to 125 mg / kg / day (the 1- to 81fold of the recommended maximum dose when people based on mg / m2)."</seg>
<seg id="98">"however, the concentrations in the human Galle found at the highest recommended daily dose of hydroxy- Aripiprazole, not more than 6% of the concentrations found in the study over 39 weeks in the Galle of apes, and are far below the border values (6%) of vitro solubility."</seg>
<seg id="99">"in rabbits these effects were observed according to dosages, which led to excuses of the 3- and 11ples of the mid-Steady-State Auc at recommended clinical dialdosis."</seg>
<seg id="100">"Perforated blister packs for delivery of aluminium in folding boxes with 14 x 1, 28 x 1, 49 x 1, 56 x 1, 98 x 1 tablets."</seg>
<seg id="101">"15 Spätdyskinesia: in clinical trials, one year or less, there were occasional reports over during treatment with Aripiprazole Dyskinesia."</seg>
<seg id="102">It is thought that the effectiveness of Aripiprazole at Schizophrenia and Bipolar-I disorder on the combination of a partial agonal effect on dopamine D2- and serotonin 5HT1- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="103">"22 In a placebo-controlled study over 26 weeks followed by a long-term extension phase over 74 weeks in German patients, with regard to the prevention of a bipolar retrospect, predominantly in the prevention of a relapse in the Mania."</seg>
<seg id="104">"27 Spätdyskinesia: in clinical trials, one year or less, there were occasional reports over during treatment with Aripiprazole Dyskinesia."</seg>
<seg id="105">It is thought that the effectiveness of Aripiprazole at Schizophrenia and Bipolar-I disorder on the combination of a partial agonal effect on dopamine D2- and serotonin 5HT1- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="106">"34 In a placebo-controlled study over 26 weeks followed by a long-term extension phase over 74 weeks in German patients, with regard to the prevention of a bipolar retrospect, predominantly in the prevention of a relapse in the Mania."</seg>
<seg id="107">"39 Spätdyskinesia: in clinical trials, one year or less, there were occasional reports over during treatment with Aripiprazole Dyskinesia."</seg>
<seg id="108">It is thought that the effectiveness of Aripiprazole at Schizophrenia and Bipolar-I disorder on the combination of a partial agonal effect on dopamine D2- and serotonin 5HT1- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="109">"46 In a placebo-controlled study conducted over 26 weeks followed by a long-term extension phase over 74 weeks in German patients, with regard to the prevention of a bipolar back, predominantly in the prevention of a setback into the meny."</seg>
<seg id="110">The recommended starting dose for Aripiprazole is 10 or 15 mg / day at a contraction of 15 mg / day once daily independently of the meals.</seg>
<seg id="111">"patients who have difficulty in drocks of ABILIFY tablets, can take the scopztabletten alternatively to ABILIFY tablets (see section 5.2)."</seg>
<seg id="112">The occurrence of suicide behaviour belongs to psychotic diseases and affective disorders has been reported in some cases after the beginning or after changing an anti-psychotic therapy (see Section 4.8).</seg>
<seg id="113">"Spätdyskinesia: in clinical trials, one year or less, there were occasional reports over during treatment with Aripiprazole Dyskinesia."</seg>
<seg id="114">"clinical manifestations of a mn are high fever, muscle tissue, alternating consciousness and signs of autonomous instability (irregular pulse or blood pressure, tachykardie, sweating and heartbeat disorders)."</seg>
<seg id="115">"a weight gain is generally observed in a schizophrenic patient and in patients with bipolar mania, due to comorbious Mania, in which weight gain is known as side-effect, and might lead to severe complications."</seg>
<seg id="116">The patients should be advised to notify their doctor if they are pregnant or having a pregnancy during treatment with Aripiprazole</seg>
<seg id="117">The following side effects are more common (≥ 1 / 100) than under placebo or were classified as possible medically relevant side effects of the drug (*):</seg>
<seg id="118">In two placebo-controlled monotherapy studies with flexible dosage with flexible dosage with flexible dosage over 3 weeks with patients with a manic or mixed episode of the Bipolar-I disorder showed Aripiprazole a compared to placebo over placebo over 3 weeks.</seg>
<seg id="119">58 In a placebo-controlled study about 6 weeks with patients with a manic or mix episode of a bipolar-I disorder which was partially over 2 weeks not to lithium- or Valproat monotherapy in therapeutical serum which revealed the companion therapy with Aripiprazole in comparison to monotherapy with lithium or Valproat.</seg>
<seg id="120">"in a placebo-controlled study over 26 weeks followed by a long-term extension phase over 74 weeks in German patients, with regard to the prevention of a bipolar retrospect, predominantly in the prevention of a relapse in the Mania."</seg>
<seg id="121">"in rabbits these effects were according to dosages, which were used to extend the 3- and 11ples of the Middle Steady-State Auc at recommended clinical stage"</seg>
<seg id="122">"patients who have difficulty in drocks of ABILIFY tablets, can take the scopztabletten alternatively to ABILIFY tablets (see section 5.2)."</seg>
<seg id="123">"Spätdyskinesia: in clinical trials, one year or less, there were occasional reports over during treatment with Aripiprazole Dyskinesia."</seg>
<seg id="124">"71 In a placebo-controlled study about 6 weeks with patients with a manic or mix episode of a bipolar-I disorder, which resulted in therapy with Aripiprazole in case of reducing manic symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="125">"patients who have difficulty in drocks of ABILIFY tablets, can take the scopztabletten alternatively to ABILIFY tablets (see section 5.2)."</seg>
<seg id="126">"Spätdyskinesia: in clinical trials, one year or less, there were occasional reports over during treatment with Aripiprazole Dyskinesia."</seg>
<seg id="127">"84 In a placebo-controlled study about 6 weeks with patients with a manic or mix episode of a bipolar-I disorder, which resulted in therapy with Aripiprazole in case of reducing manic symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="128">200 mg Fructose per ml 400 mg Sucrose per ml 1.8 mg methyl-4-hydroxybenzoat (E218) the ml of 0.2 mg casyl-4-hydroxybenzoat (E216).</seg>
<seg id="129">"the recommended starting dose for ABILIFY is 15 mg once daily, regardless of meals as monotherapy or combination therapy (see section 5.1)."</seg>
<seg id="130">"to prevent the revocation of Manischer episodes in patients who have received Aripiprazole, the treatment should be continued with the same dose."</seg>
<seg id="131">"Spätdyskinesia: in clinical trials, one year or less, there were occasional reports over during treatment with Aripiprazole Dyskinesia."</seg>
<seg id="132">"hyperglycaemia, in some cases extremely and associated with Ketoazide or death, was reported in patients who were treated with atypical anti-psychotic agents, including ABILIFY."</seg>
<seg id="133">There are no precise risk estimates for hyperglycaemia-related unwanted events with ABILIFY and other atypical antipsychotic agents treated to patients who allow direct comparisons.</seg>
<seg id="134">92 In a clinical study with healthy probanden increased a highly effective CYP2D6-Inhibitor (Chinidin) the Auc von Aripiprazum 107% while the Cmax remained unchanged.</seg>
<seg id="135">"diltiazem or Escital opram) or CYP2D6, together with ABILIFY, can be calculated with a moderate increase in the Aripierzol- concentrations."</seg>
<seg id="136">Manic episodes in Bipolar-I disorder - In a controlled study about 12 weeks was the incidence of EPS 23.5% in patients under Aripiprazol-</seg>
<seg id="137">It is thought that the effectiveness of Aripiprazole at Schizophrenia and Bipolar-I disorder on the combination of a partial agonal effect on dopamine D2- and serotonin 5HT1- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="138">"in an ox-controlled, multinational double-blind study conducted at schizophrenia over 26 weeks, the 314 patients involved in schizophrenia (N = 18 or 13% of the value of cost-value patient) in significantly less patients (i.e. an increase of at least 5,6 kg at an average weight of ca."</seg>
<seg id="139">97 In a placebo-controlled monotherapy study over 3 weeks with fixed dosage with a fixed dosage with a fixed or mixed episode of the Bipolar-I disorder showed Aripiprazole towards placebo no exaggerated effectiveness.</seg>
<seg id="140">"in a relative bioavailability study, in which the pharmakokinetics of 30 mg Aripiprazole was compared to 30 mg of Aripigeziness in a healthy balance sheet, the ratio of the geometric Cmax mean value of the solution and the value of tablets at 122% (N = 30)."</seg>
<seg id="141">99 bankruptcy of the hydroxycystic of hydroxycymbals in the Galle Completion of Aripiprazene (auc) from 25 to 125 mg / kg / day determined (the 1- to 3x of the mid Steady-State exposure (Auc) at recommended temperature dose of 25 to 125 mg / kg / day (the 1- to 81fold of recommended Maximaldosis in humans based on mg / m2).</seg>
<seg id="142">"in rabbits these effects were observed according to dosages, which led to excuses of the 3- and 11ples of the mid-Steady-State Auc at recommended clinical dialdosis."</seg>
<seg id="143">ABILIFY injection solution is used to fast control of Agidity and behavioural disorders in patients with schizophrenia or in patients with the German episodes of the Bipolar-I disorder if an orale therapy is not attached.</seg>
<seg id="144">"as soon as it is clinically attached, the treatment should be finished with Aripiprazole solution and started with the oral application of Aripiprazole."</seg>
<seg id="145">To boost resorption and minimize the variability, an injection at the M. deltoideus or deep in the gluteus-Maximus muscle is recommended under retraction of adipous regions.</seg>
<seg id="146">A lower dose of 5.2 mg (0.7 ml) can be given depending on the individual clinical status considering the drug or acute therapy (see Section 4.5).</seg>
<seg id="147">"if a further-leading treatment with Aripiprazole is indexed, see the summary of the characteristics of the medicine with ABILIFY tablets, ABILIFY Smelztabletten or ABILIFY solution to take."</seg>
<seg id="148">There are no investigations on the effectiveness of Aripipraziness of injection in patients with Agiousness and behavioral disorders which were otherwise caused by schizophrenia and manic episodes of the Bipolar-I disorder.</seg>
<seg id="149">"if a parenteral therapy with benzodiazepines is additionally considered necessary to the Aripipraziness solution as necessary, patients should be observed in terms of an extreme sedation or blood pressure in case (see Section 4.5)."</seg>
<seg id="150">Studies on safety and effectiveness of Aripipraziness solution are available for patients with alcohol or pharmaceutical poisoning (caused by prescribed or illegal medicines).</seg>
<seg id="151">"Aripiprazole should be applied with caution in patients with known cardiovascular disease (elyocardiac disease, hypovolanaemia, treatment for hypotony, hypovolaemia, treatment with hemacular drugs) or hypertonie (including acute and malignant form)."</seg>
<seg id="152">"Spätdyskinesia: in clinical trials, one year or less, there were occasional reports over during treatment with Aripiprazole Dyskinesia."</seg>
<seg id="153">"clinical manifestations of a mn are high fever, muscle stiffness, changing consciousness and signs of autonomous instability (irregular pulse or blood pressure, tachykardie, sweating and heartbeat disorders)."</seg>
<seg id="154">"Polydipes, polyurry, polyphagie and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be regularly monitored in terms of deterioration of the glucose levels."</seg>
<seg id="155">"a weight gain is generally observed in schizophrenic patients and patients with bipolar Mania, due to comorbious Mania, in which weight gain is known as side-effect, and may lead to severe complications."</seg>
<seg id="156">"nevertheless, the intensity of the Sedation was greater compared to some of Aripiprazole in a study, in which healthy probanden Aripiprazole (15 mg doses) was applied as a malination intramuscularity and at the same time Lorazepam (2 mg dose) intramuscular."</seg>
<seg id="157">"105 The H2-Antler Famotidin, a stomach acid blocker, reduces the remnant rate of Aripiprazole, but this effect is not relevant as clinically."</seg>
<seg id="158">"at CYP2D6 'bad' (=" "poor" ") Metabolisians may result in comparison to CYP2D6, the joint application with highly effective inhibitors from CYP3A4 in higher plasma."</seg>
<seg id="159">"other highly effective Inhibitors from CYP3A4, such as Itraconazol and HIV- Proteaseinhibitors, should have similar effects and therefore should be made similar dosages reduction."</seg>
<seg id="160">"after receipt of the CYP2D6- or 3A4-Inhibitors, the dosage of ABILIFY should be raised to the Dosage levels before the beginning of the companion therapy."</seg>
<seg id="161">"106 Lorazepam (2 mg dosage) intramuscular, the intensity of the Sedation was greater compared to some of Aripiprazole."</seg>
<seg id="162">The following side effects occurred in clinical trials with Aripipraziness solution more frequently (≥ 1 / 100) than under placebo or were classified as possible medically relevant side effects (*) (see section 5.1):</seg>
<seg id="163">"the frequency of the side listed below is defined by the following criteria: frequently (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="164">107 The following side effects are more common (≥ 1 / 100) than under placebo or were classified as possible mediaprazole as possible medically relevant side effects (see section 5.1):</seg>
<seg id="165">"in a placebo-controlled long-term study, over 26 weeks, the incidence of EPS 19% in patients was under Aripiprazol- treatment and 13.1% in patients under placebo."</seg>
<seg id="166">"in another study over 12 weeks, the incidence of EPS 26.6% was charged with patients under Aripiprazol- treatment and 17.6% for those under lithium treatment."</seg>
<seg id="167">During the long-term experience period over 26 weeks at a placebo-controlled study the incidence of EPS 18.2% for patients under Aripiprazole treatment and 15.7% for patients with placebo treated patients.</seg>
<seg id="168">"a comparison between the patient groups under Aripiprazole and placebo, during which potentially clinically significant changes in routinely controlled laboratories, revealed no medically significant differences."</seg>
<seg id="169">"increases the CPK (creatinphosphokinase), generally temporarily and asymptomatic, were observed in 3.5% of the patients treated with Aripiprazole patients, compared to 2.0% of patients treated with placebo."</seg>
<seg id="170">"on the side effects that has been reported in connection with an anti-psychotic therapy, the malignant neuroleptic syndrome, spätdyskinesia and increased mortality in older dementia patients, hyperglycaemia and diabetes mellitus (see Section 4.4)."</seg>
<seg id="171">110 and behavioural disturbances was the Aripipraziness injection solution with statistically significant improvements from Agiousness / behavioural disorders associated with placebo and was similar to Haloperdol.</seg>
<seg id="172">"in a placebo-controlled short-term study (24 h) with 291 patients with bipolar disorder as well as Agiousness and behavioural disturbances, the Aripiprazole solution associated with a statistically significant increase in symptoms regarding the Agiity and behavioral disorders associated with a statistically significant reference to placebo and similar to the Lorazepam- Reference-reference."</seg>
<seg id="173">The observed average improvement of the starting point on the PANSS Excitement Component score on the primary 2-hour endpoint was 5.8 for placebo, 9.6 for Lorazepam and 8,7 for Aripiprazole. "</seg>
<seg id="174">"in analyses of sub-groups in patients with mixed episodes or patients with severe deliberations, a similar effectiveness was observed in terms of overall population, but a statistical signature could be determined due to a decreased patient's number."</seg>
<seg id="175">In three placebo-controlled short-term studies (4 to 6 weeks) to 1.228 schizophrenia (oral) compared to placebo a statistically significant improvement of psychotic symptoms.</seg>
<seg id="176">"in a Half dol-controlled study, 52 percent of the share of respondents who have a response to the study of study, in both groups (Aripiprazole 77% (oral) and Half dol 73%)."</seg>
<seg id="177">"current values of Messenger which were defined as secondary studies, including PANSS and the Montgomery-depressants scale, showed a significant stronger better than with Half dol."</seg>
<seg id="178">In a placebo-controlled study over 26 weeks to stabilised patients with chronic schizophrenia (oral) a significantly higher reduction in return rates that were at 34% in the Aripiprazol- group and at 57% of placebo.</seg>
<seg id="179">"in an ox-controlled, multinational double-blind trial at Schizophrenia over 26 weeks, the 314 patients were comprised of at least 7% compared to the current value (i.e. an increase of at least 5,6 kg with an average weight of ca."</seg>
<seg id="180">111 In a placebo-controlled study about 6 weeks with patients with a German or mixed episode of a bipolar-I disorder with or without psychotic characteristics which resulted in therapy with Aripiprazole in case of reducing manic symptoms compared to monotherapy with lithium or Valproat.</seg>
<seg id="181">"in a placebo-controlled study conducted over 26 weeks followed by a 74-week degree of study in the economical phase of Randomization a remission, with regard to the prevention of a bipolar back, predominantly in the prevention of a relapse in the Mania."</seg>
<seg id="182">"the Aripiprazole Auc is in the first 2 hours after intramuscular injections, 90% greater the Auc after the same dose as tablet; the systemic exposure was similar between the two formulations."</seg>
<seg id="183">In 2 studies with healthy probands the mean time up to the achievement of the maximum plasma piping at 1 to 3 hours after application.</seg>
<seg id="184">The gift of Aripiprazole solution was tolerated by rats and monkeys well tolerated and resulting in no direct toxicity to repeated exposure to repeated exposure (Auc) which resulted in 15- or 5 times over the maximum human therapeutic exposure of 30 mg intramuscularity.</seg>
<seg id="185">"in studies on Reproductive Toxicity, after intravenous exposure, no safety-relevant concerns after maturing exposure, which was 15- (rats) and 29 times (rabbits) over the maximum human therapeutic exposure of 30 mg."</seg>
<seg id="186">"based on conventional studies with Aripipraziness (oricity) at repeated immunology, toxicity, genotoxicity and Cancerogenic potential, the preclinical data cannot recognize any particular dangers to the people."</seg>
<seg id="187">"toxicology significant effects have only been observed in doses or externalities, which have significantly exceeded the maximum dosage or exposure to human beings; therefore, they have limited limited or no meaning for the clinical use."</seg>
<seg id="188">The effects diverted a dosal-state exposure to female / kg / kg (Auc) at recommended maximum-state exposure to female) and an increase by adrenal rinse-state exposure to female rats at 60 mg / kg / day (the 10-fold of middle-state exposure (Auc) at recommended Maximaldosis in humans).</seg>
<seg id="189">"in addition, a cholelithiasis has been determined as a result of the precipitation of Sulpigezekites of the hydroxy- Metabolites from 25 to 125 mg / kg / day (the 1- to 81-times of recommended Maximaldosis, based on mg / m2)."</seg>
<seg id="190">"in rabbits these effects were observed according to dosages, which led to excuses of the 3- and 11-times of the medium-state-state Auc in the recommended clinical dialdosis, observed."</seg>
<seg id="191">"the approval system must ensure that, before and during the product, the drug kosher system, as described in the version 1.0 of module 1.8.1 of the application is described, furnished and functional."</seg>
<seg id="192">"according to the" CHMP Guideline on Risk Management Systems for Medicinal products for human use, "the updated risk management plan must be submitted at the same time with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="193">"furthermore, an updated risk management plan must be submitted when new information can be known, within 60 days after an important milestone in the pharmaceutical producers or measures to risk minimization, at the request of the EMEA."</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets 56 x 1 tablets 56 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 / 002 49 x 1 tablets EU / 1 / 04 / 276 / 004 56 x 1 tablets EU / 1 / 04 / 276 / 005 98 x 1 tablets</seg>
<seg id="196">EU / 1 / 04 / 276 / 008 49 x 1 tablets EU / 1 / 04 / 276 / 008 56 x 1 tablets EU / 1 / 04 / 276 / 010 98 x 1 tablets</seg>
<seg id="197">EU / 1 / 04 / 276 / 012 28 x 1 tablets EU / 1 / 04 / 276 / 014 56 x 1 tablets EU / 1 / 04 / 276 / 015 98 x 1 tablets</seg>
<seg id="198">EU / 1 / 04 / 276 / 018 49 x 1 tablets EU / 1 / 04 / 276 / 019 56 x 1 tablets EU / 1 / 04 / 276 / 020 98 x 1 tablets</seg>
<seg id="199">"if one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="200">"it is applied to the treatment of adults, suffering from symptoms such as listening, seeing or fold of things that are not present, distrust, insisting, unrelated language, wirres behaviour and flattering mood."</seg>
<seg id="201">"ABILIFY is used in adults for treating a condition with excessive energy, feeling excessive energy, much less sleep than usual, very easy speaking with fast changing ideas and sometimes strong stimulant."</seg>
<seg id="202">"high blood sugar or cases of diabetes (sugar disease) in the family infertility unarbitrary, irregular muscle movements, especially in the face of heart or vascular disease in the family, stroke, or temporary suffering bleeding of the brain (trans-sitorical attack / TIA), who is more blood pressure."</seg>
<seg id="203">"if you suffer as older patient's dementia (loss of memory or other intellectual abilities), you should inform yourself or a nursing doctor if you have ever had a stroke or a temporary suffering blood flow of the brain."</seg>
<seg id="204">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness with high fever, sweat, changing mind or very gentle or irregular heartbeat."</seg>
<seg id="205">Children and young people ABILIFY not apply to children and young people as it has not been studied in patients under the age of 18.</seg>
<seg id="206">"when taking ABILIFY with other medicines Please inform your doctor or pharmacist if you are taking other medicines / apply or have recently taken / applied, even if it is not prescription drugs."</seg>
<seg id="207">Medicines for the treatment of cardiac arrhythmia antidepressants or herbal medicines used to treat depression and anxiety drugs are applied to treatment of HIV infection anticonvulsions which are used for treating epilepsy</seg>
<seg id="208">"pregnancy and lactation you should not take ABILIFY if you are pregnant, unless you have discussed this with your doctor."</seg>
<seg id="209">"transport and serve of machines you should not drive car and do not operate tools or machines, until you know how ABILIFY affects you."</seg>
<seg id="210">Please take this medicine only after contacting your doctor if you know that you are suffering from intolerability to certain victors.</seg>
<seg id="211">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="212">"even if you feel better, change or set the daily dose of ABILIFY without asking your doctor before."</seg>
<seg id="213">"if you have taken a larger amount of ABILIFY if you should notice that you have taken more ABILIFY tablets than by your doctor (or if someone else has taken some of your ABILIFY tablets), contact immediately your doctor."</seg>
<seg id="214">"if you have forgotten the intake of ABILIFY if you have forgotten a dose, take the forgotten dose as soon as you think, do not take the double dose on one day."</seg>
<seg id="215">"frequent side-effects (in more than 1 of 100, less than 1 of 10 treated) uncontrollable risk, headaches, fatigue, vomiting, vomiting, vomiting, anxiety, sleefulness, teens and blurry vision."</seg>
<seg id="216">"occasional side-effects (with more than 1 of 1,000, less than 1 of 100 treated) Some persons can feel small, especially when they get out of a sitting or sitting position, or they can determine an accelerated pulse."</seg>
<seg id="217">Please inform your doctor or pharmacist if one of the listed side effects you have considerably affected or you notice side effects which are not stated in this usage information.</seg>
<seg id="218">"like ABILIFY, the content of ABILIFY 5 mg tablets are rectangular and blue, with embodiment of A-007 and 5 on one side."</seg>
<seg id="219">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness with high fever, sweat, changing mind or very gentle or irregular heartbeat."</seg>
<seg id="220">"even if you feel better, change or set the daily dose of ABILIFY without asking your doctor before."</seg>
<seg id="221">"like ABILIFY and content of the ABILIFY 10 mg tablets are rectangular and pink, with embodiment of A-008 and 10 on one side."</seg>
<seg id="222">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness with high fever, sweat, changing mind or very gentle or irregular heartbeat."</seg>
<seg id="223">"even if you feel better, change or set the daily dose of ABILIFY without asking your doctor before."</seg>
<seg id="224">"like ABILIFY, the content of ABILIFY 15 mg tablets are round and yellow, using a-009 and 15 on one side."</seg>
<seg id="225">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness with high fever, sweat, changing mind or very gentle or irregular heartbeat."</seg>
<seg id="226">"even if you feel better, change or set the daily dose of ABILIFY without asking your doctor before."</seg>
<seg id="227">"like ABILIFY, the content of ABILIFY 30 mg tablets are round and rosafarben, with embossing from A-011 and 30 on one side."</seg>
<seg id="228">"171 If you suffer as older patients (loss of memory or other intellectual abilities), you should inform yourself or a nursing physician, whether you have ever had a stroke or a temporary suffering blood flow of the brain."</seg>
<seg id="229">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness with high fever, sweat, changing mind or very gentle or irregular heartbeat."</seg>
<seg id="230">"important information about certain other parts of ABILIFY patients who have no phenylalanine to be allowed, should note that ABILIFY Same, aspartame as a source for phenylalanine is included."</seg>
<seg id="231">"find immediately after the opening of the blister packer, the tablet with dry hands and place the melting pot in the whole on the tongue."</seg>
<seg id="232">"even if you feel better, change or set the daily dose of ABILIFY without asking your doctor before."</seg>
<seg id="233">"if you have taken a larger amount of ABILIFY, when you should find out that you have taken more ABILIFY Smelztabletten than by your doctor (or if someone else has taken a few of your ABILIFY enamel, contact immediately your doctor."</seg>
<seg id="234">"Calciumtrimetasilicat, crociumbilium, crociumbilium, iylitol, aspartame, iylitol, aspartame, Acesulfam calium, iylitol, aspartame, magnesium, magnesium-conearate, iron (III) - oxide (E172)."</seg>
<seg id="235">"like ABILIFY such as ABILIFY, the ABILIFY 10 mg of melting are round and rosafarben, with embodiment of" A "about" 640 "on one side and" 10 "on the other."</seg>
<seg id="236">"177 If you suffer as older patients (loss of memory or other intellectual abilities), you should inform yourself or a nursing doctor if you have ever had a stroke or a temporary Mangelding flow of the brain."</seg>
<seg id="237">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness with high fever, sweat, changing mind or very gentle or irregular heartbeat."</seg>
<seg id="238">"Calciumtrimetasilicat, crociumbilium, crociumbilium, iylitol, aspartame, iylitol, aspartame, magnesium, magnesium-conearate, iron (III) - hydroxid-oxide x H2O (E172)."</seg>
<seg id="239">"like ABILIFY, the ABILIFY 15 mg of melting are round and yellow, using" A "about 641" "on one side and" 15 "on the other."</seg>
<seg id="240">"183 If you suffer as older patient's dementia (loss of memory or other intellectual abilities), you should inform yourself or a nursing doctor if you ever had a stroke or temporary Mangelding flow of the brain."</seg>
<seg id="241">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness with high fever, sweat, changing mind or very gentle or irregular heartbeat."</seg>
<seg id="242">"like ABILIFY such as ABILIFY, the ABILIFY 30 mg of melting are round and pink" "A" "via 643" "on one side and" 30 "on the other."</seg>
<seg id="243">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness with high fever, sweat, changing mind or very gentle or irregular heartbeat."</seg>
<seg id="244">"transport and serve of machines you should not drive car and do not operate tools or machines, until you know how ABILIFY affects you."</seg>
<seg id="245">190 Important information about certain other components of ABILIFY every ml ABILIFY solution to take contains 200 mg Fructose and 400 mg Sucrose.</seg>
<seg id="246">"if your doctor has communicated to you that you are suffering from intolerance towards particular sugar, contact your doctor before taking this medicine."</seg>
<seg id="247">The dose to ABILIFY solution must be measured with the weighted Messenger or the eives 2 ml trough pipette that are included in the package.</seg>
<seg id="248">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="249">"if you have taken a larger amount of ABILIFY, when you should take note that you have taken more ABILIFY solution to be taken than by your doctor (or if someone has taken another ABILIFY solution for insertion), contact immediately your doctor."</seg>
<seg id="250">"Dinatriumedetat, Fructose, glycerol, glycerol, methyl-4-hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat (E216), sodium hydroxybenzoat</seg>
<seg id="251">"how ABILIFY looks like ABILIFY 1 mg / ml solution for immersion is a clear, colourless up to light yellow liquid in bottles with a child secure polypropylene cap and 50 ml, 150 ml or 480 ml."</seg>
<seg id="252">"ABILIFY injection solution is applied for the rapid treatment of gestating unrest and desperate behavior that are marked as symptoms of a disease which is not present, distrust, insisting, insisting language, wirres behavior and flattering mood."</seg>
<seg id="253">"people with this disease can also be depressed to feel innocent or strained, feeling excessive energy, much less sleep than usual, very fast speaking with changing ideas and sometimes strong stimulant."</seg>
<seg id="254">"inform immediately your doctor, if you are connected to muscle stiffness or stiffness with high fever, sweat, changing mind or very gentle or irregular heartbeat."</seg>
<seg id="255">"if you use ABILIFY with other medicines Please inform your doctor or pharmacist if you are taking other medicines / apply or have recently taken / applied, even if it is not prescription drugs."</seg>
<seg id="256">Medicines for the treatment of cardiac arrhythmia antidepressants or herbal medicines used to treat depression and anxiety drugs are applied to treatment of HIV infection anticonvulsions which are applied to the treatment of epilepsy.</seg>
<seg id="257">"196 pregnant and breastfeeding you should not apply ABILIFY if you are pregnant, unless you have discussed this with your doctor."</seg>
<seg id="258">Transport and utilisation of machines you should not drive car and do not operate tools or machines if you have heard after the application of ABILIFY injection solution.</seg>
<seg id="259">"if you have concerns you get more ABILIFY injections solution as you need, please talk to your doctor or nursing staff."</seg>
<seg id="260">"frequent side-effects (in more than 1 of 100, less than 1 of 10 were treated) by ABILIFY injections are fatigue, dizziness, headaches, restlessness, nausea and vomiting."</seg>
<seg id="261">"occasional side-effects (in more than 1 of 1,000, less than 1 of 100 treated) Some persons can have a changed blood pressure, especially when freezing out of the couch or sitting, or a fast powder, have a dry feeling in the mouth or feel unbeaten."</seg>
<seg id="262">"frequent side-effects (in more than 1 of 100, less than 1 of 10 treated) uncontrollable risk, headaches, fatigue, vomiting, vomiting, vomiting, anxiety, sleefulness, teens and blurry vision."</seg>
<seg id="263">"if you need more information about your disease or its treatment, please read the package (also component of the EPAR) or contact your doctor or a pharmacist."</seg>
<seg id="264">Abraxane should only be applied under the supervision of a qualified oncologist in the application of cytostatika (Abkills of cells).</seg>
<seg id="265">"with patients who occur certain side effects on the blood or the nervous system, the dose can be reduced or the treatment can be interrupted."</seg>
<seg id="266">"(44-20) 74 18 84 00 fax (44-20) 74 18 84 00 fax, / / www.emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document, for non-commercial purposes only grant the EMEA is the particle of the particles, the so-called" nanoparticels "to be tied up to one of the people with the name Albopin."</seg>
<seg id="267">"the effectiveness of muxane was studied in a major study, attended by the 460 women with metastatic breast cancer, of which approximately three quarters of earlier had an anthracers."</seg>
<seg id="268">The effect of abraxane (in some gift or as monotherapy) was compared to the conventional Paclitaxel pharmaceutical drugs (given in combination with other medicines to reduce the side effects).</seg>
<seg id="269">"overall, in the main study 72 (31%) of 229 with abraxane treated patients treated to treatment, compared to 37 (16%) of 225 patients who were conventional Paclitaxel drug."</seg>
<seg id="270">"if one regards only the patients treated for the first time due to metastatic breast cancer, there were no difference in relation to the efficacy of illness and survival, with no difference between pharmaceuticals."</seg>
<seg id="271">"on the other hand, however, demonstrated in patients who had previously received other treatments of their metastatic breast cancer regarding these indicators that abraxane had more effective than conventional Paclitaxel drugs."</seg>
<seg id="272">"it must also not be applied to patients, who are silent or before the beginning of the treatment low neutrobes pay in the blood."</seg>
<seg id="273">"the committee for human medicines (CHMP) determined that if the first treatment no longer strikes, more effective than conventional Paclitaxel drug, and that it must not be given in other medicines as conventional Paclitaxel drugs, in order to decrease unwanted effects."</seg>
<seg id="274">January 2008 shared the European Commission of the company BioScience Limited granted approval for the ingestion of myxane in the whole of the European Union.</seg>
<seg id="275">Abraxane monotherapy is indexed for the treatment of metastatic Mammacardiac in patients where the first-line treatment for metastatic disease is missing and is not shown for the standard anthracycline therapy (see also section 4.4).</seg>
<seg id="276">In patients with severe Neutropenie (Neutrophilention &lt; 0.50 x 109 / l over a period of one week or longer) or severe sensory neuropathy during the abraxane therapy the dose should be reduced to 220 mg / m2 in the subsequent series.</seg>
<seg id="277">"with sensory Neuropathy degree 3 is to interrupt the treatment until an improvement to degree 1 or 2 is reached, and in all subsequent cycles the dose must be reduced."</seg>
<seg id="278">There is currently no adequate data for the recommendation of dosage adjustment in patients with mild to moderate impairment of the liver function (see Section 4.4 and 5.2).</seg>
<seg id="279">"there were no studies conducted with patients with impaired kidney function, and there is currently no sufficient data for the recommendation of dosage adjustment in patients with impairment of kidney function (see Section 5.2)."</seg>
<seg id="280">"abraxane is not recommended for use in children under the age of 18, due to non-sufficient data for inconceivable and effectiveness."</seg>
<seg id="281">"abraxane is an album of Paclitaxel, which could be essentially other pharmacological characteristics as other formulations of paclitaxel (see section 5.1 and 5.2)."</seg>
<seg id="282">"if an allergic reaction occurs, the drugs should be removed immediately and a symptomatic treatment should be initiated and the patient must not be treated again with Paclitaxel."</seg>
<seg id="283">"in the patient, no renewed xane treatment cycles should be introduced back to &gt; 1.5 x 109 / l and the thrombogenic rate has risen again on &gt; 100 x 109 / l."</seg>
<seg id="284">Patients with severe liver disorders (Bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with abraxane.</seg>
<seg id="285">"while a clearly named cardiotoxicity has not been proven, cardiac incidents in the indexed patient collective are not unusual, especially in patients with earlier anthracers in treatment or underlying cardiac or lung disease."</seg>
<seg id="286">"if in the patient, after the gift of abraxane nausea, vomiting and diarrhea, they can be treated with the usual antiemetika and contented means."</seg>
<seg id="287">"abraxane should not be used in pregnant or women of childbearing age, which do not use an effective conception, except the treatment of mother with paclitaxel is unavoidable."</seg>
<seg id="288">Women of childbearing age should be used during and up to 1 month after the treatment with abraxane a reliable contraction method.</seg>
<seg id="289">"male patients treated with abraxane will be enriched, while and up to six months after treatment no child shall bear witness."</seg>
<seg id="290">Male patients should be advised of treatment through a sperm count because therapy with abraxane is the possibility of irreversible infertility.</seg>
<seg id="291">"abraxane may cause side effects such as fatigue (very common) and dizziness (often), which can affect the traffic noise and the ability to serve machines."</seg>
<seg id="292">Below are the most common and most important incidents of side-effects listed at 229 patients with metastatic Mammacarcinoma who were treated in the pivotal clinical phase III study once every three weeks with 260 mg / m2.</seg>
<seg id="293">Neutropenie was the most noticeable important hemorological toxicity (in 79% of the patients) and was quickly reversible and dosisdependent; leukopenie was reported in 71% of the patients.</seg>
<seg id="294">Anemia (HB &lt; 10 g / dl) was observed at 46% of patients with abraxane treated patients and was severe (HB &lt; 8 g / dl).</seg>
<seg id="295">In table 1 the side effects listed in connection with the gift of abraxane as monotherapy in each dose and indications have occurred in studies (N = 789).</seg>
<seg id="296">"very common (≥ 1 / 10); commonly (≥ 1 / 100, &lt; 1 / 100); rare (≥ 1 / 10,000, &lt; 1 / 1000); rarely (&lt; 1 / 10,000); very rare (&lt; 1 / 10,000)."</seg>
<seg id="297">"occasionally: increased blood pressure, weight increase, elevated creatase in the blood, increased blood sugar in the blood, increased phosphere, higher phosphoror in the blood, reduced potassium in the blood of blood diseases:"</seg>
<seg id="298">"Dysphagie, blowers, tongues, dry mouth, pain-gitis, pain in the lower, orale pain, rectomal bleeding diseases of the kidneys and urinary tract:"</seg>
<seg id="299">"pain in the flibwall, weakness of the muscles, genital pain, muscle spasms, pain in the skeletal muscle, flank pain, discomfort in the limbs, muscle weakness Very common:"</seg>
<seg id="300">Restlessness 1 The frequency of hypersensitive actions will be calculated based on a definite case in a population of 789 patients</seg>
<seg id="301">"since these events have been reported on a voluntary basis during the clinical practice, no estimates of the actual frequency are possible and there was no causal connection established with these events."</seg>
<seg id="302">Paclitaxel is an antimikrotubules-active ingredient that promotes the encamping of microtubmeren and stabilize the microtubules by inhibiting their depolymerisation.</seg>
<seg id="303">This stabilisation leads to an inhibition of the normal dynamic reorganization of the mikrotubular network that is essential for the vital interphase and the mitotic cell functions.</seg>
<seg id="304">It is known that Albany in the Transcytosis of plastic components conveys and within-vitro studies has been proven that the presence of Albumine is supported by the end-helm cells by the endothelm cells.</seg>
<seg id="305">It is assumed that this improved transendotal transport through the gp-60-Albuminated recipes is conveyed and due to the albuminant Proteins ProtARC (secreted protein acidic rich in cysteine) an Paclitaxel accumulation in the area of the tumor occurs.</seg>
<seg id="306">The use of muxane for metastatic Mammacardiac is supported by some 106 patients in two single-intensive studies and of 454 patients who were treated in a randomised phase III study.</seg>
<seg id="307">"in a study, 43 patients were treated with metastatic Mammacardiac, which was given in the form of an infusion over 30 minutes with a dose of 175 mg / m2."</seg>
<seg id="308">In the second study a dose of 300 mg / m2 has been used as infusion over 30 minutes to 63 patients with metastatic Mammacardiac.</seg>
<seg id="309">This multi-centric study was conducted in patients with metastatic mlitaxel 175 mg / m2 as a 3-hour infusion with premedication for prevention of an allergic reaction (N = 225) or in the form of abraxane 260 mg / m2 as 30-minute infusion without premedication (N = 229).</seg>
<seg id="310">"when recording into the study, 64% of patients had an impaired state (ECOG 1 or 2), 79% had visceral metastases and 76% had more than 3 metastasestors."</seg>
<seg id="311">"14% of the patients previously received no chemotherapy, 27% had only a adjuvant chemotherapy, 40% only because of metastasification and 19% because of metastasification and adjuvant treatment."</seg>
<seg id="312">9. the results for the general reference rate and time until the progression of the disease as well as progression-free survival and survival for patients who receive &gt; First-line therapy are shown below.</seg>
<seg id="313">"neurotoxicity compared to Paclitaxel has been evaluated by improving a degree of patients, which at a time during therapy a periphere Neuropathy degree 3 were evaluated."</seg>
<seg id="314">The natural course of peripheral Neuropathy for the sound of lexane due to cumxane due to cumxane after &gt; 6 treatment courses was not evaluated and is still unknown.</seg>
<seg id="315">The Pharmacokinetics of the total-paclitaxel after 30- and 180-minute Infusions of muxane with a dose of 80 to 375 mg / m2 was established in clinical trials.</seg>
<seg id="316">The drug exposure (Auc) increased linear from 2653 to 16736 ng.h / ml analogue to a dose of 80 to 300 mg / m2.</seg>
<seg id="317">10 After intravenous treatment of abraxane in patients with metastatic Mammacardiac in the recommended clinical dose of 260 mg / m2 took the Paclitaxel-Plasmakonzentration in multiphashic way.</seg>
<seg id="318">The middle distribution volume was 632 l / m2; the high distribution volume points to a far-reaching extravascular distribution and / or pasture connection of paclitaxel.</seg>
<seg id="319">In a study with patients with advanced solid tumors the pharmacocular properties of Paclitaxel were compared with the values after a 3-hour injection of 175 mg / m2 of soluble paclitaxel.</seg>
<seg id="320">"the Clearance of Paclitaxel was higher (43%) after the myxlitaxel injection, and also the distribution volume was higher with muxane higher (53%)."</seg>
<seg id="321">Published in literature about in-vitro-vitro studies of human liver microphyllitaxel and two smaller Metabolites (3 "-p-hydroxypaclitaxel and 2 smaller Metabolites (3" -p-hydroxypaclitaxel and 6α-Dihydroxaclitaxel).</seg>
<seg id="322">"after a 30-minute infusion of 260 mg / m2 of mxane in patients with metastatic Mammacardiac, the mean value for cumulative urinary tract amounted to less than 1% of the total dose of 6α-hydroxypaclitaxel, and 3" -p-hydroxypaclitaxel, which indicates a far-reaching not-renal Clearance. "</seg>
<seg id="323">"however, only a few data are available via patients at the age of more than 75 years, as only 3 patients took part in the pharmacoinetic analysis."</seg>
<seg id="324">The chemical and physical stability was detected at 2 ° C - 8 ° C in the original box and light light protected over 8 hours.</seg>
<seg id="325">Paclitaxel is an zytotoxic anticardiac disease and as well as with other potentially toxic substances should be compared with the treatment of using xane caution.</seg>
<seg id="326">Utilizing a sterilen sprayer are slowly injected over a period of at least 1 minute 20 ml of a 9 mg / ml (0.9%) sodium chlorinated bottle.</seg>
<seg id="327">"after completion of the solution, the solution should rest at least 5 minutes to ensure a good benchmark of the solids."</seg>
<seg id="328">"then the steeping bottle, for at least 2 minutes should be slow and cautious, and / or inverted until a complete reset board of the pulse is done."</seg>
<seg id="329">"if denotes or sinks are visible, the steeping bottle is again gently inverted to achieve a complete reset board."</seg>
<seg id="330">"this is calculated for the patient necessary exact-file volume of the 5-mg / ml vipension, and the corresponding amount of reconstituent xane will be injected into an empty, sterile PVC- or non-PVC infusion bag."</seg>
<seg id="331">"the holder of the approval of the approval must make sure that the pharmacist of approval must be described, as described in Version 2.0 and presented in module 1.8.1 of the application of application, is established and works before and while the drug is brought to traffic."</seg>
<seg id="332">Risk management plan The owner of the approval for the ingestion is committed to perform in version 4 of risk management plan (RMP) and will be agreed in Version 4 of risk management plan (RMP) and all subsequent updates of the RMP which will be agreed with the CHMP.</seg>
<seg id="333">"according to the CHMP directive on risk management systems for drugs on human consumption, the updated RMP should be submitted at the same time with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="334">"furthermore, an updated RMP would also be an updated RMP • If new information may affect the drug specification, the pharmaceutical company plan or risk performance, • inside 60 days after reaching an important milestones (pharmacoyancy or risk imimation) • On request of the EMEA."</seg>
<seg id="335">"8 hours in the refrigerator in the steeping bottle, when it is kept in conarton, to protect the content from light."</seg>
<seg id="336">"abraxane is used for the treatment of Mammacardiac, if other therapies were tried but not successful, and if you do not come for anthracycline therapies in question."</seg>
<seg id="337">"abraxane may not be applied: • if you are absent (allergic) against paclitaxel or one of the other components of abraxane, if you are silent • if your white blood cells are humiliated (raw values for neutrobes of &lt; 1.5 x 109 / l - your doctor will inform you about it)"</seg>
<seg id="338">"special caution for use of abraxane is required: • if you have a well known kidney function, if you have a well known kidney function, if you suffer from severe liver problems, if you suffer from severe liver problems • If you have heart problems"</seg>
<seg id="339">"with other medicines Please inform the doctor if you apply other medicines or have recently applied, even if it is not prescription drugs since these may cause a interaction with abraxane."</seg>
<seg id="340">Women of childbearing age should be used during and up to 1 month after the treatment with abraxane a reliable contraction method.</seg>
<seg id="341">"in addition, they should be advised before treating a sperm count, as by using xane treatment the possibility of a lasting infertility exists."</seg>
<seg id="342">Transport and utilisation of machines abraxane may cause side effects such as fatigue (very common) and didelusion (often) that can affect the traffic noise and the ability to serve machines.</seg>
<seg id="343">"if you get other medicines within the framework of your treatment, you should consult with regard to the driving or carriage of machines from your doctor."</seg>
<seg id="344">"22 • effect on the peripheral nerves (pain and numbness) • pain in one or more joints • pain in the muscles • nausea, diarrhoea • weakness and fatigue"</seg>
<seg id="345">"the frequent side-effects (at least 1 of 100 patients are reported • Appetitlessness, skin pain • vertices, fever, hood injury or difficulty in the heart rate • swelling or abdominal pain, analgesic mouth or sore throat, painless mouth or sore tongue, mousoor, inimbalances."</seg>
<seg id="346">"the rare side effects (at least 1 of 10,000 patients) are: • lung infection • Hauling reaction to another substance according to radiotherapy • bloodstream."</seg>
<seg id="347">Please inform your doctor or pharmacist if one of the listed side effects you have considerably affected or you notice side effects which are not stated in this usage information.</seg>
<seg id="348">"if it is not used immediately, it can be stored in the flashing bottle of up to 8 hours in the refrigerator (2 ° C - 8 ° C) when it is kept in Umkarton to protect the content from light."</seg>
<seg id="349">Any transducal bottle contains 100 mg Paclitaxel. • The other component is aluminous solution from the human (contains sodium to sodium caprylate and N Acetyltryptophan (Ph.Eur.))</seg>
<seg id="350">Precautions for preparation and application Paclitaxel is an zytotoxic anticardiac disease and as well as with other potentially toxic substances should be tolerated with caution.</seg>
<seg id="351">Utilizing a sterile syringe should be slowly injected over a period of 1 minute 20 ml of a 9 mg / ml (0.9%) sodium chlorinated bottle solution in a vascular bottle.</seg>
<seg id="352">"afterwards, the steeping bottle for at least 2 minutes slowly and be careful and / or inverting, until a complete reset board of the pulse is done."</seg>
<seg id="353">"for the patient necessary exact dosages of the 5 mg / ml vipension calculate and the appropriate amount of the reconstituent xane into an empty, sterile PVC-infusion bag type IV injected."</seg>
<seg id="354">Parenteral drugs should be subjected to the application of a visual check on possible particles and discolorations whenever possible or the eldest.</seg>
<seg id="355">"stability Ungeopened flashing bottles with abraxane can be stable up to the date specified on the package, when the steeping bottle is kept in Umarton, to protect the content from light."</seg>
<seg id="356">"stability of the reconstituent Suspension in the bottle bottle, after the first reconstitution, the Suspension should be filled immediately into an infusion bag."</seg>
<seg id="357">"member states must ensure that the approval of the approval of the authorisation is the medical specialist in Dialysis centers and retail centers, with the following information and materials:"</seg>
<seg id="358">"• training brochure • Summary of the characteristics of the drug (expert information), labeling and package structures. • With unique imaging representation of the correct use of the product, refrigerators for transport through the patient."</seg>
<seg id="359">This means that Abseamed is similar to a biological medicine which has already been approved in the European Union (EU) and contains the same substance (as well as "reference therapy").</seg>
<seg id="360">"it is used in patients with normal blood formations, in connection with a blood transfusion complications might occur if before the procedure is not possible, and in which a blood loss of 900 to 1 800 ml is expected."</seg>
<seg id="361">"the treatment with Abseamed must be initiated under the supervision of a physician, the experience in the treatment of patients with diseases is indicated."</seg>
<seg id="362">"in patients with kidney problems and in patients who want to make a self-bloodshed, Abseamed is ininjected into a vene."</seg>
<seg id="363">The injection can be made by the patient or his supervisor unless they received an adequate guide.</seg>
<seg id="364">"in patients with chronic kidney failure or in patients who receive chemotherapy in the recommended area (between 10 and 12 grams per decilites, for adults or between 9.5 and 11 g / dl in children)."</seg>
<seg id="365">"the iron values of all patients have to control prior treatment to ensure that there is no iron deficiency, and iron supplements should be administered throughout the treatment."</seg>
<seg id="366">"in patients who receive chemotherapy, or in patients with kidney problems can be caused by a erythropoietindeficiency or thereby that the body has no sufficient effect on the body's own Erythropoietin."</seg>
<seg id="367">Erythropoietin is also used in operations to increase the number of red blood cells and thus prevent the consequences of a blood loss.</seg>
<seg id="368">It is produced by a cell in which a gene (DNA) was brought in to the formation of epoetin alfa.</seg>
<seg id="369">Abseamed was compared to administration when an injection was compared to a main study with 479 patients suffering from kidney problems caused by kidney problems.</seg>
<seg id="370">All patients participating in this study had been injected at least eight weeks of Eprex / Erypo for at least eight weeks before they were either converted to Abseamed or continued Eprex / Erypo.</seg>
<seg id="371">Main indicator for the effectiveness was the change of the bunmovebins between the beginning of the study and the distribution period in the weeks 25 to 29.</seg>
<seg id="372">The company also presented the results of a study in which the effects from under Eprex / Erypo were examined for 114 cancer patients who received chemotherapy.</seg>
<seg id="373">"in the study with patients suffering from one kidney problems caused by kidney problems, the hemostal binars were maintained in the same measure, as with the patient who continued Eprex / Erypo."</seg>
<seg id="374">"compared to this showed the patients that continue to Eprex / Erypo, an increase of 0.063 g / dl of the output value of 12.0 g / dl."</seg>
<seg id="375">"the commonest side-effect of Abseamed is a rise in blood pressure, which occasionally lead to symptoms of a receptionist (brain problems) like sudden, stealing migratory headache and concreteness."</seg>
<seg id="376">Abseamed may not be applied in patients who may be oversensitive (allergic) against epoetin alfa or any other components.</seg>
<seg id="377">Abseamed as injection under the skin is not recommended for treating kidney problems as further studies are required to ensure that this is caused by no allergic reactions.</seg>
<seg id="378">"at the conclusion that for Abseamed in accordance with the provisions of the European Union of evidence, the drug was produced a comparable quality, safety and efficacy profile such as Eprex / Erypo."</seg>
<seg id="379">"the company, the Abseamed, will provide medical personnel in all member states, including information about the security of the medicine."</seg>
<seg id="380">August 2007 shared the European Commission of the company Medice Arzneimittel Pütter GmbH & Co KG for the transport of Abseamed throughout the European Union.</seg>
<seg id="381">"treatment of anaemia and reduction of transfusion for adults with solid tumors, malignity lymph or multi-plem Myelom, who received chemotherapy and where the risk of transfusion due to the general body (e.g. cardiovascular status, existing anaemia at the start of chemotherapy) exists."</seg>
<seg id="382">"the treatment should be carried out only in patients with moderate anemia (hemoglobin [HB] 10 - 13 g / dl [6,2 - 8,1 mmol / l], if bloodsaving measures are not available or inadequate, for planned large surgical procedures, which demand a large volume of blood pressure (4 or more units blood for women; 5 or more units blood in men)."</seg>
<seg id="383">"for the reduction of foreign blood, Abseamed can be applied to a large electrical orthopaedic surgery, with which a high risk of transfusion instrumentation is expected to be expected."</seg>
<seg id="384">HB 10-13 g / dl) and a anticipated blood loss of 900-1800 ml are not being used in a autologist blood registrar.</seg>
<seg id="385">"the hemoglobin target centration is between 10 and 12 g / dl (6.2 - 7,5 mmol / l), except in pediatric patients, where the hemisprubination between 9.5 and 11 g / dl (5.9 - 6,8 mmol / l) should lie."</seg>
<seg id="386">"Anämiesymptomatic symptoms and favourites may vary depending on age, gender and total disease; therefore, assessing the individual clinical level of clinical and disease is required by the doctor."</seg>
<seg id="387">A rise in the hamoglobins by more than 2 g / dl (1.25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">"due to the variability between patients may occasionally be observed in a patient individual hmovebins, above or under the hemorglobinge."</seg>
<seg id="389">In view of this hemoglobinder should be tried to achieve the hemoglobin target centration of 10 g / dl (6.2 mmol / l) to 12 g / dl (7,5 mmol / l). "</seg>
<seg id="390">If the Hämoglobinars worth more than 2 g / dl (1.25 mmol / l) per month increases or if the permanent hmoglobinwert 12 g / dl (7,5 mmol / l) exceeds that is the epoetin-alfa dose to reduce 25%.</seg>
<seg id="391">"patients should be monitored engorically to ensure that epoetin alfa is required in the lowest legal dose, which is required for the control of anaemia and the illiterative symptoms."</seg>
<seg id="392">The present clinical results indicate that patients with initial low low value value (&lt; 6 g / dl or &lt; 3,75 mmol / l) may require higher exhaustion than patients in which the initial anaemia is less heavy (HB &gt; 8 g / dl or &gt; 5 mmol / l).</seg>
<seg id="393">The present clinical results indicate that patients with initial low low value (&lt; 6.8 g / dl or &lt; 4.25 mmol / l) may require higher prevalence than patients in which the initial anaemia is less heavy (HB &gt; 6.8 g / dl or &gt; 4,25 mmol / l). "</seg>
<seg id="394">Initial dose 50 i.e. / kg three times a week through intravenous application if necessary with a dosage increase of 25 to / kg (three times a week) to the desired target (this should take place in steps of at least 4 weeks).</seg>
<seg id="395">"shareholder symptoms and - follow-up factors may vary depending on age, gender and total disease; therefore, assessing the individual clinical level of medical and disease is required by the doctor."</seg>
<seg id="396">In view of this hemoglobinder should be tried to achieve the hemoglobin target centration of 10 g / dl (6.2 mmol / l) to 12 g / dl (7,5 mmol / l). "</seg>
<seg id="397">"patients should be monitored engorically to ensure that epoetin alfa will be approved in the lowest legal dose, which is required for the control of the equestrian symptom."</seg>
<seg id="398">"if after 4 treatment of the Hämoglobinars value by at least 1 g / dl (0.62 mmol / l) or the Retikulocytic number by ≥ 40,000 cells / µl over the starting-rate, the dose should be kept from 150 to / kg three times a week or 450 i.e. / kg once a week."</seg>
<seg id="399">"when the Hämoglobinan increased &lt; 1 g / dl (&lt; 0.62 mmol / l) and the Retikulocytic speed, the dose should be lifted up to 300 i.e. / kg three times a week."</seg>
<seg id="400">If after additional 4 treatment weeks with 300 and 300 / kg three times a week of the Hämoglobinars by ≥ 1 g / dl (≥ 0.62 mmol / l) or the reticurologist number around ≥ 40,000 cells / µl should be kept the dose of 300 and / kg three times a week.</seg>
<seg id="401">"on the other hand, the hemowiste value is worth &lt; 1 g / dl (&lt; 0.62 mmol / l) respectively the Retikulocytic number to increase the epoetin-alfa therapy, and the treatment should be interrupted."</seg>
<seg id="402">Patients with mild anemia (hemokrit 33 - 39%) where the pre-assorted deposits of ≥ 4 blood conserven should be Abseamed in a dose of 600 i.e. / kg body weight twice weekly for 3 weeks before the surgical procedure.</seg>
<seg id="403">"with the iron substitution should be as early as possible - for example, a few weeks before the beginning of the autologist bloodstream program, thus will be available before the beginning of the Abseamed therapy large iron reserves."</seg>
<seg id="404">"6 The recommended dosage is 600 i.e. / kg epoetin alfa, once a week about three weeks (day 21, 14 and 7) before the surgical procedure and the day of the surgery (day 0)."</seg>
<seg id="405">"this should be given epoetin alfa preoperatively 300 and / kg on 10 consecutive days, on the day of the surgery, as well as 4 days immediately afterward."</seg>
<seg id="406">"alternatively, the injection at the end of the dialysis can be given over the hose of the dialysis, followed by 10 ml isotonic cookery solution to rinse the hose, and ensure sufficient injection of drug through in the circulation."</seg>
<seg id="407">Patients suffering from treatment with any erythroblastopenie at a erythroblastopenie (Pure Red Cell Aplasia, PRCA) should be obtained no seamed or another Erythropoetin (see Section 4.4 - Erythroblastopenie).</seg>
<seg id="408">"heart attack or stroke within one month before the treatment, unabile Angina pectoris, increased risk of deep Venoarthritis (e.g. anamnestisch known venous Thromboembolia)."</seg>
<seg id="409">"in case of patients who are planned for larger electrical orthopaedic surgery, the application of epoetin disease, the application of epoetin disease, the application of epoetin disease, the application of epoetin disease, the use of epoetin disease, the application of epoetin disease, vascular disease, vascular disease, vascular disease, vascular disease, vascular disease, vascular disease, vascular disease, or cracrovascular event."</seg>
<seg id="410">Erythroblastopenie (PRCA) Very rare was reported on the occurrence of an antibody-mediated PRCA after monate- to years of treatment with subcutanem Erythropoetin.</seg>
<seg id="411">"in patients with sudden loss of loss, defined as a decreased loss of transfusions (1 - 2 g / dl per month) with increased need for transfusions, the Retikurologist or vitamin B12 shortage, aluminum or inflammation, bleeding or inflammation, bleeding or hemysis should be investigated."</seg>
<seg id="412">"if the Retikurologist value, under consideration of anemia (i.e. the Retikurologytes" Index "), is determined and if no other reason is found, the anti-erythropoetin antibodies should be determined and an investigation of the bone marrow to the diagnosis of a PRCA."</seg>
<seg id="413">The data for immunogenity at subcutters to subcutters in patients with a risk to antibody-induced PRCA (patients with renal anaemia) are not sufficient.</seg>
<seg id="414">"8 If patients with chronic kidney failure should not be exceeded under the treatment of 4.2 recommended upper limit of the hemoglobin target centration.</seg>
<seg id="415">In clinical trials an increased moral risk and risk for serious cardiovascular events have been observed if erythropoesis-stimulating agents were observed by over 12 g / dl (7,5 mmol / l).</seg>
<seg id="416">Controlled clinical studies have not shown any significant benefits that is primarily attributable to the gift of epochs when the haemglobincentration is due to the control of the illiteracy symptoms and the prevention of blood transfusions necessary.</seg>
<seg id="417">The Hämoglobinan increased by about 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="418">"in patients with chronic kidney insufficiency and clinically insulated coronary heart failure, or acid insufficiency that should not be exceeded under section 4.2 recommended upper limit of the hemoglobin target centration."</seg>
<seg id="419">"following current findings by treatment of anaemia with epoetin alfa in adults with kidney failure, which are not yet dialyzed, the progression of kidney insufficiency is not accelerated."</seg>
<seg id="420">In tumour patients the treatment of therapy of epoetin alfa should be taken into account for the assessment of therapeutic efficiency of epoetin alfa a 2 - 3-week delay between epoetin-alfa-Gift and the Erythropoetin response (patients who need to be transfunct).</seg>
<seg id="421">If the HB increase is larger than 2 g / dl (1.25 mmol / l) exceeded per month or a HB value of 13 g / dl (see Section 4.2 treatment of patients with chemisation-related anemia - Dosiscustomization with the aim of holding the hemoglobinder between 10 g / dl and 12 g / dl).</seg>
<seg id="422">The decision for application recombinant Erythropoads should be based on a benefit risk involving the patient's participation that should also take into account the specific clinical context.</seg>
<seg id="423">"in patients, intended for greater electritive orthopaedic surgery, if possible, before the beginning of the epoetin-alfa therapy, the cause of anaemia investigates and treated accordingly."</seg>
<seg id="424">"patients who undergo a greater electrified orthopedic surgery, as they should have an increased risk of throharbinger and vascular disease, especially in an underlying cardiovascular disease."</seg>
<seg id="425">"in addition, it may not be excluded that in treatment with epoetin alfa worth patients with an initial type of epoetin worth of &gt; 13 g / dl an increased risk of postoperative thrombothernia / vascular events can exist."</seg>
<seg id="426">"in several controlled studies, it has not been proven to improve overall survival or reduce the risk of tumours."</seg>
<seg id="427">4 months in patients with metastatic breast cancer who received an chemotherapy regimen when a hemmoglobin target range from 12 - 14 g / dl (7,5 - 8.7 mmol / l) was executed.</seg>
<seg id="428">"becomes epoetin alfa along with Ciclosporin, should be adapted to the blood levels of Ciclosporin and the Ciclosporindosis should be adjusted to the rising haemokrit."</seg>
<seg id="429">From in-vitro-investigations there are no evidence of interaction between epoetin alfa and G-CSF or GM-CSF with regard to hematological differentiation or proliferation.</seg>
<seg id="430">"about thrombothernia, vascular thrombals, vascular tonal attacks, ruintoxicating events, asyocardinous, roinalthrombosis, asyocardinal-treatment, as well as patients under Erythropoetin, are reported as well as patients under epoetin alfa."</seg>
<seg id="431">The most common side effect during the treatment with epoetin alfa is a dosisdependent increase in blood pressure or the deterioration of an existing hypertonic.</seg>
<seg id="432">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="433">Regardless of the Erythropoetin treatment it may come in surgical patients with cardiovascular disease infection after repeated blood spill and vascular complications.</seg>
<seg id="434">The GMOs alfa epoetin alfa is glycoed and is identical to the amino acids and of carbohydrates in the endogenous human erythropoetin which was isolated from the urine of urine patients.</seg>
<seg id="435">It could be demonstrated with the help of cultures human bone martin cells that epoetin alfa specifically stimulates the erythropoesis and not influenced the leukopoesis.</seg>
<seg id="436">"389 patients with hemostosis (221 mammacarcinome, 64 gynecological tumors, 22 gynecological tumors, 22 prostate cancer ome, 21 gastrocinome, 21 gastrointestinal, 21 gastrocinome, and 30 more)."</seg>
<seg id="437">"1895 patients with solid tumors (683 Mammazinome, 260 bronchial tumors, 174 gynecological tumors, 300 gastrointestinal tumors, and 478 other) and 802 patients with hemostblasts."</seg>
<seg id="438">Survival and tumours were examined in five large controlled studies with a total of 2833 patients; four of these studies were doublinde placebocontrolled studies and</seg>
<seg id="439">In the open study there was no difference in overall survival between the patients treated with recombinant Erythropoetin treated patients and the patient.</seg>
<seg id="440">"in these studies, patients treated with recombinant Erythropoetin treated patients with anaemia due to various more common malignancies, statistically significantly higher mortality than with the controls."</seg>
<seg id="441">Overall survival in the studies could not be explained by differences in the incidence of Thrombosis and related complications in associated human erythropoetin treated patients and by controls.</seg>
<seg id="442">There is an increased risk of thromboemboldened events which will be treated with recombinant Erythropoetin and cannot be ruled out a negative effect on the overall survival.</seg>
<seg id="443">"it is not clear how far these results are treated to the application of recombinant human erythropoetin with the aim of being treated with chemotherapy, as a few patients with these characteristics, given to a few patients with these characteristics."</seg>
<seg id="444">Epoetin-alfa-provisions following repeated intravenous application showed half a-time period of about 4 hours in healthy promoters and a somewhat prolonged half-time of about 5 hours in patients with kidney failure.</seg>
<seg id="445">"after subcutleran injection, the serum levels of epoetin alfa are much lower than the serum levels, which can be reached after intravenous injection."</seg>
<seg id="446">"there are no sorrow: the Serum levels remain equal, regardless of whether they are determined 24 hours after the first gift or 24 hours after the final gift."</seg>
<seg id="447">(bone distinctive fibrosis is a well known complication of chronic kidney failure in humans and could be attributed to a secondary hyperparathyreoidism or unknown factors.</seg>
<seg id="448">In a study at hemalyalysis which were treated three years with epoetin alfa compared to the control group with dialysis that have not been treated with epoetin alfa.</seg>
<seg id="449">"14 In animal experimental studies with almost the 20times that led to the application in humans recommended Woendtin osis, epoetin alfa led to diminishing body weight, to a delay of the oscillation and a rise in the federal mortality rate."</seg>
<seg id="450">These reports are based on vitro Befunde with cells from human tumour samples that are for the clinical situation but of unsafe significanz.</seg>
<seg id="451">"within the framework of the outpatient application, the patient Abseamed can be unique for a maximum period of 3 days outside the cooling water and not over 25 ° C."</seg>
<seg id="452">"the spraying are equipped with Graduation rings and the filler volume is displayed by an active label, so if necessary, the measurement of subsets is possible."</seg>
<seg id="453">The treatment with Abseamed must be initiated under supervision of doctors who have experience in the treatment of patients with the above mentioned indications.</seg>
<seg id="454">"21 The recommended dosage is 600 i.e. / kg epoetin alfa, once a week about three weeks (day 21, 14 and 7) before the surgical procedure and the day of the surgery (day 0)."</seg>
<seg id="455">23 For patients with chronic kidney failure should not be exceeded under section 4.2 recommended upper limit of the hemoglobin target centration.</seg>
<seg id="456">The Hämoglobinan increased by about 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="457">"about thrombothernia, vascular thrombals, vascular taut, rovenous thrombosis, asyocardinous acts, retinalthrombosis, retinalthrombosis and 26 bloodstream in artificial kidneys, was reported in patients under Erythropoetin, as well as patients under epoetin alfa."</seg>
<seg id="458">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="459">"389 patients with hemostosis (221 mammacarcinome, 64 gynecological tumors, 22 gynecological tumors, 22 prostate cancer ome, 21 gastrocinome, 21 gastrointestinal, 21 gastrocinome, and 30 more)."</seg>
<seg id="460">"29 In animal experimental studies with almost the 20times that led to the application in humans recommended Woendtin osis, epoetin alfa led to diminished body weight, to a delay of the oscillation and a rise in the federal mortality rate."</seg>
<seg id="461">"within the framework of the outpatient application, the patient Abseamed can be unique for a maximum period of 3 days outside the cooling water and not over 25 ° C."</seg>
<seg id="462">"36 The recommended dosage is 600 i.e. / kg epoetin alfa, once a week about three weeks (day 21, 14 and 7) before the surgical procedure and the day of the surgery (day 0)."</seg>
<seg id="463">"38 For patients with chronic kidney failure, should not be exceeded under section 4.2 recommended upper limit of the hemoglobin target centration."</seg>
<seg id="464">The Hämoglobinan increased by about 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="465">"about thrombothernia, vascular thrombals, vascular taut, rovenous thrombosis, asyocardinous acts, retinalthrombosis and 41 bloodstream in artificial kidneys, was reported in patients under Erythropoetin, as well as patients under epoetin alfa."</seg>
<seg id="466">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="467">"389 patients with hemostosis (221 mammacarcinome, 64 gynecological tumors, 22 gynecological tumors, 22 prostate cancer ome, 21 gastrocinome, 21 gastrointestinal, 21 gastrocinome, and 30 more)."</seg>
<seg id="468">"44 In animal experimental studies with almost the 20s that led to the application in humans recommended Woendtin osis, epoetin alfa led to diminishing body weight, to a delay of the oscillation and a rise in the federal mortality rate."</seg>
<seg id="469">"within the framework of the outpatient application, the patient Abseamed can be unique for a maximum period of 3 days outside the cooling water and not over 25 ° C."</seg>
<seg id="470">"51 The recommended dosage is 600 i.e. / kg epoetin alfa, once a week about three weeks (day 21, 14 and 7) before the surgical procedure and the day of the surgery (day 0)."</seg>
<seg id="471">53 For patients with chronic kidney failure should not be exceeded under section 4.2 recommended upper limit of the hemoglobin target centration.</seg>
<seg id="472">The Hämoglobinan increased by about 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="473">"about thrombothernia, vascular thrombals, vascular taut, rovenous thrombosis, asyocardinous, roinalthrombosis, asyocardinal-treatment, as well as patients under Erythropoetin, are reported as well as patients under epoetin alfa."</seg>
<seg id="474">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="475">"389 patients with hemostosis (221 mammacarcinome, 64 gynecological tumors, 22 gynecological tumors, 22 prostate cancer ome, 21 gastrocinome, 21 gastrointestinal, 21 gastrocinome, and 30 more)."</seg>
<seg id="476">"59 In animal experimental studies with almost the 20s that led to the application in humans recommended Woendtin osis, epoetin alfa led to diminished body weight, to a delay of the oscillation and a rise in the federal mortality rate."</seg>
<seg id="477">"within the framework of the outpatient application, the patient Abseamed can be unique for a maximum period of 3 days outside the cooling water and not over 25 ° C."</seg>
<seg id="478">"66 The recommended dosage is 600 i.e. / kg epoetin alfa, once a week about three weeks (day 21, 14 and 7) before the surgical procedure and the day of the surgery (day 0)."</seg>
<seg id="479">"68 When patients with chronic kidney failure should not be exceeded under the treatment of 4.2 recommended upper limit of the hemoglobin target centration.</seg>
<seg id="480">The Hämoglobinan increased by about 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="481">"about thrombothernia, vascular thrombosis, vascular taut, oyokardinous attacks, ruinalthrombosis, atinalthrombosis, atinalthrombosis, asyocardinal treatment, as well as patients under epoetin alfa, reported."</seg>
<seg id="482">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="483">"389 patients with hemostosis (221 mammacarcinome, 64 gynecological tumors, 22 gynecological tumors, 22 prostate cancer ome, 21 gastrocinome, 21 gastrointestinal, 21 gastrocinome, and 30 more)."</seg>
<seg id="484">"74 In animal experimental studies with nearly the 20s that led to the application in humans recommended Woendtin osis, epoetin alfa led to diminishing body weight, to a delay of the oscillation and a rise in the federal mortality rate."</seg>
<seg id="485">"within the framework of the outpatient application, the patient Abseamed can be unique for a maximum period of 3 days outside the cooling water and not over 25 ° C."</seg>
<seg id="486">"81 The recommended dosage is 600 i.e. / kg epoetin alfa, once a week about three weeks (day 21, 14 and 7) before the surgical procedure and the day of the surgery (day 0)."</seg>
<seg id="487">83 For patients with chronic kidney failure should not be exceeded under section 4.2 recommended upper limit of the hemoglobin target centration.</seg>
<seg id="488">The Hämoglobinan increased by about 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="489">"about thrombothernia, vascular thrombals, vascular tonal attacks, intoxicology and 86 bloodstream in artificial kidneys was reported in patients under Erythropoetin, as well as patients under epoetin alfa."</seg>
<seg id="490">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="491">"389 patients with hemostosis (221 mammacarcinome, 64 gynecological tumors, 22 gynecological tumors, 22 prostate cancer ome, 21 gastrocinome, 21 gastrointestinal, 21 gastrocinome, and 30 more)."</seg>
<seg id="492">89 In animal experimental studies with almost the 20times that led to the application of humans recommended Wochtin osis led epoetin alfa to dimindered body weight, to a delay of the oscillation and a rise in the federal mortality rate.</seg>
<seg id="493">"within the framework of the outpatient application, the patient Abseamed can be unique for a maximum period of 3 days outside the cooling water and not over 25 ° C."</seg>
<seg id="494">"96 The recommended dosage is 600 i.e. / kg epoetin alfa, once a week about three weeks (day 21, 14 and 7) before the surgical procedure and the day of the surgery (day 0)."</seg>
<seg id="495">"98 For patients with chronic kidney failure, should not be exceeded under section 4.2 recommended upper limit of the hemoglobin target centration."</seg>
<seg id="496">The Hämoglobinan increased by about 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="497">"about thrombothernia, vascular thrombals, vascular tonal attacks, intoxicology and 101 bloodstream in artificial kidneys was reported in patients under Erythropoetin, as well as patients under epoetin alfa."</seg>
<seg id="498">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="499">"389 patients with hemostosis (221 mammacarcinome, 64 gynecological tumors, 22 gynecological tumors, 22 prostate cancer ome, 21 gastrocinome, 21 gastrointestinal, 21 gastrocinome, and 30 more)."</seg>
<seg id="500">104 In animal experimental studies with nearly the 20times that led to the application of humans recommended Wochtin osis led epoetin alfa to diminished body weight, to a delay of the oscillation and a rise in the federal mortality rate.</seg>
<seg id="501">"within the framework of the outpatient application, the patient Abseamed can be unique for a maximum period of 3 days outside the cooling water and not over 25 ° C."</seg>
<seg id="502">"111 The recommended dosage is 600 i.e. / kg epoetin alfa, once a week about three weeks (day 21, 14 and 7) before the surgical procedure and the day of the surgery (day 0)."</seg>
<seg id="503">"113 with patients with chronic kidney failure, should not be exceeded under section 4.2 recommended upper limit of the hemoglobin target centration."</seg>
<seg id="504">The Hämoglobinan increased by about 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="505">"about thrombothernia, vascular thrombals, vascular tonal attacks, rovenous thrombosis, asyocardinous acts, retinalthrombosis, asyocardinal-treatment, as well as patients under epoetin alfa, reported."</seg>
<seg id="506">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="507">"389 patients with hemostosis (221 mammacarcinome, 64 gynecological tumors, 22 gynecological tumors, 22 prostate cancer ome, 21 gastrocinome, 21 gastrointestinal, 21 gastrocinome, and 30 more)."</seg>
<seg id="508">119 In animal experimental studies with almost the 20times that led to the application of humans recommended Wochtin-dose led epoetin alfa to diminished body weight, to a delay of the oscillation and a rise in the federal mortality rate.</seg>
<seg id="509">"within the framework of the outpatient application, the patient Abseamed can be unique for a maximum period of 3 days outside the cooling water and not over 25 ° C."</seg>
<seg id="510">"126 The recommended dosage is 600 i.e. / kg epoetin alfa, once a week about three weeks (day 21, 14 and 7) before the surgical procedure and the day of the surgery (day 0)."</seg>
<seg id="511">128 With patients with chronic kidney failure should not be exceeded under section 4.2 recommended upper limit of the hemoglobin target centration.</seg>
<seg id="512">The Hämoglobinan increased by about 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="513">"about thrombothernia, vascular thrombals, vascular tonal attacks, ruintoxicating events, asyocardinous, roinalthrombosis, asyocardinal-treatment, as well as patients under epoetin alfa, reported."</seg>
<seg id="514">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="515">"389 patients with hemostosis (221 mammacarcinome, 64 gynecological tumors, 22 gynecological tumors, 22 prostate cancer ome, 21 gastrocinome, 21 gastrointestinal, 21 gastrocinome, and 30 more)."</seg>
<seg id="516">134 In animal experimental studies with nearly the 20times that led to the application of humans recommended Wochtin osis led epoetin alfa to dimindered body weight, to a delay of the oscillation and a rise in the federal mortality rate.</seg>
<seg id="517">"within the framework of the outpatient application, the patient Abseamed can be unique for a maximum period of 3 days outside the cooling water and not over 25 ° C."</seg>
<seg id="518">"141 The recommended dosage is 600 i.e. / kg epoetin alfa, once a week about three weeks (day 21, 14 and 7) before the surgical procedure and the day of the surgery (day 0)."</seg>
<seg id="519">"143 For patients with chronic kidney failure should not be exceeded under the treatment of 4.2 recommended upper limit of the hemoglobin target centration.</seg>
<seg id="520">The Hämoglobinan increased by about 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="521">"about thrombothernia, vascular thrombals, vascular tonal attacks, ruintoxicating events, asyocardinous acts, retinalthrombosis, asyocardinal-treatment, as well as patients under epoetin alfa, reported."</seg>
<seg id="522">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment with erythropoetines.</seg>
<seg id="523">"389 patients with hemostosis (221 mammacarcinome, 64 gynecological tumors, 22 gynecological tumors, 22 prostate cancer ome, 21 gastrocinome, 21 gastrointestinal, 21 gastrocinome, and 30 more)."</seg>
<seg id="524">149 in animal experimental studies with nearly the 20times that led to the application of humans recommended Wochtin osis led epoetin alfa to dimindered body weight, to a delay of the oscillation and a rise in the federal mortality rate.</seg>
<seg id="525">"within the framework of the outpatient application, the patient Abseamed can be unique for a maximum period of 3 days outside the cooling water and not over 25 ° C."</seg>
<seg id="526">"the holder of the approval of the approval of the authorisation has been approved prior to the market launch and in accordance with the competent authorities of the member states, the medical specialists in Dialysis centers and retail outlets with the following information and materials: • With unique imaging representation of the correct use of the product, refrigerators for transport through the patient."</seg>
<seg id="527">The holder of the approval of the authorisation has to ensure that the operating system has been described in version 3.0 and in module 1.8.1 of the application used in version 3.0 and is functional before the drug is brought into the traffic and as long as the medicine is applied in the traffic.</seg>
<seg id="528">"the holder of the approval of the approval required to carry out in version 5 of the Risk Management Plan (RMP), as described in version 5 of the authorisation of the Risk Management Plan (RMP), as well as any subsequent following by the CHMP update the Risk Management Plan."</seg>
<seg id="529">"a updated RMP should be provided in accordance with the" CHMP Guideline on Risk Management Systems for Medicinal products for human use "at the same time, with the next updated report on the immemorial of the drug (Periodic Safety Update Report, PSUR)."</seg>
<seg id="530">"in addition, an updated RMP should be submitted: • upon receipt of new information, the impact on the current security specifications (Safety Specification), which may have an impact on the current security specifications (Safety Specification), which may affect the current security specifications (Safety Specification), which may affect the current security specifications (Safety Specification), which may affect the current security specifications (Safety Specification), which could be an important issue within 60 days after reaching an important (drug support or risk reduction concerned)" "milestones" "by calling for the EMEA region"</seg>
<seg id="531">"• suffered a heart attack or stroke for the first time before your treatment, • if you suffer from unstable Angina Pectoris (first ascending or increased breast cancer) • If you have occurred in the veins (deep Venoarthritis), for example, if you have already occurred such a blood rophoist in the veins."</seg>
<seg id="532">"you have recently suffered a heart disease (coronary heart disease), the arteries of the legs or arms (periphere arterial disease), the cervical disease (vascular disease of carotides) or the brain (discirovascular disease), you have recently suffered a heart attack or stroke."</seg>
<seg id="533">"during the treatment with Abseamed it may come back within the normal range to a slight dose-dependent increase in blood vessels, which returns to further treatment once more."</seg>
<seg id="534">Your doctor will carry out regular blood tests to control the number of blood vessels during the first 8 weeks of treatment.</seg>
<seg id="535">"iron deficiency, resolution of the red blood cells (hemyysis), blood loss, vitamin B12- or folly lack, should be taken into account and before starting the therapy with Abseamed."</seg>
<seg id="536">Very rare was reported on the occurrence of an antibody-mediated erythroblastopeny after monate- to years of treatment with subcutaneous (under the skin foritz) Erythropoetin.</seg>
<seg id="537">"if you suffer from Erythroblastopenie, he will break your therapy with Abseamed and define how your anaemia is treated best."</seg>
<seg id="538">"therefore, Abseamed must be given by injection into a vene (intravenous) if you are treated because of an anemia due to a kidney disease."</seg>
<seg id="539">A high bunting binder value the risk for problems with the heart or blood vessels and the death-berisiko could be increased.</seg>
<seg id="540">"for increased or increasing the potassium, your doctor can take into consideration the interruption of the treatment with Abseamed until the calibration lies again in the standard area."</seg>
<seg id="541">"if you suffer under chronic kidney disease and clinically obvious coronary heart rate, your doctor will ensure that your hemorglobinmirror will not exceed a particular value."</seg>
<seg id="542">"after the present time, findings are not accelerated by the treatment of blood poverty in adults with chronic kidney disease (kidney insufficiency) that are not yet dialyzed, the progression of kidney insufficiency is not accelerated."</seg>
<seg id="543">A 2-week delay between epoetin-alfa-Gift and the desired effect should be taken into account for assessing the effectiveness of Abseamed.</seg>
<seg id="544">200 your doctor will regularly adapt your values of the red blood fares (hemmoglobin) and adapt your debuamed dose to keep the risk of blood pressure (thrombotanical event) to keep as low as possible.</seg>
<seg id="545">"this risk should be very carefully weighed against the benefits arising from treatment with epoetin alfa. in particular, if you have an increased risk of thrombotherous vascular events, e.g. if you are already thromous vascular events (e.g. a deep Venoarthritis or pneumembolie)."</seg>
<seg id="546">"in case you are a cancer patient, consider that Abseamed work like a growth factor for blood powers and under certain circumstances can affect the tumor negative."</seg>
<seg id="547">"if you have a greater orthopaedic surgery, prior to treatment begins with Abseamed, the cause of your anaemia investigates and treated accordingly."</seg>
<seg id="548">"if your values of the red blood flow (hemoglobin) are too high, you should not get Abseamed, since an increased risk of blood pressure after the surgery exists."</seg>
<seg id="549">"please inform your doctor or pharmacist if you are taking other medicines / apply / apply recently, even if they are not prescription drugs."</seg>
<seg id="550">"if you are taking cyclosporin (funds for the suppression of the immune system) while your therapy with Abseamed, your doctor will possibly arrange certain blood tests to measure the blood levels of Ciclosporin."</seg>
<seg id="551">Laboratory studies have shown no interaction between epoetin alfa and G-CSF or GM-CSF (G-CSF or GM-CSF (G-CSF) or GM-CSF (G-CSF) or GM-CSF (G-CSF) or GM-CSF.</seg>
<seg id="552">"depending on how your blood-poverty (anaemia) refers to treatment, the dose can be adjusted approximately every four weeks before your condition is under control."</seg>
<seg id="553">Your doctor will arrange regular blutttests to verify and ensure the treatment's success and ensure that the drug does not affect a particular value.</seg>
<seg id="554">"once you are set out, you will receive regular doses of Abseamed between 25 and 50 / kg twice a week, spread over two equally major injections."</seg>
<seg id="555">Your doctor will arrange regular blutttests to check the success of the success and ensure that your haunt binder worth not exceeds a particular value.</seg>
<seg id="556">"depending on how the anaemia speaks to treatment, the dose can be adapted for every four weeks, until the condition is under control."</seg>
<seg id="557">"to make this secure and ensure that the Hämoglobinder worth a particular value, the treatable doctor will perform regular bleeding."</seg>
<seg id="558">"if it is necessary to shorten the treatment time before surgery, a dose of 300 i.e. / kg may be given to 10 consecutive days before surgery, on the day of the surgery, and another 4 days after the surgery."</seg>
<seg id="559">"however, you can if your doctor keeps this appropriate for appropriate, also learn how to injure yourself under the skin."</seg>
<seg id="560">"heart, heart-coloured, brain-coloured, arterial thrombosis, arterial thromboses, arterial thrombosis of the retina and bloodstream in artificial kidneys, reported in patients under Erythropoetin treatment."</seg>
<seg id="561">"eyelids and lips (Quincke oils) and shocking allergic reactions with symptoms such as tingling, redness, itching, heat-feeling and accelerated pulse were reported in rare cases."</seg>
<seg id="562">Erythroblastopenie means that there can no longer be formed enough red blood cells in bone marrow (see section "special in the application of Abseamed is needed.)</seg>
<seg id="563">After repeated blood donors can come - regardless of the treatment with Abseamed (thrombotherous vascular events).</seg>
<seg id="564">The treatment with Abseamed may go with an increased risk for blood formation after the surgery (postoperative vascular events) if your starting point-bike binars worth too high</seg>
<seg id="565">Please inform your doctor or pharmacist if one of the listed side effects you have considerably affected or if you notice side effects which are not stated in this usage information.</seg>
<seg id="566">"if a syringe has been taken from the fridge and room temperature has reached (up to 25 ° C), it has to be used either within 3 days or but be rejected."</seg>
<seg id="567">Aclasta is applied to treating the following diseases: • osteoporosis (a disease which makes the bone brittle) both in women after the menopause and in men.</seg>
<seg id="568">"it is applied in patients with a high fractory risk (bone marches), including in patients who have suffered a low trauma of the knob; • Morbus Paget the touch of a disease, which changed the normal course of bone growth."</seg>
<seg id="569">"in addition, patients with Morbus Paget at least 500 mg of calcium twice daily for at least 10 days after treatment; patients with hip fracture should be given a large dose of vitamin D (50 000 to 125 000 IE) oral or injecting into a muscle."</seg>
<seg id="570">"the administration of Paracetamol or Ibuprofen (means against inflammation) shortly after the application of Aclasta can reduce the symptoms in the three days after infusion of infusion, like fever, muscle pain, flu-like symptoms, joint pain and headaches."</seg>
<seg id="571">"to treat the Morbus Paget, Aclasta must be prescribed by physicians who have experience in treating this disease."</seg>
<seg id="572">"since the active ingredient in Aclasta is like in Zometa, a part of the data material for Zometa was taken up by Aclasta."</seg>
<seg id="573">"in the first study, almost 8 000 persons were involved in osteoporosis, and the number of vertsaw and hip fractures was investigated over a period of three years."</seg>
<seg id="574">"the second study formed 2 127 men and women with osteoporosis over 50 years, who had suffered a hip fracture; it was investigated the number of fractures over a period of up to five years."</seg>
<seg id="575">At Morbus Paget Aclasta was tested in two studies in a total of 357 patients and compared six months with Risedronat (another bisphosphonate).</seg>
<seg id="576">Main indicator for the effectiveness was whether the salary of the alkaline phosphatase (an enzyme building) in the blood is normalized or at least 75% compared to the starting point.</seg>
<seg id="577">"in the study with older women, the risk of spine women was reduced by patients under Aclasta (without any other osteoporoseente) over a period of three years compared to the patients under placebo by 70%."</seg>
<seg id="578">In comparison of all patients under Aclasta (with or without any other osteoporotic medication) with those under placebo the risk of hip fractures was reduced by 41%.</seg>
<seg id="579">In the study with men and women from Aclasta had 9% of patients under Aclasta (92 from 1 065) compared to 13% of patients under placebo (139 of 1 062).</seg>
<seg id="580">Most side-effects of Aclasta occur within the first three days after infusion and are less common in repetitive infusions.</seg>
<seg id="581">Aclasta must not be applied in patients who may be oversensitive (allergic) against Zoledronic acid or other bisphosphate or one of the other components.</seg>
<seg id="582">"as with all Bisphosphates, patients at Aclasta are subject to patients at Aclasta to the risk of kidney, reactions to infusion and osteonekrose (Abdie of bone tissues) in the jaws."</seg>
<seg id="583">"the manufacturer of Aclasta provides guidance material for doctors who use Aclasta to treat Aclasta to treat osteoporosis, as well as similar material for patients, in which the side effects of the medicine should be explained and indicated when they should contact the doctor."</seg>
<seg id="584">April 2005 shared the European Commission of Novartis Europharm Limited for the marketing of Aclasta throughout the European Union.</seg>
<seg id="585">"conditions ODER restrictions regarding THE ICHEREN AND effective application of DES medicine by THE DICHEREN AND EMPING application of THE drugs, THE DURCH DIE member states ZU implement S & D SIND"</seg>
<seg id="586">"treatment of osteoporosis in postmenopausal women and in men with increased risk to fractures, including in patients with a recently low-traumatic envelope."</seg>
<seg id="587">"the patient information package should be provided and the following core members include contraindications in the pregnancy and in the nursing women • Required of an appropriate access of calcium and vitamin D, appropriate physical activity, of non-smoking and symptoms for serious side effects • Wann to medical or low-care help is returned."</seg>
<seg id="588">"treatment of osteoporosis • in postmenopausal women • with a increased risk for freight rates, including in patients with a recently low-traumatic envelope."</seg>
<seg id="589">"to treat postmenopausal osteoporosis and osteoporosis in men, intravenous infusion of 5 mg Aclasta is recommended once a year."</seg>
<seg id="590">In patients with a low-traumatic hip fracture the administration of infusion of Aclasta will be recommended for two or more weeks after the operating supply of the hip fracture (see section 5.1).</seg>
<seg id="591">For the treatment of the Morbus Paget Aclasta should be prescribed by physicians who have experience in the treatment of the Morbus Paget.</seg>
<seg id="592">After a treatment of the Morbus Paget with Aclasta a long Remission period was observed in patients (see section 5.1).</seg>
<seg id="593">"in addition, it is very advisable to ensure patients with Morbus Paget an adequate intake of calcium, accordingly twice daily 500 mg elementary calcium, for at least 10 days after the gift of Aclasta (see Section 4.4)."</seg>
<seg id="594">"in patients with a recently low-traumatic envelope of hip, the initialdosis of 50,000 to 125,000, i.e. oratory or intramuscular vitamin D is recommended before the first Aclasta infusion."</seg>
<seg id="595">"the frequency of symptoms which occur within the first three days after the administration of Aclasta, can be reduced by using Paracetamol or Ibuprofen shortly after the application of Aclasta."</seg>
<seg id="596">Patients with kidney disease (see Section 4.4) In patient with a creatinine Clearance &lt; 35 ml / min Aclasta is not recommended because limited clinical experience is available for these patients.</seg>
<seg id="597">"older patients (≥ 65 years) A dosage adjustment is not necessary, as the bioavailability, distribution and elimination of older patients is similar to younger patients."</seg>
<seg id="598">"children and young people Aclasta is not recommended for use in children and young people under 18 years, because data are missing for inconceivable and effectiveness."</seg>
<seg id="599">Aclasta is not recommended in patients with severe kidney failure (Kreatinine-Clearance &lt; 35 ml / min) because for these patients population only limited clinical experience.</seg>
<seg id="600">A pre-existing hypokalzemia is before the start of therapy with Aclasta through adequate intake of calcium and vitamin D (see section 4.3).</seg>
<seg id="601">"due to the rapid setting of the effects of Zoledronic acid on the bone structure, a temporary, with symptomatic hypokalzemia can develop, whose maximum usually occurs within the first 10 days after infusion of Aclasta (see Section 4.8)."</seg>
<seg id="602">"in addition, it is very advisable to ensure patients with Morbus Paget an adequate intake of calcium, accordingly twice daily 500 mg elementary calcium, for at least 10 days after the gift of Aclasta (see Section 4.2)."</seg>
<seg id="603">"cancer disease, chemotherapy, treatment with corticosteroids, poor oral hygiene) should be performed prior to an application of Bisphosphonate a dental treatment with appropriate preventive dental treatment."</seg>
<seg id="604">"for patients who require dental attacks, there are no data available to whether the interruption of the treatment with bisphosphonate reduces the risk of osteonekrosen in oral area."</seg>
<seg id="605">Clinical assessment by the treating doctor should be basis for the treatment plan of each patient and are based on an individual benefit assessment.</seg>
<seg id="606">"the frequency of symptoms which occur within the first three days after administration of Aclasta, can be reduced by using Paracetamol or Ibuprofen shortly after the application of Aclasta (see Section 4.2)."</seg>
<seg id="607">"the incidence of patients reported as serious by-effect cases was increased in patients, the Aclasta was increased (1.3%) (51%) (0.6%) (0.6%) (22 of 3,852)."</seg>
<seg id="608">"in osteoporosis Studies (PFT, HORIZON - Recurrent Fracture Trial [RFT]) was the overall prevalence of bikers between Aclasta (2,6%) and placebo (2.2%)."</seg>
<seg id="609">"very common (≥ 1 / 10), frequent (≥ 1 / 100, &lt; 1 / 100), rare (≥ 1 / 10,000, &lt; 1 / 1,000) unwanted drug impacts are listed in table 1."</seg>
<seg id="610">Kidney functional disorder Zoledronacid was associated with kidney functional disorders that are considered to increase the kidney function (i.e. an increase in the serum creatinins) and in rare cases as acute kidney failure.</seg>
<seg id="611">The change in the creatinine Clearance (annually before administration) and the incidence of kidney failure as well as a restricted kidney function were comparable to in a clinical study in osteoporosis between the Aclasta- and the placebo group.</seg>
<seg id="612">A temporary increase in Serum creatinins within 10 days of gift was observed at 1.8% of patients with Aclasta treated patients compared to 0.8% of patients treated with placebo.</seg>
<seg id="613">"based on the evaluation of the laboratory studies, the temporary asymptomatic calcium range (less than 2.10 mmol / l), at 2.3% of patients with Aclasta, treated in a large clinical study, treated at 21% of patients with Aclasta in the Morbus Paget-studies treated patients."</seg>
<seg id="614">All patients additionally received sufficient amounts of vitamin D and calcium in the study to postmenopausal osteoporosis in the study to prevent clinical questionnaires after a hip fracture and in the Morbus Paget studies (see Section 4.2).</seg>
<seg id="615">"in the study, for the prevention of clinical fractures, the vitamin D-mirror were not routinely measured, but the majority of patients received a initialdosis vitamin D before the administration of Aclasta (see Section 4.2)."</seg>
<seg id="616">"local reactions after the administration of Zoledronacid in a large clinical trial was reported on local reactions to the infusion place, such as redness, swelling and / or pain, reports (0.7%)."</seg>
<seg id="617">"osteonekrosen in the jaw area occasionally was, above all in cancer patients, above osteonekrosen (primarily in the orthography) reported that with bisphosphonate, including Zoledronics, were treated."</seg>
<seg id="618">Many of these patients had signs of local infections including osteomyelitis and the majority of reports refers to cancer patients following the contractions or other dental interventions.</seg>
<seg id="619">7 study with 7.736 patients joined the jaw area in one with Aclasta and with placebo treated patients.</seg>
<seg id="620">"in case of overdose, which leads to a clinically relevant hypokalzemia, can be achieved through the gift of oral calcium and / or an intravenous infusion of calcium-gluconat."</seg>
<seg id="621">Clinical efficacy at the age of postmenopausal osteoporosis (PFT) 's effectiveness and safety of Aclasta 5 mg once a year for the gift of postmenopausal women (BMD) -t-score for the Schenkelhals &lt; -2,5 and at least two light or a medium-sized existing spinal cord or a BMD-T-score for the Schengen unit.</seg>
<seg id="622">Effects on morphometric vertebrates Aclasta significant over a period of three years as well as already after a year the frequency of one or more new vertebrates (see table 2).</seg>
<seg id="623">Aclasta-treated patients of 75 years and older had reduced a 60% risk for the spine-fat compared to placebo patients (p &lt; 0.0001).</seg>
<seg id="624">"effects on hip fractures Aclasta pointed out a equal effect over three years, which resulted in a by 41% (95% CI, 17% to 58%) reduced risk for hip fractures."</seg>
<seg id="625">"effect on the bone density (BMD) Aclasta raised the bone density on the steering rack, hip and on distal radius compared to placebo treatment significant at all time points (6, 12, 24 and 36 months)."</seg>
<seg id="626">"9 increase of bone density of the steering wires by 6.7%, the whole hips around 6.0%, the whole bouncing around 6.0%, of the gift of 5,1%, and the distal radius by 3.2%."</seg>
<seg id="627">Bone histology with 152 postmenopausal osteoporotic patients treated with Aclasta (N = 82) or placebo (N = 70) were taken a year after the third annual dose of bone marbiopsies from the pelvic floor.</seg>
<seg id="628">A microcomputer-tomographics (µCT) analysis showed with Aclasta treated patients in comparison to placebo an increase in the tradenular bone volume and the preservation of the trainecular bone architecture.</seg>
<seg id="629">Bone-based phosphosphere Phosphere (B1NP) in Serum and the beta-C-Telopeptid (b-CTX) in Serum were determined in sub-groups of 517 to 1.246 patients in periodic intervals during the period of study.</seg>
<seg id="630">The treatment with an annual 5-mg dose Aclasta reduced the treatment with an annual 5-mg Aclasta reduced by 30% compared to the starting point and was held at 28% below the output value up to 36 months.</seg>
<seg id="631">P1NP was significantly reduced by 61% below the starting point after 12 months and was held at 52% below the initial price up to 36 months.</seg>
<seg id="632">B-CTX was significantly reduced by 61% below the initial low value after 12 months and was held at 55% below the starting point up to 36 months.</seg>
<seg id="633">"the vitamin D-mirror were not measured by routinely, but the majority of patients received an initial dose of vitamin D (50,000 to 125,000, i.e. oral or intramuscular) 2 weeks before infusion."</seg>
<seg id="634">Total liberality was 10% (101 patients) in the group treated with Aclasta group compared to 13% (141 patients) in the placebo group.</seg>
<seg id="635">Effect on bone mineral density (BMD) In the HORIZON-RFT study the Aclasta treatment increased in comparison to placebo treatment the BMD at the total thigy and thkelhals at all time points.</seg>
<seg id="636">Aclasta treatment led over 24 months compared to placebo treatment a 5.4% increase in total threaded and around 4.3% on Schengen.</seg>
<seg id="637">Clinical efficacy in men In the HORIZON-RFT-trial were randomised 508 men and in 185 patients the BMD was judged by 24 months.</seg>
<seg id="638">The study was not designed to show a reduction in clinical fractures in men; the incidence of clinical fractures was 7.5% at Aclasta-treated males in comparison to 8.7% in placebo.</seg>
<seg id="639">In another study by men (study CZOL446M2308) the once annual administration of Aclasta was compared to the once weekly gift of Alendronat compared to the percentage of aging of Alendronate in comparison to the percentage of aging of Alendronate in comparison to the percentage of payments.</seg>
<seg id="640">Clinical efficacy of the Knobus Paget of the Knock Aclasta was studied in patients aged over 30 years ago (mean Serum mirror of the alkaline phosphatase according to the 2,6times up to 3,0times-specific upper standard when recording into the study).</seg>
<seg id="641">11 The effectiveness of infusion of 5 mg Zoledronic acid compared to the intake of 30 mg of risedronage once daily during 2 months was demonstrated in two six months of comparative studies.</seg>
<seg id="642">"after 6 months, the results were observed after 6 months a similar withdrawal of pain and pain killers compared to the starting value for Aclasta and Risedronat."</seg>
<seg id="643">Patients adopted at the end of the six month's main study as a Responsible study (submitted to the therapy) could be included in a retroobservable phase.</seg>
<seg id="644">"from the 143 with Aclasta and the 107 with risedronat, in comparison with Aclasta, compared to 71 of patients treated with risedronat, compared to 71 of the observation period, from 18 months after the application."</seg>
<seg id="645">"unique and multi-fold 5 and 15 minutes lasting infusions of 2, 4, 8 and 16 mg Zoledronic acid in 64 patients, the following pharmacocular data that proved to be dosages."</seg>
<seg id="646">"after that, the Plasmesh can quickly starting from &lt; 10% of the maximum-value after 4 h and &lt; 1% after 24 h, followed by a long-lasting phase, very low concentration, no more than 0,1% of the top value."</seg>
<seg id="647">"rapid biphasic disappearance from the large cycle with half-times, ½ α 0.24 and t ½ 1.87 hours, followed by a long elimination phase with an terminal elimination period with an terminal elimination period of ½ g 146 hours."</seg>
<seg id="648">"the early stages-spheres (α, and β, with the above-mentioned ½ values) probably represent the fast resorption in the bones, and the excretion of the kidneys."</seg>
<seg id="649">"in the first 24 h 39 ± 16% of the administered dose is tied in the urine, while the rest is tied mainly to bone tissues."</seg>
<seg id="650">"the overall body clearing is independent of the dose 5.04 ± 2.5 l / h and remains uninfluenced by gender, age, race or body weight."</seg>
<seg id="651">"an extension of the infusion period of 5 to 15 minutes led to the withdrawal of customs of customs - concentration by 30% at the end of the infusion, but had no effect on the area under the curve (Plasmakonzentration against time)."</seg>
<seg id="652">A diminished clearing of by cytochrom P450-Enzymology of metabolic substances is unlikely because Zoledronic acid is not metabolized and because it is a watchful or not a direct and / or irreversibly, hydrogen-dependent inhibitor of the P450-</seg>
<seg id="653">"special patient groups (see Section 4.2) The renal Clearance of Zoledronic acid correlated with the creatinine Clearance, namely 75 ± 33% of the Creatinine Clearance, and was in the average 84 ± 29 ml / min (area 22 to 143 ml / min)."</seg>
<seg id="654">This results in an easy (Clcr = 50- 80 ml / min) and moderate kidney staining up to 35 ml / min no dosage adjustment to the Zoledronic acid.</seg>
<seg id="655">There for heavy kidney disease (Kreatinin Clearance &lt; 30 ml / min) only restricted data are available for this population no statements.</seg>
<seg id="656">Acute toxicity The highest non-changing intravenous single dose was at mice 10 mg / kg body weight and in rats 0,6 mg / kg body weight.</seg>
<seg id="657">"in studies on dogs single doses of 1,0 mg / kg (based on Auc the 6fold of recommended human therapeutic exposure), is administered over a period of 15 minutes, good and without a renal infection."</seg>
<seg id="658">"for example, subchronic and chronic toxicity in studies with intravenous infusion was administered in intervals of 2-minute infusion with intravenous infusion in intervals of 2-minute infusion in intervals of 2- 3 weeks (a cumulative dose, which corresponds to the 70s of the human therapeutic exposure, related to the Auc, corresponds), well tolerated."</seg>
<seg id="659">"in long-term studies with cumulated expression, which exceeded the maximum of Human-exposure sufficiently, the toxial effects of other organs, including the gastrointestinal inaltrakt, and the liver, as well as at the intravenous injection point."</seg>
<seg id="660">"the most common interest in studies with repeated application was a multiply primary spontaneity in the metaphor of the long bones in animals in the growth phase with almost all dosages, a refund which reflects the pharmacological, antiresorptive effect of the substance."</seg>
<seg id="661">"to rats, one observed a teratogenity in doses from 0.2 mg / kg as outer and inner (visceral) abnormalities and such skeleton."</seg>
<seg id="662">"in rabbits no teratogenic effects or embryo-fetal effects have been observed, although the maternal toxicity can be seen at 0.1 mg / kg due to lower serum-calcium mirror."</seg>
<seg id="663">"in case the drug is not used directly, the user is responsible for the storage time and conditions of the application; usually, 24 h at 2 ° C is not exceeded at 2 ° C to 8 ° C."</seg>
<seg id="664">Aclasta is included as a package with a bottle of a bottle unit or as a bite packer consisting of 5 packages which each contain a bottle.</seg>
<seg id="665">"treatment of osteoporosis in postmenopausal women and in men with increased risk to fractures, including in patients with a recently low-traumatic envelope."</seg>
<seg id="666">"the patient information package should be provided and the following core members include contraindications in the pregnancy and in the nursing women • Required of an appropriate access of calcium and vitamin D, appropriate physical activity, of non-smoking and a healthy diet 17 • Important signs and symptoms for serious side effects • Wann to medical or low-care help is returned."</seg>
<seg id="667">"July 2007, which is completed on 29 September 2006, is completed on 29 September 2006, in the 1.8.1 of the application described pharmaceutical drug system in force and works before and while the product is marketed."</seg>
<seg id="668">Risko management plan The owner of approval for the ingestion is obliged to carry out the studies and the additional activities to the pharmacoiled version (RMP) in module 1.8.2 of the authorisation application and all the following by the CHMP approved versions of the RMP.</seg>
<seg id="669">"according to the CHMP directive on risk management systems for human medicines, the RMP should be submitted together with the next" "Periodic Safety Update Report" "(PSUR)."</seg>
<seg id="670">"a revised RMP should be filed • If new information may be known, which could affect the current statements of security, the pharmaceutical company plan or activity to minimize the risk of minimization. • inside 60 days when an important milestone (to pharmacoyancy or risk minimisation) has been reached. • In request of the EMEA."</seg>
<seg id="671">"Zoledronic acid is a representative of a substanzclass, which is called bisphosphate, and is used to treat osteoporosis in postmenopausal women, osteoporosis in men and the Morbus Paget of the touch."</seg>
<seg id="672">"decreasing blood levels of sex hormones, especially oestrogen, which are formed from androgens, play a role in the rather gradual loss of bone mass, which is observed in men."</seg>
<seg id="673">"at the Morbus Paget takes place the bone structure too fast, and new bone material is unarranged, which makes the bone material weaker than normal."</seg>
<seg id="674">Aclasta works by normalized the bone structure once more normalized with a normal bone formation and gives rise to the bones again strength.</seg>
<seg id="675">"if you are having dental treatment or have a dental surgery, please inform your doctor that you will be treated with Aclasta."</seg>
<seg id="676">"when applying Aclasta with other medicines Please inform your doctor, pharmacist or nursing staff if you are taking other medicines / apply or have recently been taken / used even if it is not prescription drugs."</seg>
<seg id="677">"for your doctor, it is particularly important to know whether you are taking medicines from which they are known to the kidneys."</seg>
<seg id="678">When using Aclasta together with food and drink you worry that according to your doctor's instructions sufficient liquid before and after the treatment with Aclasta.</seg>
<seg id="679">"osteoporosis The usual dose is 5 mg once per year, which is administered by your doctor or nursing staff as infusion into a vene."</seg>
<seg id="680">"if you have recently broken the hip, the administration of Aclasta will have two or more weeks after the operating supply of the sleeve."</seg>
<seg id="681">Morbus Paget The usual dose is 5 mg that will be administered by your doctor or nursing staff as infusion into a vene.</seg>
<seg id="682">"since Aclasta works for a long time, you will eventually need another dose for a year or longer."</seg>
<seg id="683">It's important to follow these instructions exactly to follow the calcium mirror in your blood in time after infusion is not too low.</seg>
<seg id="684">"at Morbus Paget, Aclasta can work for longer than a year, and your doctor will inform you if you need a renewed treatment."</seg>
<seg id="685">If the administration of Aclasta was fit immediately with your doctor or hospital in order to arrange a new date.</seg>
<seg id="686">Before ending the treatment with Aclasta Falls you are considering the end of treatment with Aclasta. please take your next doctor of doctor true and discuss this with your doctor.</seg>
<seg id="687">Side effects in connection with the first infusion often occur very frequently (with more than 30% of patients) after the subsequent infusions are less frequent.</seg>
<seg id="688">"fever and chills, muscle or joint pain and headaches, occur within the first three days after the administration of Aclasta."</seg>
<seg id="689">"currently it is unclear whether Aclasta causes this irregular heart attack, but you should report it to your doctor if you notice such symptoms when you get Aclasta."</seg>
<seg id="690">"physical signs of a low calcium concentration due to low calcium concentration in the blood, such as muscle cracks or criticism or numbes, especially in the area around the mouth."</seg>
<seg id="691">"flu, insomnia, fatigue, thorny, skin drying, skin drying, skin drying, tubing, reddish, skin drying, shaking, humming, temporary increase in serum-creatinins, tissues and thirst."</seg>
<seg id="692">Persistent pain and / or not curative wounds in the mouth or at the jaws were reported above all in patients who were treated with bisphosphors because of other diseases.</seg>
<seg id="693">"about allergic reactions, including rare cases of breathing problems, Nesselausschlag and angioedema (such as swelling in the face, tongue or throat), has been reported."</seg>
<seg id="694">"please inform your doctor, pharmacist or nursing staff if one of the listed side effects you have considerably affected or you notice side effects that are not listed in these usage information."</seg>
<seg id="695">"if the drug is not used directly, the user is responsible for the storage time and conditions of application, usually 24 h at 2 ° C to 8 ° C are not exceeded."</seg>
<seg id="696">"in patients with a low-traumatizing sleeve, the infusion of Aclasta is recommended, the infusion of Aclasta two or more weeks after the operating supply of the hip fracture."</seg>
<seg id="697">"before and after the administration of Aclasta, patients must be supplied sufficient with fluid; this is particularly important in patients who receive a diuretic therapy."</seg>
<seg id="698">"due to the rapid setting of the effect of Zoledronic acid on the bone structure, a temporary, sometimes symptomatic, hypokalzemia can develop, whose maximum usually occurs within the first 10 days after infusion of Aclasta."</seg>
<seg id="699">"in addition, it is very advisable to ensure patients with Morbus Paget an adequate intake of calcium, respectively at least twice daily 500 mg elementary calcium, for at least 10 days after the gift of Aclasta."</seg>
<seg id="700">"in patients with a low-traumatised hip fracture, a initial dose of 50,000 to 125,000 i.e. oratory or intramuscular vitamin D is recommended in front of infusion of Aclasta."</seg>
<seg id="701">"if you need more information about your disease or its treatment, please read the package (also component of the EPAR) or contact your doctor or a pharmacist."</seg>
<seg id="702">ACOMPLIA is used in addition to a diet and exercise for treatment of adult patients • suffering from a body base (body mass index - BMI) of 30 kg / m ² or above or • the overweight (BMI of 27 kg / m ² or above) and beyond or several I have</seg>
<seg id="703">"in addition, four studies were conducted at more than 7 000 patients in which ACOMPLIA was employed compared to a placebo as a support means of setting the noise."</seg>
<seg id="704">"to the studies on the attitude of the noise, on the other hand, no uniform results, so that the effect of ACOMPLIA was difficult to assess this area."</seg>
<seg id="705">Which risk is associated with ACOMPLIA? he found the most common side effects of ACOMPLIA which were observed during the studies (observed in more than 1 of 10 patients) were Nausea (nausea) and infection of the upper respiratory. ng The complete list of related to ACOMPLIA reported side effects is to be found in the package.</seg>
<seg id="706">"it may not be used in patients who suffer from an existing severe depression or, with anti-depressants, as it can strengthen the risk of depression and can give rise to a small minority of patients."</seg>
<seg id="707">"caution is advisable in simultaneous application of ACOMPLIA with medicines such as Ketoconazol or Itraconazol (drugs for fungal infections), Ritonavir (a means for use at HIV- infection), Telithromycin or Clarithromycin (antibiotics)."</seg>
<seg id="708">The Committee for Humanitarian Medicine (CHMP) reached the conclusion that the effectiveness of ACOMPLIA with regard to the weight reduction in patients with obesity or overweight cuts</seg>
<seg id="709">Medicines used in patients who need it from health and not for cosmetic reasons (by providing information packages for patients and doctors) and around the Arz</seg>
<seg id="710">It supplements to diet and exercise for the treatment of a obesity (BMI weighs 30 kg / m ²) or overweight patients (BMI &gt; 27 kg / m ²) who have more or more risk factors such as type 2 diabetes or dyslipidemia (see section 5.1).</seg>
<seg id="711">ACOMPLIA is not recommended for use in children and young people under 18 years of lack of data on effectiveness and inconceivable.</seg>
<seg id="712">"La depressive diseases or moods with depressive symptoms were up to 10%, suicide up to 1% of patients who received Rimonabant (see Section 4.8)."</seg>
<seg id="713">"and if depressive disorders may not be applied to Rimonabant, unless the benefit of treatment in the individual case weighs the risk (see section 4.3 and 4.8)."</seg>
<seg id="714">"he also, in patients who are - besides the obesity in itself - no recognizable risks, can occur depressed reactions."</seg>
<seg id="715">"relatives or other nearby persons) are pointed out that it is necessary to monitor the new occur of such symptoms, and immediately pick up doctor if these symptoms arise. ln"</seg>
<seg id="716">• Infirmer patients The effectiveness and immunity of Rimonabant in the treatment of patients over 75 years were not sufficiently demonstrated.</seg>
<seg id="717">Patients with cardiovascular event (myocardinal or stroke) before less than 6 months ago were made by studies with Rimonabant. ln</seg>
<seg id="718">"rifampicin, phenobarbital, phenobarbital, carbamazepine, Johanniswort) has not been studied, is assumed that the simultaneous gift of potent CYP3A4 ininductors, the Plasmakonzentration of Rimonabant."</seg>
<seg id="719">"ssis of overweight patients, as well as in patients suffering from obesity, and in addition to 3800 patients in other indications."</seg>
<seg id="720">The following table (table 1) shows the undesirable effects in placebocontrolled studies in patients suffering from weight reduction and due to accompanying metabolic disorders.</seg>
<seg id="721">"if the incidence statistically significant was significantly higher than the corresponding placeborate (for unwanted effects, ≥ 1%) or if they were clinically relevant (for undesirable effects &lt; 1%). ng In the evaluation of side-effects, the following skins are basically laid:"</seg>
<seg id="722">"very common (≥ 10%); commonly (≥ 1, &lt; 10%); occasionally (≥ 0,1, &lt; 0.1%); very t lä"</seg>
<seg id="723">"in a duplication study, in which a limited number of persons encores were administered of up to 300 mg, only slight symptoms were observed."</seg>
<seg id="724">Patients had a BMI ≥ 30 kg / m ² or BMI &gt; 27 kg / m ² and one simultaneously existing hypertension and / or dyslipidemia.</seg>
<seg id="725">"n weight reduction after a year amounted to ACOMPLIA 20 mg 6.5 kg, related to 1,6 kg for the placebo group (difference -4.9 kg CI95% -5.3; -4.4, p &lt; 0.001)."</seg>
<seg id="726">"the patients treated with ACOMPLIA 20 mg were treated and 1,2 kg in the placebo group (difference -3.8 kg; CI95% -4.3; p &lt; 0.001)."</seg>
<seg id="727">After 2 years the difference in weight reduction between ACOMPLIA and placebo -4.2 kg (CI95% -5.0%; -3,4; p &lt; 0.001).</seg>
<seg id="728">9 weight reduction and other risk factors in the studies in patients without diabetes in which a mixed population of patients with</seg>
<seg id="729">Among Rimonabant 20 mg became an average waste of the triglyceride of 6.9% (output triglyceride 1.9 mmol / l) compared to an increase of 5.4%</seg>
<seg id="730">"in a second study in patients with a obesity and with previously untreated type 2 diabetes (serenade), the absolute change of the HbA1c value (with a output value of 7.9% for both groups) after 6 months -0,8 for Rimonabant 20 mg and 0,3 under placebo."</seg>
<seg id="731">Percentage of patients who reached a HbA1c- value of &lt; 7% was 51% in the Rimonabant group and 35% in the placebo group.</seg>
<seg id="732">"the difference between the 20 mg- and the placebo group was 3.8 kg (CI95% -5.0, -2.6 p &lt; 0.001)."</seg>
<seg id="733">"improvement of the HbA1c value in patients who had taken the Rimonabant 20 mg, were about 50% due to direct effects of Rimonabant and about 50% due to the weight reduction. n eim Arz"</seg>
<seg id="734">"2 hours, the steady state-state bars were reached after 13 days (Cmax = 196 ± 28.1 ng / ml; AUC0-24 = 2960 ± 268 ng.h / ml)."</seg>
<seg id="735">"influence of food: he probanden, received the Rimonabant either in the cold state or after a fat rich meal, in case of the food supply a rose by 67% increased cmax or by 48% increased ng Auc."</seg>
<seg id="736">Patients with black skin colour can have a up to 31% smaller cmax and one by 43% lower Auc than patients of other ethnic populations.</seg>
<seg id="737">N popular analyses (age spectrum 18- 81 years) is estimated that a 75- old patient is one by 21% higher cmax and one by 27% higher Auc as a 40-year-old</seg>
<seg id="738">"5.3 of clinical effects on safety, which were not observed in clinical trials, which were not observed in clinical trials but were potentially assessed as possibly relevant for clinical application:"</seg>
<seg id="739">"in some cases, however, not in all cases the beginning of the convulsions were connected to the animals associated with the animals."</seg>
<seg id="740">"Rimonabant was given to Rimonant over a longer period before the combination (9 weeks), which allowed a recovery from the initials of Rimonabant, so they were not observed any unwanted effects on the fertilisation or cyklushing."</seg>
<seg id="741">The influence of Rimonabant on the pre- and postnatal development was examined at the Ratte in doses of up to 10 mg / kg / day.</seg>
<seg id="742">"in a study of rats on pre- and post-natal development, a exposure to Rimonabant in utero and by means of lant is no change in learning or memory."</seg>
<seg id="743">Detailed information on this medicine is available on the website of the European medications Agency (EMEA) http: / / www.emea.europa.eu / availability.</seg>
<seg id="744">"La On the package structure of the medicine must be named and address of the makers, who are responsible for sharing the concerned Charge."</seg>
<seg id="745">"26 heavy-how psychiatric events such as depression or moods, were reported in patients who received ACOMPLIA (see paragraph" "which side effects"</seg>
<seg id="746">"sse If with you symptoms of depression (see below) during the treatment with ACOMPLIA, contact your doctor and break the treatment."</seg>
<seg id="747">"dizzling, diarrhea, frightened to blue stains, sore throws (ischialgie), altered sensitivity, hurting pain, pain and spontaneous combustion (tschialgie), altered sensitivity, hurting pain and spontaneous combustion (tschialgie), unequivocal burning or tingling) to hands and feet, heat wallpapers, fall, grippal infections, joint pain."</seg>
<seg id="748">Please inform your doctor or pharmacist if one of the listed side effects you have considerably affected or you notice side effects which are not stated in this usage information.</seg>
<seg id="749">The summary of the EPAR for the Public The present document is a summary of the European Public Health Administration report (EPAR) in which explains how the Committee for Humanitarian Sciences (CHMP) has been judged to make recommendations concerning the application of drug.</seg>
<seg id="750">Actos are used to treat type 2 diabetes (also known as non-insulin-dependent diabetes). • It may be applied alone (monotherapy) in patients (in particular overweight patients). • It can be applied together with another diabetesdrug medicine (Dualtherapy).</seg>
<seg id="751">"in addition to metformin in patients (especially overweight patients) are used, which cannot be satisfactory with metformin alone in the highest tolerable dose."</seg>
<seg id="752">"in combination with a sulphonic packaging or insulin, the previous dose of the sulphonic packaging or insulin can be retained, except in patients with hypoglycaemia (low blood sugar); here, the dose of the sulphonic leukaemia or insulin is reduced."</seg>
<seg id="753">"this means that the body's own insulin can be improved better and the blood sugar mirror, which makes type-2 diabetes better set."</seg>
<seg id="754">"for more than 1 400 patients the effectiveness of Activities in Tripleotherapy has been examined; in addition, patients received a combination of metformin with a sulphonic acid, in addition, they received either an account or placebo for 3.5 years."</seg>
<seg id="755">"in the studies the concentration of a substance was measured in the blood (glycosylated hemoglobin, HbA1c), which indicates how good the blood sugar is adjusted."</seg>
<seg id="756">"Actos led to a lowering of the HbA1c value, which suggests that the blood sugar has been reduced by doses of 15 mg, 30 mg and 45 mg."</seg>
<seg id="757">"at the end of the tripleotherapy study, the effect of the additional gift of accounts for the existing treatment with metformin and a sulphylharnac demonstrated in a lowering of the HbA1c values by 0.94%, while the additional gift of placebo led to a reduction of 0.35%."</seg>
<seg id="758">"in a small study, in which the combination of Actos and insulin was studied in 289 patients, the patients, the Actos in addition to insulin, compared with 0.14% in the patient, which took additional placebo."</seg>
<seg id="759">"the most common side-effects related to Actos were visual disorders, infections of the upper respiratory tract, weight-taking and hypocratic (diminished sensitivity to stimuli)."</seg>
<seg id="760">"Actos must be applied neither in patients (allergic) to pioglitazone or one of the other components, which might be oversensitive (allergic) to pioglitazone or one of the other components, nor in patients with liver problems, heart failure or diabetic Ketoazide (high ketone mirror - acurespace - in the blood)."</seg>
<seg id="761">"it has been decided that actos in the context of a monotherapy (in a few use) is intended to serve as an alternative to standard treatment with metformin in patients, where metformin is not shown."</seg>
<seg id="762">October 2000 the European Commission issued the company Takeda Europe R & D Centre Limited for authorisation from accounts in the entire European Union.</seg>
<seg id="763">"the tablets are white to white, round, curved and carry on one side the markings" 15 "and on the other hand the wording" ACTOS. ""</seg>
<seg id="764">Pioglitazone is also displayed for combination with insulin in patients with type 2 diabetes mellitus whose blood sugar has been inadequate with insulin or incompatibility due to contraindications or intolerability (see Section 4.4).</seg>
<seg id="765">"the application of Pioglitazone in patients under 18 years of age are not available, so the application is not recommended in this age group."</seg>
<seg id="766">"in patients suffering from the presence at least one risk factor (e.g. earlier hereditary heart disease), the doctor should start treatment with the lowest available dose and increase the dose of dose."</seg>
<seg id="767">"patients should be observed on signs and symptoms of a heart failure, weight gain or oil, especially those with reduced cardiac reserve."</seg>
<seg id="768">"patients should be observed on signs and symptoms of a heart failure, weight gain and oil, when pioglitazone is applied in combination with insulin."</seg>
<seg id="769">A cardiovascular Outcome study with pioglitazone in patients under 75 years with type 2 diabetes mellitus and existing advanced macrovascular disease was performed.</seg>
<seg id="770">"in this study, an increase in reports on heart failure, however, did not lead to an increase in mortality in the study."</seg>
<seg id="771">In patients with increased output liver liver scores (ALT &gt; 2.5 x upper limit of the standard area) or with other signs of a liver may not be used Pioglitazon.</seg>
<seg id="772">"when the ALT mirror are increased until the 3-times the upper limit of the standard area, the liver scores are as soon as possible to control."</seg>
<seg id="773">"if a patient symptoms developed to indicate such a patient symptoms, such as unresolved nausea, vomiting, colonisation, Appetitlessness and / or darker Harn, are the liver values to be checked."</seg>
<seg id="774">The decision to continue whether the treatment of patients with pioglitazone should continue to be led by the laboratory parameters of the clinical assessment.</seg>
<seg id="775">"in clinical trials with Pioglitazone, a dosages weight gain has been proven to stir up fat and in some cases associated with a fluid."</seg>
<seg id="776">"as a result of a hermodically, under the therapy with pioglitazone, under the therapy with pioglitazone, a slightly reduction in the middle hour of hemostitazone (relative reduction to 4%) and the hemokrits (relative reduction to 4.1%)."</seg>
<seg id="777">Similar changes have been observed in comparatively controlled trials with pioglitazone in patients suffering from 3-4% and haemokrits by 3-4% and insulin (relative reduction of the hemmoglobins by 1-3% and the hamatokrits by 1-3.2%).</seg>
<seg id="778">"as a result of increased insulin-sensitivity, in patients, the pioglitazone as orale branch or as branch-combination therapy with insulin, is the risk of a dosisdependent hypoglycaemia."</seg>
<seg id="779">"after the market launch was reported under the treatment with Thiazolidindions, including Pioglitazone, on a occurrence or deterioration of a diabetic macular cord with a reduction in visual acuity."</seg>
<seg id="780">It is unclear whether there should be a direct connection between the intake of pioglitazone and the occurrence of maculaödems if patients report more disorders of visual acuity; a suitable ophthalmic declaration should be considered.</seg>
<seg id="781">"in a summary analysis of messages from randomized, controlled, double-blind studies over a period of up to 3.5 years with more than 8,100 patients treated with pioglitazone"</seg>
<seg id="782">The reparation incidence amounted to 1.9 questionnaires per 100 patient-years with the pioglitazone treated with pioglitazon treated women and 1.1 questionnaires in women who were treated with a comparison medication.</seg>
<seg id="783">"in the proactive study, a study conducted over 3.5 years for investigation of cardiovascular events, questionnaires at 44 / 870 (5.2%; 0.5% per 100 patient years) who were treated with a comparison medication per 100 patient years) who were treated with a comparison medication."</seg>
<seg id="784">Patients should be aware of the possibility of pregnancy and if a patient desires a pregnancy or this entry is the treatment (see Section 4.6).</seg>
<seg id="785">"studies on the investigation of the interactions have shown that Pioglitazone has no relevant effects on the pharmaceutical drugs or pharmaceutical codynamics of Digoxin, warfarin, phenprocoumon and metformin."</seg>
<seg id="786">"interactions with medicines that are metabolized by these enzymes, e.g. orale contraceptive, cyclosporin, Calciumkanalblocker and HMGCoA reductformer are not expected."</seg>
<seg id="787">The simultaneous application of pioglitazone with Gemfibrozil (a cytochrom P450 2C8- Inhibitor) resulting in an increase in the Auc of Pioglitazone around the 3-times.</seg>
<seg id="788">The simultaneous application of pioglitazone with rifampicin (a cytochrom P450 2C8-inductor) performed in a reduction of the Auc of Pioglitazone by 54%.</seg>
<seg id="789">This is due to the fact that under treatment with pioglitazone decreased in pregnancy the hyperinsulin and increased insulin resistance of the parent and thereby reduces the availability of the metabolic substrates for the federal growth.</seg>
<seg id="790">"very frequently &gt; 1 / 10; frequently &gt; 1 / 100, &lt; 1 / 100; rare &gt; 1 / 1000, &lt; 1 / 1000; very rare &lt; 1 / 10000, individual cases: unknown (not invaluable from the present data)."</seg>
<seg id="791">These lead to a temporary change in the turgor and the brake indexes of the lens as they are observed also in other hypoglycaemic active ingredients.</seg>
<seg id="792">"in clinical trials with Pioglitazone, ALT Anstice occurred frequently on such as under placebo, but more rarely than in comparison groups under metformin or sulfonylharnines."</seg>
<seg id="793">"in an Outcome study in patients with existing advanced macrovascular disease, it was the incidence of a severe heart failure under pioglitazone to 1,6% higher than under placebo if pioglitazone bzw."</seg>
<seg id="794">"since the launch of the market, it has rarely been reported about heart failure under the Pioglitazone, however, when pioglitazone was applied in combination with insulin or in patients with heart failure in anamnesis."</seg>
<seg id="795">"there has been a summary analysis of reports from randomized, controlled, double-blind studies over a period of up to 3.5 years with more than 8,100 patients treated with the pioglitazon treated groups and more than 7.400 patients treated with comparably treated groups."</seg>
<seg id="796">"in the study conducted over a period of 3.5 years of current proactive study, questionnaires at 44 / 870 (5.1%) of patients treated with pioglitazone, compared to 23 / 905 (2.5%) with patients treated with a comparison medication."</seg>
<seg id="797">"when taking the reported maximum dose of 120 mg / day over four days, then 180 mg / day over seven days occurred no symptoms."</seg>
<seg id="798">"Pioglitazone seems to have an activation of specific core prescription drug (PPAR-g), which leads to an increased insulin-sensitive activity of liver, fat, and skeletal muscle cells."</seg>
<seg id="799">It could be shown that Pioglitazone reduces the glucose production in the liver and the peripheral glucose rate in case of insulin resistance increases.</seg>
<seg id="800">A clinical study with Pioglitazone versus Gliclazide as monotherapy has been continued over two years to investigate the time until after the therapeutic effect of the therapeutic effect (defined as HbA1c ≥ 8.0% after the first 6 treatment months).</seg>
<seg id="801">"at the time after two years after the treatment of therapy, a blood sugar (defined as HbA1c &lt; 8.0%) by Pioglitazone at 69% of patients (compared to 50% of patients under Gliclazide) could be maintained."</seg>
<seg id="802">"in a placebocontrolled study of 12 months, patients whose blood sugar were discontinued despite three imonatiger optimizing phase with insulin, to pioglitazone or placebo randomised."</seg>
<seg id="803">"in patients under the Pioglitazone, the middle HbA1c was reduced by 0.45%, compared to the patients which continued to only insulin; a reduction in insulin treatment was observed in the group treated with pioglitazon."</seg>
<seg id="804">"in clinical studies over a year, a statistically significant derivation of the Albula in / creatinazone was shown in comparison to the initial values."</seg>
<seg id="805">The effect of Pioglitazone (Monotherapy with 45 mg versus placebo) was tested in a small, on 18 weeks investigation into type 2-diabetics.</seg>
<seg id="806">"in most clinical trials compared to placebo a reduction of the total plasma triglyceride and the free fatty acids, and a rise in HDL- cholesterol levels as well as slightly, however clinically not significantly increased LDL levels observed."</seg>
<seg id="807">"in clinical studies over a period of up to two years, Pioglitazone reduced in comparison to placebo, metformin or Gliclazide the total plastic wall glycemic and the free fatty acids and increased the HDL cholesterol levels."</seg>
<seg id="808">Compared to placebo a statistically significant increase in LDL cholesterol levels has been observed while under metformin and Gliclazide diminished values have been observed.</seg>
<seg id="809">"in a study over 20 weeks, Pioglitazone was reduced not only the sober triglyceride levels, but also improved the postprandial increased triglyceridmirror, this both via an effect on the triglycemic absorption as well as the hepatic triglycemic synthesis."</seg>
<seg id="810">"in the proactive study, a cardiovascular Outcome study, 5238 patients with type 2 diabetes mellitus and existing advanced macrovascular disease were randomized in groups of up to 3.5 years, in addition to existing antidiabetic and cardiovascular therapy either pioglitazone or placebo."</seg>
<seg id="811">"after orative application, Pioglitazone is rapidly resorting to unchangeable Pioglitazone on plasma usually 2 hours after application."</seg>
<seg id="812">"on this basis the contribution of M-IV is the effectiveness of the effectiveness of Pioglitazone, whereas the relative effectiveness of M-II minimized is minimized."</seg>
<seg id="813">"in Interactions studies, Pioglitazone has no relevant effect on the Pharmokinetics or pharmaceutical codynamics of Digoxin, warfarin, phenprocoumon and metformin."</seg>
<seg id="814">The simultaneous application of pioglitazone with gemfibrozil (a cytochrom P450 2C8- Inhibitor) or with Rifampicin (a cytochrom P450 2C8-inductor) or lowers the plasmaconcentric of pioglitazone (see Section 4.5).</seg>
<seg id="815">"after orative application of radioactive markied Pioglitazone, the marker was mainly found in the subjects (55%) and a lower amount in the resin (45%)."</seg>
<seg id="816">"the mean Plasma Elimination period of unchangeable pioglitazone is within the people 5-6 hours, and that of the entire active Metabolites is 16 - 23 hours."</seg>
<seg id="817">"the plasma centrations of pioglitazone and its Metabolites are lower than with patients with reduced kidney function, whereby the instalments of the oral Clearance of the dam, however, resemble."</seg>
<seg id="818">"in toxicology studies occurred in mice, rats, dogs and monkey bending after repeated administration of plasma-volume, more eccentric, anaemia and reversible eccentric heart of hypertrophy."</seg>
<seg id="819">"this is due to the fact that under treatment with pioglitazon the hyperinsulin and increased insulin resistance of the parent, thereby diminished the availability of the metabolic substrates for the federal growth."</seg>
<seg id="820">In long-term studies (up to 2 years) were induced at the Ratte increased incidences of hyperplasia (with male and female rats) and tumors (in male rats) of the urinary epithelium.</seg>
<seg id="821">In an animal-model of the family adenomatous Polyposis (FAP) the treatment with two other Thiazolidindions led to an increased frequency of colonization tumors.</seg>
<seg id="822">"the tablets are white to white, round, flat and carry on one side the marking" 30 "and on the other hand the wording" ACTOS. ""</seg>
<seg id="823">The reparation incidence amounted to 1.9 questionnaires per 100 patient-years with the pioglitazone treated with pioglitazon treated women and 1.1 questionnaires in women who were treated with a comparison medication.</seg>
<seg id="824">"in the proactive study, a study conducted over 3.5 years for investigation of cardiovascular events, questionnaires at 44 / 870 (5.2%; 0.5% per 100 patient years) who were treated with a comparison medication per 100 patient years) who were treated with a comparison medication."</seg>
<seg id="825">"in a further study of two years, the effects of a combination therapy of metformin each have been studied with Pioglitazone or Gliclazide."</seg>
<seg id="826">"in clinical trials about 1 year, a statistically significant derivation of the Albula in / creatinazone was shown in comparison to the initial values."</seg>
<seg id="827">"in a study over 20 weeks, Pioglitazon is not only sober-triglyceride, but improved beyond an effect on the Tryglycemic absorption as well as the hepatic Tryglicence synthesis."</seg>
<seg id="828">"although the study showed the target with regard to their primary endpoint, the results near the ankle, coronary coronary coronary corroborhood and revascularization of the leg arteries, lay the results near that with the intake of pioglitazone no cardiovascular long-term risks are associated."</seg>
<seg id="829">"the tablets are white to white, round, flat and carry on one side the markings" 45 "and on the other hand the wording" ACTOS. ""</seg>
<seg id="830">"in a summary analysis of reports from randomized, controlled, double-blind trials were treated over a period of up to 3.5 years with more than 8.100 patients who were treated with pioglitazone and received by more than 7.400 patients who were compared with pioglitazone."</seg>
<seg id="831">"in the proactive study, a study conducted over 3.5 years for investigation of cardiovascular events, questionnaires at 44 / 870 (5.2%; 0.5% per 100 patient years) who were treated with a comparison medication per 100 patient years) who were treated with a comparison medication."</seg>
<seg id="832">"in a study of 20 weeks, Pioglitazon is not only sober-triglyceride, but improved beyond an effect on the triglycemic absorption as well as the hepatic triglycemic synthesis."</seg>
<seg id="833">"in the package of drug, name and address of the manufacturer, which is responsible for sharing the concerned Charge is specified."</seg>
<seg id="834">"in September 2005, the pharma entrepreneur will be an extra 6 month-time peripheral Safety Update Report (PSUR) and subsequently annual PSURs, to a different decision made by the CHMP."</seg>
<seg id="835">There must be an updated risk management plan according to CHMP Guideline on Risk Management Systems for Medicinal Products for Human Use.</seg>
<seg id="836">"if you're suffering from type 2 diabetes, Actos 15 mg tablets provide control of your blood sugar by taking a better utilisation of the body's own insulin."</seg>
<seg id="837">"if you know you are suffering from intolerability, please contact your doctor before taking the account of Actos 15mg tablets."</seg>
<seg id="838">"please inform your doctor or pharmacist if you have additional medicines or have recently been taken, even if they are not prescription drugs."</seg>
<seg id="839">"if you are taking account of 15 mg tablets in combination with other medicines for treating diabetes (such as insulin, chlorclacid, Gliclazide, Gliclacid, Gliclazide, will inform you if you have to reduce the dose of your medicines."</seg>
<seg id="840">"for some patients with long-term type 2 diabetes mellitus and cardiac disease or former stroke, which were treated with Actos and insulin, developed a heart failure."</seg>
<seg id="841">"in clinical trials, in which pioglitazone was compared with other oralen antidiabetic tablets or placebo (true tablets) compared to women (but not in men), the pioglitazone took a higher number of bone marches."</seg>
<seg id="842">"if you accidentally have taken many tablets, or when another or a child has taken your medicine, you must get in touch with a doctor or a pharmacist."</seg>
<seg id="843">"like Actos and content of accounts Actos 15 mg tablets are white to white, round, vaulted tablets with the markings" 15 "on one side and the wording" ACTOS "on the other side."</seg>
<seg id="844">"if you're suffering from type 2 diabetes, Actos 30 mg tablets provide control of your blood sugar by taking a better utilisation of the body's own insulin."</seg>
<seg id="845">"if you know you are suffering from intolerability, please contact your doctor before taking an account of Actos 30mg tablets."</seg>
<seg id="846">"if you are taking account of 30 mg tablets in combination with other medicines for treating diabetes (such as insulin, chlorclacid, Gliclazide, Gliclacid, Gliclazide, will inform you if you have to reduce the dose of your medicines."</seg>
<seg id="847">"61 Information will inform you as soon as possible, if you determine signs of heart failure, such as unusual short-light or swift weight gain or local swelling (Ödeme)."</seg>
<seg id="848">"in clinical trials, in which pioglitazone was compared with other oralen antidiabetic tablets or placebo (true tablets) compared to women (but not in men), the pioglitazone took a higher number of bone marches."</seg>
<seg id="849">"like Actos and content of accounts Actos 30 mg tablets are white to white, round, flat tablets with marking" "30" "on one side and the wording" ACTOS "on the other side."</seg>
<seg id="850">"if you're suffering from type 2 diabetes, Actos 45 mg tablets provide control of your blood sugar by taking a better utilisation of the body's own insulin."</seg>
<seg id="851">"if you know you are suffering from intolerability, please contact your doctor before taking an account of Actos 45mg tablets."</seg>
<seg id="852">"if you are taking an account of 45 mg tablets in combination with other medicines for treating diabetes (such as insulin, chlorclacid, Gliclazide, Gliclacid, Gliclazide, will inform you if you have to reduce the dose of your medicines."</seg>
<seg id="853">"66 At several patients with long-term type 2 diabetes mellitus and cardiac disease, or former stroke, which were treated with Actos and insulin, developed a heart failure."</seg>
<seg id="854">"find out as soon as possible your doctor, if you determine signs of heart failure, such as unusual short-light or swift weight gain or local swelling (Ödeme)."</seg>
<seg id="855">"in clinical trials, in which pioglitazone was compared with other oralen antidiabetic tablets or placebo (true tablets) compared to women (but not in men), the pioglitazone took a higher number of bone marches."</seg>
<seg id="856">"67 If one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="857">"like Actos and contents of the Packung Actos 45 mg tablets are white to white, round, flat tablets with the markings" 45 "on one side and the wording" ACTOS "on the other side."</seg>
<seg id="858">The present document is a summary of the European Public Health Administration report (EPAR) in which explains how the committee for human medicines (CHMP) is explained to come to recommendations concerning the application of the drug.</seg>
<seg id="859">"if you need more information about your medical condition or treating your disease, please read the package (which is also part of the EPAR) or contact a doctor or a pharmacist."</seg>
<seg id="860">"if you would like more information on the recommendations of CHMP, please read the scientific discussion (which is also part of the EPAR)."</seg>
<seg id="861">Actraphane 10: soluble insulin in 10% and Isophan insane in 70% Actraphane 40: soluble insulin in 40% and Isophan insane in 60% Actraphane 50: soluble insulin in 40% and Isophan insulin in 50%</seg>
<seg id="862">Actrapane is usually applied once or twice daily when a fast initials effect will be desired together with a long lasting effect.</seg>
<seg id="863">"(44-20) 74 18 84 00 fax (44-20) 74 18 84 00 fax, / / www.emea.eu.int © EMEA 2006 Reproduction and / or distribution of this document for non-commercial purposes only the EMEA is the Humaninsulin (rDNA), is produced using the method of so-called" recombinant technology. ""</seg>
<seg id="864">"Actrapane was divided into a total of 294 patients with type 1 diabetes where the pancreas no insulin can produce, and type 2 diabetes, in which the body is unable to utilize the insulin."</seg>
<seg id="865">"in the study, after 12 weeks the concentration of a substance (glycosylated hemoglobin (HbA1c) was measured, which shows how good the blood sugar has been adjusted after 12 weeks."</seg>
<seg id="866">"Actrapane led to a withdrawal of the HbA1c spels, which pointed out that the blood sugar levels were similarly strong as with another humaninsulin."</seg>
<seg id="867">"Actrapane should not be applied in patients, which may be oversensitive (allergic) to humaninsulin (rDNA) or one of the other components."</seg>
<seg id="868">"in addition, the cans of Actrapane may need to be adapted if it is administered along with a number of other medicines that can affect the blood sugar (the complete list is available to pack)."</seg>
<seg id="869">The Committee for Humanitarian Medicine (CHMP) reached the conclusion that the benefits of Actraphanans overlacked the risks of diabetes in the treatment of diabetes.</seg>
<seg id="870">October 2002 shared the European Commission to Novo Nordisk A / S approval for the marketing of Actrapane in the whole of the European Union.</seg>
<seg id="871">Mixed insulin products are usually applied once or twice daily when a fast initials effect will be desired together with a long lasting effect.</seg>
<seg id="872">The injection needle must be at least 6 seconds long under the skin to make sure the whole dose has been injected.</seg>
<seg id="873">Patients whose blood sugar can be improved significantly for example by an intense insulin-warning symptoms. the hypoglycaemia symptom has changed and should be advised accordingly.</seg>
<seg id="874">"any changes regarding strength, brand, insulin, insulin, insulin, insulin, insulin or insulin-method (through recombinant DNS against insulin origin) can lead to a change in dosage."</seg>
<seg id="875">"if changing to Actrapane is required in patients with a dosage adjustment, it can be necessary at first dosage or during the first weeks or months after switching."</seg>
<seg id="876">"some patients, at which hypoglycemic reactions came up after a change of animal insulin in human insulin, reported that the early warnings of hypoglycaemia had less pronounced or different than with their previous insulin."</seg>
<seg id="877">"before travelling, going over several time zones, the patient should be pointed out to get the advice of his physician, as such trips can lead to other times, that insulin and meals must be applied to other times."</seg>
<seg id="878">The doctor must therefore take into account potential interactions in therapy and always ask their patients to other medicines.</seg>
<seg id="879">"4 Soap hypoglycaemia as well as hyperglycaemia, which can occur in a non-controlled diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="880">Severe hypoglycadian can lead to conscielessness and / or varicism and with temporary or permanent disturbances of brain function and even death.</seg>
<seg id="881">Diseases of the nervous system occasionally - periphere Neuropathy can be combined with complaints that are called acute painless Neuropathy and are usually reversible.</seg>
<seg id="882">"5 A intensification of insulin therapy with an abrupt improvement of the blood sugar, however, can be associated with a temporary deterioration of the diabetic retinopathy."</seg>
<seg id="883">"diseases of the skin and subhauling webes occasionally - Lipodstreamphie will arise, if failed, when failed to change the sufferer within the injection range."</seg>
<seg id="884">"general diseases and complaints at the administration of time occasionally - Local hypersensitive action on the injure place, while the insulin therapy can occur local hypersensitive reactions (redness, swelling, juckiness, pain and hematom at the injecting place)."</seg>
<seg id="885">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, itching, shaking, buttonic oils, low blood pressure and impotence, low blood pressure and impotence."</seg>
<seg id="886">Hypoglycaemia can develop in-depth however: • Unless hypoglycavities can be treated by the orale access of glucose or sugary foods.</seg>
<seg id="887">"diabetics should therefore always have traumatic or subcutaneous injections, sweets, biscuits or sugary fruit juice. • Seriousness of glucose are treated with intramuscular or subcutaneous injections by using intramuscular or subcutaneous injections, or by glucose, which is given intravenously by the doctor."</seg>
<seg id="888">"the effect starts within half an hour, the active max is reached within 2 to 8 hours and the entire active duration is up to 24 hours."</seg>
<seg id="889">Resorption The Resorption profile lies in it that the product is a mixture of insulin products with fast and hesitated resorption.</seg>
<seg id="890">A number of Spaltars (hydroly-) villages on the human insulin molecules were considered; none of which are used by the splitter Metabolites.</seg>
<seg id="891">"based on conventional studies on the safety of security, Genotoxicity, to carcinogenic potential and to Reproductive Toxicity, the preclinical data cannot recognize any particular dangers for the human being."</seg>
<seg id="892">It is recommended - after the Actraphanous flashing bottle has been extracted from the fridge - the temperature of insulin on room temperature (not over 25 ° C) to rise before it is operated in accordance with the operating instructions for the first use of resuspened.</seg>
<seg id="893">"some patients, at which hypoglycemic reactions came up after a change of animal insulin in human insulin, reported that the early warnings of hypoglycaemia had less pronounced or different than with their previous insulin."</seg>
<seg id="894">The doctor must therefore take into account potential interactions in therapy and always ask their patients to other medicines.</seg>
<seg id="895">"12 Soap hypoglycaemia as well as hyperglycaemia, which can occur in a non-controlled diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="896">13 A intensification of insulin therapy with abruptly improvement of blood sugar can be associated with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="897">The terminale half-time (t ½) is therefore more of a measure of elimination as a measure of elimination per se of insulin from the plasma (insulin in blood circulation in a distance of just a few minutes).</seg>
<seg id="898">It is recommended - after the Actraphanous flashing bottle has been extracted from the fridge - the temperature of insulin on room temperature (not over 25 ° C) to rise before it is operated in accordance with the operating instructions for the first use of resuspened.</seg>
<seg id="899">"some patients, at which hypoglycemic reactions came up after a change of animal insulin in human insulin, reported that the early warnings of hypoglycaemia had less pronounced or different than with their previous insulin."</seg>
<seg id="900">"20 Soap hypoglycaemia as well as hyperglycaemia, which can occur in a non-controlled diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="901">21 A intensification of insulin therapy with abruptly improvement of blood sugar can be associated with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="902">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, itching, shaking, buttonic oils, low blood pressure and impotence, low blood pressure and impotence."</seg>
<seg id="903">"cartridges may only be used together with products, which are compatible with them and ensure a safe and effective function of the cartridge."</seg>
<seg id="904">It is recommended - after Actraphanous penfill from the fridge was taken from the fridge - the temperature of insulin on room temperature (not over 25 ° C) to exceed it under the operating instructions for the first use resushed.</seg>
<seg id="905">"some patients, at which hypoglycemic reactions came up after a change of animal insulin in human insulin, reported that the early warnings of hypoglycaemia had less pronounced or different than with their previous insulin."</seg>
<seg id="906">"28 Soap hypoglycaemia as well as hyperglycaemia, which can occur in a non-controlled diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="907">29 A intensification of insulin therapy with abruptly improvement of blood sugar can be associated with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="908">"some patients, at which hypoglycemic reactions came up after a change of animal insulin in human insulin, reported that the early warnings of hypoglycaemia had less pronounced or different than with their previous insulin."</seg>
<seg id="909">"36 If hypoglycaemia as well as hyperglycaemia, which can occur in a non-controlled diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="910">37 A intensification of insulin therapy with abruptly improvement of blood sugar can be associated with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="911">"44 Socket hypoglycaemia as well as hyperglycaemia, which can occur in a non-controlled diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="912">45 A intensification of insulin therapy with a ruptible improvement of blood pressure can be associated with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="913">"some patients, at which hypoglycemic reactions came up after a change of animal insulin in human insulin, reported that the early warnings of hypoglycaemia had less pronounced or different than with their previous insulin."</seg>
<seg id="914">"52 Soap hypoglycaemia as well as hyperglycaemia, which can occur in a non-controlled diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="915">53 A intensification of insulin therapy with a ruptible improvement of blood pressure can be associated with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="916">The injections must be prepared before the injection so that the tin controls rose on zero and an insulin is shown at the top of the injector.</seg>
<seg id="917">"59 patients whose blood sugar has improved significantly, for example, the hypoglycaemia warning symptoms can be changed and should be advised accordingly."</seg>
<seg id="918">"hypoglycaemia as well as hyperglycaemia, which can occur in a non-controlled diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="919">A intensification of insulin therapy with an abrupt improvement of blood pressure can be associated with a temporary deterioration of the diabetic retinopathy.</seg>
<seg id="920">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, itching, shaking, buttonic oils, low blood pressure and impotence, low blood pressure and impotence."</seg>
<seg id="921">These finished products may only be used together with products that are compatible with them and ensure a safe and effective function of production.</seg>
<seg id="922">It is recommended - after Actrapane NovoLet the fridge was taken from the fridge - the temperature of insulin on room temperature (not over 25 ° C) prior to the operating instructions for the first use resushed.</seg>
<seg id="923">"67 patients whose blood sugar has improved significantly, for example, the hypoglycaemia warning symptoms can be changed and should be advised accordingly."</seg>
<seg id="924">"75 patients whose blood sugar has improved significantly, for example, the hypoglycaemia warning symptoms can be changed and should be advised accordingly."</seg>
<seg id="925">"83 patients, whose blood sugar can be improved significantly, for example, by an intense insure therapy, the hypoglycaemia symptoms can be changed and should be advised accordingly."</seg>
<seg id="926">"91 patients whose blood sugar has improved significantly, for example, the hypoglycaemia warning symptoms can be changed and should be advised accordingly."</seg>
<seg id="927">"99 patients whose blood sugar has improved significantly, for example, the hypoglycaemia warning symptoms can be changed and should be advised accordingly."</seg>
<seg id="928">"any changes regarding strength, brand, insulin, insulin, insulin, insulin, insulin, insulin or insulin-method (through recombinant DNS against insulin origin) can cause a change in dosage."</seg>
<seg id="929">It is recommended - after Actrapane InnoLet was taken from the fridge - the temperature of insulin on room temperature (not over 25 ° C) to rise before it is operated in accordance with the operating instructions for the first use of resuspened.</seg>
<seg id="930">It is recommended - after Actraphanous Flexpen was taken from the fridge - the temperature of insulin on room temperature (not over 25 ° C) to rise before it is operated in accordance with the operating instructions for the first use of resuspened.</seg>
<seg id="931">"in the package of drug, name and address of the manufacturer, which is responsible for sharing the concerned Charge is specified."</seg>
<seg id="932">"in the fridge (2 ° C - 8 ° C) Not freezing the flashing bottle in the Umarton, to protect the content from light: not in the fridge or over 25 ° C"</seg>
<seg id="933">Subcutaneous application penfill cartridges are intended for use with insisting measurement instrumentation of Novo Nordisk for use with insisting properties of Novo Nordisk for use in case of the manual depreciation Packages 10 penfill may be used only by one person</seg>
<seg id="934">"in the fridge (2 ° C - 8 ° C) Not freeze The cartridge to preserve the content from light, to protect the content from light: not in the fridge or over 30 ° C"</seg>
<seg id="935">Subcutaneous application penfill cartridges are intended for use with insisting properties of Novo Nordisk for use with insisting properties of Novo Nordisk for use of the manual detoned pack-based paper pack must be used only by one person</seg>
<seg id="936">Subcutaneous application penfill cartridges are intended for use with insisting properties of Novo Nordisk for use with insisting properties of Novo Nordisk for use with insulin gearboxes to consider Actraphane 30 penfill may be used only by one person</seg>
<seg id="937">Subcutaneous application penfill cartridges are intended for use with insisting properties of Novo Nordisk for use with insisting properties of Novo Nordisk for use in the manual detoned Packages 40 penfill may be used only by one person</seg>
<seg id="938">Subcutaneous application penfill cartridges are intended for use with insisting properties of Novo Nordisk for use with insisting properties of Novo Nordisk for use with insulin gearboxes to be used "Actrapane 50 Penfill must be used only by one person</seg>
<seg id="939">Subcutaneous application Zur use with Actrapane 10 NovoLet are NovoFine injecting treatment included in mind Actrapane 10 Novolet may be used only by one person</seg>
<seg id="940">"in the fridge (2 ° C - 8 ° C) Not to freeze for freeze: not in the refrigerator or more than 30 ° C,"</seg>
<seg id="941">Subcutaneous application Zur use with Actrapane 20 NovoLet are NovoFine injecting treatment included in mind Actrapane 20 Novolet may be used only by one person</seg>
<seg id="942">Subcutaneous application Zur use with Actrapane 30 NovoLet are NovoFine injecting treatment included in mind Actrapane 30 NovoLet only may be used by one person</seg>
<seg id="943">Subcutaneous application Zur use with Actrapane 40 NovoLet are NovoFine injecting packet of the manual detoned Packages 40 NovoLet only may be used by one person</seg>
<seg id="944">Subcutaneous application Zur use with Actrapane 50 NovoLet are NovoFine injecting treatment included in mind Actraphane 50 NovoLet only may be used by one person</seg>
<seg id="945">Subcutaneous application Zur use with Actrapane 30 InnoLet's NovoFine S injecting treatment included in mind Actrapane 30 Innolet must be used only by one person</seg>
<seg id="946">This means that about half an hour after you used it to sink your blood sugar and that the effect will stop about 24 hours.</seg>
<seg id="947">"► if you are allergic (hypersensitive) to this insulin product, metacresol or one of the other components (see section 7 other information)."</seg>
<seg id="948">Pay attention to the less than 5 Which side effects are possible? described symptoms of any allergy ► if you feel the first sign of hypoglycaemia (symptoms of a subjugation).</seg>
<seg id="949">"if your doctor has a change from an insulin or brand to another, it may need to be adapted to the dose by your doctor."</seg>
<seg id="950">"► review using the label, whether it is the correct insulin type, disinfect the rubber compound with a medical cloth."</seg>
<seg id="951">"if this is not totally undeserved when you get the steeping bottle, if it was not stored correctly or frozen (see 6 How is Actraphanous to retain?) ► if it is not unevenly white and cloudy."</seg>
<seg id="952">Use the injection technology which has recommended your doctor or your diabetesberaterin recommended ► Lassen you have the injections of at least 6 seconds long under your skin to make sure the full dose has been injected.</seg>
<seg id="953">"the waiting marks of a subordination can suddenly appear and can be: cold welding, headache, heartfelt, irritating and weakness, nervousness, nervousness or tremble, anxiety, confusion, concentration difficulties."</seg>
<seg id="954">"tell your relatives, friends and narrow workmates that they have to put you in case of consciousness in the stable side-position and immediately need a doctor."</seg>
<seg id="955">"they may not be treated to you or to drink it. ► If a severe subjugation does not treat it, this may cause (temporary or permanent) brain damage or even death penalty. if you had a shelter with conscielessness or often outsifying credit, search your doctor."</seg>
<seg id="956">"you can regain consciousness faster, if you become the hormone Glucagon by a person who is familiar with whose gift is injected."</seg>
<seg id="957">"this can happen: • If you consume too much insulin, if you eat too little or make a meal if you are more than usual physically."</seg>
<seg id="958">"amplified urinary tract, thirst, appetite, appetite or fatigue, dry skin, mouth-dry and fruity (after Aceton) smell breath."</seg>
<seg id="959">• You forget a insulin object • repeated injecting less insulin than you need • an infection or fever • more food than usual • less physical exercise than usual.</seg>
<seg id="960">"if you can often give yourself an injection at the same point, can shrink the underskin-fat tissue (Lipatrophie) or increase (Lipohypertrophy)."</seg>
<seg id="961">"in case you notice the recess or thickening of your skin at the injection point, report to your doctor or your diabettor, because these reactions may become worse or the absorption of your insulin, if you injected into such a place."</seg>
<seg id="962">"if you are looking for a doctor on • if the symptoms are spreading to other parts of the body, or • If you feel suddenly feel uncomfortable and you will have welds, nausea (vomiting), heart rust, or you have the impression to become unconscious."</seg>
<seg id="963">They may have a very rare severe allergic reaction to acetaphore or one of its components (such a systemic allergic reaction).</seg>
<seg id="964">"if one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="965">What Actrapane contains 30 - The substance is characterized by recombinant DNA technology (30% as soluble insulin and 70% as a Isophan insulin).</seg>
<seg id="966">"like Actrapane and contents of the pack's injecting will be sluggish, white, aqueous Suspension in package with 1 or 5 hexagonal bottles each with 5 motel bottles per 10 ml each."</seg>
<seg id="967">Use the injection technology which has recommended your doctor or your diabetesberaterin recommended ► Lassen you have the injections of at least 6 seconds long under your skin to make sure the full dose has been injected.</seg>
<seg id="968">It is recommended - after being taken from the fridge - the temperature of the steeping bottle has to rise to room temperature before the insulin is used in accordance with the manual for the first use of resuspened.</seg>
<seg id="969">"like Actrapane and contents of the pack's injecting will be sluggish, white, aqueous Suspension in package with 1 or 5 hexagonal bottles each with 5 motel bottles per 10 ml each."</seg>
<seg id="970">► review using the label if it is the correct insulin-type ► check out the penis fill cartridge including the rubber grip.</seg>
<seg id="971">Use them not when some damage is seen or a gap between the rubber cobs and the white bond of the label is visible.</seg>
<seg id="972">Further information can be found on the manual's manual for your insulin items. ► Desinfy the rubber compound with a medical tug. ► Beninlets you always get a new injection moulding to avoid contamination.</seg>
<seg id="973">"► in insulin pumps, if the penfill or the device that has the penfill has been dropped, damaged or crushed, is the risk of getting insulin from insulin. if it is not correctly stored or frozen?) ► if it is not correctly white and cloudy."</seg>
<seg id="974">"if you are treated with Actraphane 10 penfill and another insulin in Penfill cartridges, you should use two insulin items systems, each one for each insulin."</seg>
<seg id="975">"before you use the cartridge to use the cartridge system, move it at least 20 times between positions a and b and off (see picture), so that the glass ball moved from one end of the cartridge to the other."</seg>
<seg id="976">Use the injection technology to ensure that the total dose is described for at least 6 seconds under your skin to ensure that the total dose has been injected that the total dose has been injected after every injection the injection moulds to remove and dispose and Actrapane without open injecting injectors.</seg>
<seg id="977">"in 183 Sagen you have to put your relatives, friends and narrow workmates that they may bring you in case of consciousness in the stable side-position and immediately need a doctor."</seg>
<seg id="978">• You forget a insulin object • repeated injecting less insulin than you need • an infection or fever • more food than usual • less physical exercise than usual.</seg>
<seg id="979">"if one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="980">It is recommended - after being taken from the fridge - the temperature of the penfill cartridge has to rise to room temperature before the insulin is lowered according to operating instructions for the first use of resuspened.</seg>
<seg id="981">185 Beast the cartridges always in the Umarton if you do not use it to protect them from light.</seg>
<seg id="982">What acetaphane 10 contains - The substance is distinguished by recombinant DNA technology (10% as soluble insulin and 90% as a Isophan insulin).</seg>
<seg id="983">"like Actrapane and content of the pack's injure is provided as dull, white, aqueous Suspension in packages with 1, 5 or 10 cartridges to each 3 ml."</seg>
<seg id="984">Further information can be found on the manual's manual for your insulin items. ► Desinfy the rubber compound with a medical tug. ► Beninlets you always get a new injection moulding to avoid contamination.</seg>
<seg id="985">"if you are treated with Actraphane 20 penfill and another insulin in Penfill cartridges, you should use two insulin items systems, each one for each insulin."</seg>
<seg id="986">"189 Sagen you have to put your relatives, friends and narrow work mates that they may bring you in case of awareness into the stable side-position and immediately need a doctor."</seg>
<seg id="987">"if one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="988">191 Before always keep the cartridges always in conzarton if you do not use it to protect them from light.</seg>
<seg id="989">What Actrapane 20 contains - The substance is distinguished by recombinant DNA technology (20% as soluble insulin and 80% as a Isophan insulin).</seg>
<seg id="990">"like Actrapane and content of the pack's injure is provided as dull, white, aqueous Suspension in packages with 1, 5 or 10 cartridges to each 3 ml."</seg>
<seg id="991">Further information can be found on the manual's manual for your insulin items. ► Desinfy the rubber compound with a medical tug. ► Beninlets you always get a new injection moulding to avoid contamination.</seg>
<seg id="992">"if you are treated with Actraphane 30 penfill and another insulin in Penfill cartridges, you should use two insulin items systems, each one for each insulin."</seg>
<seg id="993">"195 Sagen you have to put your relatives, friends and more closely at your relatives, bringing you in case of awareness into the stable side-position and immediately need a doctor."</seg>
<seg id="994">"if one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="995">197 Beast the cartridges always in the Umarton if you do not use it to protect them from light.</seg>
<seg id="996">"manufacturer The manufacturer can be identified by the chargers name, which is printed on the lasche of the locker system and on the label, are identified:"</seg>
<seg id="997">"if on the second and third place of the chargers, the character combination W5, S6, K7 or ZF, is the manufacturer Novo Nordisk A / S, Novo Allé, DK- 2880 Bagsvaerd, Denmark"</seg>
<seg id="998">"if the character combination H7 or T6 appears, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F-28002 Chartres, France."</seg>
<seg id="999">Further information can be found on the operating instructions of your Insul insolvency system. ► How do you always find the rubber compound with a medical tug. ► Beninlets you always get a new injection moulding to avoid contamination.</seg>
<seg id="1000">"if you are treated with Actraphanous 40 Penfill and another insulin in Penfill cartridges, you should use two insulin items systems, each one for each insulin."</seg>
<seg id="1001">"201 Sagen you have to put your relatives, friends and narrow workmates that you have to put them in case of consciousness in the stable side position and immediately need a doctor."</seg>
<seg id="1002">"if one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="1003">"203 Before the cartridges always in the Umarton, if you do not use it to protect them from light."</seg>
<seg id="1004">What acetaphore 40 contains - The substance is distinguished by recombinant DNA technology (40% as soluble insulin and 60% as a Isophan insulin).</seg>
<seg id="1005">Further information can be found on the operating instructions of your Insul insolvency system. ► How do you always find the rubber compound with a medical tug. ► Beninlets you always get a new injection moulding to avoid contamination.</seg>
<seg id="1006">"if you are treated with Actraphane 50 penfill and another insulin in Penfill cartridges, you should use two insulin items systems, each one for each insulin."</seg>
<seg id="1007">"before you apply the penfill cartridge into the insulin system, move it at least 20 times between positions a and b on and off (see picture), so that the glass ball moved from one end of the cartridge to the other."</seg>
<seg id="1008">"207 Sagen you have to put your relatives, friends and narrow workmates that they may bring you in case of consciousness in the stable side-position and immediately need a doctor."</seg>
<seg id="1009">"if one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="1010">"209 Before the cartridges always in the Umarton, if you do not use it to protect them from light."</seg>
<seg id="1011">What Actrapane 50 contains - The substance is distinguished by recombinant DNA technology (50% as soluble insulin and 50% as Isophan insulin).</seg>
<seg id="1012">"oral antidiabetic (MAO inhibitors), monoaminoxidic acid, angiotensamomimetica, Growth hormone, Danazol, Octreotid or Langenotid."</seg>
<seg id="1013">► review using the label if it is the correct Insul intyp if it is necessary for each injection a new injection moulding to avoid contamination.</seg>
<seg id="1014">"► in insulin pumps, if the NovoLet was dropped, damaged or crushed, is the danger of getting insulin from insulin. if it was not correctly stored or frozen?) ► if it is not correctly white and cloudy."</seg>
<seg id="1015">"the waiting marks of a subordination can suddenly appear and can be: cold welding, headache, heartfelt, irritating and weakness, nervousness, nervousness or tremble, anxiety, confusion, concentration difficulties."</seg>
<seg id="1016">"214 If any one of the listed side you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="1017">"in use, NovoLet's finished and those that are used soon or as a substitute are not to be kept in the refrigerator."</seg>
<seg id="1018">"it is recommended - after it was taken from the fridge - the temperature of the NovoLet ready to rise to room temperature, before the insulin is lowered according to operating instructions for the first use of resuspened."</seg>
<seg id="1019">Leave the sealing cap of your NovoLet's ready always when NovoLet is not in use to protect the insulin in light.</seg>
<seg id="1020">"like Actrapane and content of the pack's injure is provided as dull, white, aqueous Suspension in package with 5 or 10 finished pens to each 3 ml."</seg>
<seg id="1021">"before each injection • Overview, whether at least 12 units of insulin in the cartridge are left to ensure an equal mixture."</seg>
<seg id="1022">Go back to avoid the injection of air and secure a correct dosage: • Hold you Actrapane 10 NovoLet with the injector to top • cloak a few times with the finger slightly against the cartridge.</seg>
<seg id="1023">"if bubbles are present in the cartridge, then turn the cartridge to hold up in the cartridge, drag the cartridge to keep one click on the arrow (figure C) • During the injection-button to the top, push the press button completely (figure D) • Now you must get out of the tip of injecting needle to drop a drop of insulin."</seg>
<seg id="1024">• Setting the cap back so on the finished pen that the number 0 is in front of the dosing mark (figure E) • Control if the press-button is completely hooked.</seg>
<seg id="1025">"if not, turn the sealing cap, until the press fastener is completely pushy, • Keep your Actrapane 10 NovoLet horizontally."</seg>
<seg id="1026">"if the press-button cannot move freely to the outside, insulin is pushed out of the injection cap • The scale on the sealing cap displays 0, 2, 4, 6, 10, 12, 12, 14, 16 and 18 units."</seg>
<seg id="1027">"the press-button moves out into the outside while you are turning the cap, the scale under the print button shows 20, 40 and 60 units."</seg>
<seg id="1028">"check a dose of a dose, you can check the number on the auditor directly next to the doserala • If you have set the two numbers in order to obtain the specified dose • If you have set a wrong dose, turn the sealing cap simply forward or backwards until you have set the right number of units."</seg>
<seg id="1029">Otherwise insulin from the injections and the one dosage will not be correct • If you have tried a dose of more than 78 units to set out the following steps:</seg>
<seg id="1030">Then take the sealing cap and set them up so back that the 0 of the dosing mark is opposite.</seg>
<seg id="1031">Make sure to press only during the injection on the press knob. • Keep the press fastener after the injection was caught up until the injectors out of the skin was drawn.</seg>
<seg id="1032">"if not, turn the sealing cap, until the print knob is completely thrown, and then proceed as you described in the use of using • Possible, you can listen to the wires of the print button."</seg>
<seg id="1033">"it may be inaccurate • You can adjust no dose which is higher than the number of units in the cartridge unit • You can estimate the remainder scale, how much insulin is still left."</seg>
<seg id="1034">"oral antidiabetic (MAO inhibitors), monoaminoxidic acid, angiotensamomimetica, Growth hormone, Danazol, Octreotid or Langenotid."</seg>
<seg id="1035">"224 If one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="1036">226. each injection • Check if still at least 12 units of insulin in the cartridge are left to ensure an equal mixture.</seg>
<seg id="1037">Go back to avoid the injection of air and secure a correct dosage: • Hold you Actrapane 20 NovoLet with the injection needle to top • Klop a few times with the finger slightly against the cartridge.</seg>
<seg id="1038">"if bubbles are present in the cartridge, then turn the cartridge to keep up in the cartridge, turn the cartridge to keep one click on the arrow (figure C) • During the injection-button to the top, push the press button completely (figure D) • Now you have to get out of the tip of injure needle to get a drop of insulin."</seg>
<seg id="1039">"if not, turn the sealing cap, until the press fastener is completely pushy, • Keep your Actrapane 20 NovoLet horizontally."</seg>
<seg id="1040">"oral antidiabetic (MAO inhibitors), monoaminoxidic acid, angiotensamomimetica, Growth hormone, Danazol, Octreotid or Langenotid."</seg>
<seg id="1041">"234 If any one of the listed side you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="1042">236 before each injection • Check if still at least 12 units of insulin in the cartridge are left to ensure that there is an equal mix.</seg>
<seg id="1043">Go back to avoid the injection of air and secure a correct dosage: • Hold you Actrapane 30 Novolet with the injector to top • cloak a few times with the finger slightly against the cartridge.</seg>
<seg id="1044">"if bubbles are present in the cartridge, then turn the cartridge to hold up in the cartridge, turn the cartridge to keep one click on the arrow (figure C) • During the injection-button to the top, push the press button completely (figure D) • Now you have to get out of the tip of injure needle to get a drop of insulin."</seg>
<seg id="1045">"if not, turn the sealing cap, until the print knob is completely thrown, • Keep up your Actraphane 30 NovoLet horizontally."</seg>
<seg id="1046">"oral antidiabetic (MAO inhibitors), monoaminoxidic acid, angiotensamomimetica, Growth hormone, Danazol, Octreotid or Langenotid."</seg>
<seg id="1047">"if one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="1048">246 Before any injection • Check if still at least 12 units of insulin in the cartridge are left to ensure an equal mixture.</seg>
<seg id="1049">Go back to avoid the injection of air and secure a correct dosage: • Hold you Actraphane 40 NovoLet with the injector to top • cloak a few times with the finger slightly against the cartridge.</seg>
<seg id="1050">"if bubbles are present in the cartridge, then turn the cartridge to hold up in the cartridge, drag the cartridge to keep one click on the arrow (figure C) • During the injecting machine to the top, push the press knob fully (figure D) • Now, turn out the tip of the injection needle to get a drop of insulin."</seg>
<seg id="1051">"if not, turn the sealing cap, until the print knob is completely thrown, • Keep up your Actraphane 40 NovoLet horizontally."</seg>
<seg id="1052">"oral antidiabetic (MAO inhibitors), monoaminoxidic acid, angiotensamomimetica, Growth hormone, Danazol, Octreotid or Langenotid."</seg>
<seg id="1053">"254 If any one of the listed side you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="1054">"it is recommended - after it was taken from the fridge - the temperature of the NovoLet ready to rise to room temperature, before the insulin is lowered according to operating instructions for the first use of resuspened."</seg>
<seg id="1055">256 on each injection • Check if still at least 12 units of insulin in the cartridge are left to ensure an equal mixture.</seg>
<seg id="1056">Go back to avoid the injection of air and secure a correct dosage: • Hold you Actrapane 50 NovoLet with the injector to top • cloak a few times with the finger slightly against the cartridge.</seg>
<seg id="1057">"if bubbles are present in the cartridge, then turn the cartridge to hold up in the cartridge, drag the cartridge to keep one click in the direction of the arrow (figure D) • During the injections to the arrow (figure D) • Now the injections must be made from the tip of injure needle to drop a drop of insulin."</seg>
<seg id="1058">"if not, turn the sealing cap, until the print knob is completely thrown, • Keep up your Actraphanous 50 NovoLet horizontally."</seg>
<seg id="1059">"oral antidiabetic (MAO inhibitors), monoaminoxidic acid, angiotensamomimetica, Growth hormone, Danazol, Octreotid or Langenotid."</seg>
<seg id="1060">"► in insulin pumps, if the Innolet was dropped, damaged or crushed, is the danger of getting insulin from insulin. if it was not correctly stored or frozen?) ► if it is not correctly white and cloudy."</seg>
<seg id="1061">"the waiting marks of a subordination can suddenly appear and can be: cold welding, headache, heartfelt, irritating and weakness, nervousness, nervousness or tremble, anxiety, confusion, concentration difficulties."</seg>
<seg id="1062">"264 If one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="1063">"in use, InnoLet's ready-to-use and such that are used shortly or as a substitute for replacement, are not to be kept in the refrigerator."</seg>
<seg id="1064">"it is recommended - after it was taken from the fridge - the temperature of the InnoLet ready to rise to room temperature, before the insulin is lowered according to operating instructions for the first use of resuspened."</seg>
<seg id="1065">Leave the sealing cap of your innoLet's ready always when InnoLet is not in use to protect the insulin in light.</seg>
<seg id="1066">"like Actrapane and content of the pack's injure is provided as dull, white, aqueous Suspension in packages with 1, 5 or 10 finished pens to each 3 ml."</seg>
<seg id="1067">"the movement must be repeated until the liquid is evenly white and cloudy • After the Resuspenal, you run all the following steps of the injection without delay."</seg>
<seg id="1068">• Desinfect the rubber mimic with a medical Tupfer • Bending you to avoid a contamination of an contamination of a NovoFine S injectors for each injections to avoid contamination of a NovoFine S injectors for each injection and firmly on Actraphane 30 InnoLet (figure 1B) • Ziplating the big external injector and the inner injuncle cap.</seg>
<seg id="1069">"• Control you always, whether the press fastener is complete and the tin controls on zero, • Make the number of units you need to injected by adding the tin control in the clockwise (figure 2)."</seg>
<seg id="1070">Do not use the remaining mengen- scale to measure your insulin dose • you listen to each individually tailored unit a client noise.</seg>
<seg id="1071">Run the injection technology that has shown your doctor • Give the dose by pressing the button in front of you (figure 3).</seg>
<seg id="1072">The dosage regulator has to be injected on zero and you have to listen to the injections at least 6 seconds after injecting that the total insulin-dose must be injected on zero as you can push the tin-load on zero as you can press the injection moulds after the injection. you can press the injection moulds after the injection.</seg>
<seg id="1073">"medical staff, family members, as well as other supervisors must observe general precautions for removal and disposal of injecting injectors, in order to avoid unintended bull with the injector."</seg>
<seg id="1074">"oral antidiabetic (MAO inhibitors), monoaminoxidic acid, angiotensamomimetica, Growth hormone, Danazol, Octreotid or Langenotid."</seg>
<seg id="1075">"► in insulin pumps, when the flexPen was dropped, damaged or broken, there is the danger of getting insulin from insulin. if it was not correctly stored or frozen?) ► if it is not correctly white and cloudy."</seg>
<seg id="1076">"in case you notice the recess or thickening of your skin at the injection point, report to your doctor or your diabettor, because these reactions may become worse or the absorption of your insulin, if you injected into such a place."</seg>
<seg id="1077">"274 If any one of the listed side you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="1078">In use well-flexPen finished and those that are used soon or as a substitute are not to be kept in the refrigerator.</seg>
<seg id="1079">It is recommended - after it was taken from the refrigerator - the temperature of flexpen finished on room temperature before the insulin is used in accordance with the operating instructions for the first use of resuspened.</seg>
<seg id="1080">Leave the sealing cap of your FlexPen ready-always when flexPen isn't in use to protect the insulin from light.</seg>
<seg id="1081">"like Actrapane and content of the pack's injure is provided as dull, white, aqueous Suspension in packages with 1, 5 or 10 finished pens to each 3 ml."</seg>
<seg id="1082">"manufacturer The manufacturer can be identified by the chargers name, which is printed on the lasche of the locker system and on the label, are identified:"</seg>
<seg id="1083">"275 • Falls on the second and third place of the batch designation for W5, Z6, K7, K7 or ZF, is the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France."</seg>
<seg id="1084">"B because of the finished pen between positions 1 and 2 twenty times, so that the glass ball moved from one end of the cartridge to the other."</seg>
<seg id="1085">Move the speed pen at least 10 times between positions 1 and 2 to and off until the liquid knows uniform and cloudy.</seg>
<seg id="1086">"• To reduce the risk of accidental needle, never set the inner hips back on the injection needle after you have taken it once."</seg>
<seg id="1087">279 G Hold you up the flexpen with the injection moulding up and knock a few times with the finger slightly against the cartridge that can collect existing air bubbles above in the cartridge.</seg>
<seg id="1088">"the dose can be corrected both upwards and down, by turning the Dosisvory button in the appropriate direction until the correct dose is facing the marking of the ad."</seg>
<seg id="1089">The present document is a summary of the European Public Health Administration report (EPAR) in which explains how the Committee for Humanitarian Sciences (CHMP) has been judged to make recommendations concerning the application of drug.</seg>
<seg id="1090">"the pharma and effective effective component in Actrapid, insulin, insulin, is produced by the method of so-called" recombinant technology ":"</seg>
<seg id="1091">(44-20) 74 18 84 00 fax (44-20) 74 18 84 12 00 fax (44-20) 74 18 84 12-mail: / / www.emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document for non-commercial purposes only. the EMEA is how was Actrapid investigated?</seg>
<seg id="1092">Actrapid may not be used in patients who might be oversensitive to insulin or one of the other components.</seg>
<seg id="1093">"in addition, the cans of Actrapid may need to be adapted if it is administered along with a number of other medicines that may affect the blood sugar."</seg>
<seg id="1094">October 2002 shared the European Commission to Novo Nordisk A / S approval for the marketing of Actrapid throughout the European Union.</seg>
<seg id="1095">"when two types of insulin be mixed, first the amount of fast insulin must be raised, then the amount of the long reacting insulin."</seg>
<seg id="1096">"3 case, when changing to Actrapid, a dosage adjustment is required, this can be necessary at first dosage or during the first weeks or months after conversion."</seg>
<seg id="1097">"before travelling, going over several time zones, the patient should be pointed out to get the advice of his physician, as such trips can lead to other times, that insulin and meals must be applied to other times."</seg>
<seg id="1098">"occasionally, 5 General disorders and complaints at the administration of the entrance occasionally - Local hypersensitive action on the injector of the injections during the insulin treatment (redness, swelling, juckreiz, pain and hematom at the injection point)."</seg>
<seg id="1099">"diabetics should therefore always have traumatic or subcutaneous injections, sweets, biscuits or sugary fruit juice. • Seriousness of glucose are treated with intramuscular or subcutaneous injections by using intramuscular or subcutaneous injections, or by glucose, which is given intravenously by the doctor."</seg>
<seg id="1100">A clinical trial subjected to the treatment of hyperglycaemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients (blood sugar) induced by 42% (8% compared to 4.6%).</seg>
<seg id="1101">"the effect starts within half an hour, the active max is reached within 1.5 to 3.5 hours and the entire active time period is approximately 7 to 8 hours."</seg>
<seg id="1102">Children and adolescents The pharmacoinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (aged 13 to 17 years).</seg>
<seg id="1103">"the data is limited, however, the assumption that the pharmacoinetic profile in children and adolescents is similar to that of adults."</seg>
<seg id="1104">Infusion systems with Actrapid in concentrations 0.9% sodium dichloride and 10% D- Glucose with 40 mmol / l potassium chlororid are stable for use of polypropylene from polypropylene at room temperature 24 hours a long time.</seg>
<seg id="1105">"11 If switching to Actrapid required when the patient is required, it can be necessary at first dosage or during the first weeks or months after switching."</seg>
<seg id="1106">"before travelling, going over several time zones, the patient should be pointed out to get the advice of his physician, as such trips can lead to other times, that insulin and meals must be applied to other times."</seg>
<seg id="1107">"occasionally, 13 General disorders and complaints on the administration of course, occasionally - Local hypersensitive action on the injecting place of the insulin treatment (redness, swelling, juckreiz, pain and hematom at the injecting place) can occur."</seg>
<seg id="1108">"diabetics should therefore always have traumatic or subcutaneous injections, sweets, biscuits or sugary fruit juice. • Seriousness of glucose are treated with intramuscular or subcutaneous injections by using intramuscular or subcutaneous injections, or by glucose, which is given intravenously by the doctor."</seg>
<seg id="1109">Children and adolescents The pharmacoinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (aged 13 to 17 years).</seg>
<seg id="1110">"the intravenous application of Actrapid from finished or cartridges should represent an exception and only occur in situations, in which no pumping bottles are available."</seg>
<seg id="1111">"if moving to Actrapid, a dosage adaption is required, this can be necessary at first dosage or during the first weeks or months after conversion."</seg>
<seg id="1112">21 diseases of the skin and subhauling webes occasionally - Lipodstreamphie will develop a Lipodstreamphie will arise when failed to change the charities inside the injector.</seg>
<seg id="1113">Children and adolescents The pharmacoinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (aged 13 to 17 years).</seg>
<seg id="1114">29 diseases of the skin and subhauling webes occasionally - Lipodstreamphie will develop a Lipodstreamphie will arise when failed to change the charities inside the injector.</seg>
<seg id="1115">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, itching, shaking, buttonic oils, low blood pressure and impotence, low blood pressure and impotence."</seg>
<seg id="1116">Children and adolescents The pharmacoinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (aged 13 to 17 years).</seg>
<seg id="1117">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, itching, shaking, buttonic oils, low blood pressure and impotence, low blood pressure and impotence."</seg>
<seg id="1118">38 A clinical trial subjected to the treatment of hyperglycaemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients (blood sugar) induced by 42% (8% compared to 4.6%).</seg>
<seg id="1119">"diseases of the immune system occasionally - Urtikaria, Exanthem Very rare - anaphylactic reactions, itching, shaking, buttonic oils, low blood pressure and impotence, low blood pressure and impotence."</seg>
<seg id="1120">46 A clinical trial subjected to the treatment of hyperglycaemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients (blood sugar) induced by 42% (8% compared to 4.6%).</seg>
<seg id="1121">"in the refrigerator (2 ° C - 8 ° C) Not freezing the flashing bottle in the Umarton, to protect the content from light: not in the fridge or over 25 ° C"</seg>
<seg id="1122">Subcutaneous application penfill cartridges are used for use with Novo Nordisk insulin delivery systems intended to be used to account Actrapid penetration may only be used by one person</seg>
<seg id="1123">Store the cartridge in the fridge (2 ° C - 8 ° C) Not freeze The cartridge to protect the content from light to protect the content from light: not in the fridge or over 30 ° C</seg>
<seg id="1124">Subcutaneous application Zur use with Actrapid NovoLet are NovoFine injurnadas to take note Actrapid NovoLet only may be used by one person</seg>
<seg id="1125">"in the fridge (2 ° C - 8 ° C) Not freeze On Light protect light: not in the fridge or over 30 ° C,"</seg>
<seg id="1126">Subcutaneous application Zur use with Actrapid InnoLet are NovoFine S injecting Pnodules Note Actrapid Innolet may be used only by one person</seg>
<seg id="1127">This means that about half an hour after you used it to sink your blood sugar and that the effect will stop about 8 hours.</seg>
<seg id="1128">► review using the label if it is about the correct insulin. ► Desinfy the rubber compound with a medical cloth.</seg>
<seg id="1129">"if this is not totally undeserved when you get the steeping bottle, if it was not stored correctly or frozen (see 6 How is Actrapid to preserve?) ► if it is not clear as water and colourless."</seg>
<seg id="1130">Use the injection technology which has recommended your doctor or your diabetesberaterin recommended ► Lassen you have the injections of at least 6 seconds long under your skin to make sure the full dose has been injected.</seg>
<seg id="1131">"83 Sagen you have to put your relatives, friends and narrow workmates that they have to put you in case of consciousness in the stable side-position and immediately need a doctor."</seg>
<seg id="1132">They may have a very rare severe allergic reaction to Actrapid or one of its components (such a systemic allergic reaction).</seg>
<seg id="1133">"the injection solution is provided as clear, colourless, aqueous solution in packs of 1 or 5 hexagonal bottles each with 10 ml or a bite packs of 5 hexagonal bottles per 10 ml each."</seg>
<seg id="1134">"89 Sagen you have to put your relatives, friends and more closely at your relatives, bringing you in case of awareness into the stable side-position and immediately need a doctor."</seg>
<seg id="1135">"► review using the label, whether it is the correct insulin type, so always check the cartridge including the rubber grip."</seg>
<seg id="1136">"► in insulin pumps, if the penfill or the device that contains the penfill is dropped, damaged or broken; it exists the risk of getting insulin from insulin. if it was not correctly stored or frozen?) ► if it is not clear how water and colourless looks."</seg>
<seg id="1137">"if you are treated with Actrapid Penfill and another insulin in Penfill cartridges, you should use two insulin items systems, each one for each insulin."</seg>
<seg id="1138">Use the injection technology to ensure that the total dose is described for at least 6 seconds below your skin to ensure that the total dose has been injected that the total dose has been injected after every injection the injections and actrapid without insisted injecting injectors.</seg>
<seg id="1139">"• Falls on the second and third place of the batch name, the character combination W5, S6, K7 or ZF, is the manufacturer Novo Nordisk A / S, Novo Allé, DK-2880 Bagsvaerd, Denmark"</seg>
<seg id="1140">"• Falls on the second and third place of the batch name, the character combination H7 or T6 appears, the manufacturer Novo Nordisk Production SAS, 45, Avenue d" Orléans, F- 28002 Chartres, France. "</seg>
<seg id="1141">"oral antidiabetic (MAO inhibitors), monoaminoxidic acid, angiotensamomimetica, Growth hormone, Danazol, Octreotid or Langenotid."</seg>
<seg id="1142">► review using the label whether it is the correct insulin typ. ► How do you always use a new injection moulding to avoid contamination of contamination.</seg>
<seg id="1143">"► in insulin pumps, if the NovoLet was dropped, damaged or broken; there is the risk of getting insulin from insulin. if it was not correctly stored or frozen?) ► if it is not clear how water and colourless looks."</seg>
<seg id="1144">"this can happen: • If you consume too much insulin, if you eat too little or make a meal if you are more than usual physically."</seg>
<seg id="1145">Leave the sealing cap of your NovoLet's ready always when he is not in use to protect him from light.</seg>
<seg id="1146">Take the sealing cap on using a medical Tupfer • Bending you always for any injections to avoid contamination. • Remind the injector of a NovoFine injecting NovoLet (figure A) • Ziplating the big outer cap of injure needle and the inner cap of injecting needle.</seg>
<seg id="1147">Go back to avoid the injection of air and secure a correct dosage: • Hold you Actrapid NovoLet with the injection needle to top • Klop a few times with the finger slightly against the cartridge.</seg>
<seg id="1148">"if bubbles are present in the cartridge, this will continue to collect the injections (figure B) • During the injections to the arrow (figure C) • During the injections to the arrow (figure C) • Now the injections must be made from the tip of injure needle to drop a drop of insulin."</seg>
<seg id="1149">"• Setting the folder folder again so on the finished pen, that the number 0 stands opposite the dosing mark (figure D) • Control, whether the press-button is completely hooked."</seg>
<seg id="1150">"if the press-button cannot move freely, insulin is pushed out of the injection cap • The scale on the sealing cap displays 0, 2, 4, 6, 10, 12, 12, 14, 16 and 18 units."</seg>
<seg id="1151">"the press fastener is moved to the outside, while you are turning the cap, the scale under the press-button (press-button scala) shows 20, 40 and 60 units."</seg>
<seg id="1152">"107 • Notification the highest number you can see on the printed scala • If you have set a wrong dose, turn the box folder simply forward or backwards until you have set the right number of units."</seg>
<seg id="1153">"turn it, until the press button is completely below and you will take a resistance then take the folder folder and then set them up again, that the 0 of the dosing mark is opposite."</seg>
<seg id="1154">Make sure to press only during the injection on the press-button • Keep the press fastener after the injection back down to the injection moulding from the skin.</seg>
<seg id="1155">"it may be inaccurate • You can adjust no dose which is higher than the number of remaining in the cartridge units • You can estimate the resimengenskala to estimate how much insulin is still remaining, but you cannot use it to stop your dose or select."</seg>
<seg id="1156">"oral antidiabetic (MAO inhibitors), monoaminoxidic acid, angiotensamomimetica, Growth hormone, Danazol, Octreotid or Langenotid."</seg>
<seg id="1157">"► in insulin pumps, if the Innolet was dropped, damaged or broken; there is the risk of getting insulin from insulin. if it was not correctly stored or frozen?) ► if it is not clear how water and colourless looks."</seg>
<seg id="1158">Leave the sealing cap of your innoLet's ready always when it is not in use to protect it from light.</seg>
<seg id="1159">• Desinfect the rubber mimic with a medical Tucker • Bending you always for any injections to avoid contamination. • Remove the big outer cap of injector needle and the inner cap of injecting needle.</seg>
<seg id="1160">The dosage regulator has to be injected on zero and you have to listen to the injections at least 6 seconds after injecting that the total insulin-control must be injected on zero as you can press the tin-load on zero as you can press the injection moulding after every injection.</seg>
<seg id="1161">"oral antidiabetic (MAO inhibitors), monoaminoxidic acid, angiotensamomimetica, Growth hormone, Danazol, Octreotid or Langenotid."</seg>
<seg id="1162">121 ► if it was not stored correctly or frozen (see 6 How is Actrapid to preserve?) ► if it is not clear how water and colourless looks.</seg>
<seg id="1163">"if one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor, your diabetesberaterin or your pharmacist."</seg>
<seg id="1164">Leave the sealing cap of your FlexPen ready-always when he is not in use to protect him from light.</seg>
<seg id="1165">F Hold you up the flexpen with the injection moulding up and knock a few times with the finger slightly against the cartridge that can collect existing air bubbles above in the cartridge.</seg>
<seg id="1166">The dose can be corrected both upwards and downstairs by turning the Dosisvory button in the appropriate direction until the correct dose is about the marking of the dosages.</seg>
<seg id="1167">"Adenuric is used in patients who already have signs of crystallings, including arthritis (pain and inflammation in the joints) or toxins (" "stones". "" "stones" "i.e. greater primorals that can lead to articular and bone damages)."</seg>
<seg id="1168">"if the urinary tract is still over 6 mg per decilite, the dose can be increased at once a day of 120 mg."</seg>
<seg id="1169">"during the first treatment months, still toxicity may still occur; therefore, patients may take at least during the first six months under treatment with Adenuric even further medicines for preventing poison."</seg>
<seg id="1170">The medicine is not recommended in children and in patients who had an organ transplantation as it has not been studied for these groups.</seg>
<seg id="1171">"in the first study, recorded by 1 072 patients, the efficacy three different Adenuric doses (once daily 80, 120 and 240 mg) compared with one of the placebo (hypomedikaments) and Allopurinol (another medicine for the treatment of hyperuridic)."</seg>
<seg id="1172">"in the second study, two doses of Adenuric (once daily 80 and 120 mg) were compared to 762 patients with Allopurinol."</seg>
<seg id="1173">"in both studies, Allopurinol was applied in a dose of 300 mg each day; patients with kidney problems received only 100 mg per day."</seg>
<seg id="1174">"main indicator for the effectiveness was the number of patients, their urinary bars in the blood for the last three measurements under 6 mg / dl."</seg>
<seg id="1175">"in the first study 48% (126 of 262) of the patients, the Adenuric took place in a dose of once daily 80 mg, and 65% (175 of 269) of patients having a urinary level in the blood of under 6 mg / dl."</seg>
<seg id="1176">In comparison this was about 22% (60 of 268) of patients under Allopurinol and with none of the 134 patients under placebo.</seg>
<seg id="1177">"the most common side effects of Adenuric (observed at 1 to 10 of 100 patients) are headaches, diarrhea, nausea (Nausea), rash and abnormal liver values."</seg>
<seg id="1178">"in particular, in patients with the heart of heart, there may be an increased risk of certain side effects that affect the heart and blood vessels."</seg>
<seg id="1179">"at the conclusion that Adenuric was more effective in lowering the urinary epithelium in the blood than Allopurinol, but it could also be a higher risk of side effects related to the heart and blood vessels."</seg>
<seg id="1180">"treatment of chronic hyperuritic disease in diseases, which have already led to urantics (including one of the history of the history known or currently present toxins, and / or a Gichtarthritis)."</seg>
<seg id="1181">"if the serum acid level after 2-4 weeks still amounts to &gt; 6 mg / dl (357 µmol / l), a dosage increases on ADENURIC 120 mg 1 x daily."</seg>
<seg id="1182">"in patients with severe kidney disease, the effectiveness and safety so far have not been fully investigated (creative Clearance &lt; 30 ml / min, see Section 5.2)."</seg>
<seg id="1183">Children and young people since children and young people have no experience in children and young people who are not recommended using Febuxostat in this patient group.</seg>
<seg id="1184">"in case of organically transplants, it is not recommended for organically transplants, the application of Febuxostate in this capacity is not recommended (see section 5.1)."</seg>
<seg id="1185">Cardiovascular disease In patients with ischaary heart disease or decompensated heart failure the treatment with Febuxostate is not recommended (see Section 4.8).</seg>
<seg id="1186">"as with other harnseatic medicines, it may come during treatment start to an acute attack because due to the reduction of the Serumharnsäurespiegels initially may be mobilized in the tissue."</seg>
<seg id="1187">B. in malignant diseases and their treatment, Lesch- Nyhan-Syndrome) the absolute concentration of Xanthin in urine in rare cases rise as far as to a deposit in the urinary tract.</seg>
<seg id="1188">Liver disease During the clinical trials of phase 3 have been observed slight refreshes of the liver feature with Febuxostat treated patients (3.5%).</seg>
<seg id="1189">"it is therefore recommended, before the beginning of the Febuxostattreatment and in the further course depending on the clinical use of a liver test (see section 5.1)."</seg>
<seg id="1190">Theophyllon was done no exchange studies on Febuxostate but it is known that the XO-Hemp can lead to an increase in theophylline level (an inhibition of the metation of theophylline was also reported for other XO inhibitors).</seg>
<seg id="1191">"at Probanden, the simultaneous gift of Febuxostat and Naproxen 250 mg 2 x daily associated with a rise in Febuxostature (Cmax 28%, Auc 41% and T1 / 2 26%)."</seg>
<seg id="1192">In clinical studies the application of Naproxen or other NSAR / Cox-2-shirts are not related to a clinically significant increase in unwanted events.</seg>
<seg id="1193">Colchicin / Indometacin / hydrochlorthiacid / Warfarin Febuxostate can be applied together with Colchicin or Indometacin without a dosage adjustment for Febuxostat or at the same time required other substance.</seg>
<seg id="1194">"in a study with Probanden 120 mg ADENURIC 1 x a medium 22% increase in Auipramine, one CYP2D6 substrate, resulting in a possible weak inhibitor effect of Febuxostat on the CYP2D6 enzymes in vivo."</seg>
<seg id="1195">"Antazida It could be shown that the simultaneous taking of a tazidums, the Magnesiumhydroxid and aluminum oxide, the absorption of Febuxostate (around 1 hour) delayed and a drop in the Cmax by 32%, but not a significant change in the auc."</seg>
<seg id="1196">Pregnancy data on a very limited number of expired pregnancies can not include side effects of Febuxostat on the pregnancy or the health of the fetus / newborns.</seg>
<seg id="1197">"animal experimental studies do not allow direct or indirect harmful effects on pregnancy, embryonic / fetal development or birth (see section 5.3)."</seg>
<seg id="1198">"patients should be careful on the taxes of a vehicle, serving machines or in the exercise of hazardous activities until they can be assured that ADENURIC may not be influenced by ADENURIC."</seg>
<seg id="1199">A numerically higher incidence of the Test-related events in the Piotpurinol group was observed in the overall febuxostatGroup compared to the Allopurinol Group compared to the Allopurinol group in the Piotpurinol Group compared to the Allopurinol group in the Piotpurinol Group compared to the Allopurinol group in the Piotpurinol Group compared to the Allopurinol group in the Piotpurinol Group compared to the Allopurinol group in the overall febuxostats group in comparison to the Allopurinol group in the Piotpurinol Group compared to the Allopurinol group in the overall febuxostats group in comparison to the Allopurinol group in the overall febuxostats group in comparison to the Allopurinol group in the overall febuxostats group in comparison to the Allopurinol group in the overall febuxostats group in comparison to the Allopurinol group in the overall febuxostats group in comparison to the Allopurinol group in the overall febuxostats group in comparison to the Allopurinol group in the overall febuxostats group in comparison to the Allopurinol group in the overall febuxostats group in comparison to the Allopurin</seg>
<seg id="1200">The risk factors in these patients were an arterioserotic disease and / or a myocardincolor or a decompensated heart failure in medical history.</seg>
<seg id="1201">"frequent (≥ 1 / 100 to &lt; 1 / 10), occasional (≥ 1 / 100 to &lt; 1 / 10), which appeared in the treatment groups with 80 mg / 120 mg Febuxostat and which were reported in all Febuxostat treatment groups in total more than once, are listed below."</seg>
<seg id="1202">Diarrhoea and vomiting are more common in patients who are treated at the same time with Colchicin. * * In the clinical trials were observed no heavy rash or heavy oversensitive actions.</seg>
<seg id="1203">"7 Offene long-term studies In the open longterm studies studies, 906 patients up to 1 year long, 322 patients up to 3 years and 53 patients with Febuxostate 80 mg / 120 mg."</seg>
<seg id="1204">The events related to long-term studies reported to those who were reported in the studies of phase 3 (see table 1).</seg>
<seg id="1205">"the following treatment-related events have been reported more than once more than once and appeared in patients who received Febuxostat 80 mg / 120 mg in long-term studies studies (up to 4 years with a exposure time of &gt; 1,900 patients years), according to the specifications."</seg>
<seg id="1206">The following treatment-related events have either not been reported in the pivotal studies of phase 3 for these doses or with a lower frequency:</seg>
<seg id="1207">"diabetes, hyperinsufficiency, skin-insufficiency, skin-insufficiency, erectile dysfunction, rise in potassium concentrations in the blood, decline of lymphocytes, decline of the number of white blood cells."</seg>
<seg id="1208">Active mechanism of uric acid is by humans the endproduct of Purinmetabolic and is created in the context of reactkade hypoxanthin → Xanthin → uric acid.</seg>
<seg id="1209">"Febuxostat is a powerful, not Purin-selective Inhibitor the XO (NP-SIXO) with a Ki-value for the vitro inhibitor, which lies below the nanomolar area."</seg>
<seg id="1210">Clinical study results The effectiveness of ADENURIC was shown in two pivotalstudies of phase 3 (APEX Study and Fact study as described below) which were conducted with 1,832 patients with hyperuritic and gout.</seg>
<seg id="1211">The primary efficacy sendpoint was in every study of the proportion of patients in which the last three month has undergone &lt; 6.0 mg / dl (357 µmol / l).</seg>
<seg id="1212">"placebo (n = 134), ADENURIC 80 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269), ADENUR</seg>
<seg id="1213">The APEX study showed that the treatment with ADENURIC 80 mg 1 x daily compared to the treatment with ADENURIC 80 mg 1 x daily compared to the treatment with conventional doses Allopurinol 300 mg (n = 258) / 100 mg (n = 10).</seg>
<seg id="1214">The Fact study showed with regard to the permanent reduction of the Serumharnsäurespid under 6 mg / dl (357 µmol / l) the statistically significant superiority of both the treatment with ADENURIC 120 mg 1 x daily compared to the treatment with the conventional dose of Allopurinol 300 mg.</seg>
<seg id="1215">Patients with serum cancer &gt; 1.5 and &lt; 2.0 mg / dl) or 300 mg 1 x daily (n = 509) were compiled for analyses. * p &lt; 0.001 versus Allopurinol, # p &lt; 0.001 versus 80 mg</seg>
<seg id="1216">Lowering of the Serumharnsäurespiping on &lt; 6.0 mg / dl (357 µmol / l) was observed in the physician visit 2 and permanently maintained over the entire treatment.</seg>
<seg id="1217">"509 patients received Allopurinol 300 mg 1 x daily; 10 patients with serum creatininvalues &gt; 1.5 and &lt; 2,0 mg / dl received 100 mg 1 x daily."</seg>
<seg id="1218">Primary endpoint in the subgroup of patients with kidney work restricts The APEX study rated the effectiveness of 40 patients with kidney functions (d. h.</seg>
<seg id="1219">"with ADENURIC, the primary efficacy level at 44% (80 mg 1 x daily), 45% (120 mg 1 x daily) and 60% (240 mg 1 x daily) of patients."</seg>
<seg id="1220">"there were no clinically significant differences with regard to probanden, regardless of their kidney function (58% in the group with normal kidney function and 55% in the group with severe kidney functional disorders)."</seg>
<seg id="1221">Primary endpoint in the subgroup of patients with serum harnacid recentrates ≥ 10 mg / dl Etwa 40% of the patients (APeline) had a serumharnacid recentration of ≥ 10 mg / dl.</seg>
<seg id="1222">The survey conducted in two years of the open transition study of gypsy (&lt; 357 µmol / l) revealed that less than 3% of patients needed in the months 16-24 (i.e. more than 97% of patients needed no treatment against a gypsum).</seg>
<seg id="1223">"this was associated with a reduction of gypsum size, which in 54% of patients had a complete disappearance of the toxins up to month 24."</seg>
<seg id="1224">Increased TSH- values (&gt; 5.5 µIE / ml) were observed in patients who received a long-term treatment with Febuxostate (5.0%) and also in patients who received Allopurinol (5.8%) in the open long-term studies. (see Section 4.4).</seg>
<seg id="1225">With healthy probances increased the maximum Plasmaconcentric (Auc) of Febuxostat after administration simple and multiple doses from 10 mg to 120 mg dosages.</seg>
<seg id="1226">For doses between 120 mg and 300 mg for doses between 120 mg and 300 mg is observed for Febuxostate an increase in the Auc which is larger than the dosisary increase.</seg>
<seg id="1227">After taking easier or multiple doses of 80 and 120 mg 1 x daily is the Cmax about 2.8-3.2 µg / ml and 5.0-5.3 µg / ml per day.</seg>
<seg id="1228">"however, no clinically significant change was observed in the percentage decline of serum harnacid, provided this has been tested (multiple doses of 80 mg)."</seg>
<seg id="1229">Distribution The apparent Steady state-state volume (VSS / F) of Febuxostat is located in the area of 29 to 75 l after taking doses of 10-300 mg.</seg>
<seg id="1230">The Plasmapron of Febuxostat is about 99.2% (primary bond to Albumin) and is consistent with the concentration width which is reached with doses of 80 and 120 mg.</seg>
<seg id="1231">"in vitro-studies at humanen liver microsummer, CYP1C8, CYP1C8, and that Febuxostatglucuronid is primarily formed by UGT 1A1, 1A8 and 1A9."</seg>
<seg id="1232">After taking a 80 mg dose of 14C-markuxostate found about 49% of the dose in urine as unchangeable Febuxostate (3%) whose well-known oxidative Metabolites and their Konjugate (13%) as well as other unfamiliar Metabolites (3%).</seg>
<seg id="1233">"in addition to the excretion of urine, approximately 45% of the dose found in the chair as unchangeable Febuxostate (1%), whose well-known oxidative Metabolites and their Konjugate (25%) as well as other unfamiliar Metabolites (7%)."</seg>
<seg id="1234">"special patient groups kidney insufficiency After taking multiple mg of 80 mg ADENURIC in patients with mild, moderate or severe kidney failure, the Cmax of Febuxostate did not change in relation to proportions associated with normal kidney function."</seg>
<seg id="1235">The average overall Auc von Febuxostat took around the 1.8-fold of 7.5 μ g in the group with normal kidney function to 13.2 μ g in the group with severe Nierendysfunction.</seg>
<seg id="1236">12 liver functional layers of 80 mg of ADENURIC in patients with mild (Child- Pugh-classification A) or moderate-classification (Child-Pugh-classification A) or moderate-classification (Child-Pugh-classification A) or moderate-classification (Child-Pugh-classification A) or moderate-classification (Child-Pugh-classification A) or moderate-classification (Child-Pugh-classification A) or moderate-classification (Child-Pugh-classification B). liver functional (Child-Pugh-classification A) or a moderate-classification (Child-Pugh-classification A) or a moderate-classification (Child-Pugh-classification A) or a moderate-classification (Child-Pugh-classification B). liver functional (Child-Pugh-classification A) or a moderate-classification (Child-Pugh-classification A) or a moderate-classification (Child-Pugh-classification A) or a moderate-classification (Child-Pugh-classification B). liver functional (Child-Pugh-classification A) or a moderate-classification (Child-Pugh-classification A) or a moderate-classification (Child-Pugh-classification B). liver functional (Child-</seg>
<seg id="1237">Age There were not any significant changes in terms of the Auc von Febuxostat or its Metabolites after taking multiple doses of ADENURIC in older patients compared to younger subjects.</seg>
<seg id="1238">"carcinogenesis, Mutagenese, impairment of fertility When male rats has been found a statistically significant increase by uranthin-stones (transitional cell papillome and carcinome) only in connection with Xanthin-stones in the highly treated group, at approximately the 11-times of exposure to humans."</seg>
<seg id="1239">These findings are seen as a consequence of a specific Purinmetabolic and urine composition and is not relevant for clinical use as non-relevant.</seg>
<seg id="1240">It was found that Febuxostat in oralen doses of up to 48 mg / kg / day has no effect on the fertility and reproductive performance of male and female rats.</seg>
<seg id="1241">"at high doses, which were approximately with 4.3- times of human therapeutic exposure, maternal toxicity came up, which went with a reduction in the performance and a development delay in the descendants of rats."</seg>
<seg id="1242">"teratological studies in trailing rats with expositions, which carried out about the 4,3-fold and in trailing rabbits with expositions, which carried out about the 13-times of human therapeutic exposure, had no teratogenic effects."</seg>
<seg id="1243">Colchicin / Indometacin / hydrochlorthiacid / Warfarin Febuxostate can be applied together with Colchicin or Indometacin without a dosage adjustment for Febuxostat or at the same time required other substance.</seg>
<seg id="1244">Diarrhoea and vomiting are more common in patients who are treated at the same time with Colchicin. * * In the clinical trials were observed no heavy rash or heavy oversensitive actions.</seg>
<seg id="1245">"21 Offene long-term studies In the open longterm studies studies, 906 patients up to 1 year long, 322 patients up to 3 years and 53 patients with Febuxostate 80 mg / 120 mg."</seg>
<seg id="1246">The primary efficacy sendpoint was in every study of the proportion of patients in which the last three month has undergone &lt; 6.0 mg / dl (357 µmol / l).</seg>
<seg id="1247">The survey conducted in two years of the open transition study of gypsy (&lt; 357 µmol / l) revealed that less than 3% of patients needed in the months 16-24 (i.e. more than 97% of patients needed no treatment against a gypsum).</seg>
<seg id="1248">26 as unchangeable Febuxostate (3%) Acylatex curve (30%) whose well-known oxidative Metabolites and their Konjugate (13%) as well as other unfamiliar Metabolites (3%).</seg>
<seg id="1249">"liver functionally, after taking multiple mg of 80 mg ADENURIC in patients with mild (child- Pugh-classification A) or moderate-classification (Child-Pugh-classification B), for example, the Cmax and Auc of Febuxostate and its Metabolic is not significant compared to proportions associated with normal liver function."</seg>
<seg id="1250">"carcinogenesis, Mutagenese, impairment of fertility When male rats has been found a statistically significant increase by uranthin-stones (transitional cell papillome and carcinome) only in connection with Xanthin-stones in the highly treated group, at approximately the 11-times of exposure to humans."</seg>
<seg id="1251">"the holder of the approval of the authorisation will be safe to make sure a pharmaceutical system as described in version 2.0 module 1.8.1 of the application, is ready before the drug is brought in traffic, and as long as the medicine is brought in traffic."</seg>
<seg id="1252">Updated RMP is currently under the CHMP Guideline to risk management systems for human medicines with the next Periodic Safety Update Report (PSUR).</seg>
<seg id="1253">"in addition, an update of the RMP required • if new information is available, which have an impact on the security information, the pharmaceutical agents or activities to risk minimization • within 60 days after reaching important milestones in achieving important milestones (pharmaceuticals or risk imperfections) • at the request of the EMEA region"</seg>
<seg id="1254">"in some people, the uric acid in the blood can be reached in the blood and can reach concentrations that are so high that uric acid is insoluble."</seg>
<seg id="1255">"if you keep the urethral concentric due to the 1 x daily intake of ADENURIC, the crystalline is prevented and thus reached in this way a minus of the complaints."</seg>
<seg id="1256">ADENURIC may not be taken if you are oversensitive (allergic) against the active ingredient Febuxostat or one of the other components of ADENURIC.</seg>
<seg id="1257">Inform your doctor before you start taking this medication by starting with taking this medicine if you have a heart infection or have suffered or an other heart problem. • if you have suffered a cardiac disease or an other heart problem (a rare innate condition in which there is too much uric acid in the blood).</seg>
<seg id="1258">"if you have a gypsum of heavy pain, pressure-sensitivity, redness, heat and money-swelling), you are waiting until the Gichtan accident, before you start with ADENURIC."</seg>
<seg id="1259">"this does not have to be in any way, but in particular during the first treatment weeks or - monads occur if you are taking ADENURIC."</seg>
<seg id="1260">Your doctor will prescribe other medicines to treat a pochtal case or to treat the associated symptoms (such as pain and joint).</seg>
<seg id="1261">"please inform your doctor or pharmacist if you are taking other medicines / apply / apply recently, even if they are not prescription drugs."</seg>
<seg id="1262">"it is particularly important to inform your doctor or pharmacist if you are taking medication / apply one of the above-mentioned substances, as interactions with ADENURIC may occur and your doctor may require necessary measures as interactions with ADENURIC (for the treatment of asthma) • Warfarin (for the treatment of asthma) • Warfarin (for the treatment of asthma) • Warfarin (to treat asthma)."</seg>
<seg id="1263">"no studies have been carried out on the effects of ADENURIC on the traffic noise, and the ability to serve machines."</seg>
<seg id="1264">Please take ADENURIC only after contacting your doctor if you know that you are suffering from intolerability to certain victors.</seg>
<seg id="1265">"at the back of the leaf packer, the individual weekdays are reprinted, so you can check if you've taken a tablet every day. • The tablets must be swallowed and can be taken with or without food."</seg>
<seg id="1266">"if you deliberately have taken an overdose, please contact your doctor or at the reception of the nearest hospital."</seg>
<seg id="1267">"if you have forgotten the intake of ADENURIC, you will get this as fast as the next intake is just before."</seg>
<seg id="1268">"when you break the ADENURIC, your urine-gyms can rise again, and your complaints can worsen because new urine crystals can form in your joints and the kidneys, as well as their environment."</seg>
<seg id="1269">"frequent side effects (more than 1 of 100 treated, but less than 1 of 10 were treated): • showcased liver testvalues • diarrhea headache • rash"</seg>
<seg id="1270">"rare side-effects (more than 1 of 10,000 treated, but less than 1 of 1,000 treated): • weakness • Nervosity • During sense • heartbeat"</seg>
<seg id="1271">Please inform your doctor or pharmacist if one of the listed side effects you have considerably affected or you notice side effects which are not stated in this usage information.</seg>
<seg id="1272">ADENURIC is available in 2 leaflets with 14 tablets (Packages with 28 tablets) or in 6 Blisterpackets with 14 tablets (Packung with 84 tablets).</seg>
<seg id="1273">How to broadcast live Faufour Ipsen Pharma 24 rue Erlanger F-75781 Paris Cedex 16 France Tél: + 33 - 1 - 44 96 13 13</seg>
<seg id="1274">"Danmark, Norge, Norge, Suomi / Finland, Sverige, Ísland Institute dyögatan 33 SE - 164 51 Kista / Sími / Sími / Sími / Sími: + 46 8 588 370 70"</seg>
<seg id="1275">ADROVANCE is used to treat osteoporosis (a disease where the bones are brittle) in women after menopause in which there is a risk for a low vitamin D mirror.</seg>
<seg id="1276">"the patient must take the tablet with a full glass of water (no mineral water) at least 30 minutes before eating, drinking or taking other medicines (including Antazida, Calcium- and vitamin supplements)."</seg>
<seg id="1277">"to avoid a irritation of the esophagus, the patient may take up to after the first food intake of the day, the earliest 30 minutes after taking the tablet should not lie down."</seg>
<seg id="1278">"since Alendronate and vitamin D3 are already used separately in pharmaceuticals, which are approved in the European Union, presented the data from earlier studies and published literature."</seg>
<seg id="1279">"the company also conducted a study with 35 men and 682 postmenopausal women with osteoporosis, in order to prove the effectiveness of ADROVANCE regarding the increase in the vitamin D mirror."</seg>
<seg id="1280">"after a 15-week treatment, the proportion of patients with low vitamin D-mirror had been treated with ADROVANCE (11%) than those with ADROVANCE (32%)."</seg>
<seg id="1281">"the company also presented data to indicate that the Alendronate Alendron dose corresponds exactly the dose, which is needed for preventing bone loss."</seg>
<seg id="1282">"the most common side-effects (observed for 1 to 10 of 100 patients) are headaches, pain of movement apparatus (muscles, bones or joints) and symptoms of the digestive apparatus (diarrhoea), sorceration, dysphagie (diarrhea), flatulence (diarrhoea), flatulence (diarrhoea), flatulence (diarrhoea), flatulence (diarrhea), flatulence (diarrhoea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhoea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhea), flatulence (diarrhe</seg>
<seg id="1283">"in patients with limited hypersensitivity (allergy) against Alendronate, Vitamin D3 or any of the other components, ADROVANCE may not be applied."</seg>
<seg id="1284">"it must not be applied in case of the food waste, in patients with hypocalcemia (gerinconsistent calcium levels) or in patients who are not at least 30 minutes long standing or sit."</seg>
<seg id="1285">January 2007 the European Commission issued the company Merck Sharp & Dohme Ltd. approval for the marketing of ADROVANCE in the entire European Union.</seg>
<seg id="1286">"capsule-shaped, white to broken white tablets, marked with the outline of a button on one side and" 710 "on the other side."</seg>
<seg id="1287">ADROVANCE is only with water (not with mineral water) at least 30 minutes before the first meal, beverage or inhalation of drugs (including Antazida, Calcium- and Vitaminsupplementation) for the day.</seg>
<seg id="1288">"the following indications are to be observed precisely to reduce the risk for ösophageal irritation, and associated side effects (see Section 4.4):"</seg>
<seg id="1289">• ADROVANCE should be swallowed up by the day with a full glass of water (at least 200 ml). • The patients should not leave the tablet as a risk of oropharyngeal Ulzera. • The patients should not take place before the first food intake of the day that shall be at the earliest 30 minutes after taking the tablet.</seg>
<seg id="1290">"B. peptic Ulkus, active gastrointestinal alpha bleeding or surgical procedures in the upper Gastrointestinal inaltrakt, except Pylorlasty, only under special caution should be given (see section 4.3)."</seg>
<seg id="1291">"Ösophageal reactions, such as oil-hagitis, ösophageal Ulzera and ösophageal erooms, rarely followed by ösophageal ropes, were reported in patients under the intake of Alendronate (partly were these severe and required a hospital reference)."</seg>
<seg id="1292">"the doctor should therefore look attentive to all signs and symptoms to point out the adverse reactions such as dysphagie, pain while dropping or retroernernale pain, or new or implimatial sodburn, to apply the medicine and get medical advice (see Section 4.8)."</seg>
<seg id="1293">"3 The risk of severe ösophageal side-effects seems to be increased in patients who are not properly taking correctly and / or after the occurrence of symptoms, which refer to a ösophageal irritation."</seg>
<seg id="1294">It is very important that all Doing instructions are passed on to the patient and understood by the patient (see Section 4.2).</seg>
<seg id="1295">"while in large-scale clinical trials with Alendronate no higher risk was found, rarely (after market launch) stomach and duodenalulzera, including some severe and with complications, reports (see Section 4.8)."</seg>
<seg id="1296">"osteonekrose of the jaw, usually related to a tooth extraction and / or of a local infection (including osteomyelitis), was reported in cancer patients whose therapy has been predominantly intravenously intravenous Bisphosphonate."</seg>
<seg id="1297">"there are no data available to provide the clues, whether the subscriber of a bisphosphonattherapy in patients who require a orthosurgical procedure, reduces the risk of a osteonekrose of the jaw."</seg>
<seg id="1298">Clinical evaluation by the treating doctor is crucial for the therapy planning on each patient based on an individual benefit risk assessment.</seg>
<seg id="1299">Patients should be instructed to take notice of the intake of a dose of ADROVANCE the tablet for the next morning after they have noticed their omistion.</seg>
<seg id="1300">"you should not take two tablets on the same day, but take the intake of one tablet per week, as originally planned on the scheduled weekday."</seg>
<seg id="1301">"other diseases, which affect the mineral metabolism (such as vitamin D deficiency and hypoparathyreoidism), should also be treated at the beginning of therapy with ADROVANCE."</seg>
<seg id="1302">"alendronate food and drinks (including mineral water), calcium supplement, antazida and some orale medicines may affect the resorption of alendronate if taken at the same time."</seg>
<seg id="1303">Therefore patients must wait at least 30 minutes after the intake of Alendronate at least 30 minutes before they take other medicines (see sections 4.2 and 5.2).</seg>
<seg id="1304">"although specific Interactions studies were not performed, Alendronate was taken together with a variety of commonly prescribed medicines, without clinically relevant exchange effects."</seg>
<seg id="1305">ADROVANCE is only intended for use in postmenopausal women and therefore it is not valid during pregnancy.</seg>
<seg id="1306">"animal studies with Alendron leave no indication of direct harmful effects in terms of pregnancy, the embryo / fetal or post-natal development."</seg>
<seg id="1307">"osteonekrose of the jaw was reported in patients under Bisphosphate, but most reports were reported by cancer patients, but was also reported in Osteology patients."</seg>
<seg id="1308">"nevertheless, the Serum-Calcium took up to &lt; 8.0 mg / dl (2,0 mmol / l) and the Serum- Phosphate to &lt; 2,0 mg / dl (0.65 mmol / l) in both treatment groups with similar frequency."</seg>
<seg id="1309">"Alendron as a result of oral overdose can hypocalcemia, hypophosphere, and side-effects in the upper gastrointestinal inaltrakt, as gastripe, sodburn, oil-hagitis, gastritis or Ulzera."</seg>
<seg id="1310">Colecalciferol (vitamin D3) vitamin D3 is produced in the skin through ultraviolet light on the transformation of 7-stretching out to vitamin D3.</seg>
<seg id="1311">"the main-effect of 1,25-Dihydrooping D3 is the increase in the intestinal resorption of calcium and phosphate, as well as regulation of serum calcium, the renal excretion of calcium and of phosphors, bone formation and bone resorption."</seg>
<seg id="1312">"in severe cases, a lack of secondary hyperparathyreoidism, hypophosphataemia, weakness of the proximal muscles and osteomalazie and thus further increased risk of falls and bone bursts for osteoporotischen people."</seg>
<seg id="1313">"bone mineral resources) at spinal or hip, which lies 2.5 standard deviations below the mean value for a normal, young population, or regardless of bone density as present pathological questionnaires."</seg>
<seg id="1314">The patients received ADROVANCE in the lower strength (70 mg / 2.800) (n = 350) or FOSAMAX (n = 332); additional vitamin D supplements were prohibited.</seg>
<seg id="1315">After 15-weekly treatment the medium Serum levels of 25-hydroxylenANCE (26%) in the group under Alendronate alone (46 nmol / l [18.2 ng / ml]) than in the group under Alendronate alone (46 nmol / l [18.2 ng / ml]).</seg>
<seg id="1316">ADROVANCE (70 mg / 2.800) lowered proportion of patients with vitamin D insufficiency (serum value of 25-hydroxynmol / l [&lt; 15 ng / ml]) by 62.5% compared to Alendronate alone (12% vs.</seg>
<seg id="1317">Studies with Alendronate once weekly 70 mg (n = 519) and Alendronate 10 mg daily (n = 370) was detected in a-year-multicent study on postmenopausal women with osteoporosis.</seg>
<seg id="1318">The effects of alendronate on bone mass and fractures for postmenopausal women were examined in two phase III studies of identical design (n = 944) as well as in the fracture intervention (FIT: n = 6.459).</seg>
<seg id="1319">"in Phase III studies, the middle anchoes of the BMD amounted to 10 mg / day in proportion to placebo after 3 years 8% at the spine, 5.9% at the Femurhals and 7.8% at the Trochanter."</seg>
<seg id="1320">"in the group treated with Alendronate group, a reduction of 48% (Alendronate 3,2% compared to placebo 6.2%) in the proportion of patients, one or more typology suffered."</seg>
<seg id="1321">"in the two-year extension of these studies, the attacks of the BMD of spinal column and trochanters continued to continue; also the BMD of the Femurhalses and the entire body was maintained."</seg>
<seg id="1322">"fit consisted of two plazebocontrolled studies, where Alendronate daily (5 mg daily over 2 years and then 10 mg daily was taken either over 1 or 2 years):"</seg>
<seg id="1323">In this study the daily gift of Alendron reduced the appearance of at least a new spine of 47% (Alendronate 7.9% compared to placebo 15,0%).</seg>
<seg id="1324">Resorption related to a intravenous reference dose was the mean orale bioavailability of Alendronate in women 0.64% for cans between 5 and 70 mg after nocturnal fasting and two hours before recording a standardized breakfast.</seg>
<seg id="1325">The bioavailability accepted accordingly to approximately 0.46% and 0.39% off when Alendronate was taken or half an hour before a standardised breakfast was taken.</seg>
<seg id="1326">"in Osteosestuary, Alendronate was effective if it was taken at least 30 minutes before the first meal or drinking of the day."</seg>
<seg id="1327">With healthy progangs the gift of oral prednison (20 mg three times a day over five days) to no clinically significant change in oral bioverlability of alendronate (increase in funds in the area of 20% to 44%).</seg>
<seg id="1328">"9 distribution studies on rats have yielded that Alendronate spread after intravenous treatment of 1 mg / kg temporarily into pasture-carvings, but then quickly redistributed to the bone or rescued with urine."</seg>
<seg id="1329">"excretion of intravenous treatment of a single dose of 14C-Alendronate, about 50% of the radioactive substance were reduced within 72 hours with urine and little or no radioactivity was found in the subjects."</seg>
<seg id="1330">After intravenous gift of a single dose of 10 mg the renal Clearance from Alendronate 71 ml / min and the systemic Clearance passed not 200 ml / min.</seg>
<seg id="1331">Alendronat will not be left over the suction or alkaline transport system of the kidneys and therefore it is not assumed that in humans the excretion of other medicines has been influenced by these transport systems.</seg>
<seg id="1332">Resorption of healthy adult probanden (women and men) after the gift of ADROVANCE after nightly fasting and two hours before taking a meal the average area under the Serum concentration time-curve (AUC0-120 h) for vitamin D3 296.4 ng • h / ml (without consideration endogenous vitamin D3 mirror).</seg>
<seg id="1333">The average maximum concentration in Serum (Cmax) of vitamin D3 was 5.9 ng / ml and the media until reaching the maximum level of serum (Tmax) 12 hours.</seg>
<seg id="1334">"Biotransformations Vitamin D3 will quickly be hydroxyleneck in the liver and then in the kidney to 1,25-DihydroxyD3, the biologically active form, metabolic."</seg>
<seg id="1335">"separation of radioactive vitamin D3 in healthy promoters, the mean balance between radioactivity in urine after 48 hours 2,4%, in the subjects after 4 days 4.9%."</seg>
<seg id="1336">"characteristics with patients preclinical studies have shown that the proportion of Alendronate, who is not deposited in bone, quickly expire over the urine."</seg>
<seg id="1337">"although there is no clinical data about it, it is nevertheless reckon that the renal elimination of Alendronate like in the animal try to be reduced in patients with reduced kidney function."</seg>
<seg id="1338">"therefore, in patients with reduced kidney function, is to be expected in the bone of alendronate in bone (see Section 4.2)."</seg>
<seg id="1339">"Alendron non-clinical data based on conventional studies on the safety of security, for chronic toxicity, to genotoxicity and Cancerogenic potential do not allow any special danger to the people."</seg>
<seg id="1340">Studies on rats showed that the gift of Alendronat went up with the appearance of dystokie with the appearance of Dystokie in the womb that was due to hypocalcemia.</seg>
<seg id="1341">Micro-crystalline cellulum Cellulose hormone (Ph.Eur.) Lactose dioxide magnesium ariumsteared (Ph.Eur.) (E 572) Butylhydroxytoluol (Ph.Eur.) (E 321) thickness (Ph.Eur.) (E 321) Stylated silicat (E 554)</seg>
<seg id="1342">"Etui with sealed aluminium / aluminum aperture packs in umarton (1 Etui with 4 tablets), 4 (3 Etuis with 4 tablets), 12 (3 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets."</seg>
<seg id="1343">EU / 1 / 06 / 364 / 002 - 4 tablets EU / 1 / 06 / 364 / 004 - 12 tablets EU / 1 / 06 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"right-up, white to broken white tablets, marked with the outline of a button on the one side and" 270 "on the other side."</seg>
<seg id="1345">13 • The patients should not lie down at ADROVANCE at least 30 minutes. • ADROVANCE should not be taken before bedtime or prior to the first appearance of the day.</seg>
<seg id="1346">"the risk of severe ösophageal side-effects seems to be increased in patients who are not properly taking correctly and / or after the occurrence of symptoms, which refer to a ösophageal irritation."</seg>
<seg id="1347">"while in large-scale clinical trials with Alendronate no higher risk was found, rarely (after market launch) stomach and duodenalulzera, including some severe and with complications, reports (see Section 4.8)."</seg>
<seg id="1348">18 Colecalciferol (vitamin D3) vitamin D3 is produced in the skin through ultraviolet light on the transformation of 7-stretching out to vitamin D3.</seg>
<seg id="1349">The patients received ADROVANCE in the lower strength (70 mg / 2.800) (n = 350) or FOSAMAX (n = 332); additional vitamin D supplements were prohibited.</seg>
<seg id="1350">Vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) once weekly corresponds to 619 postmenopausal women with osteoporosis.</seg>
<seg id="1351">After 24-weekly treatment the medium Serum levels of 25-hydroxylend (69 nmol / l [27,6 ng / ml]) than in the 2.800-I.E.-vitamin D3-group (64 nmol / l [25,5 ng / ml]).</seg>
<seg id="1352">There was no statistically significant difference between treatment groups in proportion of patients with hypercalciuria at the end of the 24-week extension.</seg>
<seg id="1353">3.1% of the entire hips in the group with 70 mg once a week or in the 10 mg daily.</seg>
<seg id="1354">In this study the daily gift of Alendron reduced the appearance of at least a new spine of 47% (Alendronate 7.9% compared to placebo 15,0%).</seg>
<seg id="1355">The bioavailability accepted accordingly to approximately 0.46% and 0.39% off if Alendronate was one or half an hour before a standardised breakfast</seg>
<seg id="1356">"distribution studies on rats have yielded that Alendronate spread after intravenous treatment of 1 mg / kg temporarily into pasture-carvings, but then quickly redistributed to the bone or rescued with urine."</seg>
<seg id="1357">Resorption In healthy adult probanden (70 mg / 5.600) was after the gift of ADROVANCE (70 mg / 5.600 h) after a meal of ADROVANCE (AUC0-80 h) for vitamin D3 490,2 ng • h / ml (without consideration endogenous vitamin D3 mirror).</seg>
<seg id="1358">The average maximum concentration in Serum (Cmax) of vitamin D3 was 12.2 ng / ml and the media until reaching the maximum level of serum (Tmax) 10.6 hours.</seg>
<seg id="1359">Smaller amounts are distributed in fat and muscle tissues and are stored there as vitamin D3 in order to be given later in the circulation systems.</seg>
<seg id="1360">"21 vitamin D3 is rapidly distributed in the liver to 25-hydroxyja D3 hydroxyleneck and then in the kidney to 1,25-DihydroxyD3, the biologically active form, metabolic."</seg>
<seg id="1361">There were no indications of a satiation of the absorption of the button after long-term dotization of cumulative intravenous doses up to 35 mg / kg in animals.</seg>
<seg id="1362">"Etui with sealed aluminium / aluminum aperture packs in umarton (1 Etui with 2 tablets), 4 (1 Etui with 4 tablets), 12 (3 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets."</seg>
<seg id="1363">The holder of the approval of the approval of the authorisation is to make sure a pharmacoyancy system is described as in version 2 module 1.8.1 the filing is ready before the drug is brought into the traffic and so long is available how the market has been brought into traffic.</seg>
<seg id="1364">"risk management plan The owner of approval for the marketing is obliged to perform studies and further drug activities of the pharmacower-plan, which are described in the risk-management plan (RMP) and its corresponding updates in accordance with version 1 module 1.8.2 of the regulatory filing."</seg>
<seg id="1365">Updated RMP is in accordance with CHMP Guideline to risk management systems for human health care systems with the next Periodic Saftey Update Report (PSUR).</seg>
<seg id="1366">"in addition, an update of the RMP required − if new information is available, which have an impact on the safety information, the pharmaceutical and drug activities - within 60 days after reaching important milestones (pharmaceuticals or risk immune) - on request of the EMEA."</seg>
<seg id="1367">"take a ADROVANCE tablet after the recording, as well as before the first meal and drinking, and before taking any other medicines, by taking the tablet with a full glass of water (not with mineral water) (not chewing, and not lutches)."</seg>
<seg id="1368">"maybe you would like to read them later again. • If you have further questions, please contact your doctor or pharmacist. • This medicine has been dedicated to you personally."</seg>
<seg id="1369">"in the menopause the ovaries do not produce female hormones, estrogen, more, which help to preserve the skeleton of women healthy."</seg>
<seg id="1370">"the fraternity usually arise at the hip, the spine or the wrist, and cannot only cause considerable problems like a bowed attitude (" Witwenbule ") and a loss of flexibility."</seg>
<seg id="1371">ADROVANCE not only prevents loss of bone mass but also contributes to reducing the bone loss again and reduce the risk for spinal and hip breakthroughs.</seg>
<seg id="1372">"if it is not possible to sit down at least 30 minutes or stand alone, (4) if your doctor has found that your calcium content is humiliated in the blood."</seg>
<seg id="1373">"40 • If you're having problems in the blood or with the digestion, • If your calcium levels are lower in the blood, • if you have a chemotherapy or radiotherapy, • if you take steroids (cortisonentiate) • If you are not routinely go to dental care."</seg>
<seg id="1374">These complaints can occur in particular if the patients are taking the ADROVANCE tablet with a full glass of water and / or move again from 30 minutes after the intake.</seg>
<seg id="1375">"when taking ADROVANCE with other medicines Calciumsupplementation, Antazida and some other medicines can take the effectiveness of ADROVANCE during simultaneous intake."</seg>
<seg id="1376">"certain medicines or food additives can hinder vitamin D in the body, including artificial fat materials, minerals, orlistat and the cholesterinsenkenden drug cholestyramine and colestipol."</seg>
<seg id="1377">"please inform your doctor or pharmacist if you are taking other medicines / apply / apply recently, even if it is not prescription drugs"</seg>
<seg id="1378">Please take this medicine only after contacting your doctor if you know that you are suffering from intolerability to certain victors.</seg>
<seg id="1379">"please follow the indications 2), 3), 4) and 5) to reduce the transport of ADROVANCE tablet into the stomach and to reduce the possible irritation of the esophagus (Ösophagus - the tube, which connects your mouth with the stomach)."</seg>
<seg id="1380">(2) Take the ADROVANCE tablet after the first appearance and before intake of any food or beverages as well as intake of any other medicines only with a full glass (with or without carbon water). • Not with coffee or tea. • Not with juice or milk.</seg>
<seg id="1381">"(3) Leave yourself not to - stay completely upright (sitting, in the stand or walking) - at least 30 minutes after taking the tablet."</seg>
<seg id="1382">"(5) If in case of any difficulty or pain in hiding, pain behind the nipbone, replacent or deteriorating soburn, you are entitled ADROVANCE and look for your doctor."</seg>
<seg id="1383">"(6) Wait after the slip of your ADROVANCE tablet for at least 30 minutes before you take your first food, drinks or other medicines such as Antazida (mainstaller), calcium or vitamin parate to take this day."</seg>
<seg id="1384">"should you accidentally have taken many tablets at once, drink a full glass of milk and please immediately contact your doctor."</seg>
<seg id="1385">"if you have failed to have taking a tablet, take only one tablet in the next morning after you have noticed your verse."</seg>
<seg id="1386">"frequently: • acid loophagus; sorting down the saucer (Ösophagus - the tube, which connects your mouth with your stomach), the pain in the chest, sodburn, and / or joint pain, instipation; diarrhea; diarrhea; diarrhea, • headaches."</seg>
<seg id="1387">"occasionally: • nausea; vomiting, • irritation and inflammation of the esophagus (Ösophagus - the tubes, which connects your mouth with your stomach) or the gastrikskin, • black or teerlike chair, • rash; itching skin."</seg>
<seg id="1388">"according to market launch, the following side-effects were reported (incidence -) dizziness, • fatigue, • fatigue, • orthodonor infections, often after pulling of teeth, • swelling at hands or legs."</seg>
<seg id="1389">43 For is it helpful if you want to note what complaints you had when they began and how long they stopped.</seg>
<seg id="1390">"the other components are microcrystalline cellulose (E 460), Lactose, moderate triglycerium, superfylhydroxyuol (Ph.Eur.) (E 321), thickness, modified (mac), and alumnatriumsilicat (E 554)."</seg>
<seg id="1391">The tablets are available in Etuis with sealed aluminium / aluminium blister packages • 4 tablets (1 Etui with 4 tablets in aluminum blister packages) • 40 tablets (10 Etuis with 4 tablets in aluminum blister packs) • 40 tablets (10 Etuis with 4 tablets in aluminum blister packages).</seg>
<seg id="1392">"in the menopause the ovaries do not produce female hormones, estrogen, more, which help to preserve the skeleton of women healthy."</seg>
<seg id="1393">"48 • If you have allergies, if you have trouble when you're dropping or with digestion, • If you have a cancer risk, • If you have a chemotherapy or radiotherapy, • if you're taking mortality or radiotherapy, • if you are not routinely go to dental care."</seg>
<seg id="1394">"when taking ADROVANCE with other medicines Calciumsupplementation, Antazida and some other medicines can take the effectiveness of ADROVANCE during simultaneous intake."</seg>
<seg id="1395">2) Take the ADROVANCE tablet after the first appearance and before intake of any food or beverages as well as intake of any other medicines only with a full glass (with or without carbon water). • Not with coffee or tea. • Not with juice or milk.</seg>
<seg id="1396">"3) Leave yourself not to - stay completely upright (sitting, in the stand or walking) - at least 30 minutes after taking the tablet."</seg>
<seg id="1397">"5) If in case of any difficulty or pain in hiding, pain behind the nipbone, replacent or deteriorating soburn, you are entitled ADROVANCE and look for your doctor."</seg>
<seg id="1398">"6) Wait after the slip of your ADROVANCE tablet for at least 30 minutes before you take your first food, drinks or other medicines such as Antazida (mainstaller), calcium or vitamin parate to take this day."</seg>
<seg id="1399">"• (torque) dizziness, • fatigue, • fatigue, • baldness, • junition problems (osteonekrose) in connection with delayed wound healing and infections, often after pulling of teeth, • swelling at hands or legs."</seg>
<seg id="1400">"tablets are available as legitimate, white to broken white tablets, marked with the outline of a button on the one side and" 270 "on the other side."</seg>
<seg id="1401">Advaginal is given adult patients who was given a kidney or liver transplants to prevent a depletion of the transplanted organ by the immune system.</seg>
<seg id="1402">"as Tacrolimus and Prograf / Prograft are already used in the EU, the company has submitted the results from previously done studies with Prograf / Prograft and data from the published literature."</seg>
<seg id="1403">"in addition, the results of a clinical study were presented to 668 patients with kidney transplantation, whereby the application of Advagaries was compared to Prograf / Prograft or Ciclosporin."</seg>
<seg id="1404">"main indeer of the effectiveness was the number of patients in which the transplant was repainted after a treatment duration of one year (for example, how often renewed organtransplant or a resumption of dialysis was required)."</seg>
<seg id="1405">"in addition, recent studies of 119 patients with kidney transplantation and 129 patients were conducted with liver transplant and studied patients with liver transplantation, as compared to Prograf / Prograft from the body."</seg>
<seg id="1406">"tremor (tremor), headache, nausea, diarrhea (hyperglycaemia), kidney problems, increased blood pressure (hypertension), hypertension (hypertension) as well as insomnia (insomnia)."</seg>
<seg id="1407">"in patients with limited hypersensitivity (allergy) against tacrolimus, macrolid antibiotics (such as erythromycin) or one of the other components may not be applied."</seg>
<seg id="1408">Patients and doctors have to be cautious when others (especially some herbal) medicines must be taken simultaneously with Advaginal medicines as the Advaginal dose or the dose of the same may be adjusted accordingly.</seg>
<seg id="1409">"tungsten carbide islands, retardant yellow-orange yellow, printed in red ink with" 0.5 mg "and on the orange-part with" "this 647" "; they contain white powder."</seg>
<seg id="1410">"only doctors, who are familiar with the immunosuppressive therapy and the treatment of transplant patients, this drug adress or changes in the immunosuppressive therapy."</seg>
<seg id="1411">"due to clinically relevant differences of systemic exposure to tacrolimus this can lead to transplant tattoo or to increased incidence of side effects, including under- or overimmunisation."</seg>
<seg id="1412">Patients should always keep the same tacrolimus formulation and the corresponding daily dosage; realizations of the formulation or the regime should only be made under the engorally control of an experienced physician in the transplant medical physician (see sections 4.4 and 4.8).</seg>
<seg id="1413">"in a sequence of conversion to an alternative formulation, a therapeutic drug surveillance and corresponding dosage adjustment must be carried out to ensure that the systemic exposure of Tacrolimus remains intact."</seg>
<seg id="1414">"the Dosage of Advaginal, should be based primarily on the clinical assessment of depletion and tolerability in individual cases and to blood-level regulations (see" "Recommendations" "below"</seg>
<seg id="1415">"after switching from Prograf to Advaginal, the Tacrolimus talent should be controlled prior to conversion and over two weeks after conversion."</seg>
<seg id="1416">"on Day 4 the system of systemic, measured as a talent mirror, with both formulations comparable to both kidney and leberated patients."</seg>
<seg id="1417">Meticulous and repetitive controls of the Tacrolimus valley levels are recommended during the first two weeks after transplant under Advaginal in order to ensure proper substance exposure in the immediate aftermath phase.</seg>
<seg id="1418">"since Tacrolimus is a substance with low Clearance, an adjustment of the Advaginal Dosisschemas can take several days before the Steady State is reached."</seg>
<seg id="1419">"if the condition of the patient allowed in the first postoperative phase, the Tacrolimus treatment intravenous (Prograf 5 mg / ml concentrations for the production of an infusion solution) are introduced with a dose of ca."</seg>
<seg id="1420">Duration of the application Zur repression of transpleness must be maintained; consequently the maximum duration of oral therapy cannot be specified.</seg>
<seg id="1421">Dosage recommendations - kidney transplantation's prophylaxis Prophylaxis Prophylaxis The orale Advaginal therapy should start with 0.20 - 0.30 mg / kg / day as a day daily gift in the morning.</seg>
<seg id="1422">Further dosage adaptions can be later required since the Pharmokinetics of Tacrolimus can change in the course of the stabilization of the patient after the transplant.</seg>
<seg id="1423">Dosage recommendations - liver transplantation Prophylaxis of the Tranale Advaginal therapy should start with 0.10 - 0.20 mg / kg / day as a day daily gift in the morning.</seg>
<seg id="1424">"dosage recommendations - conversion from Prograf to Advagraf must be reversed by twice daily dosage of Prograf capsules at once daily intake of Advaginal capsules, so this conversion in proportion is 1: 1 (mg: mg), related to the whole daily dose."</seg>
<seg id="1425">Kidney and liver transplantation After a conversion from other immunosuppressants to Advagant once daily must begin treatment with each in kidney and liver transplant initialdosis for the prophylaxis of the transplant tattoo.</seg>
<seg id="1426">"the heart transplant in adult patients, which are converted to Advaginal, is an orale initialdosis of 0.15 mg / kg / day every day."</seg>
<seg id="1427">"other transplantants received not clinical experience in a oralen initialdosis of 0.10 - 0,15 mg / kg / day, in case of panelled initials in a oralen initialdosis of 0.3 mg / kg / day, in a oral initialdosis of 0.3 mg / kg / day for application."</seg>
<seg id="1428">Dosage adaptations in special patient groups patients with reduced liver function Zur maintenance in the targeted area can be necessary in patients with severe liver disorders that may be necessary in patients with severe liver dysfunctions.</seg>
<seg id="1429">"patients with reduced kidney function, As the kidney function is not an effect on the Pharmacology of Tacrolimus, it can be assumed that a dosage adjustment is not required."</seg>
<seg id="1430">"however, due to the nephrotoxic potentiality of Tacrolimus, however, a careful monitoring of the serum of serum is recommended (including a regular determination of serum Creativity), a calculation of the creatininlays and a monitoring of the urinary volume)."</seg>
<seg id="1431">Conversion of Ciclosporin at Advaginal At the conversion from a Ciclospore to the Tacrolimus-based therapy is advisable (see sections 4.4 and 4.5).</seg>
<seg id="1432">"recommendations to the valley level in full blood The dose should be based primarily on the clinical assessment of depletion and tolerability in the individual case, under the aid of full blufft-tacrolimus-level controls."</seg>
<seg id="1433">"it is recommended to perform frequent controls of the Tacrolimus valley level during the first two weeks after transplant, followed by periodic controls during the maintenance therapy."</seg>
<seg id="1434">"blood-Tallevels of Tacrolimus should also be controlled after switching from Prograf to Advaginal, dosage adjustment, changes of immunosuppressive therapy or in simultaneous application of substances, which could change the Tacrolimus thoroughtonation (see section 4.5)."</seg>
<seg id="1435">"since Advaginal is a medicine with a low Clearance, adjustments of the dose may need several days until the Steady State has entered."</seg>
<seg id="1436">"according to clinical studies, the information in clinical studies make sure that a successful treatment in most cases is possible if the valley levels in the blood 20 ng / ml not exceed."</seg>
<seg id="1437">"in clinical practice, the valley levels of Tacrolimus in full blood usually lie in the full time after liver transplantations in the period of 5 - 20 ng / ml and with snow and hearty transplants patients at 10 - 20 ng / ml."</seg>
<seg id="1438">"during the recolding therapy of liver, kidney, and cardiac transplants were generally used blood concentrations in the range of 5 - 15 ng / ml."</seg>
<seg id="1439">"this has led to serious unwanted events, including transplant tattoo or other side effects, which can occur in the sequence of Tacrolimus under- or overexposure."</seg>
<seg id="1440">Patients should always keep the same tacrolimus formulation and the corresponding daily dosage; realizations of the formulation or the regime should only be made under the engorally control of an experienced physician in the transplant medical physician (see sections 4.2 and 4.8).</seg>
<seg id="1441">"5 Zur treatment of adult patients with transplant treatment, which proved to be proven compared to other immunosuppressants as therapists, are still no clinical data for the retarded formulation Advaginal."</seg>
<seg id="1442">"to prophylaxis of the transplant tattoo, for adult heart transplants and transplant tattoo, there are still no clinical data for the retarded formulation of Advaginal."</seg>
<seg id="1443">"due to possible interactions, which can lead to a lowering of the Tacrolimbo levels in the blood and a detonation of the clinical effect of Tacrolimus, the currannel (hypericum perforatum) is to avoid or prevent other plant healing during a treatment with Advaginal (see Section 4.5)."</seg>
<seg id="1444">"in patients with diarrhoea a particularly meticulous monitoring of the Tacrolimus concentrations in the blood, since the Tacrolimus blood levels can be subjected to significant fluctuations under such circumstances."</seg>
<seg id="1445">"in rare cases, there was a chamber of Lyme cardiomyopathia recorded as a cardiomyopathia and observed hypertrophy, which can therefore occur under Advaginal."</seg>
<seg id="1446">"further factors that increase the risk of such clinical disorders are an already existing heart suffer, a treatment with corticosteroids, hypertension or liver disorders, infections, liquid overload and oil."</seg>
<seg id="1447">"as with other immunosuppressants, the effect of sunlight or ultraviolet light should be restricted by appropriate clothing or use of a solar protection by means of a high protection factor."</seg>
<seg id="1448">"if patients are taking the Tacrolimus symptoms, symptoms for Pres such as headaches, changed state of consciousness, crows and visual disorders, a radiological investigation should be a radiological investigation (e.g.."</seg>
<seg id="1449">"da Advaginal cemented, retarded, lactose, is presented in patients with the rare hereditary Galactose-intolerance, lactase deficiency or gluten-Galactose-Malabsorption special caution."</seg>
<seg id="1450">The simultaneous application of medicines or herbal remedies known as Hemmer or inductors from CYP3A4 can increase the metabolism of Tacrolimus and therefore reduce the blood values of Tacrolimus or reduce the blood values of Tacrolimus.</seg>
<seg id="1451">"therefore, it is recommended to change the Tacrolimus- blood levels at the same time of current substances that can change the CYP3A metabolism, and adjust the tacrolimus dose to maintain equitable concentrations accordingly (see sections 4.2 and 4.4)."</seg>
<seg id="1452">"pronounced interaction with antimykotika such as Ketoconazol, Fluconazol, Itraconazol, and Voriconazol, as well as the Macrolid antibiotic Erythromycin and HIV-Proteasants (z."</seg>
<seg id="1453">"Pharmokinetics studies report that the increase in blood levels mainly from the increased bioavailability of tacrolimus, due to the inhibition of the gastrointestinal combustion, results."</seg>
<seg id="1454">"high dose prednisolon or methylprednisolon, as it is used in acute reactions, the concentration of tacrolimus can increase or reduce the concentration of tacrolimus in the blood."</seg>
<seg id="1455">Effect of Tacrolimus on the metabolism of other medicines tacrolimus is known as CYP3A4 inhibitor; therefore the simultaneous application of Tacrolimus can be metabolized by CYP3A4 metabolic.</seg>
<seg id="1456">"since Tacrolimus, the Clearance of steroid contractiva can put down the Clearance of steroid-contractiva and thus can increase the hormone exposure, is especially careful in decisions regarding receptive measures."</seg>
<seg id="1457">The results of animals have shown that tacrolimus potentially reduce the Clearance of pentobarbital and phenazone and extend their half-time.</seg>
<seg id="1458">The results of a small number of investigations on transplant patients do not provide any indication that under Tacrolimus compared to other immunosuppressors the higher risk for unwanted events with regard to the course and result of pregnancy.</seg>
<seg id="1459">"in utero exposure, a monitoring of the newborn is recommended to possible harmful effects of Tacrolimus (especially regarding its impact on the kidneys)."</seg>
<seg id="1460">"there is the risk of an early birth (&lt; week 37) and a hyperalic of the newborn (incidence 8 of 111 newborn newborn, i.e.,:"</seg>
<seg id="1461">The side-effective profile of immunosuppressants can often be seen due to the diunderpatient of the patient and the simultaneous treatment with a variety of other medicines.</seg>
<seg id="1462">"following the side effects after their incidence in descending order are listed below: very common (≥ 1 / 100, &lt; 1 / 100), rare (≥ 1 / 10,000, &lt; 1 / 1000), rarely (frequency 1 / 10,000, not known (frequency based on the available data does not be invaluable)."</seg>
<seg id="1463">"ischaemia disorders of the cardiac disease, tachykarst arrhythmia, myocardiac disease, stiraventricular arrhythmia, myocardiac disease, anomalies in EKG, abnormal heart and pulsation frequency."</seg>
<seg id="1464">"diarrhoea, Stomeptic signs and symptoms, Assheptic signs and symptoms, lestipation, flatulence and Ascensions, loosening chair, signs and symptoms in the stomach-intestinal area"</seg>
<seg id="1465">"infections and parasitism for other highly effective immunosuppressants is treated with patients who are treated with tacrolimus, the susceptibility for infections, bacterial, mycotic, protozoale)."</seg>
<seg id="1466">Cases of BK-Virus-associated Nephropathy and JC virus-related multifoal leukoencephalopathy (PML) were reported in patients under immunosuppressive therapy (PML).</seg>
<seg id="1467">It was reported about benign or malignant Neoplastics including EBV- Associated lymphobic diseases and skin tumors in connection with the treatment with Tacrolimus.</seg>
<seg id="1468">"due to its high molecular weight, its low water-soluble and high bond of erythrocytes and plastic rotary can be assumed that tacrolimus is not dialyzed."</seg>
<seg id="1469">Active mechanism and pharmacodynamic effects in molecular level should be conveyed the effects of Tacrolimus through its bond to an cytosolic protein (FKBP12) which is responsible for the enrichment of the connection in the cellular country.</seg>
<seg id="1470">"this leads to a calciumdependent inhibition of signal transducation because of the T-cell, thus preventing the transcription of a certain number of lymphokin genes."</seg>
<seg id="1471">"tacrolimus suppresses the activation of T cells and those of T-Helfermentation cells, the formation of lymphokins (like interleukin-2, interleukin-3 and g -Interferon) as well as the expression of the interleukin-2 receptors."</seg>
<seg id="1472">12 confirmed appraisal was within the first 24 weeks in the Advaginal group (N = 237) 32.6% and in the Prograf group (N = 234) 29.3%.</seg>
<seg id="1473">"patients-survival rates after 12 months of EUR 89.2% for Advaginal and 90,8% for Prograf; in the Advaginal arm came 25 (14 women, 11 men) and in Prograf arm 24 (5 women, 19 men)."</seg>
<seg id="1474">"kidney transplantation's effectiveness and security, in combination with Mycophenolatmofetil, in combination with Mycophenolatmofetil (MMF) and corticosteroids, in combination with Mycophenolatmofeather (MMF) and corticosteroids, compared to 667 de Novo Niertransplantation."</seg>
<seg id="1475">"patients" survival rates after 12 months of adolescence and 97.5% for Prograf; in the Advaginal arm appeared 10 (3 women, 7 men) and in Prograf arm 8 (3 women, 5 men) death accidents. "</seg>
<seg id="1476">"the effectiveness and safety of Prograf, Ciclosporin and Advaginal was compared in combination with Basilicata. antibody induces, MMF and corticosteroids, compared to 638 de Novo Niertransplantation."</seg>
<seg id="1477">"incidence of therapy claims after 12 months (defined as death, transplantive loss, biopsy-confirmed loss or missing Follow - data) was 14.0% in the Prograf group (N = 212) and 17.0% in the Ciclosporin group (N = 212)."</seg>
<seg id="1478">"the treatment difference was -3.0% (Advagraf- Ciclosporin) (95.2%, 4.0%) for Advaginal% (Prograf-Ciclosporin) (95.2%, 4.2%]) for Prograf vs Ciclosporin."</seg>
<seg id="1479">"in Advagant arm 3 (men), in the Prograf arm 10 (3 women, 7 men) and in Ciclosporin arm 6 (3 women, 3 men) death accidents."</seg>
<seg id="1480">Published results of the primary immunisation with tacrolimus in form of twice daily Prograf in form of twice daily prograf capsules after other primary organ transplants Prograf has become a recognized primary immunoscopic um according to pancreatic, lung and intestinal transplants. "</seg>
<seg id="1481">"175-ranging transplantation patients, with 475 patients who had subjected itself to panic attack and in 630 cases, according to a intestinal transplant as the primary transplant immunoscopic."</seg>
<seg id="1482">"overall, the security profile of oral Prograf in these published studies were applied to the observations in the major studies where Prograf at liver, kidney, and cardiac transplants have been applied to the primary immune system."</seg>
<seg id="1483">"production planning in an interim analysis about a recently run, multi-centric study with oral prograf was reported more than 110 patients who received either Tacrolimus or Ciclosporin."</seg>
<seg id="1484">"also a chronic transplant tattoo, the bronchitis obliterans- syndrome, was less common in the first year after the transplant (2.2% versus 8.57%)."</seg>
<seg id="1485">"the survival rates after one year was 80,8% in the Tacrolimus- and 83% in the Ciclosporin group (Treede et al., 3rd ICI San Diego, USA, 2004; Abstract 22)."</seg>
<seg id="1486">"in the patients treated with tacrolimus patients, it occurred in 21.7% of cases to the emergence of a bronchiolitis compared to 38.0% below Ciclosporin (p = 0,025)."</seg>
<seg id="1487">"the number of cases to be converted to Tacrolimus (n = 13), was significantly larger (n = 13), was significantly larger (n = 13) (Keenan et al., Ann Thoracic Surg 1995; 60: 580)."</seg>
<seg id="1488">"the number of cases in which there came to no accumulations, was after 6 months (57.7% versus 45,8%) and after 1 year (50% versus 45,3%) and after 1 year (50% versus 43.3%) with the efficiency of patients of the Tacrolimus group bigger (Treede et al., J Heart Lung Transplit 2001; 20: 511)."</seg>
<seg id="1489">"in a study, the incidence of the emergence of a bronchiolitis was obliterated - syndroms in the patients treated with tacrolimus treated patients."</seg>
<seg id="1490">Pancredential study with oral Prograf was carried out in 205 patients which was simultaneously subjected to a Pancreatic and kidney transplantation following a randomized trial Tacrolimus (n = 103) or Ciclosporin (n = 102).</seg>
<seg id="1491">The orale initialdosis (per protocol) of Tacrolimus was 0.2 mg / kg / day and was afterwards to reaching the drawer level from 8 to 15 ng / ml the 5.</seg>
<seg id="1492">"the published clinical results of a monocentric study, with oral prograf, showed by 155 patients (65 only the intestine, 75 liver and intestinal and 25 multiveal transplations) among 155 patients (65 only intestine, 75 liver and intestinal and 25 multiveal transplants) under Tacrolimus and Prednisone, five% after 5 years and 42% after 10 years."</seg>
<seg id="1493">"methods for the early detection of Epstein-Barr (EBV) - and CMV infections, bone capitalistic, additional gift of the interleukin-2-antagonists Daclizumab, lower first-grains of Tacrolimus (Abu-Elmagd et al., Ann Surg 2001; 234: 404)."</seg>
<seg id="1494">"factors such as a low hemocular value and low protein concentrations, resulting in an increase in the unbundled faction of Tacrolimus, or one through treatment with corticosteroids are intended to be held responsible for the transplant higher clearing-edges after the transplant."</seg>
<seg id="1495">"this leaves that tacrolimus is almost completely metabolized in front of the excretion, whereby the excretion is mainly carried out above all."</seg>
<seg id="1496">"in stable patients, provided by Prograf (once daily) in relation to 1: 1 (mg: mg) in relation to 1: 1 (mg) on Advagus (AUC0-24), was the systematic exposure of Tacrolimus (AUC0-24) under Advaginal 10% lower than under Prograf."</seg>
<seg id="1497">"it is recommended to perform frequent controls of the Tacrolimus valley level during the first two weeks after transplant, followed by periodic controls during the maintenance therapy."</seg>
<seg id="1498">"21 Zur treatment of adult patients with transplant treatment, which proved to be proven compared to other immunosuppressants as therapists, are still no clinical data for the retarded formulation Advaginal."</seg>
<seg id="1499">"further factors that increase the risk of such clinical disorders are an already existing heart suffer, a treatment with corticosteroids, hypertension or liver disorders, infections, liquid overload and oil."</seg>
<seg id="1500">28 confirmed appraisal was within the first 24 weeks in the Advaginal group (N = 237) 32.6% and in the Prograf group (N = 234) 29.3%.</seg>
<seg id="1501">"the effectiveness and safety of Prograf, Ciclosporin and Advaginal was compared in combination with Basilicata. antibody induces, MMF and corticosteroids, compared to 638 de Novo Niertransplantation."</seg>
<seg id="1502">"hard-orange cheese, it printed gray-orange yellow, printed in red soup with" "5 mg" "and the orange-section with" "The 687", "they contain white powder."</seg>
<seg id="1503">"it is recommended to perform frequent controls of the Tacrolimus valley level during the first two weeks after transplant, followed by periodic controls during the maintenance therapy."</seg>
<seg id="1504">"37 Zur treatment of adult patients with transplant treatment, which proved to be proven compared to other immunosuppressants as therapists, are still no clinical data for the retarded formulation Advaginal."</seg>
<seg id="1505">"further factors that increase the risk of such clinical disorders are an already existing heart suffer, a treatment with corticosteroids, hypertension or liver disorders, infections, liquid overload and oil."</seg>
<seg id="1506">44 confirmed latches were within the first 24 weeks in the Advaginal group (N = 237) 32.6% and in the Prograf group (N = 234) 29.3%.</seg>
<seg id="1507">"the effectiveness and safety of Prograf, Ciclosporin and Advaginal was compared in combination with Basilicata. antibody induces, MMF and corticosteroids, compared to 638 de Novo Niertransplantation."</seg>
<seg id="1508">"in total, 34 patients were converted from Ciclosporin to Tacrolimus, while only 6 tacrolimus patients needed another therapy (Bechstein et al., Transplantation 2004; 77: 1221)."</seg>
<seg id="1509">"the published clinical results of a monocentric study, with oral prograf, showed by 155 patients (65 only the intestine, 75 liver and intestinal and 25 multiveal transplations) among 155 patients (65 only intestine, 75 liver and intestinal and 25 multiveal transplants) under Tacrolimus and Prednisone, five% after 5 years and 42% after 10 years."</seg>
<seg id="1510">"this leaves that tacrolimus is almost completely metabolized in front of the excretion, whereby the excretion is mainly carried out above all."</seg>
<seg id="1511">Risk management plan The owner of the approval of the authorisation is committed to perform the studies and additional pharmaceuticals in the drug plan (RMP) and will be approved in version 1.8.2. of the application agreement (RMP) and all other updates of the RMP that will be approved by the CHMP.</seg>
<seg id="1512">"according to the CHMP Guidelines on risk management systems for drugs on human health, the updated RMP must simultaneously be submitted with the next periodic security report (Periodic Safety Update Report, PSUR)."</seg>
<seg id="1513">"maybe you get Advaginal also for the treatment of your liver, kidney or heart transplantate or another transplanted organ or because the immune response of your body could not be ruled by a predicted treatment."</seg>
<seg id="1514">"when taking Advaginal with other medicines Please inform your doctor or pharmacist if you are taking other medicines or have recently taken, even if they are not prescription drugs or remedies."</seg>
<seg id="1515">"Amilorid, Triamteren or Spironolacton), certain pain killers (so called non-steroidal anti-logistika like ibuprofen), anticoagulum or medicines to take treatment of diabetes mellitus."</seg>
<seg id="1516">"pregnancy and lactation If a pregnancy is planned or already exists, ask before taking any medicines your doctor or pharmacist for advice."</seg>
<seg id="1517">"transport and serve of machines you may not sit at the tax of a vehicle or operate tools or machines, if you feel after taking Advaginal snaky or sleepy or blurred."</seg>
<seg id="1518">"important information about certain other ingredients of Advaginal Please take Advaginal first to return with your doctor if you know, that you are suffering from intolerability to certain sugar."</seg>
<seg id="1519">Make sure that you will always receive the same tacrolimus medicine if you solve your prescription unless your medical doctor has explicitly agreed a change of the Tacrolimus preparation.</seg>
<seg id="1520">"if you get a medicine whose appearance is devided from the inhabited, or the dowsing instructions, please speak as soon as possible using your treating doctor or pharmacist, so that you will have the right medicine."</seg>
<seg id="1521">"so that your doctor can determine the right dose and adjust from time to time, he must then regularly perform blood tests."</seg>
<seg id="1522">"if you have taken a larger amount of Advaginal, than you should If you accidentally taken a bigger amount of Advaginal, look immediately to your doctor or the emergency department of the nearest hospital."</seg>
<seg id="1523">"if you have forgotten the intake of Advaginal, If you have forgotten the capsules, pick this out at the same day at the earliest time."</seg>
<seg id="1524">"if you break the intake of Advaginal At the end of the treatment with Advaginal, the risk of a depletion of your transponder can increase."</seg>
<seg id="1525">"Advaginal 0,5 mg carbide, retarded, are Hartgelaple, whose brimming upper part with" 0.5 mg "and their orange subsection with" "this 647" "are filled with red powder and which are filled with white powder."</seg>
<seg id="1526">"Advaginal 1 mg of carbide, retarded, are Hartgelato, whose white upper part with" "1 mg" "and their orange subsection with" "The 677" "are printed and which are filled with white powder."</seg>
<seg id="1527">"Advaginal picked 5 mg hard-islands, retardant, are Hartgelato, their grassy rotary with" 5 mg "and their orange subsection with" "The 687" "are filled with red powder and which are filled with white powder."</seg>
<seg id="1528">"România Astellas Pharma Internaan ional Detalii de contact pentru România, Clă dire 1, Parter, 013696-Bucureş ti Tel: + 40 (0) 21 361 0495"</seg>
<seg id="1529">Slovenska Republika Astellas Pharma s.r.o., organizač ná de Galvániho 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">"Advate is used for treatment and prevention of bleeding in patients with hemhilie A (one through the lack of factor VIII-conditioned, innate blood disorder)."</seg>
<seg id="1531">Dosage and frequency of application are based on whether advocating to the treatment of bleeding or the prevention of bleeding for surgical procedures is applied.</seg>
<seg id="1532">Patients with hemhilie A suffer from a factor VIII deficiency that causes bloodstream issues such as bleeding in joints, muscles or inner organs.</seg>
<seg id="1533">"Octocog alfa is not extracted from human plasma, but according to a method that is known as" recombinant DNA technology ":"</seg>
<seg id="1534">It is produced by a cell in which a gene (DNA) was brought in to the formation of the human being factor VIII.</seg>
<seg id="1535">"Advate is another approved in the European Union, similarly, it is similar, but the drug does not contain proteins or animal origin, so that the medicine contains no proteins or animal origin."</seg>
<seg id="1536">"in three additional studies in patients with severe to moderate hemhilie A, including a study with 53 children under six years, the application of the medicine was examined using the prevention of blood cells as well as surgical procedures."</seg>
<seg id="1537">"in the main study the effectiveness of Advate was awarded in 86% of 510 new blood-septum in 86% of 510 new blood-septum with" "excellent" "or" "good". ""</seg>
<seg id="1538">"the most common side effects of Advate (observed at 1 to 10 of 100 patients) are dizziness, headache, pyrexie (fever), and the formation of antibodies to factor VIII."</seg>
<seg id="1539">"Advate must not be applied in patients, which may be oversensitive (allergic) against the human being factor VIII, mouse or hamster-protein or any of the other components."</seg>
<seg id="1540">March 2004 shared the European Commission of Baxter AG approving the acceptance of a advent of Advate in the entire European Union.</seg>
<seg id="1541">"dosage The dosage and duration of substitution therapy is based on the severity of the factor VIII-defect, after the place and the extent of the blood and the clinical condition of the patient."</seg>
<seg id="1542">"in the following case of morrhagical events, the factor VIII activity in the relevant period does not fall under the stated plastic bars (in% of the norm or in i.e. / dl)."</seg>
<seg id="1543">Injection all 12-24 hours (8-24 hours in patients under 6 years) for 3-4 days or longer repeat until pain and acute impairment are eliminated.</seg>
<seg id="1544">Injection all 8-24 hours (6-12 hours in patients under 6 years) repeat until the danger to the patient is above.</seg>
<seg id="1545">"during the treatment process, controlling the dose of the too far and the frequency of injections is recommended to the control of the factor VIII-plastic bars."</seg>
<seg id="1546">Individual patients may differ in their response to factor VIII to reach various in vivo recovery and have different semi-value times.</seg>
<seg id="1547">3 Prophylaxis Zur's long-term prophylaxis in patients with severe hemhilie A should be given between 20 and 40 as a factor VIII per kg body weight by 2-3 days.</seg>
<seg id="1548">"if the expected factor is not to be achieved or if the bleeding is not ruled by a reasonable dose, a test must be carried out in order to indicate an inhibitor."</seg>
<seg id="1549">"in patients with high inhibitorvalues, it is possible that the factor VIII therapy is not effective, so other therapeutic interventions must be erased."</seg>
<seg id="1550">"the enrichment speed should be directed after the patient, with maximum injection rate of 10 ml / min should not be exceeded."</seg>
<seg id="1551">The formation of neutral antibodies (inhibitors) against factor VIII is a known complication in the treatment of patients with hemhilie A.</seg>
<seg id="1552">These Inhibitors are always against the procoagulatory activity of factor VIII aligned IgG immunoglobuline which will be quantified in Bethesda units (B.E.) per ml plasma using modified Bethesda Assay.</seg>
<seg id="1553">"the risk of having to develop inhibitors, correlate with the extent of exposure to the factor VIII, whereby the risk within the first 20 externalization days is the biggest and of genetic and other factors."</seg>
<seg id="1554">"in pre-treated patients (PTPs) with more than 100 expositions days and anamnestisch-known inhibitor development, after switching from a recombinant factor VIII product to another, the re-occur (lower) inhibitors."</seg>
<seg id="1555">"due to the rare occurrence of the herehilie A in women, there are no experience whatsoever about the application of factor VIII during pregnancy and lactation."</seg>
<seg id="1556">"the ADRs were inhibitors against factor VIII (5 patients), all previously untreated patients who have higher risk to the formation of inhibitors, headaches (5 patients), fever and dizziness (3 patients)."</seg>
<seg id="1557">"very common (≥ 1 / 10), commonly (≥ 1 / 100 to &lt; 1 / 100), rare (≥ 1 / 1000 to &lt; 1 / 1000), very rare &lt; 1 / 10,000), rarely (frequency based on the available data is not estimated)."</seg>
<seg id="1558">A) The percentage of the patients was calculated by the sum of the individual patients (234) calculated. b) The unexpected waste of the blood pressure factor VIII-Spiegels occurred in postoperative (10 - 14 postoperative day) in a patient under continuous ADVATE Infusion.</seg>
<seg id="1559">The blood clotting was maintained throughout the time and both the factor VIII- mirror in the plasma as well as the Clearance rate showed sufficient values on 15 postoperative day.</seg>
<seg id="1560">In clinical trials with ADVATE in 145 children and adults 2 with diagnostic difficult to moderate hemhilie A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrations (2.4 B.E. in the fashionable Bethesda approach) showed only one patient after 26 appointment days with ADVATE (2.4 B.E. in the fashionable Bethesda approach).</seg>
<seg id="1561">"in addition, at any of the 53 paediatric patients with an age of less than 6 years and diagnosed heavy to medium-severe hemhilie A (FVIII &lt; 2%) after prior exposure to factor VIII- concentrations (≥ 50 days) a FVIII-Inhibitor."</seg>
<seg id="1562">"in previously, patients of a current clinical trial formed 5 out of 25 (20%) with ADVATE patients inhibitors against factor VIII."</seg>
<seg id="1563">"the immune response of the patient to traces of contaminated proteins was analyzed by the investigation of antibodies against these proteins, laboratory parameters and reported side effects."</seg>
<seg id="1564">"a patient showed a statistically significant upsurge as well as an ongoing peak of antibodies against anti-CHO cell disease, otherwise, however, no sign or symptoms associated to an allergic reaction or hypersensitivity."</seg>
<seg id="1565">"in four patients, over the appearance of Urtikaria, Pruritus, rash and increased number of eosinophiles granurologytes were reported in several repeated product texts as part of the study."</seg>
<seg id="1566">"7 As with other intravenous products, ADVATE has been reported by allergic type, including anaphylactic / anaphylactic reactions of reactions (incidence is not known)."</seg>
<seg id="1567">The active factor VIII acts as a cofactor for the active factor IX and accelerates the formation of activated factor X out of factor X.</seg>
<seg id="1568">All pharmaceutical studies with ADVATE were conducted in pre-treated patients with severe or moderate hemhilie A (base value of the factor VIII-activity &lt; 2%).</seg>
<seg id="1569">The pharmacoinetic parameters come from a cross-over study with ADVATE in 100 previously treated patients or &gt; 10 years and are listed in table 3 listed below.</seg>
<seg id="1570">Table 3 summary of the Pharmacokinetic parameters of ADVATE in 100 patients with severe to moderate hemhilie A (factor VIII &lt; 2%) PK parameters (Pharmokinetics)</seg>
<seg id="1571">"non-clinical data, based on the studies on security makology, too acute, repeated and local toxicity and to genotoxicity, do not show a special risk for the human being."</seg>
<seg id="1572">"each individual pack consists of a bottle of bottle with powder, a bottle of bottle with 5 ml solvents (both glass type I with chlorobutyl-rubber-moulds), and a device for the reconstitution (BAXJECT II)."</seg>
<seg id="1573">"when the product is stored in the fridge, both transit bottles with ADVATE powder and solvent from the fridge can be found in space temperature (between 15 and 25 ° C)."</seg>
<seg id="1574">A clear increase in the pulse frequency can be reduced by slow or temporary underbreak of injecting usually back immediately (see sections 4.4 and 4.8).</seg>
<seg id="1575">14 Prophylaxis Zur's long-term prophylaxis in patients with severe hemhilie A should be given between 20 and 40 as a factor VIII per kg body weight by 2-3 days.</seg>
<seg id="1576">"due to the rare occurrence of the herehilie A in women, there are no experience whatsoever about the application of factor VIII during pregnancy and lactation."</seg>
<seg id="1577">"3 newborns (at the age of 0-1 month), infants (at the age of 1 month - 2 years), young people (at the age of 12-16 years), adults (over 16 years) (over 16 years)"</seg>
<seg id="1578">In clinical trials with ADVATE in 145 children and adults 4 with diagnostic difficult to moderate hemhilie A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrations (2.4 B.E. in the fashionable Bethesda approach) showed only one patient after 26 appointment days with ADVATE (2.4 B.E. in the fashionable Bethesda approach).</seg>
<seg id="1579">"18 As with other intravenous products, ADVATE has been reported by allergic type, including anaphylactic / anaphylactic analogue of reactions (incidence is not known)."</seg>
<seg id="1580">Table 3 summary of the Pharmacokinetic parameters of ADVATE in 100 patients with severe to moderate hemhilie A (factor VIII &lt; 2%) PK parameters (Pharmokinetics)</seg>
<seg id="1581">"non-clinical data, based on the studies on security makology, too acute, repeated and local toxicity and to genotoxicity, do not show a special risk for the human being."</seg>
<seg id="1582">25 Prophylaxis Zur's long-term prophylaxis in patients with severe hemhilie A should be given between 20 and 40 as a factor VIII per kg body weight by 2-3 days.</seg>
<seg id="1583">"5 newborns (at the age of 0-1 month), infants (at the age of 1 month - 2 years), young people (at the age of 12-16 years), adults (over 16 years) (over 16 years)"</seg>
<seg id="1584">In clinical trials with ADVATE in 145 children and adults 6 with diagnostic difficult to moderate hemhilie A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrations (2.4 B.E. in the fashionable Bethesda approach) showed only one patient after 26 appointment days with ADVATE (2.4 B.E. in the fashionable Bethesda approach).</seg>
<seg id="1585">29 How with other intravenous products has been reported at ADVATE about hypersensitive reactions from allergic type, including anaphylactic / anaphylactic reactions of reactions (incidence is not known).</seg>
<seg id="1586">"non-clinical data, based on the studies on security makology, too acute, repeated and local toxicity and to genotoxicity, do not show a special risk for the human being."</seg>
<seg id="1587">36 Prophylaxis Zur's long-term prophylaxis in patients with severe hemhilie A should be given between 20 and 40 as a factor VIII per kg body weight by 2-3 days.</seg>
<seg id="1588">"7 new born (at the age of 0-1 month), infants (aged 1 month - 2 years), young children (at the age of 12-16 years), adults (over 16 years) (over 16 years)"</seg>
<seg id="1589">In clinical trials with ADVATE in 145 children and adults 8 with diagnostic difficult to moderate hemhilie A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrations (2.4 B.E. in the fashionable Bethesda approach) showed only one patient after 26 appointment days with ADVATE (2.4 B.E. in the fashionable Bethesda approach).</seg>
<seg id="1590">40 How with other intravenous products has been reported at ADVATE about hypersensitive reactions from allergic type, including anaphylactic / anaphylactic reactions of reactions (incidence is not known).</seg>
<seg id="1591">"non-clinical data, based on the studies on security makology, too acute, repeated and local toxicity and to genotoxicity, do not show a special risk for the human being."</seg>
<seg id="1592">47 Prophylaxis Zur's long-term prophylaxis in patients with severe hemhilie A should be given between 20 and 40 as a factor VIII per kg body weight by 2-3 days.</seg>
<seg id="1593">"9 newborns (at the age of 0-1 month), infants (aged 1 month - 2 years), youth (at the age of 12-16 years), adults (over 16 years) (over 16 years)"</seg>
<seg id="1594">In clinical trials with ADVATE in 145 children and adults 10 with diagnostic difficult to moderate hemhilie A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrations (2.4 B.E. in the fashionable Bethesda approach) showed only one patient after 26 appointment days with ADVATE (2.4 B.E. in the fashionable Bethesda approach).</seg>
<seg id="1595">51 How with other intravenous products has been reported at ADVATE about hypersensitive reactions from allergic type, including anaphylactic / anaphylactic reactions of reactions (frequency not known).</seg>
<seg id="1596">"non-clinical data, based on the studies on security makology, too acute, repeated and local toxicity and to genotoxicity, do not show a special risk for the human being."</seg>
<seg id="1597">58 Prophylaxis Zur's long-term prophylaxis in patients with severe hemhilie A should be given between 20 and 40 as a factor VIII per kg body weight by 2-3 days.</seg>
<seg id="1598">"11 newborns (at the age of 0-1 month), infants (aged 1 month - 2 years), youth (at the age of 12-16 years), adults (over 16 years) (over 16 years)"</seg>
<seg id="1599">In clinical trials with ADVATE in 145 children and adults 12 with diagnostic difficult to moderate hemhilie A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrations (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1600">62 How to other intravenous products has been reported at ADVATE about hypersensitive reactions from allergic type, including anaphylactic / anaphylactic reactions of reactions (incidence is not known).</seg>
<seg id="1601">"non-clinical data, based on the studies on security makology, too acute, repeated and local toxicity and to genotoxicity, do not show a special risk for the human being."</seg>
<seg id="1602">"the regulatory system must make sure that a pharmaceutical system must ensure a pharmacy system, as described in the chapter 1.1 of the chapter 1.8.1 The drug information, was established and that this system remains in the market throughout the period, where the product is on the market."</seg>
<seg id="1603">"as defined in CHMP Directive on the risk-Managment Plan for Human-medicines, these updates will be submitted at the same time with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="1604">"• if new information is available, the influence on the valid security system, the pharmaceutical co-plan or measures to risk minimization • could have an important event within 60 days of an important event (regarding pharmaceuticals, or regarding a measure at risk minimization)"</seg>
<seg id="1605">"1 hexagonal bottle with ADVATE 500 I.E Octocog alfa, 1 hexagonal water for injections, 1 BAXJECT II medicine product."</seg>
<seg id="1606">"1 hexagonal bottle with ADVATE 1000 I.E Octocog alfa, 1 hexagonal water for injections, 1 BAXJECT II medicine product"</seg>
<seg id="1607">"special caution at the application of ADVATE is required you should inform your doctor if you have recently been treated with factor VIII products, especially if you have developed inhibitors."</seg>
<seg id="1608">"these symptoms can represent early signs of an anaphylactic lap, which may include the following symptoms: extreme dizziness, consciousness of consciousness and extreme respiratory."</seg>
<seg id="1609">"when taking other medicines Please inform your doctor if you are taking other medicines or have recently taken, even if it is not-prescription drugs."</seg>
<seg id="1610">"your doctor will charge your dose ADVATE (in international units or i.e.), depending on your physical activity and your body weight, and whether it is used to prevent or treat bleeding."</seg>
<seg id="1611">Patients who develop factor-VIII-Inhibitors If the expected factor VIII mirror can not be reached in your plasma with ADVATE or the bleeding may not be ruled by factor VIII-</seg>
<seg id="1612">"in conjunction with operations Katheterinfancy, lower number of red blood cells, swelling of limbs and joints, prolonged bleeding after the removal of a dragon, decreased factor-VIII mirror and postoperative hematome."</seg>
<seg id="1613">Rare unwanted side effects on the introduction of the drug in the market has been isolated over heavy and potentially life-threatening reactions (Anaphylaxie) and other allergic reactions (see above).</seg>
<seg id="1614">Inform your doctor if any of the listed side effects you have considerably affected or if you notice side effects that are not listed in this package.</seg>
<seg id="1615">Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira, Edifício 10 P-2710-089 Sintra Tel: + 351 21 925 25 00</seg>
<seg id="1616">"notes for the production of the solution • Do not use when its sterile barrier is broken, its packaging is damaged or sign of a manipulation, like in the icon"</seg>
<seg id="1617">Important note: • Not to submit yourself before you have received the special training of your doctor or nurse you have received. • Registered the product to check out the product on sulpples or discolouration.</seg>
<seg id="1618">"the solution should be slow down with an infusion speed, which is able to apply to patients and will not exceed 10 ml per minute."</seg>
<seg id="1619">106 in case of bleeding events should be the factor VIII mirror within the appropriate period of time (in% or in that / ml).</seg>
<seg id="1620">"these symptoms can represent early signs of an anaphylactic lap, which may include the following symptoms: extreme dizziness, consciousness of consciousness and extreme respiratory."</seg>
<seg id="1621">Patients who develop factor-VIII-Inhibitors If the expected factor VIII mirror can not be reached in your plasma with ADVATE or the bleeding may not be ruled by factor VIII-</seg>
<seg id="1622">"occasional side-effects Juckling, amplified taste, diarrhea, shameful taste, diarrheals, ggestions, skin-breaks, extreme shellings, extreme shellings,"</seg>
<seg id="1623">116 In case of bleeding events should be the factor VIII mirror within the appropriate period of time (in% or in that / ml).</seg>
<seg id="1624">"these symptoms can represent early signs of an anaphylactic lap, which may include the following symptoms: extreme dizziness, consciousness of consciousness and extreme respiratory."</seg>
<seg id="1625">Patients who develop factor-VIII-Inhibitors If the expected factor VIII mirror can not be reached in your plasma with ADVATE or the bleeding may not be ruled by factor VIII-</seg>
<seg id="1626">126 In case of bleeding events should be the factor VIII mirror within the appropriate period of time (in% or in that / ml).</seg>
<seg id="1627">"these symptoms can represent early signs of an anaphylactic lap, which may include the following symptoms: extreme dizziness, consciousness of consciousness and extreme respiratory."</seg>
<seg id="1628">Patients who develop factor-VIII-Inhibitors If the expected factor VIII mirror can not be reached in your plasma with ADVATE or the bleeding may not be ruled by factor VIII-</seg>
<seg id="1629">136 in case of bleeding events should be the factor VIII mirror within the appropriate period of time (in% or in that / ml).</seg>
<seg id="1630">"these symptoms can represent early signs of an anaphylactic lap, which may include the following symptoms: extreme dizziness, consciousness of consciousness and extreme respiratory."</seg>
<seg id="1631">Patients who develop factor-VIII-Inhibitors If the expected factor VIII mirror can not be reached in your plasma with ADVATE or the bleeding may not be ruled by factor VIII-</seg>
<seg id="1632">146 In case of bleeding events should be the factor VIII mirror within the appropriate period of time (in% or in that / ml).</seg>
<seg id="1633">"these symptoms can represent early signs of an anaphylactic lap, which may include the following symptoms: extreme dizziness, consciousness of consciousness and extreme respiratory."</seg>
<seg id="1634">Patients who develop factor-VIII-Inhibitors If the expected factor VIII mirror can not be reached in your plasma with ADVATE or the bleeding may not be ruled by factor VIII-</seg>
<seg id="1635">"occasional side-effects Juckling, amplified taste, diarrhea, shameful taste, diarrheals, ggestions, skin-breaks, extreme shellings, extreme shellings,"</seg>
<seg id="1636">Rare unwanted side effects on the introduction of the drug in the market has been isolated over heavy and potentially life-threatening reactions (Anaphylaxie) and other allergic reactions (see above).</seg>
<seg id="1637">156 in case of bleeding events should be the factor VIII mirror within the appropriate period of time (in% or in that / ml).</seg>
<seg id="1638">"based on the data available since the initial data has been reviewed by the CHMP, the CHMP has been valued as positive, but considering that the security profile has to be closely monitored for the following reasons:"</seg>
<seg id="1639">"therefore, the CHMP on the basis of the safety profils of ADVATE, which makes a filing of PSURs all 6 months, decided that the approval in 5 years should apply for a further development process."</seg>
<seg id="1640">December 2008 shared Gendux Molecular Limited to the Committee for Humanitarian Medicine (CHMP) officially that the company has resigned its application for approval for the treatment of Li-Fraumeni cancer.</seg>
<seg id="1641">"usually, however, the chest, the brain, the bones or the pasture parts (tissues that connect the other structures in the body, surrounds and leans) of it."</seg>
<seg id="1642">"this is a sort of virus that has been changed genetically, that it may carry a gene into the body's cells."</seg>
<seg id="1643">"with the virus in Advexan, it is a" Adenovirus "that has changed so that there is no copies of itself and therefore cannot trigger infections in humans."</seg>
<seg id="1644">"Advexin could have been pruned directly into the tumors, thus enabling cancer cells to form the normal p53 protein."</seg>
<seg id="1645">"the p53 protein, which is made of not defective in the human body made available p53-gene, carries usually to restore damaged DNA and to kill the cells when the DNA can not be recovered."</seg>
<seg id="1646">"at Li-Fraumeni Cancer, in which the p53-gene is broken, the p53 protein does not work properly, and the cancer cells can continue to grow and share."</seg>
<seg id="1647">"the company presented data from a study with a patient, at the Li-Fraumeni Cancer in the field of sub-construction, entered into bone and brain."</seg>
<seg id="1648">"after the CHMP had tested the answers of the company on the questions, were still some questions unanswered."</seg>
<seg id="1649">"based on the examination of the initial submitted documents, the CHMP creates a list of questions that will be sent to the company."</seg>
<seg id="1650">According to the CHMP was not sufficiently demonstrated that the injection of Advexine in Li-Fraumeni Tumore will bring benefits to patients.</seg>
<seg id="1651">"the committee also had concerns about the processing of drug through in the body, the type of administration and the safety of the drug."</seg>
<seg id="1652">"in addition, the company had not sufficiently demonstrated that Advexin can be produced in a reliable way and that it is neither for the environment nor for people who come in close contact with the patient."</seg>
<seg id="1653">"the company did not notice the CHMP not in knowledge of whether the return consequences for patients, which currently has clinical trials or" Commodifying Use "programs with Advexin."</seg>
<seg id="1654">Changing active medicine means that the tablets are so composite that one of the effective components immediately and the other slowly is released over a few hours.</seg>
<seg id="1655">"Aerinaze is applied to the treatment of the symptoms of seasonal allergic Rhinitis (hay fever, through an allergy to pollen), with patients with nasal slices (petrifter nose)."</seg>
<seg id="1656">For adults and young adults over 12 years the recommended dose of aerinaze is twice a tablet that should be taken entirely with a glass of water with or without food.</seg>
<seg id="1657">"the duration of the treatment should be as short as possible and will be terminated as soon as the symptoms, above all the swelling of the nose-grinder (hidden nose), are sealed."</seg>
<seg id="1658">A treatment duration of more than 10 days is not recommended because the effects of the drug can be traced to the stipation of the nose.</seg>
<seg id="1659">"the main-effective symptoms were the changes in the severity of the hypocrisy symptoms, which were reported by the patients before the beginning of the treatment and during the 15-day treatment."</seg>
<seg id="1660">"during the study, the patients bore their symptoms all 12 hours into a diary with a standard scala, as difficult symptoms have been in the last 12 hours."</seg>
<seg id="1661">"when considering all grasps of the nose reported the patients, the aerinaze, about a decrease of symptoms by 46.0%, compared to 35.9% in the patient who took pseudoephedrine alone."</seg>
<seg id="1662">"if only the swelling of the nasal slices was seen, the patients under the aerinaze showed a alleviation of symptoms by 26.7% compared to 26.7% in patients who took the Desloratadin alone."</seg>
<seg id="1663">"the most common side effects of Aerinaze (watch for 1 to 10 of 100 patients) are tachykarst (throat infection), mouth-drying, tibility, insomnolence (sleeiness), somnolenz (sleeiness), insomatic disorders, and nervousness."</seg>
<seg id="1664">"aerinaze can be used in patients who are potentially hypersensitive (allergic) against Desloratadin, pseudo-substance or Loratadin (another medicine for the treatment of allergies), are not applied."</seg>
<seg id="1665">"aerinaze must also be used in patients with hypertension (tworthless water), cardiac or vascular disease (hypertension of the thyroid) or have already had a hemorrhagic stroke (hypertension the thyroid) or have a risk for a hemorhagic stroke."</seg>
<seg id="1666">"on 30 July 2007, the European Commission adopted the company SP Europe for the marketing of aerinaze in the whole of the European Union."</seg>
<seg id="1667">"the tablet can be taken with a glass of water, but is to swallow in the whole (i.e. without them to crush or chewing)."</seg>
<seg id="1668">Aerinaze should not be applied to children under 12 years due to misconception and effectiveness (see Section 5.1) in children under 12 years of age.</seg>
<seg id="1669">The duration of the application is as short as possible and should not be continued after the symptoms.</seg>
<seg id="1670">It is recommended to limit the use time of 10 days since during long-term application the activity of pseudoephedrine can take time with time.</seg>
<seg id="1671">"after the decrease in the swelling of the mugs in the upper respiratory, the treatment can be continued when required with Desloratadas as monotherapy."</seg>
<seg id="1672">"as Aerinaze pseudoephedrine contains, the medicinal product is also contraindicated in patients who are treated with monoaminoxidase (MAO) inhibitors or within 2 weeks after completion of such therapy."</seg>
<seg id="1673">"this is applied to alphamimentary activity with other vasoconstrictors such as bromocritin, caburid, caburid, graylephrine, phenylephrine, ephedrine, oxymetacolin, Naphazolin etc.)."</seg>
<seg id="1674">Safety and effectiveness of this combination therapy have not been checked for this patient collective and the data does not extend to pronounce appropriate recommendations for dosage.</seg>
<seg id="1675">The safety and efficacy of the aerinaze were not tested in patients with kidney or liver disorder and the data does not extend to pronounce appropriate recommendations for dosage.</seg>
<seg id="1676">"patients must be informed about the treatment in the occurrence of a hypertonic or a tachycaror, heart rhythmical symptoms, nausea or any other neurological symptoms (such as headaches or reinforcement of headaches) must be dropped."</seg>
<seg id="1677">"in the treatment of the following patients, patients under DIGITALIS • patients with hypertonic disorders • patients with hypertonic disorders in anamnese, diabetes mellitus, bladder construction or bronchipasmus in Anamnesis."</seg>
<seg id="1678">"Aerinaze is at least 48 hours before implementing the matological tests, since Antihistaminika can prevent otherwise positive reactions to indicators, prevent or reduce their extent in their extent."</seg>
<seg id="1679">"in the context of clinical trials with Desloratadin, where Erythromycin or Ketoconazol were added in addition, however, no clinically relevant exchange effects or changes of the Plasmakonzentration of Desloratadin has been observed."</seg>
<seg id="1680">"at the results of the psychomotor tests, no significant differences could be determined between the patients with Desloratadin and those treated with placebo treated patients regardless of whether desloratadin alone or with alcohol was taken."</seg>
<seg id="1681">"this is not yet identified for Metabolism of Desloratadin responsible enzymes, so that interactions with other medicines could not be completely excluded."</seg>
<seg id="1682">"Desloratadin hemmed in-vivo CYP3A4, and in-vitro studies have shown that the drugs CYP2D6 did not inhibit and neither a substrate nor an Inhibitor of P-glykopred is one."</seg>
<seg id="1683">The inconceivable of the use of aerinaze during pregnancy is not guaranteed to have experiences of a large number of affected pregnancies however no increase in frequency of abnormalities compared to the frequency when compared to the normal population.</seg>
<seg id="1684">"since reproductive studies on animals are not always transferred to the human being, and on the basis of vasoconstric properties of pseudoephedrine, aerinaze should not be applied in pregnancy."</seg>
<seg id="1685">"however, patients should be found that it may come in very rare cases to a bending, which can lead to an impairment of traffic noise, or the ability to serve machines."</seg>
<seg id="1686">"the symptoms can vary between a ZNS depression (Sedation, Apnoe, diminished mental attention, cyanosis, lift, convulsions) and a ZNS stimulation (insomnia, hallucinations, tremor, convulsions) with possible lettering processes."</seg>
<seg id="1687">"headaches, anxiety, sensuality, heart rhythmia, thirst, disturbances, coronary pain, disharpenal, disilently, twilight, tenacity, visual disorders, and hypotony or hypotony."</seg>
<seg id="1688">"a ZNS stimulation is especially probable in children as well as atropin-typical symptoms (mouth-dry, pupillenrigid and - dilatation, Hauling, hyperthermia, and gastrointestinal symptoms)."</seg>
<seg id="1689">"this close both the imitation of the release of proinflammatory cytokines like IL-4, IL-6, IL-8 and IL-13 from human macular cells, IL-6, and IL-13 from human macular cells, IL-6, IL-8 and IL-13 out of human macular cells."</seg>
<seg id="1690">"at a single dose trial with adults, Desloratadin 5 mg does not affect standard measurement sizes including the strengthening subjective blows or the tasks associated with the flies."</seg>
<seg id="1691">"controlled clinical trials were found at the recommended dosage of 5 mg every day, no increased frequency of sleepiness compared to placebo."</seg>
<seg id="1692">"the orale application of pseudoephedrine in recommended dosage can give further sympathetic effects, such as an increase in blood pressure, a tachykarst or manifestations of a ZNS arousal."</seg>
<seg id="1693">"there were 1,248 patients aged between 12 and 78 years with seasonal allergic rhinitis, where 414 patients Aerinaze tablets were received."</seg>
<seg id="1694">"in both studies, the histamine antagonistic effectiveness of aerinaze tablets, determined by the total-level for symptom atics (except nasal-sskin-swelling), significantly higher than under a monotherapy with pseudoephedrin over the 2-week treatment period."</seg>
<seg id="1695">"the efficacy of the aerinaze tablets with regard to the diminishing effect, determined by the nose-slimming effect, was significantly higher than under a monotherapy with desloratadin over the 2-week treatment period."</seg>
<seg id="1696">The efficacy of the aerinaze tablets showed no significant differences in terms of sex, age or ethnic affiliation. "</seg>
<seg id="1697">In the context of a single-dose study of aerinaze is Desloratadin within 30 minutes of administration in the plasma.</seg>
<seg id="1698">"according to the peroral application of Aerinaze with healthy promoters over 14 days, the fly-weight of Desloratadin, 3-hydroxydesloratadin and pseudoephedrine was reached in day 10."</seg>
<seg id="1699">"in the context of a pharmacoinetic multi-type study, which was carried out with the formulation as tablet to healthy adult Probanden, was found that four Probanden Desloratadin poorly uniformities."</seg>
<seg id="1700">"a component Interactions study reveals that the exposure (Cmax and Auc) from pseudoephedrine, according to the allubiedrals of pseudoephedrine in biofuels, was in exposure to the gift of an aerinaze tablet."</seg>
<seg id="1701">"based on conventional studies on the safety of security, toxicity, genotoxicity and Reproductive Toxicity, allow to recognize the preclinical data with Desloratadin, however, not to recognize any particular dangers for the human being."</seg>
<seg id="1702">"the combination of no greater toxicity than their individual components, and the observed effects were generally related to the ingredient pseudoephedrine."</seg>
<seg id="1703">The combination of Loratadin / pseudoephedrals was a combination of up to 150 mg / kg / day and a rabbit in a dosage of up to 120 mg / kg / day not teratogenic.</seg>
<seg id="1704">"March 2007 and in module 1.8.1 of the application described drug drug system is established and works, before and while the product is on the market."</seg>
<seg id="1705">"antihistaminika contribute to alleviating the allergic symptoms, by preventing that histamine, can unfold a body's substance, its effect can unfold."</seg>
<seg id="1706">"aerinaze tablets alleviate symptoms, which occur in connection with seasonal allergic rhetoric (hay fever), such as Niesen, current or juicy nose and trendental eyes with simultaneous constipation of the nose."</seg>
<seg id="1707">"20 Under certain circumstances, you may be particularly sensitive to the mucosal drugs pseudoephedredrine, which is included in this medicine."</seg>
<seg id="1708">"(sugar disease), a stenositive stomach sdoor (intestinal clashes), a stripe of stomach or the esophagus (intestinal lock), a delusion of the stomach or the esophagus (intestinal muscles), a strife, or problems with the liver, the kidneys, or the bladder."</seg>
<seg id="1709">"inform your doctor, if you may occur or diagnosed with the use of aerinaze following symptoms or diseases: • hypertension the following symptoms or diseases might occur or be diagnosed: • hypertension, heartbeat • heart rhythmia • nausea and headaches or strengthening of existing headache."</seg>
<seg id="1710">"when taking any of the aerinaze with other medicines Please inform your doctor or pharmacist if you are taking other medicines or have recently been taken, even if they are not prescription drugs."</seg>
<seg id="1711">"transport and supply of machinery for use in recommended dosage is not to reckon that aerinaze leads to bending, or the attention gets down."</seg>
<seg id="1712">If you have taken a larger amount of aerinaze than you should inform you immediately your doctor or pharmacist if you have taken a greater amount of aerinaze than you should.</seg>
<seg id="1713">"if you have forgotten the intake of aerinaze If you have forgotten, take a dose of time, pick up the application as soon as possible and turn the next dose for the planned time."</seg>
<seg id="1714">Please inform your doctor or pharmacist if one of the listed side effects you have considerably affected or you notice side effects which are not stated in this usage information.</seg>
<seg id="1715">"hunting, chatting with more physical activity, mouthlessness, shalloy, sense, fatigue, headaches, headaches, sleeping disorders, nervousness and bending."</seg>
<seg id="1716">"coronary eyes, clockling, nose, nasal, nose, nose, nose, nasal, nose, nose, nose, nose, nose, nose, nose, nose pain, blackness, strips, nose pain, blackness, strife, anxiety, anxiety, anxiety and irritability, blackish liver values, anxiety, anxiety, anxiety and stimuli."</seg>
<seg id="1717">"after the launch of Desloratadin has been very rare in cases of severe allergic reactions (respiratory, whistle, itching breathing, hickiness and tails) or skin attacks."</seg>
<seg id="1718">"more than cases of heartbeat, heart pain, nausea, vomiting, vomiting, vomiting, vomiting, vomiting, vomiting, vomiting, penelessness, turnical activity, unicelessness, turnical activity, more cases of liver infection and above cases of conspicuous liver, was also very rare reported."</seg>
<seg id="1719">"it is available as a 5 mg tablet, 5 mg- Lyopphilisate (soluble tablet), 2.5 mg- and 5 mg scarf (tablets that dissolve in the mouth), 0.5 mg / ml syrup and as 0,5 mg / ml solution available."</seg>
<seg id="1720">"for children aged one to five years, the dose is 1.25 mg once daily, in the form of 2.5 ml syrup."</seg>
<seg id="1721">"for children aged six to eleven years, the dose is 2.5 mg once daily, either in the form of 5 ml syrup."</seg>
<seg id="1722">Aerius was examined in a total of eight studies with some 4 800 adults and young people with allergic rhinitis (including four studies of seasonal allergic rhinitis and two studies of patients who were also asthma).</seg>
<seg id="1723">"the effectiveness was measured by changing the symptoms of symptoms (juckiness, number and size of quaddles, impairment of sleep, and efficiency on the day) before and after six weekly treatment."</seg>
<seg id="1724">"further studies were presented, in order to prove that the body will take the syrup, the solution and melting in the same way as the tablets and the application in children are harmless."</seg>
<seg id="1725">"in case of allergic rhinitis, when the results of all studies have been taken into account, the two-week treatment with 5 mg Aerius became an average withdrawal of the symptom (symptom score) to 25 to 32%, compared to the acceptance of 12 to 26% in patients who received placebo."</seg>
<seg id="1726">"in both studies at Urtikaria, the cancellation of the symptom was after six-week treatment with Aerius 58 and 67%, compared to 40 and 33% in the patients treated with placebo."</seg>
<seg id="1727">"Aerius must not be applied in patients, which may be oversensitive (allergic) against desloratadin, Loratadin, or any of the other components."</seg>
<seg id="1728">"January 2001, the European Commission adopted the company SP Europe for approval by Aerius across the European Union."</seg>
<seg id="1729">"one tablet once daily, with one or without a meal, to alleviate the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see below 5.1)."</seg>
<seg id="1730">There are limited experience from clinical studies for the effectiveness in the application of Desloratadin for young people from 12 to 17 years (see sections 4.8 and 5.1).</seg>
<seg id="1731">The treatment of intermittent allergic rhinitis (occurrence of symptoms for less than 4 days a week or less than 4 weeks) should be carried out according to the previous disease changes and may be resumed after the crash of symptoms and may be resumed by the symptoms.</seg>
<seg id="1732">"in the persistent allergic rhinitis (occurrence of symptoms, 4 or more days per week and more than 4 weeks), patients can be recommended during the most allergen time."</seg>
<seg id="1733">"clinically relevant interactions were not found in the context of clinical studies with Desloratadin tablets, in which erythromycin or Ketoconazol were added in addition (see below 5.1)."</seg>
<seg id="1734">In a clinically pharmacological study was inconclusive of Aerius and alcohol the powerful effect of alcohol (see below 5.1).</seg>
<seg id="1735">"however, patients should be figured out that in very rare cases it may come to bending, which can lead to an impairment of traffic noise, or the ability to serve machines."</seg>
<seg id="1736">"in clinical trials at different indications, including allergic rhinitis and chronically idiopathic urtikaria, were reported in the recommended dose of 5 mg every day 3% more side-effects in patients with Aerius, than in patients treated with placebo."</seg>
<seg id="1737">"the most common side effects on which is reported more common than in placebo were fatigue (1,2%), mouth-drying (0.8%) and headaches (0.6%)."</seg>
<seg id="1738">"at a clinical study with 578 youthful patients from 12 to 17 years old, the commonest side effect headaches had been treated at 5.9% of patients who were treated with Desloratadin and at 6.9% of patients treated with placebo."</seg>
<seg id="1739">"in a multi-dosage study, in which up to 45 mg Desloratadin (nineteen clinical dose) were administered, no clinically relevant effects were observed."</seg>
<seg id="1740">"this includes both the inhibition of the release of proinflammatory cytokines like IL-4, IL-6, IL-8 and IL-13 from human macular cells, IL-6, IL-8 and IL-13 from human macular cells. P-selektin to Endothelialcells."</seg>
<seg id="1741">"as part of a clinical study with multiple entries, in desloratadin in a dosage of up to 20 mg was administered daily over 14 days, no statistically significant or clinically relevant cardiovascular effect was described."</seg>
<seg id="1742">"in a clinically pharmacological study, in the Desloratadin in a dosage of 45 mg daily (the ninth of the clinical dose) was administered for ten days, is not an extension of the QTc Intervalls."</seg>
<seg id="1743">"at a single dosages trial with adults, Desloratadin 5 mg does not affect standard measurement sizes including the strengthening subjective blows or the tasks associated with the flies."</seg>
<seg id="1744">"in patients with allergic rhinitis, Aerius was effective in relieving the symptoms such as Niesen, nasal secretion and redness of the nose, juckling river and redness of the eyes as well as jotreiz on the palate."</seg>
<seg id="1745">"in addition to the established classification in seasonal and perennial, allergic rhetoric can also be classified depending on the duration of symptoms alternatively in intermittent allergic rhinitis and persistence allergic rhinitis."</seg>
<seg id="1746">Intermittent Rhinitis is defined as the occurrence of symptoms for less than 4 days a week or less than 4 weeks.</seg>
<seg id="1747">Persistent Rhinitis is defined as the occurrence of symptoms in 4 or more days a week and more than 4 weeks.</seg>
<seg id="1748">"as shown by the total level of cargo for the quality of life at Rhino-economics, Aerius effectively was reduced by seasonal allergic rhinitis caused by seasonal Rhinitis."</seg>
<seg id="1749">"chronically idiopathic urtikaria is investigating for more forms of the Urtikaria, since the underlying pathology in the different forms is similar and chronic patients may be able to recruit more quickly."</seg>
<seg id="1750">"since the histaminfreiscation is a causal factor in all urticular disorders, it is expected that Deslorry is also confirmed in other forms of the Urtikaria in other forms of the Urtikaria as well; this is confirmed by the recommendations of clinical guidelines."</seg>
<seg id="1751">"in two placebo-controlled studies over 6 weeks in patients with chronic idiopathic urtikaria, Aerius was effective in improving puritus and the reduction of size and number of quaddles at the end of the first tin."</seg>
<seg id="1752">"as in other studies with anti-histaminika, in chronic idiopathic urtikaria, the minority of patients, which did not respond to antihistaminika, from the study."</seg>
<seg id="1753">An improvement of the itch by more than 50% was observed in 55% of patients with Desloratadin treated patients compared to 19% of patients treated with placebo.</seg>
<seg id="1754">The treatment with Aerius reduced the disturbance of the sleeping and of the wax significantly as it was measured by a 4-point scale on evaluating these variables.</seg>
<seg id="1755">"in a pharmacoineinetics study, in which the patients Demographics were comparable with the general seasonal Rhinitis-population, was achieved at 4% of patients a higher concentration of Desloratadin."</seg>
<seg id="1756">There are no clue to a clinically relevant grief after even daily use of Desloratadin (5- 20 mg) over 14 days before.</seg>
<seg id="1757">"however, this is not yet identified for Metabolism of Desloratadin responsible enzymes, however, so that interactions with other medicines have not been excluded completely."</seg>
<seg id="1758">"Desloratadin hemmed in-vivo not CYP3A4 and in-vitro studies have shown that the drugs CYP2D6 did not inhibit, and neither a substrate nor an Inhibitor of P-glykopred is one."</seg>
<seg id="1759">"in a single dose study with Desloratadin in a dosage of 7.5 mg, meals (fatty, calorie rich breakfast) did not rely on the availability of Desloratadin."</seg>
<seg id="1760">"the studies with Desloratadin and Loratadin conducted preclinical studies, in a comparable degree of exposure to Desloratadin, no quality or quantifiable differences in the toxicity of Desloratadin and from Loratadin."</seg>
<seg id="1761">"based on the conventional studies on safety harology, toxicity, genotoxicity and Reproductive Toxicity, the preclinical data with Deslorry can be seen in no particular dangers for the people."</seg>
<seg id="1762">"coloured movie (contains lactose-monohydrat, hydropholess, titanium dioxide, Macrogol 400, Indigocarmin (E 132), Macrogol 400, Carnaubadia, baked wax."</seg>
<seg id="1763">Aerius can be taken independently of the meals to alleviate the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see below 5.1).</seg>
<seg id="1764">The prescribing doctor should be aware that most cases of rhinitis are caused by infection under 2 years (see under Section 4.4) and that no data is available to support a treatment of infectious rhinitis with Aerius.</seg>
<seg id="1765">"besides the exclusion of upper respiratory infections or anatomical anomalies, in the diagnosis the anamnese, physical examinations and corresponding laboratory and skin tests should play a role."</seg>
<seg id="1766">"about 6% of adults and children between the ages of 2 and 11, metabolic Desloratadin limited and learn a higher substanzload (see in section 5.2)."</seg>
<seg id="1767">"the security of Aerius syrup in children between 2 and 11 years, which is restricted to children, is identical to those in children, which is normal."</seg>
<seg id="1768">"this drug contains saccharose and Sorbitol; therefore patients should not take patients with inherited problems of fructose intolerant, glucose insufficiency or Saccharase isomaltase- insufficiency of this medicine."</seg>
<seg id="1769">"clinically relevant interactions were not found in the context of clinical studies with Aerius tablets, in which erythromycin or Ketoconazol were added in addition (see below 5.1)."</seg>
<seg id="1770">In a clinically pharmacological study was inconclusive of Aerius tablets and alcohol the powerful effect of alcohol (see below 5.1).</seg>
<seg id="1771">The overall prevalence of side effects in children between 2 and 11 years was similar to the Aerius Sirup group as well as with the placebo group.</seg>
<seg id="1772">"in clinical trials with adults and young adults in different indications, including allergic rhinitis and chronic idiopathic urtikaria, were reported in the recommended dose 3% more side-effects in patients with Aerius, than in patients treated with placebo."</seg>
<seg id="1773">"in a multi-dose study of adults and young people, where up to 45 mg Desloratadin (nineteen clinical dose) were administered, no clinically relevant effects were observed."</seg>
<seg id="1774">Children aged between 1 and 11 years old who were asked for an antihistamine therapy in question received a daily disaster of 1.25 mg (aged between 1 and 5 years) or 2.5 mg (aged between 6 and 11 years).</seg>
<seg id="1775">"because the course of allergic rhinitis / chronic idiopathic urtikaria and the profile of Desloratadin in adults and children are similar, the efficacy data of Desloratadin in adults can be enrolled for children's population."</seg>
<seg id="1776">"as part of a clinical study with multiple adults and young people, the Desloratadin in a dosage of up to 20 mg was applied over 14 days, no statistically significant or clinically relevant cardiovascular effect was described."</seg>
<seg id="1777">"in a clinical-pharmacological study of adults and young people, in desloratadin in a dosage of 45 mg daily (the ninth of the clinical dose) was applied for ten days at adults, there was no extension of the QTc Intervalls."</seg>
<seg id="1778">"controlled clinical trials were found at recommended dosage of 5 mg daily for adults and teenagers, no increased frequency of sleepiness compared to placebo."</seg>
<seg id="1779">"at a single-day dose of 7.5 mg, Aerius tablets in adults and young people in clinical trials do not require any impairment of the psychomotor."</seg>
<seg id="1780">In clinical-pharmacological studies in adults it came through the simultaneous intake of alcohol neither to a strengthening of alcohol-induced performance impaired even to an increase in the sleepiness.</seg>
<seg id="1781">"with adult and adolescent patients with allergic rhinitis Aerius tablets are effective in relieving the symptoms such as Niesen, nasal secretion and redness of the nose, itching-flow and redness of the eyes as well as jotreiz on the palate."</seg>
<seg id="1782">"as shown by the total level of cargo for the quality of life at Rhino-economics, Aerius tablets could effectively be produced by seasonal allergic rhinitis."</seg>
<seg id="1783">"in two placebo-controlled studies over 6 weeks in patients with chronic idiopathic urtikaria, Aerius was effective in improving puritus and the reduction of size and number of quaddles at the end of the first tin."</seg>
<seg id="1784">"the spread of this limited metabolic phenotype was comparable to adults (6%) and children between 2 and 11 years (18% adults, 16% children) than in Caucasians (2% adults, 3% children)."</seg>
<seg id="1785">Similar pharmacoinetic parameters were observed in a pharmacoosis study with the syrup in children between 2 and 11 years with allergic rhinitis that are restricted.</seg>
<seg id="1786">The loading (Auc) by Desloratadin was approximately 6times higher and the Cmax about 3 to 4times higher with an terminal half-time of about 120 hours.</seg>
<seg id="1787">There are no clue to a clinically relevant drug adulation after even daily use of Desloratadin (5- 20 mg) over 14 days in adults and young people.</seg>
<seg id="1788">12 In various single-dose studies revealed that AUC- and Cmax-values of Desloratadin at paediatric patients were comparable to those of adults who received desloratadin syrup in a dosage of 5 mg.</seg>
<seg id="1789">"however, this is not yet identified for Metabolism of Desloratadin responsible enzymes, however, so that interactions with other medicines could not be completely excluded."</seg>
<seg id="1790">"Aerius syrup is offered in type-III-brown glass bottle with child safer polypropylene cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1791">"equipped with a rigid, perpleting polystyrene messy, calibrated with 2.5 ml and 5 ml or with an application splashing for ingestions with scalings of 2.5 ml and 5 ml (only for the 150 ml bottle)."</seg>
<seg id="1792">A dose of Aerius Lyophilisat to take once daily into the mouth to alleviate the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see below 5.1).</seg>
<seg id="1793">"immediately prior to the application, the blister needs to be carefully opened and the dose of the Lyophilisats must be taken from, without damaging it."</seg>
<seg id="1794">"clinically relevant interactions were not found in the context of clinical studies with Aerius tablets, in which erythromycin or Ketoconazol were additionally applied (see below 5.1)."</seg>
<seg id="1795">"in clinical trials at different indications, including allergic rhinitis and chronically idiopathic urine, were reported in the recommended dose of 5 mg every day 3% more side-effects in patients with Aerius tablets, than in patients treated with placebo."</seg>
<seg id="1796">"in a multi-dosage study, in which up to 45 mg Desloratadin (nineteen clinical dose) were applied, no clinically relevant effects were observed."</seg>
<seg id="1797">"in two single-dose studies, Aerius Lyophilisat was well tolerated; this was documented by clinical laboratory results, medical studies, Vitalmarks and EKG-Intervalldates."</seg>
<seg id="1798">"as part of a clinical study with multiple entries, in desloratadin in a dosage of up to 20 mg every day was applied over 14 days, no statistically significant or clinically relevant cardiovascular effect was described."</seg>
<seg id="1799">"in a clinically pharmacological study, in the Desloratadin in a dosage of 45 mg daily (the ninth of the clinical dose) was applied for ten days, not an extension to the QTc Intervalls."</seg>
<seg id="1800">"controlled clinical trials were found at the recommended dosage of 5 mg every day, no increased frequency of sleepiness compared to placebo."</seg>
<seg id="1801">"at a 17 single-dose study with adults, Desloratadin 5 mg has no influence on standard measurement output including the strengthening subjective blows or the tasks connected to the flies."</seg>
<seg id="1802">"in patients with allergic rhinitis Aerius tablets are effective in relieving the symptoms such as Niesen, nasal secretion and redness of the nose, itching-flow and redness of the eyes as well as joureiz on the palate."</seg>
<seg id="1803">"as shown by the total level of cargo for the quality of life at Rhino-economics, Aerius effectively was reduced by seasonal allergic rhinitis caused by seasonal Rhinitis."</seg>
<seg id="1804">18 In a pharmaceutical study study in which the patients Demographics of the general seasonal Rhinitis were comparable in 4% of patients has been achieved a higher concentration of Desloratadin.</seg>
<seg id="1805">Food has no significant impact on Auc and Cmax of Aerius Lyophilisate while food Tmax from Desloratadin from 2.5 to 4 hours and Tmax of 3-OH-Desloratadin from 4 to 6 hours extended.</seg>
<seg id="1806">Gelatine Mannitol Aspartan (E 951) Polacrilin Aspartan (E 951) Polacrilin Aspartan (E 464) (E 464)) aroma Tutti-Frutti waterproof-free Citronensacid</seg>
<seg id="1807">An Aerius 2.5 mg of meltdown once daily in the mouth place for alleviating the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see below 5.1).</seg>
<seg id="1808">Two Aerius 2.5 mg of melting shell once daily in the mouth place for alleviating the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see below 5.1).</seg>
<seg id="1809">There are limited experience from clinical studies for the effectiveness in the application of Desloratadin for young people from 12 to 17 years (see sections 4.8 and 5.1)</seg>
<seg id="1810">"immediately prior to the application, the blister needs to be carefully opened and the dose of the chimney, without damaging it."</seg>
<seg id="1811">The effectiveness and the unthinkable of Aerius 2.5 mg of melting shell in the treatment of children under 6 years of age have not been proven.</seg>
<seg id="1812">The overall prevalence of side effects between the Desloratadine Sirup- and the placebo group was equal and turned not significantly from the safety profile provided with adult patients.</seg>
<seg id="1813">"for the recommended dose, Aerius Schmelztablette was proved to be the Aerius 5 mg of conventional tablets formulation and the Aerius 5 mg of Lyopphilisat to dealership formulation of Desloratadin."</seg>
<seg id="1814">"in the context of a clinical study with multiple entries, in desloratadin in a dosage of up to 20 mg every day was applied over 14 days, no statistically significant or clinically low."</seg>
<seg id="1815">"at a single dose trial with adults, Desloratadin 5 mg has no influence on standard measurement output including the strengthening subjective blows or the tasks connected to the flies."</seg>
<seg id="1816">"the spread of this bad metabolic phenotype was comparable to adult (6%) and paediatric patients aged between 2 and 11 years (6%), and under black (adult 18%, children 16%), but the safety profile of these patients was not devided from that of the general population."</seg>
<seg id="1817">In single-dose-crossover studies of Aerius Schmelttablette with Aerius 5 mg conventional tablets or Aerius 5 mg of lyophilisat to include the formulations of biofuels.</seg>
<seg id="1818">Aerius 2.5 mg tablets were not studied in paediatric patients to support the pharmacoinetic data for Aerius Schmelztabletten the use of 2.5 mg dosage for children from 6 to 11 years.</seg>
<seg id="1819">Food has no significant impact on Auc and Cmax Aerius Lyophilisate while food Tmax from Desloratadin from 2.5 to 4 hours and Tmax of 3-OH- Desloratadin from 4 to 6 hours extended.</seg>
<seg id="1820">The overall analysis of preclinical and clinical irritation tests for the melting pot revealed that this formulation represents an unlikely risk for local irritation during clinical application.</seg>
<seg id="1821">Micro-crystine cellulose methylxymethyl-sodium polyacrylate-sodium alkaline dioxide oxide clubitol Aspartan (E951) flavor Tutti Frutti</seg>
<seg id="1822">"the cold-format foil consists of polyvinylchloride (PVC) laminated laminated on an aluminum foil, liable laminated to a polyvinyl chloride (PVC) film."</seg>
<seg id="1823">"a Aerius 5 mg of melting tableonce daily in the mouth, for alleviating the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and Urtikaria (see below section 5.1)."</seg>
<seg id="1824">"for the recommended dose, Aerius 5 mg scmelztablette was turned into the Aerius 5 mg of conventional tablets formulation and the Aerius 5 mg of Lyopphilisat to take up the wording of Desloratadin."</seg>
<seg id="1825">"as part of a clinical study with multiple entries, in desloratadin in a dosage of up to 20 mg every day was applied over 14 days, no statistically significant or clinically relevant cardiovascular effect was described."</seg>
<seg id="1826">"at a 30 single dose trial with adults, Desloratadin 5 mg has no influence on standard measurement output including the strengthening subjective blows or the tasks connected to the flies."</seg>
<seg id="1827">"in patients with allergic rhinitis Aerius tablets are effective in relieving the symptoms such as Niesen, nasal secretion and redness of the nose, itching-flow and redness of the eyes as well as joureiz on the palate."</seg>
<seg id="1828">In single-dose-crossover studies of Aerius 5 mg scmelttabs with Aerius 5 mg conventional tablets or Aerius 5 mg of lyophilisat to include the formulations of biofuels.</seg>
<seg id="1829">The overall analysis of preclinical and clinical irritation tests for the melting pot revealed that this formulation represents an unlikely risk for local irritation during clinical application.</seg>
<seg id="1830">"the safety of Desloratadin in children between 2 and 11 years, which is restricted to children between 2 and 11 years, is identical to those in children, which is normal."</seg>
<seg id="1831">"this drug contains sorbitol; therefore, patients should not take patients with inherited problems of fructose, glucose-sorceration or Saccharase isomaltase-insufficiency of this medicine."</seg>
<seg id="1832">The overall prevalence of side effects in children between 2 and 11 years was similar to Desloratadin group like with the placebo group.</seg>
<seg id="1833">"for small children between 6 and 23 months, the most common side effects on which are reported more often than in placebo (3.7%), fever (2.3%) and sleeplessness (2.3%)."</seg>
<seg id="1834">"in an additional study, one additional study was observed in a single study by 2.5 mg Desloratadin solution for taking no side effects in patients aged between 6 and 11 years."</seg>
<seg id="1835">"for recommended doses, the Plasma concentrations of Desloratadin (see in section 5.2) in the children and adult population comparable."</seg>
<seg id="1836">"controlled clinical trials were found at recommended dosage of 5 mg daily for adults and teenagers, no increased frequency of sleepiness compared to placebo."</seg>
<seg id="1837">"in addition to the established classification in seasonal and perennial, allergic rhinitis can also be associated with the duration of symptoms alternatively in intermittent Rhinitis and"</seg>
<seg id="1838">"as shown by the total level of cargo for the quality of life at Rhino-economics, Aerius tablets could effectively be caused by seasonal allergic rhinitis caused by seasonal Rhinitis."</seg>
<seg id="1839">"the spread of this limited metabolic phenotype was comparable to adults (6%) and children between 2 and 11 years (18% adults, 16% children) than in Caucasians (2% adults, 3% children)."</seg>
<seg id="1840">"since Aerius solution to install the same concentration on Desloratadin, there was no biodegradation study and it is expected that it matches the syrup and the tablets."</seg>
<seg id="1841">"in different single-dose studies, AUC- and Cmax-values of Desloratadin at paediatric patients were comparable with those of adults, the Desloratadin syrup in a dosage of 5 mg."</seg>
<seg id="1842">"Sorbitol, propylene glycol E 955, sodium citrate 2 H2O, natural and artificial flavors (Bubble-Gum), waterproof citronensic acid, sodium citrus (Ph.Eur.), framed water."</seg>
<seg id="1843">"Aerius solution to insertion is offered with 30, 50, 60, 100, 120, 225, and 300 ml in type III Braunglass bottles with a multi-scale polyethylene combined with a multi-scale polyethylene combined."</seg>
<seg id="1844">All packages except the 150 ml pack size are offered with a measuring spoon with markings for doses of 2.5 ml and 5 ml.</seg>
<seg id="1845">The 150 ml pack size is a measuring spoon or an application of application for preparations to take with scaling from 2.5 ml and 5 ml.</seg>
<seg id="1846">"subsequently, the approval of the authorisation will be the regularly updated reports on the inconceivable of a drug for every two years, except it will be a bit different from the CHMP."</seg>
<seg id="1847">"1 film tabletten, 3 film tabletten, 3 film tabletten, 30 film tabletten, 30 film tabletten, 30 film tabletten, 100 film tabletten, 100 movie-coated tablets"</seg>
<seg id="1848">"1 film tabletten, 3 film tabletten, 3 film tabletten, 30 film tabletten, 30 film tabletten, 30 film tabletten, 100 film tabletten, 100 movie-coated tablets"</seg>
<seg id="1849">Syrup 30 ml with 1 measuring spoon 100 ml with 1 mspoon 100 ml with 1 mspoon 100 ml with 1 mspoon 100 ml with 1 mspoon 100 ml with 1 mspoon measuring 150 ml with 1 mspoon 300 ml with 1 measurement-spoon 300 ml with 1 measuring spoon</seg>
<seg id="1850">30 ml with 1 measuring spoon 100 ml with 1 mspoon 100 ml with 1 mspoon 100 ml with 1 mspoon 100 ml with 1 mspoon 100 ml with 1 mspoon measuring 150 ml with 1 mspoon 300 ml with 1 measurement-spoon 300 ml with 1 measuring spoon</seg>
<seg id="1851">1 dose of Lyophilisat to take 2 cans lyophilisat to take 15 cans lyophilisat to take 15 cans lyopphilisat to take 15 cans lyopphilisat to take 30 cans lyopphilisat to take 100 cans lyopphilisat to take 100 cans lyopphilisat to take 100 cans lyopphilisat to take 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyopphilisat to take up 100 cans lyophilisat to</seg>
<seg id="1852">"5 Schmelztabletten, Zmelztabletten 5zmelztabletten, 30 smelztabletten 5zmelztabletten 5zmelztabletten 5zmelztabletten 100 shmelztabletten 100 shmelztabletten,"</seg>
<seg id="1853">Solution for taking up 30 ml with 1 measuring spoon 100 ml with 1 mspoon 100 ml with 1 mspoon 100 ml with 1 mspoon 100 ml with 1 mspoon 100 ml with 1 mspoon 100 ml with 1 mspoon 300 ml with 1 measurement-spoon 300 ml with 1 measuring spoon</seg>
<seg id="1854">Pregnancy and lactation questions during pregnancy and lactation before taking any medicines your doctor or pharmacist for advice.</seg>
<seg id="1855">"transport and serve of machinery for use in recommended dosage is not to reckon that Aerius leads to bending, or the attention gets down."</seg>
<seg id="1856">"if you have told by your doctor you have an intolerance against certain sugar, ask your doctor before taking this medicine."</seg>
<seg id="1857">"regarding treatment duration, your doctor will find the type of allergic rhinitis under which you are suffering and will define how long you are taking Aerius."</seg>
<seg id="1858">"if your allergic Rhinitis is intermittently (symptoms rarely occur as 4 days a week or less than 4 weeks, your doctor will recommend you a treatment scheme that depends on your previous disease course."</seg>
<seg id="1859">"if your allergic rhetoric is persistent (symptoms in 4 or more days per week, and more than 4 weeks old), your doctor can recommend a longer lasting treatment."</seg>
<seg id="1860">"if you have forgotten the intake of Aerius If you have forgotten your dose to take in time, take them as soon as possible, and then follow the normal treatment plan."</seg>
<seg id="1861">"71 After market launch of Aerius was very rare about cases of severe allergic reactions (difficulties when breathing, whaling breathing, itching, nest-hand and swelling) and rash reports."</seg>
<seg id="1862">"more than cases of heartbeat, heart attack, diarrhea, dizziness, dizziness, muscular pain, insomnia, chatting, muscular activity, liposuction and unusual liver functional, was also very rare reported."</seg>
<seg id="1863">"tablet bar consists of coloured movie (includes lactose- monohhydrate, titanium dioxide, Macrogol 400, Indigocarmin (E 132), Macrogol 400, Carnaubadia, geblight wax."</seg>
<seg id="1864">"Aerius 5 mg of film-coated tablets are individually wrapped in Blisterpackaging with 1, 2, 3, 10, 15, 20, 21, 30, 50, 90, 90 or 100 tablets."</seg>
<seg id="1865">"Aerius Sirup is displayed for children between 1 and 11 years, adolescents (12 years and older) and adults, older people included."</seg>
<seg id="1866">Important information about certain other ingredients of Aerius you should take Aerius Sirup unless you are 110 allergic to the colour e.</seg>
<seg id="1867">"if your doctor has communicated you that you have an intolerability to some sugar-types, please contact your doctor before taking this medicine."</seg>
<seg id="1868">"when Sirup has put an application of injector for preparation with scams, you can use this alternatively to take the appropriate amount of syrup."</seg>
<seg id="1869">"regarding treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer and will define how long you should take Aerius Sirup."</seg>
<seg id="1870">"however, in children under 2 years diarrhoea, fever and insomnia common side-effects, while in adults fatigue, oral drying and headaches are more often reported than with placebo."</seg>
<seg id="1871">"according to market introduction of Aerius, it was rarely reported about cases of severe allergic reactions (difficulties while breathing, whistening breathing, itching, nests and tails) and rash."</seg>
<seg id="1872">"77 Aerius Sirup is available in bottles with child safer sealing cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1873">Aerius Lyophilisat to take improved the symptoms in allergic rhinitis (through an allergy caused inflammation of the nasal length, for example hay fever or house dust-allergy allergy).</seg>
<seg id="1874">Intake of Aerius Lyophilisat to take along with food and drink Aerius Lyophilisat to take a need not be taken with water or other fluid.</seg>
<seg id="1875">"regarding the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer and will define how long you are taking Aerius Lyophilisat."</seg>
<seg id="1876">81 If you have forgotten the taking of Aerius Lyophilisat to accept If you've forgotten your dose to take in time you take it as soon as possible and then follow the normal treatment plan.</seg>
<seg id="1877">"according to market introduction of Aerius, it was rarely reported about cases of severe allergic reactions (difficulties while breathing, whistening breathing, itching, nests and tails) and rash."</seg>
<seg id="1878">"Aerius Lyophilisat for immersion is individually wrapped in Blisterium with 1, 2, 3, 10, 15, 20, 21, 30, 50 or 100 cans of the lyopphilisate."</seg>
<seg id="1879">"Aerius Schmelztablette improves the symptoms in allergic rhinitis (through an allergy causing inflammation of the nasal length, for example hay fever or house dust-dusty allergy)."</seg>
<seg id="1880">With the intake of Aerius Schmelztablette together with food and drink Aerius Schmelztablette does not need to be taken with water or other fluid.</seg>
<seg id="1881">"regarding the treatment duration, your doctor will determine the type of allergic rhinitis under which you are suffering and will determine how long you should take Aerius shmelztabletten."</seg>
<seg id="1882">"86 If you forget the intake of Aerius shmelztablette If you have forgotten your dose to take in time, take them as soon as possible, and then follow the normal treatment plan."</seg>
<seg id="1883">"Aerius Schmelttablette is individually packed with 5, 6, 10, 12, 15, 20, 20, 50, 60, 90, 90 and 100 doses of shmelztablette."</seg>
<seg id="1884">With the intake of Aerius Schmelztablette together with food and drink Aerius Schmelztablette does not need to be taken with water or other fluid.</seg>
<seg id="1885">"if you have forgotten the intake of Aerius chmelztablette If you have forgotten your dose to take in time, take them as soon as possible, and then follow the normal treatment plan."</seg>
<seg id="1886">"according to market introduction of Aerius, it was rarely reported about cases of severe allergic reactions (difficulties while breathing, whistening breathing, itching, nests and tails) and rash."</seg>
<seg id="1887">"Aerius solution to take is displayed for children between 1 and 11 years, adolescents (12 years and older) and adults, older people included."</seg>
<seg id="1888">"if the solution to insertion provides an applicator for preparations for insertion, you can use this alternatively to take the appropriate amount of solution for taking."</seg>
<seg id="1889">"regarding the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer and will determine how long you are taking Aerius solution to take."</seg>
<seg id="1890">"however, in children under 2 years diarrhoea, fever and insomnia common side-effects while in adults fatigue, oral drying and headaches are more often reported than with placebo."</seg>
<seg id="1891">"97 Aerius solution to install is available in bottles with child-safer sealing cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1892">The 150 ml pack size is a measuring spoon or an application of injectors for reviewing with scrape by 2.5 ml- and 5 ml doses.</seg>
<seg id="1893">"June 2008, Novartis Vaccines and Diagnostics S.r.l. of the Committee for Humanitarian Medicine (CHMP) officially launched its application for approval of Aflunov to the prevention of aviaries H5N1-Influenza by adults and older people."</seg>
<seg id="1894">Aflunov should be applied to protection against influenza (type) H5N1 of the Influenza-A virus.</seg>
<seg id="1895">"this is a special kind of vaccine that could cause a tribe of the flu, which could cause a future pandemic."</seg>
<seg id="1896">"a flu-pandemic breaks off when a new tribe of the flu is turned out, which can easily spread from man to man, because people still have no immunity (no protection) against it."</seg>
<seg id="1897">"according to administration of the vaccine, the immune system recognises the parts contained in the vaccine being contained in the vaccine as" "physical" "and forms antibodies against it."</seg>
<seg id="1898">"by doing so, the immune system is later able to form in contact with a flu virus of this genealogical antibodies."</seg>
<seg id="1899">"subsequently, the membrane kegel of the virus with the" surface antigens "(proteins on the membrane surface, which recognizes the human body as the body of body), agreed and used as a component of the vaccine."</seg>
<seg id="1900">A survey of some of the study buildings showed that the study was not conducted according to the "good clinical practice" (GCP).</seg>
<seg id="1901">"by doing so, the scope of clinical data base for the evaluation of the security of the vaccine is not enough to meet the requirements of the EMEA's guidelines for pre-pandemic vaccines."</seg>
<seg id="1902">"should you take part in a clinical examination and need more information about your treatment, please contact your doctor's doctor."</seg>
<seg id="1903">"if you would like more information on the basis of the recommendations of CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="1904">"it is used in combination with other anti-viral medicines for the treatment of adults and children over four years, which are infected with human immune system virus from type 1 (HIV-1) which is the acquired immunficiency Syndrome (AIDS)."</seg>
<seg id="1905">"for patients who may not swallow the capsules, Agenerase is available as a solution, but this cannot be taken together with Ritonavir because the security of this combination has not been studied."</seg>
<seg id="1906">Agenerase should then be subordinated only if the doctor has tested what anti-viral medicines has taken before and the likelihood is that the virus will appeal to the drug.</seg>
<seg id="1907">The recommended dose for patients over twelve years is 600 mg twice daily which are taken along with twice a day 100 mg Ritonavir and with other anti-viral medicines.</seg>
<seg id="1908">In children between four and twelve years and in patients with a body weight of less than 50 kg the recommended dose of Agenerase is based on the body weight.</seg>
<seg id="1909">Agenerase decreases in combination with other antiviral medicines the HIV amount in the blood and keeps them at a low level.</seg>
<seg id="1910">"AIDS is not able to cure AIDS, however, the damage of the immune system and hence the development of AIDS related infections and diseases are hesitant."</seg>
<seg id="1911">"Agenerase was studied in combination with other anti-viral medicines, but without Ritonavir, in two main studies with 736 HIV-infected adult who had previously not been treated with Proteasants."</seg>
<seg id="1912">"this was compared with low dosified konavir, Agenerase was compared with 206 adults, who had been used earlier protein inhibitors, with other proteasants."</seg>
<seg id="1913">Main indicator for the effectiveness was the proportion of patients with non-detectable concentrations of HIV in the blood (virus last) or the change in the viral load after the treatment.</seg>
<seg id="1914">"in the studies with patients who had previously taken no protein earlier, after 48 weeks more patients had a viral load below 400 copies / ml than under placebo, but Agenerase was less effective than Indinavir."</seg>
<seg id="1915">"in children, Agenerase has also reduced the viral load, though of the children who had previously been treated with Proteasants, very few of the treatment mentioned earlier."</seg>
<seg id="1916">"in the study with adults, who had previously been treated with protonavir, the Viral last after 16-weekly treatment as effective as other proteasants:"</seg>
<seg id="1917">"in patients with HIV, which was resistant to four other proteasants, it came under Agenerase to become a stronger waste of the Viral last after four weeks than in patients who took their previous prototype earlier:"</seg>
<seg id="1918">"the most common side effects of Agenerase (observed in more than 1 of 10 patients) are headaches, diarrhoea (diarrhoea), Flatulenz (diarrhea), Nausea (nausea), vomiting, rash and FAIR (fatigue)."</seg>
<seg id="1919">"2 / 3 Agenerase must not be applied in patients, which may be oversensitive (allergic) against amspecavir or one of the other components."</seg>
<seg id="1920">"Agenerase must also not be used in patients, the curb weed (a herbal supplement for treating depression) or medicines that are exactly like Agenerase and are harmful to high concentrations in the blood of health."</seg>
<seg id="1921">"as with other drugs against HIV, the risk of a Lipodstreamphie (change in the distribution of the body fat), the risk of a Lipodstreamphie (changes in the distribution of the body fat), a osteonekrose (symptoms of an infection caused by the immune system)."</seg>
<seg id="1922">"in conclusion, the benefits of Agenerase for use in combination with other antiretroviral medicines used in combination with other anti-retroviral medicines for the treatment of protein previously untreated HIV-1-infected adult and children over four years towards the risks."</seg>
<seg id="1923">"Agenerase is usually taken along with the pharmacoinetic vertically Ritonavir, but the committee determined that the benefit of Agenerase is in combination with Ritonavir in patients who have not been detected before."</seg>
<seg id="1924">"Agenerase was originally approved under" extraordinary circumstances, "as at the time of approval for scientific reasons only limited information is available."</seg>
<seg id="1925">October 2000 shared the European Commission to the company Glaxo Group Limited for the marketing of Agenerase throughout the European Union.</seg>
<seg id="1926">"Agenerase is in combination with other antiretroviral medicines used to treat HIV-1- infected, protrudenmer (PI) -pre-treated adults and children older than 4 years."</seg>
<seg id="1927">For usually Agenerase capsules for pharmacoinetic boosts of amspecavir are administered together with low doses of Ritonavir (see sections 4.2 and 4.5).</seg>
<seg id="1928">The use of Amspecavir should take account of the individual viral mutsters and the treatment of the patient (see section 5.1).</seg>
<seg id="1929">The bioavailability of amspecavir as a solution is reduced by 14% less than a capsule; therefore Agenerase capsules and solution are not interchangeable on a milligram basis (see Section 5.2).</seg>
<seg id="1930">The recommended dose for Agenerase capsules is 600 mg of Amkled avir twice daily with 100 mg kkavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="1931">"2 If Agenerase capsules are applied without the amplified addition of Ritonavir (booster), higher doses must be applied to Agenerase (1200 mg twice daily)."</seg>
<seg id="1932">The recommended dose for Agenerase capsules is 20 mg Amkled avir / kg body weight twice daily in combination with other antiretroviral medicines up to a daily dose of 2400 mg of Amkled avir that should not be exceeded (see section 5.1).</seg>
<seg id="1933">"Pharmacokinetics, effectiveness and safety of Agenerase in combination with low doses of Ritonavir or other proteasants were not examined in children."</seg>
<seg id="1934">"Agenerase is not recommended for use in children under 4 years, due to the failure of data to inconceivable and effectiveness (see Section 5.2)."</seg>
<seg id="1935">"based on the pharmacoinetic data, the dose should be reduced to Agenerase capsules at 450 mg twice daily and in patients with severe liver disorders that can be reduced to 300 mg twice daily."</seg>
<seg id="1936">The simultaneous application should be treated with caution with mild or moderate liver disorder in patients with severe liver disorder it is contraindicated (see section 4.3).</seg>
<seg id="1937">"Agenerase must not be given simultaneously with medicines that have a low therapeutic width, and also substrates of cytochrom P450-Isoenzyme 3A4 (CYP3A4)."</seg>
<seg id="1938">Herbal supplements which contain curiswort (hypericum perforatum) may not be applied due to risk reduced plastic maconcentric and a diminished therapeutic effect of amspecavir during the intake of amspecavir (see Section 4.5).</seg>
<seg id="1939">Patients should be advised that Agenerase or any other antiretroviral therapy does not lead to a cure in HIV infection and that they also continue to develop opportunist infections or other complications of HIV infection.</seg>
<seg id="1940">The current antiretroviral therapy including the treatment with Agenerase does not prevent the risk of transferring HIV to others through sexual contact or contamination with blood.</seg>
<seg id="1941">Usually Agenerase capsules are to be applied with low doses of Ritonavir and in combination with other antiretroviral medicines (see Section 4.2).</seg>
<seg id="1942">"patients who suffer from chronic hepatitis B or C and treated with an antiretroviral combination therapy, have an increased risk of severe liver impacts with potentially fatal course."</seg>
<seg id="1943">"for the case of a simultaneous antiviral treatment of hepatitis B or C, please read the information of this medicine."</seg>
<seg id="1944">Patients with existing reduced liver function including a chronic-active hepatitis show an increased frequency of liver dysfunctions under an antiretroviral combination therapy and should be monitored according to clinical practice.</seg>
<seg id="1945">"the simultaneous application of Agenerase and other glucooids changes, which is not recommended via CYP3A4, is not recommended, unless the potential benefit of a treatment the risk of systemic cortisation, including Morbus Cushing and Suppression of the adrenal function (see Section 4.5)."</seg>
<seg id="1946">Since the metabolism of HMG CoA reductase inhibitors and mevastatin is highly recommended by CYP3A4 is a simultaneous administration with Lovastatin and Simvastatin because of the increased risk of myopathia including Rhabdomyolysen not recommended.</seg>
<seg id="1947">"4 For some medicines, which can cause severe or life-threatening side effects, such as Carbamazepine, phenobarbital, phenotoin, tricyclic antidepressants and warfarin (under supervision of the International normalisation ratio), methods for determining the drug concentration are available."</seg>
<seg id="1948">"in patients who take these medicines at the same time, Agenerase can be less effective because of reduced plastic fuel bars (see Section 4.5)."</seg>
<seg id="1949">"due to the possibility of metabolic interactions with Ampera avir can be the effectiveness of hormonal contraceptive pills, however the information is not sufficient to estimate the nature of the interactions."</seg>
<seg id="1950">"if methadone is given simultaneously with Amspecavir, patients should therefore be monitored on opatatentment symptom symptom, especially when there are also low doses of Ritonavir."</seg>
<seg id="1951">"due to the potential risk of a toxicity because of the high propylene glycol solution, this form of form is contraindicated in children under an age of four years and should be applied with caution for certain other patients."</seg>
<seg id="1952">Agenerase should be set to duration 5 if a rash is accompanied by systemic or allergic symptoms or are involved (see Section 4.8).</seg>
<seg id="1953">"in patients who received an antiretroviral therapy, including proteasants, was reported on the occurrence of diabetes mellitus, hyperglycaemia or an extradition of an existing type of diabetes."</seg>
<seg id="1954">Many of the patients had other ailments to their therapy medications that are associated with the development of diabetes mellitus or hyperglycaemia.</seg>
<seg id="1955">"B. higher age, and with drug dependent factors, such as a longer lasting antiretroviral treatment and the associated metabolic disorders associated with it."</seg>
<seg id="1956">"with hates-ophiles patients (type A and B), the reports were treated with protectors, are reports of an increase of bleeding including spontaneous cutters, including spontaneous cutters, and hailthrows."</seg>
<seg id="1957">"at the time of the introduction of an antiretroviral combination therapy (ART), an inflammatory reaction to asymptomatic or residual opportunist infections can develop the severe clinical states or deterioration of symptoms."</seg>
<seg id="1958">"although a multifactorial optiology is accepted (including application of corticosteroids, alcohol consumption, severe immunisation, higher body-measure index), cases were reported by osteonekrose especially in patients with advanced HIV disease and / or long-term application of an antiretroviral combination therapy (ART)."</seg>
<seg id="1959">"CYP3A4 substrates with low therapeutic width Agenerase must not be given simultaneously with medicines that have a low therapeutic width, and also substrates of cytochrom P450-Isoenzyme 3A4 (CYP3A4)."</seg>
<seg id="1960">"CYP2D6 substrates with low therapeutic width Agenerase with low therapeutic width Agenerase, with Ritonavir must not be combined with medicines, whose active ingredients are chiefly above CYP2D6 and are associated with heavier and / or life-threatening side effects."</seg>
<seg id="1961">It has been shown that Rifampicin causes an 82% reduction in the Auc of Amspecavir that can lead to a virological failure and lead to a resome development.</seg>
<seg id="1962">"in trying to equip the reduced plastic bars by a dosage increase of other Protease inhibitors in combination with Ritonavir, very often have been observed unwanted effects on the liver."</seg>
<seg id="1963">St. John's Wort (Hypericum perforatum)) The Serummirror of AmSpecavir (Hypericum perforatum) can be humiliated by the simultaneous application of herbal preparations (hypericum perforatum).</seg>
<seg id="1964">"when a patient is already taking St. John's weed, the amspecavirmirror are possible and, if possible, to check the viral load and put it in the currant."</seg>
<seg id="1965">A dosage adjustment for one of the medicine is not required when Nelfinavir is administered along with amspecavir (see also Efavirenz below).</seg>
<seg id="1966">508% increases for Cmax at about 30% if kpavir (100 mg twice daily) in combination with Ampping avir capsules (600 mg twice daily) was administered.</seg>
<seg id="1967">"in clinical trials, doses were used twice daily and Ritonavir 100 mg twice daily, which occupy the effectiveness and unthinkable of this treatment schematas."</seg>
<seg id="1968">52% humiliates if Amspecavir (750 mg twice daily) in combination with Kaletra (400 mg of Lopinavir + 100 mg kavionavir twice daily) was administered.</seg>
<seg id="1969">The Cmin values of Amspecavir (600 mg twice daily) with Kaletra (400 mg of Lopinavir twice daily) are approximately 40 to 50% lower than if Amkled avir (600 mg twice daily) in combination with 100 mg kkavir twice daily is administered.</seg>
<seg id="1970">"a dosing recommended for the simultaneous administration of Amspecavir and Kaletra can not be given, but there is a constant surveillance recommended, since the effectiveness and inconceivable of this combination is not known."</seg>
<seg id="1971">"there was no pharmacocular study performed to apply Agenerase in combination with didanosine, but is recommended because of the imaginative component of didanosine, however, that the revenues of Didanosin and Agenerase are at least one hour apart (see Antazida below)."</seg>
<seg id="1972">This is why with the Gift of Efavirenz in combination with Amspecavir (600 mg twice daily) and konavir (100 mg twice daily) no dosage adjustment required.</seg>
<seg id="1973">The treatment with Efavirenz in combination with Amspecavir and Saquinavir is not recommended because the exposure of both protrugum would become low.</seg>
<seg id="1974">The effect of nevirapine to other protrudmer and available limited data can suggest that nevirgade may lowers the serum concentration of Amspecavir.</seg>
<seg id="1975">"if these drugs should be used at the same time, caution is advisable because Delavirdin may be less effective because of the decreased or possibly subtherapeutic plastic bars could be less effective."</seg>
<seg id="1976">"if these drugs are applied together, caution is advisable; a thorough clinical and virological surveillance should be made, as a precise prediction of the effect of the combination of amspecavir and Ritonavir on Delavirdin is difficult."</seg>
<seg id="1977">The simultaneous Gift of Amspecavir and Rifabutin led to an increase in Plasmakonzentration (Auc) by Rifabutin by 193% and thus to an increase in part with Rifabutin side effects.</seg>
<seg id="1978">"if it is necessary for clinical reasons, Rifabutin is necessary along with Agenerase, will become a reduction in the dosage of Rifabutin to at least half of the recommended dose, although there is no clinical data."</seg>
<seg id="1979">"Pharmokinetic studies with Agenerase in combination with erythromycin were not performed, but could be increased the plastic bars of both medicines in the case of simultaneous administration."</seg>
<seg id="1980">Simultaneous application of twice daily 700 mg Fosaminavir and 100 mg kacol in the plasma with 200 mg Ketoconazol once daily led to an increase of Ketoconazol in the plasma with 200 mg Ketoconazol at once daily without the simultaneous application of Fosamspecavir with Ritonavir.</seg>
<seg id="1981">"other medicines that are listed below, including substrates, inhibitors or inductors from CYP3A4, if they are applied together with Agenerase, possibly leading effects."</seg>
<seg id="1982">Patients should therefore be applied to toxic reactions which are associated with these drugs if they are used in combination with agenerase.</seg>
<seg id="1983">"based on the data of other proteasants, it is advisable that Antazida will not be taken at the same time as Agenerase, since it can come to Resoratory disorders."</seg>
<seg id="1984">"the simultaneous application of anticonvulsions known as enzymes (phenytoin, phenobarbital, Carbamazepine), with amspecavir can lead to a degradation of the plasma level of amspecavir."</seg>
<seg id="1985">"the Serum concentrations of Calciumkanalblock, diltiazem, diodipin, instipin, lefepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin, Nifepin</seg>
<seg id="1986">"simultaneous ingestion with Agenerase, whose Plasmaconcentric may increase considerably and strengthen with PDE5 inhibitors in connection of the side effects including hypotension, visual disorders and priapism (see Section 4.4)."</seg>
<seg id="1987">"in a clinical study, in the konavir 100 mg capsules twice daily along with 50 µg Fluticasonpropionat intranasal (4 times daily) over 7 days to probanden were increased, while the endoticasonpropiononpropionate plastic (4 times daily) were increased by approximately 86% (90% -confidenzinterinterval from 82 to 89%)."</seg>
<seg id="1988">"as a result, the simultaneous gift of Agenerase with Ritonavir is not recommended along with these glucocosteroids, unless the potential benefit of a treatment is the risk of systemic cortisation of effect (see Section 4.4)."</seg>
<seg id="1989">"at HMG-CoA reductase inhibitors, such as Lovastatin and Simvastatin, whose hydrogen increases are highly dependent on CYP3A4, are to be expected to expect the untimely administration of Agenerase."</seg>
<seg id="1990">Since plasmaspips increased this HMG CoA reductase inhibitors to myopathia including a Rhabdomyolyse, the combined application of these drugs with amspecavir is not recommended.</seg>
<seg id="1991">"it is recommended to be a frequent monitoring of the therapeutic concentrations up to the stabilization of the mirror, since the Plasma concentrations of Cyclosporin, Rapamycin and Tacrolimus can be increased with equal treatment of amspecavir (see Section 4.4)."</seg>
<seg id="1992">"therefore, Agenerase may not be applied together with oral engenase Midazolam (see section 4.3) while on the simultaneous application of Agenerase with parenteral Midazolam caution."</seg>
<seg id="1993">Data for simultaneous application of parenteral Midazolam with other protrudolors point to a possible increase in the plastic bars of Midazolam around the 3- to 4-fold.</seg>
<seg id="1994">"if methadone is administered along with Amspecavir, patients should therefore be monitored on opatatentment symptom symptom, especially when there are also low doses of Ritonavir."</seg>
<seg id="1995">"because of the low reliability of historical Versame, there is no recommendation at present to adjust how the amspecavir- dose is to be adjusted when Amkled avir is administered at the same time using methadone."</seg>
<seg id="1996">"simultaneous Gift from Warfarin or other oralen anticoagulum, along with Agenerase, an increased control of the INR (International normalisation ratio) is recommended for the possibility of a shutdown or strengthening of the anti-thromous effect (see Section 4.4)."</seg>
<seg id="1997">"the effect of an additional administration of Ritonavir on hormonal contraceptive pills, therefore, are also recommended as alternative methods of contraception."</seg>
<seg id="1998">A careful monitoring of the therapeutic effects and side effects of tricyclic antidepressants (for example desipramine and Nortryptilin) is recommended in the current gift of Agenerase (see Section 4.4).</seg>
<seg id="1999">"during pregnancy, this medicine may only be applied after careful use of potential usability for the mother compared to the potential risks for fetus."</seg>
<seg id="2000">"in the milk lactic rats, ambitavir-related substances have been proven, but it is not known whether Amkled avir is overflowing with people into the mother's milk."</seg>
<seg id="2001">A reproduction study on tolerable rats that has been administered by adjusting in the uterus up to the end of the lactation period in the lacterus to the end of the lactation period.</seg>
<seg id="2002">The further development of descendants including Fertility and reproductive capacity was not affected by the administration of Amspecavir to the womb.</seg>
<seg id="2003">The inconceivable of Agenerase was investigated with adults and children from 4 years in controlled clinical trials in combination with various other antiretroviral medicines.</seg>
<seg id="2004">"most of the side effects associated with the Agenerase treatment of side effects were slightly up to moderated, early on and led rarely to the treatment of treatment."</seg>
<seg id="2005">"with many of these events, it is not clear whether they are used in connection with taking Agenerase or another at the same time for HIV treatment, or whether they are a consequence of the atrocity."</seg>
<seg id="2006">"most of the listed side effects come from two clinical trials (PROAB3001, PROAB3006) where with proteasants, patients had received 1200 mg Agenerase twice daily."</seg>
<seg id="2007">Events (level 2 to 4) were performed by the investigators in connection with the study's medicines and performed in more than 1% of patients as well as under the treatment changes (degree 3 to 4).</seg>
<seg id="2008">"antiretroviral combination therapy has been associated with a redistribution of the body fat, including a loss of peripheral and amental sub-fat tissues, multiply intraabdominals and visceral fat tissues, hypertrophy of breasts and thorsoar fat collection (stitched)."</seg>
<seg id="2009">"among 113 antiretroous persons, who were treated with Amspecavir in combination with Lamivudin / Zidovudine over a medium duration of 36 weeks, was only observed (Stickers) (&lt; 1%)."</seg>
<seg id="2010">In the study PROAB 3006 the patients (3%) compared to 27 cases (3%) compared to 27 cases (11%) compared to 27 cases (11%) in combination with various NRTIs over a medium duration of 56 weeks (p &lt; 0.001).</seg>
<seg id="2011">"rash charges were usually slightly up to moderately pronounced, erythematant or makulopapal nature, with or without itching week, and disappeared spontaneously during the second treatment week and disappeared spontaneously during the second treatment week and disappeared spontaneously during the second treatment week and disappeared spontaneously during the second treatment week and disappeared spontaneously during the second treatment week."</seg>
<seg id="2012">"cases of Osteonekrose were reported in particular in patients with generally well-known risk factors, advanced HIV illness or long-term application of an antiretroviral combination therapy (ART)."</seg>
<seg id="2013">"at the time of the introduction of an antiretroviral combination therapy (ART), an inflammatory reaction to asymptomatic or residual opportunist infections can develop (see Section 4.4)."</seg>
<seg id="2014">"with PI pre-treated patients, the 600 mg Agenerase twice daily, were the type and frequency of side effects (degree 2 to 4), and CPK values, which were obtained with low doses of triglycerid- and CPK values, which received in patients who were agenerase together with low dosified konavir., very often appeared."</seg>
<seg id="2015">"in case of overdose the patient is to be observed in signs of an intoxication (see Section 4.8), if necessary, necessary support measures are required."</seg>
<seg id="2016">"Amspecavir binds to the active center of HIV-1-Protease, and thereby preventing the process of viral viral and gag-poll polyproteins with the sequence of education, not infective viral particles."</seg>
<seg id="2017">"the antiviral activity of Amspecavir in vitro against HIV-1 IIIB has been studied in both acutely and chronic lymphocylastic cell lines (MT-4, CEM-CCRF, H9) as well as on the peripheral bleeding."</seg>
<seg id="2018">"the 50% Hemmconcentric (IC50) is located in the range from 0,012 to 0.08 µm for acutely infected cells and amounts to 0.41 µm for chronic, infected cells"</seg>
<seg id="2019">The connection between the activity of amspecavir against HIV-1 in vitro and the inhibition of HIV-1 replication is not yet defined.</seg>
<seg id="2020">In the treatment of antiretroless patients with the currently approved Fosamspecavir / Ritonavir-doses were reported - as with other Ritonavir stooed treatment schemas with proteaseinhibitors - the described mutations rarely observed.</seg>
<seg id="2021">"for sixteen of 434 antiretroless patients who have received 700mg Fosamr twice daily in the study ESS100732, a virological failure, up to week 48, where 14 insulates could be investigated."</seg>
<seg id="2022">"a genotype analysis of the insulates of 13 out of 14 children, with which a virological failure occurred within 59, with proteasants, showed resistance patterns, which were similar to those in adults."</seg>
<seg id="2023">"L10F / I / V, V11V, I2V, I7V, I71V, A71V, A71V, V82V, I84V, L90V, L90M, L90V and I93L / M."</seg>
<seg id="2024">"in the study APV30003 and its extension of APV30005 (700 mg of Fosamgenavir twice daily: n = 107) in patients with virological failure, about 96 weeks, the following protrudenmer mutations:"</seg>
<seg id="2025">On genotype-based analysis of generic interpreting systems can be applied to the assessment of the activity of Amspecavir / Ritonavir / Ritonavir in patients with Proteasants-resistant insulates.</seg>
<seg id="2026">"the current (July 2006) ANRS-AC-11-algorithm for Fosamspecavir / C / T / V, I62V, I2V / C / C / C / C / C / C / C / C / C / C / C / C / C, I62V, I84A / C / C / C, I62V, I84A / C / C / C, I62V, ITO V, or at least 4 of the following mutations L10F, ITO V, or at least 4 of the following mutations L10F, I62V, I84A / C / C / C, I62V, ITO V, or at least 4 of the following mutations L10F, I62V, I84A / C / C / G, I62V, ITO V and L90M, with a decreased probability of a virological contact (resistance)."</seg>
<seg id="2027">"the conclusions regarding the relevance of certain mutations or mutation patterns may be subject to changes due to additional data, and it is recommended to always draw up current interpreting systems to analyze the results of resome tests."</seg>
<seg id="2028">On phenomenal expansion-based analyses planed phenotype-interpreting systems can be applied in conjunction with the genotype data for the assessment of the activity of Amspecavir / Ritonavir / Ritonavir in patients with the protein-resistant insulating insulates.</seg>
<seg id="2029">Companies that expel diagnostic tests with clinically-phenotype cut-offs (dividing points) for FPV / RTV developed to be applied to the interpretation of results of a resource tests.</seg>
<seg id="2030">"each of these four with a decreased sensitivity to Amspecavir associated genetic patterns creates a certain crushing resistance to Ritonavir, the sensitivity to indinavir, Nelfinavir and Saquinavir but generally preserved."</seg>
<seg id="2031">"there are currently data on crushing resistance between Amspecavir and other proteasants, for all 4 Fosamspecaviade, either alone or in combination with other mutations."</seg>
<seg id="2032">"on the basis of twenty-five antiretrosavir (one of 25 isolates), indinavir / Ritonavir (one of 25 isolates), indinavir / Ritonavir (one of 25 insulation), indinavir / Ritonavir (three of 25 isolates),"</seg>
<seg id="2033">"conversely, Amspecavir reserves its activity against some other proteasants-resistant insulates; the preservation of these activity seems to be dependent on the number and type of resistance mutations in isolation."</seg>
<seg id="2034">The early interruption of a secular therapy is recommended to keep the accumulation of a variety of mutations in limits that may affect the following treatment.</seg>
<seg id="2035">"the evidence of the effectiveness of Agenerase (600 mg twice daily) is based on the study PRO30017, a randomized study, in which with PI pre-treated adults (100 mg twice daily) and nuclosidanaloga (NRTI) or a standard therapy (standard of care, soC) with a PI, predominantly with low-dosified konavir" "geboostert". ""</seg>
<seg id="2036">"three-three-threes (n = 163) patients with proven virus sensitivity to Agenerase, at least one other PI and at least one NRTI were included in the study by PRO30017."</seg>
<seg id="2037">"the primary analysis presented the non-underembarrassment of APV / Ritonavir (HIV-1 RNA) in the virus after 16 weeks, with a non-underscore of 0.4 log10 copies / ml."</seg>
<seg id="2038">"the proof of the effectiveness of ungeboostered Agenerase is based on two uncontrolled studies with a total of 288 HIV infected children aged 2 to 18, of which 152 with PI was treated."</seg>
<seg id="2039">"in the studies, Agenerase solution was to take and capsules three times daily, 20 mg / kg twice daily, 20 mg / kg twice daily, whereby the majority of patients received 20 mg / kg twice daily."</seg>
<seg id="2040">There was no low dosified konavir at the same time; the majority of those with PI presented patients had previously made at least one (78%) or two (42%) of the NRTIs together with Agenerase.</seg>
<seg id="2041">"after 48 weeks, approximately 25% of patients were included in the study a plasma HIV-1 RNA concentration &lt; 10,000 copies / ml and 9% &lt; 400 copies / ml in a median increase of the CD4 cell number from 26 cells / mm ³ (n = 74) compared to the output value."</seg>
<seg id="2042">19 Basics on this data should be considered in therapy optimization with PI pre-treated children of the expected benefit of "ungeboostered" Agenerase.</seg>
<seg id="2043">"after orative administration, the medium duration (tmax) is about 1 to 2 hours for the capsule and about 0,5 to 1 hour for the solution."</seg>
<seg id="2044">508% increased for Cmax at about 30% if kpavir (100 mg twice daily) was administered together with amil avir (600 mg twice daily).</seg>
<seg id="2045">"the administration of Amspecavir with a meal leads to a 25% reduction of the auc, but has no effect on the concentration of Amkled avir 12 hours to dosage (C12)."</seg>
<seg id="2046">"therefore, the minimum concentration in the steady state (Cmin, ss) has remained uninfluenced by the food intake, although the simultaneous food intake influenced the extent and rate of resorption."</seg>
<seg id="2047">The apparent distribution volume is about 430 l (6 l / kg with a body weight of 70 kg) and leaves to include a large distribution volume as well as an unchecked penetration of Amspecavir from the bloodstream into the tissue.</seg>
<seg id="2048">"this change leads to a decrease in the total concentration of the substance in the plasma, with the amount of unbundling amspecavir which represents the active part, probably remains unchanged."</seg>
<seg id="2049">"while the absolute concentration of ungebem ambitrr remains constant, fluctuates percentage of free active components in the Steady State depending on the area of Cmax, ss to Cmin."</seg>
<seg id="2050">"therefore, drugs have to induce or induce the CYP3A4 or a substrate of CYP3A4 if they are given simultaneously with Agenerase (see sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2051">"the gift of Agenerase capsules, either 20 mg / kg twice or 15 mg / kg three times daily, leads to a similar daily Ambitrr-exposure such as in adults with a dosage of 1200 mg twice daily."</seg>
<seg id="2052">Amspecavir is from the solution 14% less bioverfeet than from the capsules; therefore Agenerase solution and Agenerase capsules are not interchangeable on a milligram base.</seg>
<seg id="2053">"also the renal Clearance of Ritonavir is neglected, hence the impact of a kidney disease is likely to be low in the elimination of Amspecavir and Ritonavir."</seg>
<seg id="2054">These treatment schemata lead to amspecavir plasma comparable to those that are generated in healthy progangs after a dose of 1200 mg of Amdelavir twice daily without the simultaneous administration of Ritonavir.</seg>
<seg id="2055">"in long-term studies of canogenicity to mice and rats occurred in male animals, the 2,0-times (mice) or 3,8- times (rat) of exposure to the people, after twice daily qualifying of 1200 mg of Amkled avir."</seg>
<seg id="2056">The 21 underlying mechanism for the emergence of the hepatocellular adenome and carcinome was not yet solved and the relevance of this observed effects for man is unclear.</seg>
<seg id="2057">"from the present expositional data on the human being, both from clinical trials and therapeutic application, however, there were little evidence of the adoption of a clinical relevance of these findings."</seg>
<seg id="2058">"in a standard battery of In-vivo- and In-vitro-Genotoxics, microkerntest to rats and chromosome aberration of human periphers Lymphocytes, was Amkled avir neither mutanoxic or genotoxic."</seg>
<seg id="2059">"these liver toxic can be monitored and proven in clinical everyday life by measurement of AST, ALT and the activity of alkaline phosphatase."</seg>
<seg id="2060">"so far, clinical studies have not been observed in clinical trials at patients, neither during the administration of Agenerase nor after the end of the treatment."</seg>
<seg id="2061">Studies for juvenile juveniles who were treated from an age of 4 were revealed both in the control and with amspecavir animals of a high mortality.</seg>
<seg id="2062">"with a systemic plasma exposure, the significant under (rabbits) or not significant higher (rats) than expected exposure to therapeutic dosage in humans, however, a number of minor changes including tymuselongation and low-sized skeletal changes have been observed, which pointed to an delayed development."</seg>
<seg id="2063">"24 If Agenerase capsules without the amplified addition of Ritonavir (booster), higher doses must be applied to Agenerase (1200 mg twice daily)."</seg>
<seg id="2064">The recommended dose for Agenerase capsules is 20 mg Amkled avir / kg body weight twice daily in combination with other antiretroviral medicines up to a daily dose of 2400 mg of Amkled avir that should not be exceeded (see section 5.1).</seg>
<seg id="2065">The simultaneous application should be treated with caution in patients with swatchful or easier liver disorder in patients with severe liver disorder it is contraindicated (see section 4.3).</seg>
<seg id="2066">"26 For some medicines, which can cause severe or life-threatening side effects, such as Carbamazepine, phenobarbital, phenotoin, tricyclic antidepressants and warfarin (under supervision of the International normalisation ratio), methods for determining the drug concentration are available."</seg>
<seg id="2067">Agenerase should be set up on duration 27 when a rash is accompanied by systemic or allergic symptoms or are involved (see Section 4.8).</seg>
<seg id="2068">"an increased risk for a Lipodstreamphie has been associated with individual factors, such as higher age, and with drug dependent factors, such as a longer lasting antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="2069">It has been shown that Rifampicin causes an 82% reduction in the Auc of Amspecavir that can lead to a virological failure and lead to a resome development.</seg>
<seg id="2070">508% increases for Cmax at about 30% if kpavir (100 mg twice daily) in combination with Ampping avir capsules (600 mg twice daily) was administered.</seg>
<seg id="2071">The Cmin values of Amspecavir (600 mg twice daily) with Kaletra (400 mg of Lopinavir twice daily) are approximately 40 to 50% lower than if Amkled avir (600 mg twice daily) in combination with 100 mg kkavir twice daily is administered.</seg>
<seg id="2072">"a dosing recommended for the simultaneous administration of Amspecavir and Kaletra can not be given, but there is a constant surveillance recommended, since the effectiveness and inconceivable of this combination is not known."</seg>
<seg id="2073">The treatment with Efavirenz in combination with Amspecavir and Saquinavir is not recommended because the exposure of both protrugum would become low.</seg>
<seg id="2074">"if these drugs are applied together, caution is advisable; a thorough clinical and virological surveillance should be made, as a precise prediction of the effect of the combination of amspecavir and Ritonavir on Delavirdin is difficult."</seg>
<seg id="2075">"if it is necessary for clinical reasons, Rifabutin is necessary along with Agenerase, will become a reduction in the dosage of Rifabutin to at least half of the recommended dose 31, although there is no clinical data."</seg>
<seg id="2076">"the Serum concentrations of calcium-blockers like Amlodipin, diltipin, instipin, lefepin, Nifepin, Nifepin, Nifepin, Nifepin, Nantdipin and Verapamil can be increased by amodiavir, causing possibly the activity and toxicity of this medicine increases."</seg>
<seg id="2077">"in a clinical study, in the konavir 100 mg capsules twice daily along with 50 µg Fluticasonpropionat intranasal (4 times daily) over 7 days to probanden were increased, while the endoticasonpropiononpropionate plastic (4 times daily) were increased by approximately 86% (90% -confidenzinterinterval from 82 to 89%)."</seg>
<seg id="2078">"simultaneous Gift from Warfarin or other oralen anticoagulum, along with Agenerase, an increased control of the INR (International normalisation ratio) is recommended for the possibility of a shutdown or strengthening of the anti-thromous effect (see Section 4.4)."</seg>
<seg id="2079">The simultaneous administration of Ortho-Novum 1 / 35 (0.035 mg Ethinylestradiol plus 1.0 mg Norethindron) led to a decrease in the Auc and Cmin from Amkled avir by 22% bzw.</seg>
<seg id="2080">"during pregnancy, this medicine may only be applied after careful use of potential usability for the mother compared to the potential risks to the fetus."</seg>
<seg id="2081">A reproduction study on tolerable rats that has been administered by adjusting in the uterus up to the end of the lactation period in the lacterus to the end of the lactation period.</seg>
<seg id="2082">The inconceivable of Agenerase was investigated with adults and children from 4 years in controlled clinical trials in combination with various other antiretroviral medicines.</seg>
<seg id="2083">"in case of overdose the patient is to be observed in signs of an intoxication (see Section 4.8), if necessary, necessary support measures are required."</seg>
<seg id="2084">"the antiviral activity of Amspecavir in vitro against HIV-1 IIIB has been studied in both acutely and chronic lymphocylastic cell lines (MT-4, CEM-CCRF, H9) as well as peripheral bleeding."</seg>
<seg id="2085">"the 50% Hemmconcentric (IC50) is located in the range from 0.012 to 0.08 µm for acutely infected cells and amounts to 0.41 µm for chronic, infected cells (1 µm = 0,50 µg / ml)."</seg>
<seg id="2086">"conversely, Amspecavir reserves its activity against some other proteasants-resistant insulates; the preservation of these activity seems to be dependent on the number and type of resistance mutations in isolation."</seg>
<seg id="2087">"based on this data should be considered in therapy optimization, with PI pre-treated children of the expected benefit of" ungeboostered "Agenerase."</seg>
<seg id="2088">"while the absolute concentration of ungebem ambitrr remains constant, fluctuates the percentage of free active components in the Steady State depending on the area of Cmax, ss to Cmin, ss.."</seg>
<seg id="2089">"therefore, drugs have to induce or induce the CYP3A4 or a substrate of CYP3A4 if they are given simultaneously with Agenerase (see sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2090">Also the renal Clearance of Ritonavir is neglected; therefore the impact of a kidney disease is likely to be low in the elimination of Amspecavir and Ritonavir.</seg>
<seg id="2091">In long-term studies on seducogenicity with Amspecavir to mice and rats occurred at male animals benigne hepatocellular adenome at dosages who spoke the 2,0-times (mice) or 3.8- times (rat) of exposure to people after twice daily qualifying of 1200 mg of Amkled avir.</seg>
<seg id="2092">The underlying mechanism for the emergence of the hepatmosaic Adenome and carcinome was not yet solved and the relevance of this observed effects for man is unclear.</seg>
<seg id="2093">"however, from the present expositional data on the human being, both from clinical studies and the therapeutic application, however, little hints for the adoption of a clinical relevance of these findings."</seg>
<seg id="2094">"in a standard battery of In-vivo- and In-vitro Genotoxizers, mouse-lymphatic test, micro-lymphocytes, micro-lymphocytes, was Amkled avir neither mutanoxic or genotoxic."</seg>
<seg id="2095">Studies for juvenile juveniles who were treated from an age of 4 were revealed both in the control and with amspecavir animals of a high mortality.</seg>
<seg id="2096">"these results do conclude that in juveniles the Metabolishment are not yet fully mature, so Amspecavir or other critical components of the formulation (z."</seg>
<seg id="2097">"Agenerase solution to insertion is combined with other antiretroviral medicines for the treatment of HIV-1-infected, protrudenmer (PI) -pre-treated adults and children older than 4 years."</seg>
<seg id="2098">The benefits of using Ritonavir "geboosterter" Agenerase solution for immersion has not been used not with PI pre-treated patients with PI pre-treated patients.</seg>
<seg id="2099">The bioavailability of amspecavir as a solution is reduced by 14% less than a capsule; therefore Agenerase capsules and solution are not interchangeable on a milligram basis (see Section 5.2).</seg>
<seg id="2100">Patients should be as soon as they are able to swallow the capsules with taking the solution to stop taking (see Section 4.4).</seg>
<seg id="2101">The recommended dose for Agenerase solution is 17 mg (1.1 ml) Amoked avir / kg body weight three times daily in combination with other antiretroviral medicines up to a daily dose of 2800 mg of Amkled avir that should not be exceeded (see section 5.1).</seg>
<seg id="2102">"additionally, since no dosage recommendations must be given for the simultaneous application of Agenerative ase solution and can be given low dosified konavir, this combination of these patients."</seg>
<seg id="2103">Although a dosage adjustment for amspecavir is not considered necessary is an application of Agenerase solution to take in patients with kidney failure (see section 4.3).</seg>
<seg id="2104">"due to the potential risk of a toxic reaction to a toxic reaction as a result of the high propylene glycol is Agenerase solution for taking in small children and children under 4 years, in pregnant women, in patients with reduced liver function or liver failure and in patients with kidney failure."</seg>
<seg id="2105">The simultaneous administration can lead to a communicative inhibiting of metation of these medicines and possibly lead serious and / or life-threatening side effects such as heartbeat disorders (z.</seg>
<seg id="2106">Patients should be advised that Agenerase or any other antiretroviral therapy does not lead to a cure in HIV infection and that they continue to develop opportunist infections or other complications of HIV infection.</seg>
<seg id="2107">The current antiretroviral therapy including the treatment with Agenerase does not prevent the risk 47 of HIV to others through sexual contact or contamination with blood.</seg>
<seg id="2108">"for some medicines that can cause severe or life-threatening side effects, such as Carbamazepine, phenobarbital, phenotoin, tricyclic antidepressants and warfarin (under supervision of the International normalisation ratio), methods for determining the drug concentration are available."</seg>
<seg id="2109">Agenerase should be set to duration if a rash is accompanied by systemic or allergic symptoms or are involved (see Section 4.8).</seg>
<seg id="2110">"an increased risk for a Lipodstreamphie has been associated with individual factors, such as higher age, and with drug 49 dependent factors, such as a longer lasting antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="2111">"with hates-ophiles patients (type A and B), the reports were treated with protectors, are reports of an increase of bleeding including spontaneous cutters, including spontaneous cutters, and hailthrows."</seg>
<seg id="2112">It has been shown that Rifampicin causes an 82% reduction in the Auc of Amspecavir that can lead to a virological failure and lead to a resome development.</seg>
<seg id="2113">508% increases for Cmax at about 30% if kpavir (100 mg twice daily) in combination with Ampping avir capsules (600 mg twice daily) was administered.</seg>
<seg id="2114">"simultaneous ingestion with Agenerase, whose Plasmaconcentric may increase considerably and strengthen with PDE5 inhibitors in connection of the side effects including hypotension, visual disorders and priapism (see Section 4.4)."</seg>
<seg id="2115">On the basis of the data on 54 other CYP3A4 Inhibitors are expected to have significantly higher plasma concentrations of Midazolam.</seg>
<seg id="2116">The potential risk for people is not known. Agenerase solution is allowed to take effect due to possible toxic reactions of the fetus to the coated propylene glycol (see section 4.3).</seg>
<seg id="2117">"in the milk lactic rats, ambitavir-related substances have been proven, but it is not known whether Amkled avir is overflowing with people into the mother's milk."</seg>
<seg id="2118">A reproduction study on tolerable rats that has been administered by adjusting in the uterus up to the end of the lactation period in the lacterus until the late lactation period.</seg>
<seg id="2119">The inconceivable of Agenerase was investigated with adults and children from 4 years in controlled clinical trials in combination with various other antiretroviral medicines.</seg>
<seg id="2120">"with many of these events, it is not clear whether they are used in connection with taking Agenerase or another at the same time for HIV treatment, or whether they are a consequence of the atrocity."</seg>
<seg id="2121">In the treatment of antiretroless patients with the currently approved Fosamspecavir / Ritonavir-doses were reported - as with other Ritonavir stooed treatment schemas with proteaseinhibitors - the described mutations rarely observed.</seg>
<seg id="2122">The early departure of a confused 60 therapy is recommended to keep the accumulation of a variety of mutations in limits that may affect the following treatment.</seg>
<seg id="2123">62 Basics on this data should be considered in therapy optimization with PI pre-treated children of the expected benefit of "ungeboostered" Agenerase.</seg>
<seg id="2124">The apparent distribution volume amounts to approximately 430 l (6 l / kg with a body weight of 70 kg) and leaves to include a large cannum volecation from the bloodstream into the tissue.</seg>
<seg id="2125">The underlying mechanism for the emergence of the hepatocellular adenome and carcinome was not yet solved and the relevance of this observed effects for man is unclear.</seg>
<seg id="2126">"with a systemic plasma exposure, the significant under (rabbits) or not significant higher (rats) than expected exposure to therapeutic dosage in humans, however, a number of minor changes including tymuselongation and low-sized skeletal changes have been observed, which pointed to an delayed development."</seg>
<seg id="2127">"maybe you would like to read them later again. − If you have any further questions, please contact your doctor or pharmacist. − This drug was dedicated to you personally."</seg>
<seg id="2128">"it can harm other people, even if these have the same complaints as you. − If one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor or pharmacist."</seg>
<seg id="2129">"your doctor will usually point out, Agenerase capsules along with low doses Ritonavir to enhance the effect of Agenerase."</seg>
<seg id="2130">The use of Agenerase is based on your doctor for you an individual viral disease test and your treatment history.</seg>
<seg id="2131">Inform your doctor if you suffer from one of the above conditions or taking any of the above medicines.</seg>
<seg id="2132">"if your doctor has recommended that you are taking Agenerase capsules along with low doses of Ritonavir to enhance the effect (boosts), make sure that you have carefully read the use of manual information on Ritonavir."</seg>
<seg id="2133">"likewise, there are no adequate information to recommend the application of Agenerase capsules with Ritonavir to the efficiency of children aged 4 to 12 years or in general in patients suffering from 50 kg body weight."</seg>
<seg id="2134">"therefore, it is important that you can read the section" Add to Agenerase with other medicines, before starting with taking Agenerase. "</seg>
<seg id="2135">"possibly, you need additional factor VIII to control the bloodstream. − For patients who receive an antiretroviral combination therapy, can occur a redistribution, accumulation or loss of body fat."</seg>
<seg id="2136">"if you can take certain medicines that can lead to serious side effects such as Carbamazepine, phenamycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricyclical antidepressants, will perform extra blood tests to minimize possible security problems."</seg>
<seg id="2137">It is recommended that HIV-positive women should not satisfy their children under no circumstances to avoid transmission of HIV.</seg>
<seg id="2138">Transport and the use of machines There have been no studies on the influence of aging or the ability to serve machines.</seg>
<seg id="2139">Please take this medicine only after contacting your doctor if you know that you are suffering from intolerability to certain victors.</seg>
<seg id="2140">"taking Didanosine) is advisable that you are taking this more than an hour before or after Agenerase, otherwise, the effects of Agenerase can be diminished."</seg>
<seg id="2141">Dose of Agenerase capsules is 600 mg twice daily along with 100 mg konavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="2142">If your doctor decides that the intake of Ritonavir is not suitable for you will have to take higher doses (1200 mg of Amkled avir twice daily).</seg>
<seg id="2143">"85 Damit Agenerase brings as much benefits as possible, it is very important that you take the whole daily dose which has prescribed your doctor."</seg>
<seg id="2144">"if you have taken a larger amount of Agenerase, than you should If you have taken more than the prescribed dose of Agenerase, you should immediately contact your doctor or a pharmacist."</seg>
<seg id="2145">"if you forget the intake of Agenerase If you have forgotten the intake of Agenerase, take it once you think, and then continue the intake as before."</seg>
<seg id="2146">"in treating a HIV infection, it is not always possible to say whether dispute side effects by Agenerase, by other medicines which are taken at the same time, or caused by HIV disease."</seg>
<seg id="2147">"headache, troubles, fatigue, vomiting, vomiting, vomiting, vomiting, brass, or juckiness) - occasionally the rash may be serious nature and you can break up the intake of this drug."</seg>
<seg id="2148">"sorry, depression, depression, sleeping disorders, appetitloss cribbles in the lips and in the mouth, soft movements, rise of certain liver enzymes, the transaminasen, increase in the pancreas called amylase."</seg>
<seg id="2149">"increased blood values for sugar or cholesterol (a certain blood-fat) of blood values of a substance named Bilirubin swelling of the face, the lips and the tongue (angioeovar."</seg>
<seg id="2150">"this can include fat loss of legs, arms and face, a fat gain at the stomach and in other inner organs, chest enlargement and fat sülste in neck (" stitched ")."</seg>
<seg id="2151">Please inform your doctor or pharmacist if one of the listed side effects you have considerably affected or you notice side effects which are not stated in this usage information.</seg>
<seg id="2152">"therefore, it is important that you can read the section" Add to Agenerase with other medicines, before starting with taking Agenerase. "</seg>
<seg id="2153">"with some patients who receive an antiretroviral combination treatment, one can develop an antiretroviral combination treatment, can develop a osteonekrose (Abdie of bone tissues as a result of insufficient blood supply of the bone) of bone marital."</seg>
<seg id="2154">"taking Didanosine) is advisable that you are taking this more than an hour before or after Agenerase, otherwise, the effects of Agenerase can be diminished."</seg>
<seg id="2155">"94 Damit Agenerase brings as much benefits as possible, it is very important that you take the whole daily dose which has prescribed your doctor."</seg>
<seg id="2156">"if you forget the intake of Agenerase If you have forgotten the intake of Agenerase, take it once you think, and then continue the intake as before."</seg>
<seg id="2157">"headache, troubles, fatigue, vomiting, vomiting, vomiting, vomiting, brass, or juckiness) - occasionally the rash may be serious nature and you can break up the intake of this drug."</seg>
<seg id="2158">Please inform your doctor or pharmacist if one of the listed side effects you have considerably affected or you notice side effects which are not stated in this usage information.</seg>
<seg id="2159">Dose of Agenerase capsules is 600 mg twice daily along with 100 mg konavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="2160">"thus Agenerase provides as much value as possible, it is very important that you take the whole daily dose which has prescribed your doctor."</seg>
<seg id="2161">"if you have taken bigger quantities of Agenerase, than you should If you have taken more than the prescribed dose of Agenerase, you should immediately contact your doctor or a pharmacist."</seg>
<seg id="2162">"the benefits of using Ritonavir" "geboosterter" "Agenerase solution for immersion has not been used with proteasant patients, nor with Proteasants previously presented patients."</seg>
<seg id="2163">For the use lower doses of Ritonavir (usually applied to reinforcement of the effect [booster] of Agenerase capsules) together with Agenerase solution to insertion cannot be given a dosing fee.</seg>
<seg id="2164">Ritonavir solution for insertion) or additionally propylene glycol during the intake of Agenerase solution (see also Agenerase may not be taken).</seg>
<seg id="2165">"your doctor will possibly be on side effects which are associated with the propylene glycolcontent of the Agenerative ase solution, observe, especially if you have a kidney or liver illness."</seg>
<seg id="2166">"111 If you can take certain drugs that can lead to severe side effects such as Carbamazepine, phenamycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricycliycin, tricyclical antidepressants, will perform extra blood tests to minimize possible security problems."</seg>
<seg id="2167">Ritonavir solution for insertion) or additional propylene glycol are not included while taking Agenerase (see Agenerase may not be taken).</seg>
<seg id="2168">Important information about certain other components of Agenerase solution for taking the solution contains Propylenglycol which can lead to side effects in high doses.</seg>
<seg id="2169">"propylene glycol can cause a number of side-effects including crush-seizures, bending, heart ramps, and the reduction of the red blood cells (see also Agenerase may not be taken, special caution when taking Agenerase is required precautions)."</seg>
<seg id="2170">"if you forget the intake of Agenerase If you have forgotten the intake of Agenerase, take it once you think, and then continue the intake as before."</seg>
<seg id="2171">"headache, troubles, fatigue, vomiting, vomiting, vomiting, vomiting, brass, or juckiness) - occasionally the rash may be serious nature and you can break up the intake of this drug."</seg>
<seg id="2172">"this can include fat loss of legs, arms and face, a fat gain at the stomach and in other inner organs, chest enlargement and fat sülste in neck (" stitched ")."</seg>
<seg id="2173">"the other components are propylene glycol, Acesulfam calium, chesullabeler 400 (polyethylene glycol 400), alchargeable acid, sodium citrate-Dihlava, rounded water."</seg>
<seg id="2174">"the applicationsand the duration of the treatment with Aldara depend on the treatment of Aldara for a maximum of 16 weeks. • In case of small basal cell disease, the cream is weekly during one or two four-week treatment cycles, with four weeks break between treatment cycles, three times weekly."</seg>
<seg id="2175">"the cream is in front of sleep slippery to the affected skin surfaces, so that they remain enough for a long time (about eight hours) on the skin before they washed off."</seg>
<seg id="2176">"in all studies, Aldara was compared with a placebo (the same cream, but without the substance). Aldara was tested in four main studies on 923 patients with warts in the genital area each 16 weeks."</seg>
<seg id="2177">"main indicator for the effectiveness was the number of patients treated with small basal cell disease in two studies, where patients were treated for six weeks and Aldara or placebo either daily or five times a week."</seg>
<seg id="2178">Main indicator for the effectiveness was the number of patients with complete downgrade of tumors after twelve weeks. • Aldara also tested in two studies on a total of 505 patients with acute ceramics.</seg>
<seg id="2179">"in all studies, Aldara was more effective than placebo. • At the treatment of warts in the genital area amounted to all four main studies 15% to 52% in all four main studies, but only 3% to 18% involving patients treated with Aldara treated patients compared to 0% to 3% in the placebo group."</seg>
<seg id="2180">The most common side effects of Aldara (observed in more than 1 of 10 patients) are reactions to the use of the cream (pain or juckiness).</seg>
<seg id="2181">"clinically typical, non-hypercorous, not hypertropic ceramics (AKs) in the face or the scalp at immuncompetent adults, if the size or number of lesions limit the effectiveness and / or acceptance of a cryotherapy, and other topical treatment options contraindicated or less suitable."</seg>
<seg id="2182">"Monday, Wednesday and Friday or Tuesday, Thursday and Saturday) before going to bed and leave 6 to 10 hours on the skin."</seg>
<seg id="2183">The treatment with Imiquimod cream is so long to continue until all visible fats have disappeared in the genital or peripheral region or up to a maximum of 16 weeks per treatment period.</seg>
<seg id="2184">A break in the above treatment should be done when intensive local inflammation appear (see Section 4.4) or if used in the treatment area an infection is observed.</seg>
<seg id="2185">"if during the follow-up examination 4 to 8 weeks after the second treatment period, the treated lesions are only incomplete, another therapy should be started (see Section 4.4)."</seg>
<seg id="2186">"when a dose was left out, the patient recorded the cream when he / she noticed this and then continue with the usual therapy plan."</seg>
<seg id="2187">"Imiquimod-cream is in a thin layer, and in the framed, instituted infected skin-area, until the cream is completely drawn."</seg>
<seg id="2188">"in these patients, there should be a breakdown of treatment between the treatment of Imiquimod and the risk associated with the possible worsening of their autoimmune disease."</seg>
<seg id="2189">"in these patients, there should be a breakdown of treatment between the treatment of Imiquimod and the risk associated with a possible organ or graft-versus-hostal reaction."</seg>
<seg id="2190">"in other studies, in which no daily pre-authauthyhygiene was performed, two cases of severe phimosis were observed, and a case with one to the circumcision strife has been observed."</seg>
<seg id="2191">"with an application of Imiquimod cream in higher than the recommended doses, an increased risk for severe local skin irritation (see section 4.2.) In rare cases, there were also severe local skin irritation, which made a treatment required and / or to have a temporary physical impairment."</seg>
<seg id="2192">"in cases where such reactions occurred at the outcome of the urethra, some women had trouble passing urine, which required an emergency catheterization and treatment of the affected area."</seg>
<seg id="2193">"for the application of Imiquimod-cream directly following a treatment with other cutters used in the genital warring means, so far there are no clinical experience prior to the treatment of Imiquimod."</seg>
<seg id="2194">"limited data indicate at an increased rate of low-positive patients in HIV-positive patients, Imiquimod cream has shown in this capacity to eliminate the removal of fats."</seg>
<seg id="2195">"the treatment of the basic cell disease in Imiquimod with Imiquimod within 1 cm to the eyelids, the nose, the lips, or the hairline was not examined."</seg>
<seg id="2196">Local bonding actions are often but the intensity of these reactions takes back in general during therapy or reactions form after completion of the treatment with Imiquimod cream.</seg>
<seg id="2197">"if it is necessary because of the discomfort of the patient or due to the severity of local bonding actions, a treatment break can be made by several days."</seg>
<seg id="2198">The clinical result of therapy can be assessed after the regeneration of the treated skin approximately 12 weeks after the end of the treatment.</seg>
<seg id="2199">"since there is no data on long-term healing rates of more than 36 months after treatment should be considered at ultra-free basal cell disease, other suitable therapy forms."</seg>
<seg id="2200">"in patients with recurrent and pre-treated BCCs do not have a clinical experience, therefore the application is not recommended in previously untreated tumours."</seg>
<seg id="2201">Data from an open clinical trial indicate that at large tumors (&gt; 7.25 cm2) a lower probability of reference to the Imiquimod therapy.</seg>
<seg id="2202">"Imiquimod was not examined for treatment of acute ceramics, inside the nose or the ears or on the lip area within the Lip."</seg>
<seg id="2203">There are only very limited data on the application of Imiquimod for the treatment of Imiquimod for the treatment of acute ceramics to anatomical bodies outside the face and the scalp.</seg>
<seg id="2204">"the available data on acute keratmosis to underpoor and hands does not support the effectiveness in this application for the purposes, therefore such an application is not recommended."</seg>
<seg id="2205">"local bonding actions often occur, but these reactions usually take back in the course of therapy to intensity or go back after lowering the therapy with Imiquimod cream."</seg>
<seg id="2206">"if local bonding actions can cause great discomfort or very strong, the treatment may be exposed for several days."</seg>
<seg id="2207">"from the data of an open clinical trial, patients with more than 8 AK- lesions pose a lower complete healing rate than patients with less than 8 lesions."</seg>
<seg id="2208">"due to the immunotherapeutic properties, Imiquimod cream should be applied with caution in patients who receive immunosuppressive treatment (see 4.4)."</seg>
<seg id="2209">"from animal studies no direct or indirect harmful effects on pregnancy, the embryo / federal development, the reparations or post-natal development (see 5.3)."</seg>
<seg id="2210">"although neither after one-one-more topical application, quantifiable serum levels (&gt; 5ng / ml) have been reached, there can be no recommendation for application during downtime period."</seg>
<seg id="2211">The most common mitones and as likely or possibly with the application of Imiquimod cream in connection with three-week treatment were local reactions at the place of treatment of fats (33.7% of the patients treated with Imiquimod treated patients).</seg>
<seg id="2212">Among the most commonly reported and as likely or possibly with the application of the Imiquimod cream in the context of side-effects include complaints at the applicationssite with an incidence of 28.1%.</seg>
<seg id="2213">The studies of 185 with Imiquimod-cream treated by a placebo-controlled clinical trial of phase III reported below are listed below.</seg>
<seg id="2214">The most common one as likely or possibly with the application of the Imiquimod cream in the context of the imiquimod in the context of this studies were a reaction to the application location (22% of the patients treated with Imiquimod treated patients).</seg>
<seg id="2215">The side effects contained from 252 in placebocontrolled clinical trials of phase III with Imiquimod-cream specified patients with acute keratosis are listed below.</seg>
<seg id="2216">"these according to the testing assessment of the clinical signs show that in these placebo-controlled clinical trials with Imiquimod cream frequently came to local bonding actions including Erytheminates (61%), excitation (23%), excitation (23%) and (14%) (see Section 4.4)."</seg>
<seg id="2217">"these according to the testing assessment of the clinical signs show that in these studies with Imiquimod cream very often appears to severe Erythemes (31%), heavy erosion (13%), and to severe melt-formation and currustung (19%)."</seg>
<seg id="2218">"in clinical studies for the treatment of Imiquimod, for treatment of acute keratosis, Alopezie was established with an incidence of 0.4% (5 / 1214) at the treatment site or in the surrounding area."</seg>
<seg id="2219">"the perceptive unique recording of 200 mg of Imiquimod, which corresponds to the content of about 16 bags, could result in nausea, vomiting, headaches, myalgia and fever."</seg>
<seg id="2220">"the clinically heaviest side effect, which occurred after several oralen doses of &gt; 200 mg, consisted in hypotony, which is normalized after oratory or intravenous fluid."</seg>
<seg id="2221">In a pharmacoinetic examination the increasing systemic concentrations of the alpha interference and other cytokine were detected after the topic application of Imiquimod.</seg>
<seg id="2222">In 3 basic phase 3 efficacy studies could be shown that the effectiveness in a full healing treatment has been significantly superior for an imiquimod treatment over 16 weeks of placebo treatment.</seg>
<seg id="2223">At 60% of a total of 119 with Imiquimod treated patients were fully exploited. this was at 20% of 105 with placebo treated patients in the case (95% CI:</seg>
<seg id="2224">A total absorption was achieved at 23% of 157 with Imiquimod treated male patients compared to 5% of 161 with placebo treated male patients (95% CI:</seg>
<seg id="2225">"the efficacy of Imiquimod for five-year use per week over 6 weeks was examined in two double flashes, a placebo-controlled clinical studies."</seg>
<seg id="2226">The target cavore were histologically confirmed single primary supercell basal cell disease with a minimum size of 0.5 cm2 and a maximum diameter of 2 cm.</seg>
<seg id="2227">"the data from an open, uncontrolled long-term study after four years of present data show that about 79,3% [95% CI (73.7%, 84.9%)] of all treated patients were clinically cured and this remained for 48 months."</seg>
<seg id="2228">"the effectiveness of Imiquimod during three weeks of treatment in one or two treatment periods of 4 weeks, interrupted by a four-week, treatment-free period, was examined in two double flashes, placebocontrolled clinical studies."</seg>
<seg id="2229">"the patients had clinically typical, visible, discrete, not hypertropes AK- lesions within a-related 25 cm2 large treatment areasthan on the unhairy scalp or on the face."</seg>
<seg id="2230">The pre-year data from two combined observation studies show for patients with clinically exhaust after one or two treatment periods a recurrenal rate of 27% (35 / 128 patients).</seg>
<seg id="2231">"the approved indications of inclinically warts, actincal keratosis, and Superfielles Basalcell, usually do not act at paediatric patients and were therefore not examined."</seg>
<seg id="2232">"Aldara Creed has been studied in four randomized, double-blind studies of children aged 2 to 15 years with Molluscum Contagiosum (Imiquimod n = 576, placebo n = 313)."</seg>
<seg id="2233">The efficacy of Imiquimod could not be shown in these studies at the dosages (3x / week for a period of &lt; 16 weeks bzw.</seg>
<seg id="2234">A minimum system recording of the 5% Imiquimod cream by the skin of 58 patients with acute keratmosis was observed during the three weekly application during 16 weeks.</seg>
<seg id="2235">"the highest drug concentrations in the Serum at the end of the week 16 were observed between 9 and 12 hours and amounted to 0,1, 0,2 and 1,6 ng / ml during the application (12.5 mg, 2 bags) and on the hands / arms (75 mg, 6 bags)."</seg>
<seg id="2236">"the calculated-obvious half-time lay approximately 10times higher than the 2hour half-time after the subcutaneous application in one earlier study, which indicates a prolonged retention of the drug in the skin."</seg>
<seg id="2237">The data on systemic exposure showed that the Resorption of Imiquimod was low for topical application of patients aged 6 to 12 years and comparable to that of healthy adults and adults with acute keratmosis or superficially basal cellor.</seg>
<seg id="2238">"in a four-month study for the paint-painting toxicity in the instalments, doses of 0.5 and 2.5 mg / kg kg to significantly lower body weight and increased milk weight; one also four months long led study to the paint application made by the mouse no similar effects."</seg>
<seg id="2239">A two year-year study of carcinogenicity at mice with dermal administration at three days a week induced no tumors at the time of application.</seg>
<seg id="2240">"the corresponding mechanism is not known, but since Imiquimod only has a small systemic absorption from human skin and is not mutated, is a risk to people due to systemic exposure to a very low."</seg>
<seg id="2241">"the tumors appeared in the group of mice, treated with the real-free cream, formerly and in greater numbers than in the control group with small UVR."</seg>
<seg id="2242">"it can harm other people, even if these same symptoms have as you. − If one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor or pharmacist."</seg>
<seg id="2243">● Feigwarts (Condylomata acuminata) which is formed on the skin in the area of genitals (Geschlechtsorgans) and of the anus (after) is a common relofold, slowly growing form of skin-persevering with very low probability of propagation to other parts of the body.</seg>
<seg id="2244">"if it remains untreated, it can lead to disappearances, especially in the face - therefore is an early detection and - treatment important."</seg>
<seg id="2245">Actincal keratants are predatory areas of the skin that occur in men that were exposed to the sun-radiation during their previous life.</seg>
<seg id="2246">Aldara should only be applied at flat actincal keratosis in the face and on the scalp in patients with a healthy immune system where your doctor has decided that Aldara is the most suitable treatment.</seg>
<seg id="2247">Aldara Creates supports your body-own immune system in the production of natural substances that help your body to fight the superficial Basalcell cardiac or the responsible virus responsible for infection.</seg>
<seg id="2248">"o If you have applied earlier once Aldara cream or other, similar preparations have been applied, please inform your doctor if you have problems with your immune system. o Informing your doctor if you are cured of your doctor after a previous drug or operating treatment. o avoid the contact with eyes, lips and nose-loop."</seg>
<seg id="2249">In seeing contact the cream by dropping with water. o Wing you no more cream than your doctor will fail. o paint you won the cream place after the wear of Aldara cream does not appear to you with an association or patches. o Falls reactions to the treated place will occur that you prepare to give you strong inconvenience to you wash the cream with a mild soap and water.</seg>
<seg id="2250">"once the reactions are deducted, you can continue the treatment. o Informing your doctor if they have no normal blood image"</seg>
<seg id="2251">"if this daily cleaning is not performed under the foreskin, can be calculated with increased occurrence of skin swelling, fertilizers, the skin or difficulty in retraction the foreskin."</seg>
<seg id="2252">"turn Aldara Cream not in the Urethra (urethra), in the vagina (Scheide), the Zervix (cervix) or within the anus (anus)."</seg>
<seg id="2253">Taking other medications serious problems with your immune system should you use this medication for no more than one treatment cycle.</seg>
<seg id="2254">If you have during the infection with fats in the genital area of sexual intercourse is the treatment with Aldara cream after sexual intercourse (not previously).</seg>
<seg id="2255">"please inform your doctor or pharmacist if you apply other medicines or have recently applied, even if they are not prescription drugs."</seg>
<seg id="2256">"satisfy your infant during the treatment with Aldara cream, not known as Imiquimod enters into the mother's milk."</seg>
<seg id="2257">"the frequency and duration of the treatment are different in case of feigwarts, basal cell disease and acute keratosis (see specific instructions for each application area)."</seg>
<seg id="2258">"wear a thin layer Aldara Cream to the clean, dry skin spot with the feigwarts and scrub the cream carefully on the skin until the cream is complete."</seg>
<seg id="2259">Men with fencing warts under the foreskin must withdraw the foreskin every day and wash the skin area below (see section 2 "What do you need to consider before the application of Aldara cream?).</seg>
<seg id="2260">Please talk to your doctor or pharmacist if you have the impression that the effect of Aldara is too strong or too weak.</seg>
<seg id="2261">6 weeks each week a sufficient amount of Aldara cream in order to cover the affected area and 1 cm in order to cover this area.</seg>
<seg id="2262">Very common side effects (for less than 1 of 10 patients) are occasional side-effects (for less than 1 of 100 patients) occasional side effects (for less than 1 of 1,000 patients) Very rare side-effects (for less than 1 of 10,000 patients expected).</seg>
<seg id="2263">Inform your doctor / your doctor or pharmacist / your pharmacist immediately when you do not feel at ease during the use of Aldara cream.</seg>
<seg id="2264">"if your skin responds to the treatment with Aldara cream, you should not continue to use the cream, the affected skin area with water and a mild soap wash and your doctor or a pharmacist."</seg>
<seg id="2265">A humiliated number of blood cells may make you more susceptible to infections; it can cause that in your faster a blue spot comes or she can cause resistance.</seg>
<seg id="2266">Inform your doctor or pharmacist if one of the listed side effects you have considerably affected or you notice side effects which are not stated in this usage information.</seg>
<seg id="2267">"in addition, you can have Juckreiz (32% of patients), burning (26% of patients) or pain in the areas that you have raised Aldara cream (8% of the patients)."</seg>
<seg id="2268">Usually it is about lighter skin reactions which are within approximately 2 weeks after receipt of the treatment again.</seg>
<seg id="2269">"occasionally, some patients notice changes at the applicationslocation (wound secretion, inflammation, swelling, dermatitis, dermatitis) or irritability, nausea, dry mouth, flu-similar symptoms and fatigue."</seg>
<seg id="2270">"occasionally, some patients suffer from the applicability, inflammation, whips, saddling, saddling, swelling, buttonous, swelling, buttonation, heat-grading, buttonous, breast-grading, fever, limbs, fever, weakness or chills."</seg>
<seg id="2271">Aldurazyme is used in patients with a secure diagnosis of a mukopolysaccharide (MPS I; α-Iduronidase deficiency) to treat the non-neurological manifestations of the disease (the symptoms that are not related to brain or nerves in connection).</seg>
<seg id="2272">"this means that certain substances (glycosaminoglyes, gags) will not be dismantled, and thus in most organs in the body and these are ashamed."</seg>
<seg id="2273">"the following non neurological symptoms of MPS I can occur: enlarged liver, stiff joints, the movements difficult, decreased lung volume, cardiac and ogenerdiseases."</seg>
<seg id="2274">"the treatment with Aldurazyme should be monitored by a doctor, the experience in the treatment of patients with MPS I or other inherited metabolic diseases."</seg>
<seg id="2275">"the administration of Aldurazyme should be carried out in a hospital or clinic with reproduction, and patients need to prevent corresponding medicines before administration, to prevent an allergic reaction."</seg>
<seg id="2276">(44-20) 74 18 84 00 fax (44-20) 74 18 84 12 00 fax (44-20) 74 18 84 68 E-mail: / / www.emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document for non business purposes only the EMEA is how Aldurazyme works?</seg>
<seg id="2277">"in the study the safety of drug was mainly examined, however, it was also measured by its effectiveness (in relation to reducing the GAG concentrations in urine and in relation to the size of the liver)."</seg>
<seg id="2278">"for children under five years of Aldurazyme, the GAG concentrations in the urine around 60%, and half of the treated children at the end of the study showed a normal large liver at the end of the study."</seg>
<seg id="2279">"the most common side effects of Aldurazyme at patients aged over five years (observed in more than 1 of 10 patients) are headaches, nausea, stomach pains, pain in the limbs (in hands and feet), heat feeling, fever and reactions to the infusion place."</seg>
<seg id="2280">"very common side-effects in patients under five years are increased blood pressure, decreased oxygen intake (a measuring size of the lung function), tachykarst (accelerated heart rate), fever and chills."</seg>
<seg id="2281">Aldurazyme may respond to patients who might be strongly oversensitive (allergic) to laronidase or one of the other components (anaphylactic reaction).</seg>
<seg id="2282">"the European Drugs Agency (EMEA) is all new information that may be known, check and update this summary."</seg>
<seg id="2283">The manufacturer of Aldurazyme will receive patients who receive Aldurazyme as a result of reactions to infusion and development of antibodies.</seg>
<seg id="2284">June 2003 the European Commission of Genzyme Europe B.V. adopted approval by Aldurazyme across the European Union.</seg>
<seg id="2285">Laronidase is a recombinant form of human α-Iduronidase and is produced using recombinant DNA technology under the use of CHO-mammal-cellular cultures (Chinese Hamster Ovary, Eierstock of the Chinese Hamsters).</seg>
<seg id="2286">Aldurazyme is indigent therapy in patients with secure diagnosis of a mukopolysaccharide (MPS I, α-L-Iduronidase-shortage) indexed to treat the non-neurological manifestations of the condition (see section 5.1).</seg>
<seg id="2287">"the treatment with Aldurazyme should be done by a doctor, the experience in the treatment of patients with MPS I or other inherited metabolic disorders."</seg>
<seg id="2288">The initial infusion rate of 2 E / kg / h can when the patient carries this out every 15 minutes in single steps to a maximum dose of 43 E / kg / h.</seg>
<seg id="2289">The safety and efficacy of Aldurazyme in adults over 65 years has not been determined and for these patients cannot be recommended for a Dozation scheme.</seg>
<seg id="2290">"the safety and efficacy of Aldurazyme in patients with kidney or liver insufficiency was not established, and for these patients cannot be recommended for a dofication scheme."</seg>
<seg id="2291">"with Aldurazyme, patients can develop infusion-conditioned reactions that are defined as each in connection effect, which occurs during infusion or until the end of the infusion day (see Section 4.8)."</seg>
<seg id="2292">"for this reason, these patients should continue to be monitored quickly and the infusion of Aldurazyme should only be made available in an appropriate clinical environment, in the retention of medical emergencies for medical emergencies."</seg>
<seg id="2293">"due to the clinical phase 3 study, it is expected to form nearly all patients of IgG antibodies against laronidase, usually within 3 months from the start of treatment."</seg>
<seg id="2294">Patients who develop antibodies or symptoms of infusion-related reaction must be treated with caution when using Aldurazyme (see sections 4.3 and 4.8).</seg>
<seg id="2295">"as little experience regarding the resumption of treatment after a longer break, has to be cautious carefully due to the theoretically increased risk reaction after a interruption of the treatment."</seg>
<seg id="2296">Treat 60 minutes before the beginning of infusion with medications (antihistaminika and / or anti-pyretica) to minimize the potential occurrence of infusion-related reactions.</seg>
<seg id="2297">"in case of a slight or moderate infusion-related reaction should the treatment with Antihistaminika and Paracetamol / Ibuprofen erges and / or a reduction in infusion rate, in which the reaction occurred."</seg>
<seg id="2298">"in case of a single, difficult infusion-related reaction must be stopped infusion until the symptoms are brought to, a treatment with Antihistaminika and Paracetamol / Ibuprofen is to be treated."</seg>
<seg id="2299">Infusion can be added with a reduction in infusion rate on 1 / 2 - 1 / 4 of the infusion rate where the reaction occurred has been resumed.</seg>
<seg id="2300">3 will be 3 (Antihistaminika and Paracetamol / Ibuprofen and / or corticosteroids) as well as reduction of infusion rate at 1 / 2 - 1 / 4 of the infusion rate where the preformed reaction occurred.</seg>
<seg id="2301">Aldurazyme should not be used simultaneously with chloroquin or Procain because a potential risk of interference with intracellular intake of laronidase exists.</seg>
<seg id="2302">"animal experimental studies do not allow direct or indirect harmful effects on pregnancy, the embryo / fetal development, birth and post-natal development (see section 5.3)."</seg>
<seg id="2303">"since there is no data on newborns, which were served towards Laronidase over the mother's milk, is recommended, while the treatment with Aldurazyme is not to be silent."</seg>
<seg id="2304">The side effects in clinical trials were mainly prescribed by 53% of patients in phase 3 study (treatment duration of up to 4 years) and 35% of patients in the study with participants under 5 years of age (treatment duration of up to 1 year).</seg>
<seg id="2305">"unwanted drug transactions in connection with Aldurazyme observed in connection with Aldurazyme aged 5 years or older at a total treatment duration of up to 4 years, often (≥ 1 / 10); frequently (≥ 1 / 100 to &lt; 1 / 10)."</seg>
<seg id="2306">"in some patients with severe MPS-I-related involvement of the upper respiratory tract and lungs in the pre-history, there occurred serious reactions, including bronchospasm, respiratory and facial Treatment (see Section 4.4)."</seg>
<seg id="2307">"children unsolicited drug impacts relating to Aldurazyme, which were reported during a phas- 2 study with a total of 20 patients aged under 5 years, with overwhelmingly heavy-form and treatment duration of up to 12 months, are listed in the table."</seg>
<seg id="2308">"100 E / kg intravenously once weekly (recommended dose), 200 E / kg intravenously once weekly, 200 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks."</seg>
<seg id="2309">"during the treatment of patients during the age of three months, it occurred within 3 months after the treatment of a seroconversions, with the patients aged under the age of 5 (average after 26 days with patients aged 5 and older)."</seg>
<seg id="2310">"up to the end of the Phase 3 study (or up to a premature retirement from the study) at 13 / 45 patients were not reported by radioimmunoprene zipitation (RIP) Assay, including 3 patients, where it has never been to serf."</seg>
<seg id="2311">Patients with missing reduction of the GAG-Spider in Harn to ascertain while in patients with high antibodies a variable decrease of GAG in Harn was ascertained.</seg>
<seg id="2312">Four patients (three in phase 3 study and one in phase 2 study) showed a marginally to low neutralised effect on enzymatic Laronidase- activity in vitro which did not interfere with clinical efficacy and / or reducing GAG in Harn.</seg>
<seg id="2313">"the presence of antibodies did not seem to stand in connection with the incidence of unwanted drug transactions, even if the occurrence of unwanted drug transactions typically coincided with the formation of IgG antibodies."</seg>
<seg id="2314">The reason for the enzyme therapy lies in one for the hydrolysis of the accumulated substrate and the prevention of further accumulation sufficient restoration of the enzymes.</seg>
<seg id="2315">"according to intravenous infusion, laronidase is rapidly removed from the cycle and absorbed by cells into lysosomes, most likely about Mannose-6 phosphates receptors."</seg>
<seg id="2316">"the safety and efficacy of Aldurazyme were examined in a randomized, double blind, placebocontrolled phase-3 study to 45 patients aged 6 to 43 years."</seg>
<seg id="2317">"although patients were recruited for the study that had been recruited to the entire disease, the majority of patients were from the middle phenotype and only one patient pointed to the heavy phenotype."</seg>
<seg id="2318">Patients have been recruited if they had a forciated expiratory volume (FEV) of less than 80% of the expected value (FEV) of less than 80% of the expected value and they had to be able to stand 6 minutes and walk 5 meters.</seg>
<seg id="2319">The primary endpoints for the effectiveness were the percentage change of the FEV and the absolute walking distance in the 6-minute walk.</seg>
<seg id="2320">All patients were recruited for an open-record survey where they received another 3.5 years (182 weeks) every week 100 E / kg Aldurazyme every week.</seg>
<seg id="2321">"after 26 weeks of therapy, which treated with Aldurazyme treated patients compared to the placebo group, an improvement of the lung function and the secret capacity that is shown in the following table."</seg>
<seg id="2322">"during the open extension study, an improvement and / or maintenance of these effects of up to 208 weeks in the Aldurazyme / Aldurazyme group, and of 182 weeks in the placebo / Aldurazyme group, as seen from the following table."</seg>
<seg id="2323">The acceptance of the expected percentage FEV is not significant over this period clinically not significant and the absolute pulmonary volumina increased further proportionally to the height of growing children.</seg>
<seg id="2324">From 26 patients with a hepattainable before treatment reached 22 (85%) to the end of the study a normal liver size.</seg>
<seg id="2325">"within the first 4 weeks, a significant waste of the GAG mirror in the Harn (µg / mg Kreatinine) has been fixed, which remained constant up to the degree of study."</seg>
<seg id="2326">"with regard to the heterogeneous disease within the patient, the clinical significant changes caused by using a combined endpoint test, was generally a improvement in 26 patients (58%), no change at 10 patients (22%) and a deterioration in 9 patients (20%)."</seg>
<seg id="2327">A one-year open phase 2 study was conducted primarily by Aldurazyme in 20 patients at the time of their inclusion in the study under 5 years of age (16 patients with the heavy course form and 4 of the middle-course form).</seg>
<seg id="2328">"in four patients the dosage was increased due to increased GAG- mirror in Harn, 22 weeks in the last 26 weeks to 200 E / kg."</seg>
<seg id="2329">"in several patients, a total of growth (n = 7) and a weight increase (n = 3) has been determined after the Z-score for these age group. the younger patients with the difficult course-form (&lt; 2.5 years) and all 4 patients with the middle-level form of cancer (&lt; 2.5 years), and all 4 patients with severe form-form, were limited to the older patients with severe damage, or no progress in cognitive development."</seg>
<seg id="2330">"in a phase-4 study, examinations have been carried out on the GAG mirror in the Harn, the liver volume, and the 6-minute chassis."</seg>
<seg id="2331">"100 E / kg intravenously once weekly (recommended dose), 200 E / kg intravenously once weekly, 200 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks."</seg>
<seg id="2332">"the Dozation scheme with 200 E / kg intravenous every 2 weeks can represent a reasonable alternative in patients, the difficulties with weekly infusions; however, it is not proven that the long-term clinical efficacy of these two Dorationschemata is equivalent."</seg>
<seg id="2333">"the European Medicines Agency (EMEA) will evaluate any new information which will be available annually, and if necessary, the summary of the characteristics of the drug will be updated."</seg>
<seg id="2334">The pharmacoinetic profile in patients under the age of five was similar to those with older and less severely affected patients.</seg>
<seg id="2335">"based on conventional studies on safety, toxicity, toxicity of repeated gift and reproduction, the preclinical data cannot recognize any particular dangers to the human being."</seg>
<seg id="2336">"since no sealing studies were performed, this medicine may not be mixed with other medicines except with the 6.6th listed."</seg>
<seg id="2337">"if the ready-to-use preparation is not used immediately, it is no longer used as 24 hours at 2 ° C - 8º C, provided the dilution under controlled and validated aseptic conditions."</seg>
<seg id="2338">5 ml concentrations for making a solution in diameter (type I-glass) with stopovers (silicone chloryl-rubber) and sealing (aluminium) with ripping cap (polypropylene).</seg>
<seg id="2339">10 preparation of the Aldurazyme infusion (by means of aseptic technology) • Je to body weight of the individual patient first determine the number of fertilizers.</seg>
<seg id="2340">The owner of the approval of the authorisation will conclude within the time the following study program, whose results make the basis for the annual evaluation report to the benefit of the risk-risk ratio. "</seg>
<seg id="2341">"this tab will be treated as long-term safety and efficacy formations to patients, which were treated with Aldurazyme, as well as data for the natural profiling of the disease in patients without this treatment."</seg>
<seg id="2342">"in patients suffering from MPS I, a enzyme named α-L-Iduronidase is a enzyme called α-L-Iduronidase, which is missing certain substances in the body (glycosaminoglyes), either in small amount, or this enzyme is completely absent."</seg>
<seg id="2343">If you are allergic to one of the ingredients of Aldurazyme or if you have a severe allergic reaction to Laronidase has occurred.</seg>
<seg id="2344">An infusion conditional reaction is any side effect that occurs during infusion or until the end of the infusionday (see section 4 "Which side effects are possible").</seg>
<seg id="2345">"when using Aldurazyme with other medicines Please inform your doctor if you are taking medications that contain chloroquin or Procain, because a possible risk of a diminished effect of aldurazyme."</seg>
<seg id="2346">"please inform your doctor or pharmacist if you are taking other medicines or have recently been taken, including non-prescription drugs."</seg>
<seg id="2347">Notes for handling - dilution and application The concentration at the production of an infusion solution must be dilated before the application and is intended for intravenous application (see information for doctors and medical practitioners).</seg>
<seg id="2348">"the initial infusion rate of 2 E / kg / h can, if the patient carries this, every 15 minutes gradually increased to a maximum dose of 43 E / kg / h."</seg>
<seg id="2349">"with some patients with severe MPS-I--related participation of the upper respiratory and lungs in prehistory, but heavy reactions occurred, including bronchospasm, respiratory and facial oils."</seg>
<seg id="2350">Very frequent (appearance at more than 1 of 10 patients): • headaches less pain • skin pain; pain pain, back pain, pain in arms and legs • Erredded • fever • fever • hypertonie • lower oxygen • hypertonie • less oxygen in the blood • reaction to the Infusion Centre</seg>
<seg id="2351">"the European medications Agency (EMEA) will evaluate any new information that will be available annually, and if necessary, the package will be updated."</seg>
<seg id="2352">"if the ready-to-use preparation is not used immediately, it is no longer used as 24 hours at 2 ° C - 8º C, provided the dilution under controlled and validated aseptic conditions."</seg>
<seg id="2353">"preparation of the Aldurazyme infusion (by means of aseptic technology) • Je to body weight of the individual patient, first of all determine the number of fertilizers."</seg>
<seg id="2354">"Alimta is applied together with cisplatin (another medicine against cancer) when cancer is not removed, or spreads slightly to other parts of the body. • advanced or metastatic" non-small "lung cancer, which is not the turnocated epithelium cells."</seg>
<seg id="2355">"Alimta is used in patients who have not been treated before, in combination with cisplatin and in patients who have previously received other chemotherapies as a few therapy."</seg>
<seg id="2356">"to reduce side effects, patients should take a corticosteroid as well as folic acid (a vitamin) and injections of vitamin B12."</seg>
<seg id="2357">"if Alimta administered together with Cisplatin, should be given in front of or after the gift of Cisplatin in addition an" antiemetic "(drug against vomiting) and liquids (to prevent a fluid lack)."</seg>
<seg id="2358">"in patients whose blood painting changed or during which certain other side effects occur, the treatment should be reduced, or the dose should be reduced."</seg>
<seg id="2359">The active form of Pemetrexed slows down the formation of DNA and RNA and prevents the cells share.</seg>
<seg id="2360">"the transformation of Pemetrexed into its active form is easier than in cancer cells than in healthy cells, resulting in higher concentrations of the active form of the drug and a longer active duration of cancer cells."</seg>
<seg id="2361">Alimta has been examined for the treatment of malignant Pleuramesothelioms Alimta in a major study of 456 patients who had previously received no chemotherapy against their illness.</seg>
<seg id="2362">"in the treatment of non-single lung cancer, the effects of Alimta were treated in a study of 571 patients with local advanced or metastatic disease, which had previously been treated with the effects of docetaxel (another medicine against cancer)."</seg>
<seg id="2363">Alimta was also compared with gemcitabine (another medicine against cancer) and both in combination with Cisplatin in a study at 1 725 patients who had previously received no chemotherapy for lung cancer.</seg>
<seg id="2364">"patients treated with Alimta and Cisplatin, on average 12.1 months, compared to 9.3 months in the sole administration of Cisplatin."</seg>
<seg id="2365">"in patients who had previously received an chemotherapy was the average survival time with Alimta 8,3 months, compared to 7.9 months at Docetaxel."</seg>
<seg id="2366">"however in both studies patients, in which cancer is not the plate of SCF cells, in the administration of Alimta longer survival times than with the comparative medicine."</seg>
<seg id="2367">"in September 2004, the European Commission of Eli Lilly Nederland B.V. passed a licence for Inlimta in the whole of the European Union."</seg>
<seg id="2368">Every breakthrough-bottle has to be applied with 4.2 ml 0.9% of sodium chlororid injection solution (9 mg / ml) - resulting from a solution of 25 mg / ml.</seg>
<seg id="2369">The corresponding volume of the necessary do- is taken from a bottle of bottles and with 0.9% of sodium chloride injection solution (9 mg / ml) on 100 ml (see section 6.6).</seg>
<seg id="2370">ALIMTA is displayed in combination with cisplatin for first-line therapy of patients with locally advanced or metastatic non-small bronze cancers except with excessive plattenal epitheliology (see section 5.1).</seg>
<seg id="2371">ALIMTA in monotherapy is displayed for treatment in second-line treatment of patients with lo- Kal advanced or metastatic non-small bronze cancer unless with excessive plattenal epithelial histology (see section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² body base (KOF) administered as intravenous infusion over a period of 10 minutes on the first day of each 21-day treatment cycle.</seg>
<seg id="2373">The recommended dose of Cisplatin is 75 mg / m ² COF as infusion over a period of 2 hours approximately 30 minutes after completion of Pemetrex- Infusion on the first day of each 21-day treatment cycle.</seg>
<seg id="2374">"in patients with non-single bronze statue, the recommended dose of ALIMTA 500 mg / m ² KOF is administered as intravenous infusion over a period of 10 minutes on the first day of each 21-day treatment cycle."</seg>
<seg id="2375">"to reduce the frequency and severity of skin reactions must be given day before and on the day of the Pemetreed-gift, as well as the day after treatment a cortikosteroid."</seg>
<seg id="2376">"during the seven days prior to the first dose of Pemetrexed, at least 5 cans folic acid must be taken and the intake must be continued during the entire therapy period, as well as for other 21 days after the last Pemetrex- dose."</seg>
<seg id="2377">Patients also need an intramuscular injection of vitamin B12 (1000 micrograms) in the week prior to the first Pemetremixed dose as well as after each third installment cycle.</seg>
<seg id="2378">"in patients, the Pemetrexed received, should be created before each gift a complete blood image created - the, including a differentiation of the leucocytes and a Thrombozytenstadl."</seg>
<seg id="2379">The alkaline Phosphatase (AP), aspartat transaminase (AST or SGOT) and Alanin transaminase (ALT or SGPT) should be &lt; 3-times of the upper limit value.</seg>
<seg id="2380">At the beginning of a new treatment cycle a dosage examination must take place under Berücktion - the Nadirs of the blood image or the maximum not-ugly therapy cycles.</seg>
<seg id="2381">"according to recovery, patients must be treated according to the information in the tables 1, 2 and 3, which are used for ALIMTA as monotherapy or in combination with cisplatin."</seg>
<seg id="2382">These criteria correspond to the definition of the National Cancer Institute Common Market Criteria (CTC v2.0; NCI 1998) ≥ CTC degree 2 bloodstream.</seg>
<seg id="2383">Should patients not be interspermatological toxicity (except neurotoxicity) must be interrupted (except neurotoxicity) that the patient must be interrupted by ALIMTA until the patient has the value of treatment before treatment</seg>
<seg id="2384">The treatment with ALIMTA must be interrupted if in patients after 2 dosistho- or not-ugly toxicity or not-ugly toxicity or so- continued during the appearance of degree 3 or 4 neurotoxicity.</seg>
<seg id="2385">Clinical studies have no indication that in patients aged 65 Yahweh - or compared to patients under the age of 65 an increased risk risk - ko.</seg>
<seg id="2386">ALIMTA is not recommended for use in children under 18 years of age because of non-sufficient data for inconceivable and effectiveness.</seg>
<seg id="2387">"in clinical trials, patients with a creatinine Clearance were necessary in patients with a creatinine Clearance of ≥ 45 ml / min no dosage adaptions needed to go beyond the dosage for all patients recommended dosage adjustment."</seg>
<seg id="2388">The data base in patients with a creatinine Clearance from less than 45 ml / min was not sufficient; therefore the use is not recommended (see Section 4.4).</seg>
<seg id="2389">"however, patients with a liver functional from &gt; to the 1,5-times of the upper limit value (with abrasion of liver metastatic phases) or &gt; 5.0-times of the upper limit value (with the presence of liver abnormalities) are not specifically examined in the studies."</seg>
<seg id="2390">Patients must be monitored with regard to the button market and Pemetrexed may not be administered in patients before their absolute neutrons figure again a value of ≥ 1500 cells / mm ³ and the thrombogenic amounts again has reached a value of ≥ 100 000 cells / mm ³.</seg>
<seg id="2391">A dosage reduction for further cycles is based on the Nadir of the absolute Neutrobes number, theses number and maximum non-ugly - the (see Section 4.2).</seg>
<seg id="2392">A smaller toxicity and a reduction of degree 3 / 4 hematropie and infection with degree 3 / 4 neutropenie was beamed when a pre-treatment with folic acid and vitamin B12 had taken place.</seg>
<seg id="2393">"therefore, all patients must depend on Pemetrexed treated patients, folic acid and vitamin B12 as prophy- lactic measure for reduction of-related toxicity (see Section 4.2)."</seg>
<seg id="2394">Patients with mild to medium insufficiency (creatinine-Clearance 45 to 79 ml / min) the simultaneous intake of non-steroidal anti-logistika (&gt; 1.3 g daily) for at least 2 days before the therapy, on the day of therapy and mindes- TENS 2 days after the therapy with Pemetrexed (see Section 4.5).</seg>
<seg id="2395">"all patients, for which treatment with Pemetrexed has to be used for at least 5 days prior to therapy, on the day of therapy and at least 2 days after the therapy with Pemetrexed (see Section 4.5)."</seg>
<seg id="2396">"many patients with which these events occurred, corresponding risk factors for the occurrence of renal events, including elongation, existing hypertension or diabetes."</seg>
<seg id="2397">Therefore in patients with clinically significant liquid - accumulation in the transcellular room will be a drain of the result before the Pemetrexed treatment.</seg>
<seg id="2398">"5 serious cardiovascular events, including myocardinous events, including myocardincolor, and zerebrovascular events have been reported in clinical trials with Pemetrexed occasionally, if this substance is commonly administered in combination with another cytotoxic substance."</seg>
<seg id="2399">"for this reason, the simultaneous application of catchy living (except yellow fever, this vaccination is contraindicated) not recommended (see section 4.3 and 4.5)."</seg>
<seg id="2400">"as the possibility of a missive skull, the reproductive capacity consists of Pemetrexed, men should be pointed out prior to treatment - gum to obtain advice regarding sperm count."</seg>
<seg id="2401">"in patients with normal kidney function (Kreatine-Clearance 7,1600 mg / day) and Acetylsalicylacid in high dosage (≥ 1.3 g per day)) and acetylsalicylacid in high dosage (≥ 1.3 g per day) to a decreased Pemetreed excretion with the result of a multiplicity of side effects."</seg>
<seg id="2402">"therefore, caution is advisable when in patients suffering from normal kidney function (Kreatinine Clearance ≥ 80 ml / min) high doses of NSAIDs or Ace- tylsaline acid in high dosage."</seg>
<seg id="2403">"ibuprofen or acetylsalicyl- acid in high dosage for at least 2 days before the therapy, the day of therapy and mindes- TENS 2 days after the therapy with Pemetrexed (see Section 4.4)."</seg>
<seg id="2404">"since there is no data regarding interaction potential than with NSAIDs with long half-time like Piro- xicam or Rofecoxib, the simultaneous application of Pemetrexed must be avoided for at least 5 days before the therapy, on the day of therapy and at least 2 days after the therapy with Pemetre- xed."</seg>
<seg id="2405">The large intra-individual variation of the smell status during the disease and the possibility of interactions between oral anticoagulancia and antineoplastic chemotherapy requires an increased monitoring frequency of INR (International normalisation ratio) when the decision was made to treat the patient - ducks with oral anticoagulum.</seg>
<seg id="2406">"there are no data for the use of Pemetrexed in pregnant, but as with ande- ren anal-timites are expected at an application in pregnancy heavy birth defects."</seg>
<seg id="2407">"Pemetrexed may not be applied during pregnancy, except if necessary, and after careful abrasion of usability for the mother and risk of risk to the foetus (see Section 4.4)."</seg>
<seg id="2408">"as the possibility of a irreversible skull of the reproductive capacity consists of Pemetrexed, men should be pointed out before the treatment begins to take advice on the sperm count."</seg>
<seg id="2409">"it is not known whether Pemetremixed into the mother's milk, and unwanted effects in glued infant can not be ruled out."</seg>
<seg id="2410">"the following table shows the frequency and severity of unwanted effects which were reported in &gt; 5% of 168 patients with Mesotheliom, as well as in 163 patients with Mesotheliom, which received randomised Cisplatin as monotherapy."</seg>
<seg id="2411">"side effects of side effects: very common (≥ 1 / 10 and &lt; 1 / 100), occasionally (≥ 1 / 1000 and &lt; 1 / 1000), rarely (&lt; 1 / 10,000 and &lt; 1 / 1000), very rare (&lt; 1 / 10,000) and not known (based on the available data from spontaneity will not be invaluable)."</seg>
<seg id="2412">* regarding the National Cancer Institute CTC Version 2 for any toxicity except the event "Creatinine-Clearance" * * which is derived from the term "kidneys / genital trakt others." * * * related to National Cancer Institute CTC (v2.0; NCI 1998) should taste a taste of disorder and hair loss just as degree 1 or 2.</seg>
<seg id="2413">"for this table, a threshold of 5% for the recording of all events, where the reporting doctor has kept a connection with Pemetrexed and Cisplatin possible."</seg>
<seg id="2414">"clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of the patients were reported the randomised cplatin and Pemetrexed, embraced arrhythmia and motoric Neuropathy."</seg>
<seg id="2415">The following table shows the frequency and severity of unwanted effects which were reported on &gt; 5% of 265 patients who were randomized Pemetrexed as monotherapy with gifts of mammals - re and vitamin B12 as well as 276 patients who were randomized docetaxel as monotherapy.</seg>
<seg id="2416">* regarding National Cancer Institute CTC Version 2 for any toxicity level. * * related to National Cancer Institute CTC (v2.0; NCI 1998) should only be reported as degree 1 or 2.</seg>
<seg id="2417">"for this table, a threshold of 5% for the recording of all events, where the reporting doctor has kept a connection with Pemetrexed for possible."</seg>
<seg id="2418">"clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of the patients were reported the randomized Pemetrexed, comprising supraventricular arrhythmities."</seg>
<seg id="2419">"the clinically relevant laboratory toxicity (n = 164) of phase 2 was similar to the combined results of three single Pemetrexed Monsters (n = 164), except Neutropenie (12.8% compared to 5.3%) and an increase in the Alanintransaminase (15.2% compared to 1.9%)."</seg>
<seg id="2420">These sub-differences are likely to result in differences in patient population as the Pha- se 2 studies inchemonaive as well as clearly pretreated breast cancer patients with existing liver metastatic and / or degradation of the liver tests.</seg>
<seg id="2421">"the following table shows the frequency and severity of unwanted effects which may be possible at &gt; 5% of 839 patient - ducks with NSCLC, the randomised Cisplatin and Pemetrexed received and 830 patients with NSCLC, which received randomised Cisplatin and gemcitabine."</seg>
<seg id="2422">"11 * P-values &lt; 0.05 comparison of Pemetrexed / Cispline / Cisplatin, under use of the" Fisher Exact. * * * related to National Cancer Institute CTC (v2.0; NCI 1998) should taste a taste of disorder and hair loss just as degree 1 or 2. "</seg>
<seg id="2423">"for this table, for inclusion of all events, where the reporting doctor has been linked to Pemetrexed and Cisplatin, a threshold of 5%."</seg>
<seg id="2424">"clinically relevant toxicity, which were reported by ≥ 1% and &lt; 5% (often) the patients were reported, the randomised Cisplatin and Pemetrexed received, embraced:"</seg>
<seg id="2425">"clinically relevant toxicity, which were reported at &lt; 1% (occasionally) of the patients were reported, the rannized Cisplatin and Pemetremixed received:"</seg>
<seg id="2426">"serious cardiovascular and cervical events, including myocardinality, Angina pectoris, crush ascular and transitoric attacks were administered in hospitals - studies with Pemetrexed that is commonly used in combination with another cytotoxic active substance, occasionally reported."</seg>
<seg id="2427">"from clinical trials were occasionally reported in patients with Pemetrexed treatment occasionally cases of coli- tis (including intestinal and rectal bleeding, sometimes fatal infant, intestinal perfo- Ration, intestinal necrose and typhlitis)."</seg>
<seg id="2428">From clinical trials were reported in patients with Pemetrexed treatment occasionally cases of sometimes fatal interstitial pneumonitis with respiratory insufficiency.</seg>
<seg id="2429">It has been reported on cases of acute kidney failure at Pemetrexed Monotherapy or in combination with other chemotherapists (see Section 4.4).</seg>
<seg id="2430">"there were cases of radipneumonitis in patients reported before, during or after their Pemetreated therapy (see Section 4.4)."</seg>
<seg id="2431">ALIMTA (Pemetrexed) is a antineoplastic anti-folate that exerts its effect by wired-resistant metabolic processes that are necessary for the cell replication.</seg>
<seg id="2432">In vitro studies showed that Pemetrexed has been blocked as an antifolate with multiple steps (TS) Dihyardylatetase (DHFR) and glycinotional synthase (TS); Dihyardylatch (DHFR) and glycinotional synthase (TS).</seg>
<seg id="2433">"EMPHACIS, a multi-centric, randomized, simple-blind phase 3 study by ALIMTA and Cisplatin with malignant patients with malignant Pleuramesotheliom showed that with ALIMTA and Cisplatin patients had prolonged survival over such patients with cisplatin container."</seg>
<seg id="2434">The primary analysis of this study was conducted in the population of all patients which received the test medication in the treatment arm (randomised and treated).</seg>
<seg id="2435">A statistically significant improvement of the clinically relevant symptoms (pain and dyspnea) in connection with the malignant Pleuramesotheliom has been shown in the ALIMTA / Cisplatin-arm (212 patients) compared to the allotted (218 patients).</seg>
<seg id="2436">The differences between the two treatment arms have been increased in the ALIMTA / Cisplatin-arm and a narrower of the lung function throughout the time in the controversy.</seg>
<seg id="2437">"a multi-centric, randomized, open phase III study with ALIMTA against docetaxel in Patients with locally advanced or metastatic NSCLC after previous chemotherapy received a median survival period of 8,3 months with docetaxel treated patients (ITT = 288)."</seg>
<seg id="2438">"an analysis of the influence of histology on the treatment effect, with a predominantly not plattenal histological type (n = 399, 6.2 versus 8.4 months, adapted HR = 1.56; 95% CI = 1.08-2.8, p = 0,018)."</seg>
<seg id="2439">"limited data of a separately randomized, controlled phase 3 study indicate that efficacy data (survival and progression-free survival) for Pemetremixed between patients with (n = 41) and without (n = 540) pre-treatment by Docetaxel are similar."</seg>
<seg id="2440">The efficacy analyses of the PQ Population are consistent with the analyses of the ITT population and support the non-submission of ALIMTA Cisplatin combination against the gemcitabine cplatin combination.</seg>
<seg id="2441">"medium PFS was 4.8 months for the combination of ALIMTA Cisplatin compared to 5,1 months for the combination of ALIMTA compared to 28.2% (95% CI = 25,0 - 31.4) for the combination of gemcitabine in Cisplatin."</seg>
<seg id="2442">"the analysis of influence of the NSCLC Histology on the survival showed clinically relevant sub-differences according to histology, see below the table below."</seg>
<seg id="2443">CI = Confidenzinterinterval; ITT = Intent-to-Treat; N = size of total population a statistically loss for non-underembarrassment with a total confidenzinterinterval of 1.17645 (p &lt; 0.001).</seg>
<seg id="2444">"patients treated with ALIMTA and Cisplatin, needed less transfusions (16.1% versus 28.0.001), Erythrozytaller fusions (1,8% versus 4.5%, p = 0,002)."</seg>
<seg id="2445">"moreover, the patients needed the gift of Erythropoetin / Darbopoetin (10.4% versus 6.1%, p = 0,004), and Eisenpreparate (4.3% versus 7.0%, p = 0,021)."</seg>
<seg id="2446">The pharmacoinetic properties of Pemetrexed according to gift as monotherapist were examined at 426 cancer patients with various solid tumors in doses from 0.2 to 838 mg / m ² in infusi- over a period of 10 minutes.</seg>
<seg id="2447">Pemetrexed is mainly unchanged in the urine and 70% to 90% of the administered dose will be found unchanged within 24 hours after application.</seg>
<seg id="2448">Pemetrexed has a total of 91.8 ml / min and the half-time in the plasma is 3.5 hours in patients with normal kidney-clearing (Kreatinin-Clearance 90 ml / min).</seg>
<seg id="2449">In a study with beagle dogs obtained for 9 months intravenous Bolus injections (Degenetics / necang of the seminal epithelial epithelies) have been observed.</seg>
<seg id="2450">"if not properly applied, storage times and conditions are not covered in the responsibility of the user, and should normally no 24 hours at 2 to 8 ° C, unless the preparation / dilution has taken place under controlled and validated aseptic conditions."</seg>
<seg id="2451">Solve the content of the 100 mg-up bottles with 4.2% of 0.9% of sodium chlororid- injection solution (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives.</seg>
<seg id="2452">The entalled solution is clear and the coloring ranges from colourless to yellow or green yellow without the product quality is affected.</seg>
<seg id="2453">Every breakthrough-bottle has to be applied with 20 ml 0.9% of sodium chlororid injection solution (9 mg / ml) - resulting from a solution of 25 mg / ml.</seg>
<seg id="2454">"23 serious cardiovascular events, including myocardinous events, including myocardincolor, and zerebrovascular events have been reported in clinical trials with Pemetrexed occasionally, if this substance is commonly administered in combination with another cytotoxic substance."</seg>
<seg id="2455">* regarding the National Cancer Institute CTC Version 2 for any toxicity except the event "Creatinine-Clearance" * * which has been derived from the term "kidneys / genital trakt." * * * related to National Cancer Institute CTC (v2.0; NCI 1998) are intended to be reported only as degree 1 or 2.</seg>
<seg id="2456">"for this table, a threshold of 5% for the recording of all events, in which the reporting doctor had a connection with Pemetrexed and Cisplatin possible."</seg>
<seg id="2457">* regarding National Cancer Institute CTC Version 2 for any toxicity level. * * related to National Cancer Institute CTC (v2.0; NCI 1998) should only be reported as degree 1 or 2.</seg>
<seg id="2458">"29 * P-values &lt; 0.05 comparison of Pemetrexed / Cispline / Cisplatin, under use of the" Fisher Exact ". * * * related to National Cancer Institute CTC (v2.0; NCI 1998) ought to be reported only as degree 1 or 2."</seg>
<seg id="2459">"clinically relevant toxicity, which were reported at &lt; 1% (occasionally) of the patients were reported, the rannized Cisplatin and Pemetremixed received:"</seg>
<seg id="2460">"an analysis of the influence of histology on the treatment effect, with a predominantly not plattenal his- tological type (n = 399, 6.2 versus 8.4 months, adapted HR = 1.56; 95% CI = 1.08-2.8, p = 0,018)."</seg>
<seg id="2461">Solve the contents of the 500 mumchloride bottles with 20 ml 0.9% of sodium chlororid- injection solution (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives.</seg>
<seg id="2462">The entalled solution is clear and the dye ranges from colourless to yellow or green yellow without the product quality is affected.</seg>
<seg id="2463">"the holder of the approval of the approval must be responsible for providing the drug - cooperative system, as described in Version 2.0, as described in Version 2.0, as soon as the product has been brought to traffic, and while the product is located in the market."</seg>
<seg id="2464">"risk Management Plan The owner of the approval of the authorisation is required to carry out the studies and the supplementary pharmaceutical activities according to the drug management plan (RMP), as agreed in the version 1.2 of the Risk Management Plan (RMP), as agreed in the version 1.2 of the RMP, which was decided by the CHMP."</seg>
<seg id="2465">"according to" CHMP Guideline on Risk Management Systems for Medicinal products for human use "must be submitted to the next" "Periodic Safety Update Report" "(PSUR)."</seg>
<seg id="2466">"in addition, an updated RMP must be filed • If new information is available, which could have an impact on the current security specifications which could have an impact on the current security specifications, which could have an impact on the current security specifications, the pharmaceutical company plan or risk group, • within 60 days after reaching an important (pharmacy, balance or risk group), • On request by the EMEA."</seg>
<seg id="2467">ALIMTA 100 mg of powder for the production of a focus on the production of an infusion solution - FIMTA 500 mg of powder for the production of a concentrations to produce an infusion soldering -</seg>
<seg id="2468">"ALIMTA is used in patients who have received no previous chemotherapy, used for the use of malignant Pleuramesothelioms (malicious disorder of the Rippenfells) in combination with cisplatin, another medicine for the treatment of cancer diseases."</seg>
<seg id="2469">"if you have suffered a kidney or had earlier one, please discuss this with your doctor or health-bike, since you may not receive ALIMTA."</seg>
<seg id="2470">"with you, each infusion of blood tests will be carried out; there will be checked whether your kidney and liver function is sufficient and whether you have enough blood cells to get ALIMTA to 49."</seg>
<seg id="2471">Your doctor may possibly change the dose or interrupt the treatment provided that it requires your general state and when your blood values are too low.</seg>
<seg id="2472">"if you also receive Cisplatin, your doctor will ensure that your body contains sufficient water and you get the noteworthy drug to avoid the break before and after the Cisplatin-Gift."</seg>
<seg id="2473">"should you be a fluid collection around the lungs around, your doctor can decision to remove this liquid before you get ALIMTA."</seg>
<seg id="2474">"if you would like to have a child in the treatment or in the first six months after the treatment, please talk to your doctor or a pharmacist."</seg>
<seg id="2475">"interactions with other medicines Please tell your doctor if you are taking medication against pain or inflammation (sponges), including drugs, which are not prescription (like ibuprofen)."</seg>
<seg id="2476">"depending on the planing of your ALIMTA infusion and / or extent of your kidney function, your doctor will tell you which other medicines you may take, and when."</seg>
<seg id="2477">"please inform your doctor or pharmacist if you are taking other medicines or have recently been taken, even if it is not prescription drugs."</seg>
<seg id="2478">A hospital in health care provider who care staff or a doctor will mix the ALIMTA powder with steriler 0.9% of sodium chlororid injection solution (9 mg / ml) before it is used for you.</seg>
<seg id="2479">Your doctor will prescribe cortison tablets (accordingly 4 mg Dexametha- two times daily) that you must take the day before, during the day and on the day after the application of ALIMTA.</seg>
<seg id="2480">Your doctor will take you folic acid (a vitamin) to take or multivitamins that contain folic acid (350 to 1000 micrograms) that you have to take during the application of ALIMTA during the application of ALIMTA.</seg>
<seg id="2481">This week before the application of ALIMTA and approximately every 9 weeks (correspondingly 3 cycles of treatment with ALIMTA) you will also get an injection of Vi- tamin B12 (1000 micrograms).</seg>
<seg id="2482">"in this manual information a side effect is described as" "very common", "this means that it was reported by at least 1 of 10 patients."</seg>
<seg id="2483">"a side effect is described as" frequently, "this means that it was reported by at least 1 of 100 patients but was reported less than 1 of 10 patients."</seg>
<seg id="2484">"if a side effect is described as" "occasionally", "this indicates that they reported from at least 1 of 1,000 but less than 1 of 100 patients, this means that it was reported by at least 1 of 10,000 but less than 1 of 1,000 patients."</seg>
<seg id="2485">"fever or infection (common): if you have a body temperature of 38 ° C or above, sweating or other signs of infection have (because you may have less white blood cells as normal, which is very common)."</seg>
<seg id="2486">If you feel tired or weak to get rapidly in breathing or pale quickly (because you might have less bunmoglobin as normal that is very common).</seg>
<seg id="2487">"if you have a bloody of the gum, the nose or the mouth or some other blood of blood that doesn't come to a standstill, or a reddish or pink or pink or pink urine (because you may have less blood-plets than normal, which is very common)."</seg>
<seg id="2488">"occasionally (occurs at least 1 of 1,000 patients, but less than 1 of 100 patients) increased pulse rate colitis (inflammation of the inner clutches in the intestine and enddarm) Interstitielle pneumonitis (resignation of water into the body tissue, which leads to swelling)."</seg>
<seg id="2489">"rare (occurs in more than 1 of 10,000 patients, but less than 1 of 1,000 patients)" radiation Recall "(a rash similar to a heavy sunburn), appearance on the skin, which was exposed before (some days to years) of a radiotherapy."</seg>
<seg id="2490">"occasionally, in patients, ALIMTA, usually joined with other cancers, the ALIMTA, usually obtained, a stroke or stroke with a reduced skull."</seg>
<seg id="2491">"in patients who have received a radiotherapy treatment, before, during or after their ALIMTA treatment may also occur an radiation-treatment inflammation of the pulmonary fibrous, which is related to the lung treatment in connection)."</seg>
<seg id="2492">"52 Informing your doctor or pharmacist if one of the listed side effects you considerable, or if you notice side effects that are not recorded in this package."</seg>
<seg id="2493">"provided as prescribed, chemical and physical stability of diluted and infusion solution in storage was detected in the fridge or at 25 ° C for a period of 24 hours."</seg>
<seg id="2494">"Tél / Tel: + 32- (0) 2 548 84 84 of the" "Content Assistant" "live output. + 359 2 491 41 40 Česká Republika Eli Lilly ČR, s.r.o."</seg>
<seg id="2495">"Tel: + 420 234 664 111 Danmark Eli Lilly Holly Deutschland GmbH Tel. + 4926441100, vis Eesti Lilly H. Eesti Eli Lilly H. Eesti Eli Lilly H. Eesti Eli Lilly H. Eesti Eli Lilly H. Eesti Eli Lilly H. Eesti Eli Lilly H. Eesti Eli Lilly 50EUR"</seg>
<seg id="2496">Tel: + 34-91-623 France Lilly France SAS Tél: + 33- (0) 1 55 49 34 34 Ireland Eli Lilly and Company (Ireland) 661 4377 Ísland Icepharma HF.</seg>
<seg id="2497">"Tel: + 39- 055 425,000 Latvija Eli Lilly Holdings Limited poully Li Lilly Holdings Limited betuva Eli Lilly Holdings Limited atstovybė Tel. + 370 (5) 2649600"</seg>
<seg id="2498">Tel Aviv: + 48 440 33 00 Portugal Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351-21-4126600 România România S.R.L.</seg>
<seg id="2499">Tel: + 421 220 663 Sweden AB Rih / Tel: + 358- (0) 9 7378800 United Kingdom Eli Lilly and Company Limited Tel: + 44- (0) 1256 315999</seg>
<seg id="2500">Solve the content of the 100 mg-up bottles with 4.2 ml 0.9% of sodium chlororid- injection solution (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives.</seg>
<seg id="2501">Solve the contents of the 500 mumchloride bottles with 20 ml per 0.9% sodium diaphrag- injection solution (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives.</seg>
<seg id="2502">The entalled solution is clear and the coloring ranges from colourless to yellow or green yellow; without the pro- quality is impaired.</seg>
<seg id="2503">"it is used in overweight adults with a body measurement (Body Mass Index - BMI) of ≥ 28 kg per square meter in connection with low-calorie, fetching diet."</seg>
<seg id="2504">"patients who are taking the Alli, and after 12 weeks no weight can be recorded, should consult their doctor or a pharmacist."</seg>
<seg id="2505">"these enzymes are inhibited, they can't disintegrate some fats in the food, thereby causing about a quarter of the fats unfolded from the intestines."</seg>
<seg id="2506">In a third study Alli was compared with 391 overweight patients with a BMI between 25 and 28 kg / m2 with placebo.</seg>
<seg id="2507">"in both studies in patients with a BMI of ≥ 28 kg / m2 had patients, the Alli 60 mg, after one year an average weight loss of 4.8 kg, compared to 2.3 kg when taking placebo."</seg>
<seg id="2508">"in the study with Alli in patients with a BMI between 25 and 28 kg / m2, no loss of weight loss could be observed."</seg>
<seg id="2509">"the most common side-effects of Alli (observed in more than 1 of 10 patients) are öy spots on after, Flatus (Winds) with Stuhlabeling, Stuhldurge, fetters of the secretion, Flatulence (Winde) and soft chairs."</seg>
<seg id="2510">It must not be used in patients who are treated with Ciclosporin (to prevent the organableage in transplant tattoo) or with medicines such as warfarin to prevent hemispheres.</seg>
<seg id="2511">"it must not be used in patients who are absorbed by a long term Malabsorpancy syndrome (in which not enough nutrients are absorbed from the digestive tract) or at cholestase (of liver disease), and in pregnant or breastfeeding mothers."</seg>
<seg id="2512">July 2007 shared the European Commission to the company Glaxo Group Limited for approval by Orlistat GSK across the European Union.</seg>
<seg id="2513">Alli is indebted to the weight reduction of adults with overweight (body-measure index BMI ≥ 28 kg / m2) and should be applied in conjunction with an easily hypocalorischen diet.</seg>
<seg id="2514">"alli may not be applied to children and juveniles under the age of 18, because there is not enough data on efficacy and safety."</seg>
<seg id="2515">"however, since Orlistat however only minimal resorb is absorbed in older and with patients with reduced liver and / or kidney function, no adjustment of dosage is necessary."</seg>
<seg id="2516">• hypersensitivity to the active ingredient or any other components • simultaneous treatment with Ciclosporin (see Section 4.6) • Premature treatment with warning-time (see Section 4.6) • simultaneous treatment with warfarin or other oral anticoagularity (see sections 4.5 and 4.8)</seg>
<seg id="2517">The probability of the treach gastrointestinal symptoms (see Section 4.8) can increase if alli is taken along with a fat-rich single meal or fat-rich diet.</seg>
<seg id="2518">"as the weight reduction in diabetes can be accompanied by diabetes with improved metabolic control, patients who take a medicine against diabetes before starting a therapy with alli a doctor or pharmacist, because the dosage of antidiabetic diabetic needs to be adjusted."</seg>
<seg id="2519">Patients who take the alli as well as medicines for hypertension or have increased cholesterol levels should consult their doctor or pharmacists if the dosage of these medicines must be adjusted.</seg>
<seg id="2520">"it is recommended to prevent additional fluctuations to measures, in order to prevent additional fluctuation measures in the event of severe diarrhoea possible failure (see Section 4.5)."</seg>
<seg id="2521">Both in a study regarding interactions of medicines and in several cases with equivalent application of Orlistat and Ciclosporin has been observed a distraction of Ciclosporin-plastic bars.</seg>
<seg id="2522">"in the application of warfarin or other oralen anticoagularity in combination with Orlistat could be influenced the Quick-values (internationally normal, INR) (see Section 4.8)."</seg>
<seg id="2523">"in most patients who were treated in clinical trials up to 4 full years with Orlistat, the concentrations of the vitamins A, D, E and K and the beta-carotene remained in normzone."</seg>
<seg id="2524">"however, the patient should be recommended before bedtime a supplement to the multivitamal supplement to ensure sufficient vitamins (see Section 4.4)."</seg>
<seg id="2525">"after the gift of a maldosage Amiodaron was observed in a limited number of healthy volunteers, which at the same time the Orlistat was observed."</seg>
<seg id="2526">"animal experimental studies have no direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth or post-natal development (see Section 5.3)."</seg>
<seg id="2527">The side effects of Orlistat are mainly gastrointestinal nature and hang together with the pharmacological effect of the drug as the absorption is prevented from contained fat.</seg>
<seg id="2528">The gastrointestinal side effects were obtained from clinical studies with Orlistat 60 mg over a period of 18 months to 2 years and were generally light and temporary.</seg>
<seg id="2529">"the frequencies are defined as follows: very common (≥ 1 / 10), commonly (≥ 1 / 100, &lt; 1 / 100), rare (≥ 1 / 10,000, &lt; 1 / 1000), and very rare (&lt; 1 / 10.000), not known (frequency based on the available data does not be invaluable)."</seg>
<seg id="2530">"the frequency of known side effects which were determined after the launch of Orlistat is not known, as these events have voluntarily been reported by a population of a population."</seg>
<seg id="2531">Defining It is plausible that treatment with alli is to lead to conversion with regard to possible or actual gastrointestinal intestinal side effects.</seg>
<seg id="2532">Individual dots of 800 mg Orlistat and multi-type of up to 400 mg three times daily were administered over a period of 15 days to normal and overweight progangs without significant clinical findings.</seg>
<seg id="2533">"in the majority of the cases reported after the market launch reported by Orlistat overdose, either side effects or similar side-effects such as in the recommended dose of Orlistat have been reported."</seg>
<seg id="2534">"based on research on man and animal can be attributed from a rapid backformation of systemic effects which, on the lipassions of Orlistat are made."</seg>
<seg id="2535">The therapeutic effect sets in the lumbar of the magens and the upper thin-intestine by kovalente by kovalente to the active servo-rest of gastral and pannical lipassions.</seg>
<seg id="2536">"from clinical trials was derived that 60 mg Orlistat, three times a day, the absorption of about 25% of the food is blocked."</seg>
<seg id="2537">"two double flashes, randomized, placebocontrolled studies in adults with a BMI ≥ 28 kg / m2 occupy the effectiveness of 60 mg Orlistat, which was taken three times daily in combination with a hypokalorical, fetal diet."</seg>
<seg id="2538">"the primary parameter, the change in the body weight (at the time of Randomisation), has been assessed as follows: as a change in body weight in the course of course (table 1) and as percentage of those study participants that have lost more than 5% or more than 10% of their output weight (table 2)."</seg>
<seg id="2539">"although in both studies the weight reduction has been observed over 12 months, the largest weight loss in the first six months occurred."</seg>
<seg id="2540">The average change in the overall cholesterolat was awarded with Orlistat 60 mg -2.4% (output value 5.20 mmol / l) and with placebo + 2.8% (output value 5.26 mmol / l).</seg>
<seg id="2541">The average change of the LDL cholesterol was reduced with Orlistat 60 mg -3.5% (output 3.30 mmol / l) and with placebo + 3.8% (output 3.41 mmol / l).</seg>
<seg id="2542">The average change - 4.5 cm with Orlistat 60 mg (starting 103.7 cm) and with placebo -3.6 cm (output value 103,5 cm).</seg>
<seg id="2543">Plasmakonzentrations of not metabolic orlistat were 8 hours after the oralen for 360 mg Orlistat (&lt; 5 ng / ml).</seg>
<seg id="2544">"7 In general, when therapeutic doses could not be sporadically in the plasma only sporadically and in extremely low concentrations (&lt; 10 ng / ml or 0.02 µmol) and without signs of a grief."</seg>
<seg id="2545">"in a study with adipous patients, which was administered the minimally fenced dose, namely two main metabolic, namely M1 (in position 4 hydrolysited lactonring) and M3 (M1 after lowering of the N-style hotonring) and M3 (M1 after lowering of the N-format-leucine group), which nearly 42% of total plasmakonzentration were created."</seg>
<seg id="2546">"based on conventional studies on safety of security, Genotoxicity, Cancerous potential and Reproductive Toxicity, the preclinical data cannot recognize any particular danger to the people."</seg>
<seg id="2547">"the holder of the approval of the approval must make sure that the drug use of approval must be assured, according to the version of July 2007, as described in module 1.8.1 of the application, is applied and working before and while the product is available on the market."</seg>
<seg id="2548">Risk management planning The owner of the approval of the authorisation is required to carry out the studies and additional pharma activities such as in the drug management plan (RMP) of October 2008 and thus agreed to the agreement of the risk management plan (RMP) of October 2008 as well as to all other updates of the RMPs which will be agreed with the Committee for Humanitarian Affairs (CHMP).</seg>
<seg id="2549">"according to the CHMP guidelines on risk management systems for human medicines, the updated RMP must be submitted at the same time with the next PSUR (Periodic Safety Update Report)."</seg>
<seg id="2550">"furthermore, an updated RMP should be submitted: • if new information is available, the current security policies, the pharmaceutical agents or risk management, are concerned, within 60 days of the accessibility of an important, pharmacoyancy or risk assessment, on request from the European Pharmacology Agency (EMEA)."</seg>
<seg id="2551">"12 PSURs The holder of approval for the marketing will be issued in the first year after the Commission's approval for the authorisation to the alli 60 mg of PSU PSURs every 6 months, then for two years and after that every three years."</seg>
<seg id="2552">"do not use, • if you are under 18, • If you are getting pregnant or do any other components, • If you are suffering from irrigation or other blood-thin, • if you are suffering from dropping or other blood thinning, • if you are suffering from dropping-flow (disease the liver, in which the Galleabflow is disturbed), • if you have trouble with the food (chronic Malabsorpancy syndrome)."</seg>
<seg id="2553">"• take three capsules per day with each main meal, the fat contains, a capsule with water. • You should take once a day, a multivitamintablette (with vitamins A, D, E and K)."</seg>
<seg id="2554">"application: • take three capsules per day with each main meal time, a capsule with water. • You should take a capsule with water. • You should take once daily, before bedtime a multivitamins (with vitamins A, D, E and K). • You should no longer use a multivitamins (with vitamins A, D, E and K)."</seg>
<seg id="2555">"maybe you would like to read it later again. • If you need further information or a advice if you need further information or advice, if you need further information or advice. if you have not reached any weight reduction by alli, ask a doctor or a pharmacist for advice."</seg>
<seg id="2556">"possibly you need to end the intake of alli. if one of the listed side effects you have considerably affected or you notice side effects which are not indicated in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="2557">What do you need to consider before taking alli of alli? • alli may not be applied • For intake of alli with other medicines • At intake of alli along with food and drink • pregnancy and breastfeeding period • traffic noise and breastfeeding for machines 3.</seg>
<seg id="2558">How to take up your weight reduction? • How can you prepare your weight reduction? O adults starting from 18 years of age o How long should I take alli? o If you have taken alli in to large quantities o When you have taken the intake of alli 4.</seg>
<seg id="2559">Which side effects are possible? • serious side-effects • Very common side effects • Frequent side effects • effects on blood examinations • How can you control serious companion escort?</seg>
<seg id="2560">Further information • What alli contains • How alli does and content of the package • pharmaceutical entrepreneurs and manufacturers • Additional information</seg>
<seg id="2561">Alli is used to reduce weight reduction and is used in overweight adults over the age of 18 with a body-measure index (BMI) of 28 or above. alli should be applied in conjunction with a liposuction and low-calorie diet.</seg>
<seg id="2562">The BMI will help you determine if you're in proportion to your body size a normal weight or is overweight.</seg>
<seg id="2563">"even if these diseases do not first assume that you feel uncomfortable, you should nevertheless ask your doctor for checkup examination."</seg>
<seg id="2564">"for each 2 kg body weight, which you take within a diet, you can lose an extra kilogram with the help of alli."</seg>
<seg id="2565">"please inform your doctor or pharmacist if you are taking other medicines or have recently taken, even if they are not prescription drugs."</seg>
<seg id="2566">Ciclosporin is used after organically transplantations, in severe rheumatoid arthritis and certain heavy skin diseases. • Warfarin or other medicines which have a blemissive effect.</seg>
<seg id="2567">Orale Conception and alli • The effect of oral increasing funds for pregnancy contraception (pill) will be shielded under circumstances or waives if you have strong diarrhoea (diarrhoea).</seg>
<seg id="2568">Please contact your doctor or pharmacist if you are taking: • Amiodaron to treat cardiac arrhythmia. • Acarbose used to treat diabetes.</seg>
<seg id="2569">"ask your doctor or pharmacist if you take alli and if you need medicines to high blood pressure, as possibly dosage needs to be adjusted. • If you take medicines to high cholesterol levels, as possibly the dosage needs to be adjusted."</seg>
<seg id="2570">"how to define your calorienziele and fat limits, you will find out more helpful information on the blue pages in section 6."</seg>
<seg id="2571">"if you leave a meal or contains a meal no fat, take no capsule. alli can only work if the food contains fat."</seg>
<seg id="2572">"if you are taking the capsule with a meal that contains too much fat, risk-related companion lists (see section 4)."</seg>
<seg id="2573">"to get used to your body to the new eating habits, start before the first captives with a cold and fetching diet."</seg>
<seg id="2574">"dietary supplements are effective because you can understand at any time what you eat, how much you eat and it will probably fall easier to change your dietary habits."</seg>
<seg id="2575">"in order to achieve your target weight, you should set in advance two daily goals: one for the calories and one for fat."</seg>
<seg id="2576">• nutritional supplements to decrease the likelihood of malnourished escort (see section 4). • Try to move more before you start taking capsules.</seg>
<seg id="2577">"remember to ask your doctor in advance of your doctor if you are not used to physical activity. • Stay stay during the intake, and even after ending the intake of alli physically active."</seg>
<seg id="2578">"• alli may not be taken for longer than 6 months. • If you can cancel your weight after twelve weeks of application, please ask your doctor or pharmacist for advice."</seg>
<seg id="2579">"under circumstances, you must end the intake of alli. • For a successful weight reduction, it is not about how to switch the diet only and then return to old habits."</seg>
<seg id="2580">"• If less than an hour since the last meal has passed, take the intake of the capsule. • If more than one hour since the last meal has passed, you don't take a capsule."</seg>
<seg id="2581">"blowers with and without the extradition, sudden or multiply marhldurge and softer stools) are due to the active mechanism (see Section 1)."</seg>
<seg id="2582">"heavy allergic reactions • Scale reactions responses to the following changes: heavy breaths, welders, goubreaks, gouterings in the face, heart beats, circulations."</seg>
<seg id="2583">"29 Very common side-effects These can occur in more than 1 of 10 people, the alli taking place. • Bläence (Flatulence) with and without the exient resignation • softer chair, check out your doctor or pharmacist if any of these side effects are reinforced or you have significantly impaired."</seg>
<seg id="2584">"frequent side-effects These can occur in 1 of 10 people, which may occur, • incontinence • incontinence • defenses • deflemmings • Beklemmed Informing your doctor or pharmacist if any of these side effects are reinforced or you have significantly impaired."</seg>
<seg id="2585">"effects on blood tests It is not known, how often these effects occur. • increase from certain liver clots • effects on blood clotting in patients, the warfarin or other hemorthinner (anti-kosher) medicines."</seg>
<seg id="2586">Please inform your doctor or pharmacist if one of the listed side effects you have considerably affected or you notice side effects which are not stated in this usage information.</seg>
<seg id="2587">The most common side effects hang together with the effect of the capsules and thereby arise that fat is out of the body out of the body.</seg>
<seg id="2588">These side-effects usually occur within the first weeks of treatment at the beginning of during the first few weeks as at this time you have not consistently reduced the fat share in the diet.</seg>
<seg id="2589">"with the following rules you can learn to minimize the nutritional-related companions: • Beginside you already have some days, or better a week, prior to the first intake of capsules with an fetched diet. • Learning more about the usual fat content of your favourite dish and about the size of the servings you normally take."</seg>
<seg id="2590">"if you know exactly how much you eat, sinks the probability that you exceed your fat. • Use your recommended fat intake evenly on the daily meals."</seg>
<seg id="2591">"save the amount of calories and fat that you are allowed to take you per meal, not to take them in the form of a fat rich head or a full afterward. • The majority of those who appear to do these guides, learn to control this time by adapting their diets."</seg>
<seg id="2592">• Buy medicine for children unavailable. • You may not apply more than 25 ° C. • The eldest date does not apply to protect the content from moisture. • The bottle contains two white sealed container with sicagel which serve to keep capsules dry.</seg>
<seg id="2593">Swallow this in no case. • You can guide your daily dose in the blue conveyor box (shuttle) which lies with this package.</seg>
<seg id="2594">"FAMAR, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, Great Oakley, Coramptonshire NN18 8HS, United Kingdom"</seg>
<seg id="2595">Obesity has influence on your health and increases risk for the emergence of various serious diseases such as diabetic diseases • Distincite cancers • Repoarthritis • Share it with your doctor about your risk for these diseases.</seg>
<seg id="2596">"a lasting weight reduction, for example by improving the diet and more exercise, can result in prevention of gravity and has a positive impact on your health."</seg>
<seg id="2597">"choose meals that contain a wide range of nutrients, and learn to learn permanently healthy."</seg>
<seg id="2598">Energy is also measured in kilogram which you can also find as indication of the packaging of foods. • The recommended calorie intake indicates how many calories you should take up to a maximum of per day.</seg>
<seg id="2599">Note the further down in this section tables. • The recommended fetching intake in grams is the maximum amount of fat that you should take with every meal.</seg>
<seg id="2600">"what is suitable for you, refer to the number of calories that is suitable for you. • Due to the effect of the capsule, the compliance with the recommended damage is crucial."</seg>
<seg id="2601">"if you take the same amount of fat as far as so far, this can mean that your body cannot process this amount of fat."</seg>
<seg id="2602">"due to compliance with the recommended fetching, you can maximize the weight reduction and at the same time diminishing the likelihood of malnourished escort. • You should try to increase gradual and continuously."</seg>
<seg id="2603">34 This reduced number of calories should allow you to step gradually and continuously lose about 0,5 kg per week without any frustrations and disappointments.</seg>
<seg id="2604">"the more active you are, the higher your recommended calorie intake. •" low physical activity "means that you are going to work every day little or not at all, e.g. by 3 km walking, 30- to 45-minute gardening or 2 km of running in 15 minutes."</seg>
<seg id="2605">• For a permanent weight reduction it is necessary to put realistic calorie- and fat goals and adhere to it. • Finally is a nutritional book with information about calcium and fat content of your meals. • Try to move more before you start the intake of alli.</seg>
<seg id="2606">"the alli program for supporting weight reduction combines the capsules with a food plan and a large number of other information materials that can help you feed the cold and fetching guidelines, to become physically active."</seg>
<seg id="2607">"in combination with one to your type, program for support of weight reduction, this information can help you develop a healthier lifestyle and reach your target weight."</seg>
<seg id="2608">"Aloxi is used in chemotherapy for nausea and vomiting (such as Cisplatin), as well as in chemotherapy, the moderate trigger for nausea and vomiting (such as Cyclophosphate, Doxorubicin or Carboplatin)."</seg>
<seg id="2609">The efficacy of Aloxi can be increased by the additional gift of a corticosteroids (a drug that can be used as antiemetic).</seg>
<seg id="2610">The application in patients under 18 years of age is not recommended as the effects in this age group does not exist enough information.</seg>
<seg id="2611">"this means that the substance is prevented by the substance of a chemical substance in the body, 5-hydroxyloyptamin (5HT, also known as serotonin), to the receptors in the intestines."</seg>
<seg id="2612">"Aloxi was studied in three main studies on 1 842 adults, the chemotherapy received, which were strong or moderate trigger for nausea and vomiting."</seg>
<seg id="2613">"in chemotherapy, the strong trigger for nausea and vomiting are, 59% of the patients were treated with Aloxi in 24 hours following chemotherapy (132 from 223), compared to 57% of the patients treated with Ondansetron, treated patients (126 from 221)."</seg>
<seg id="2614">"with chemotherapy, the moderate trigger for nausea and vomiting, 81% of the patients were treated with Aloxi in 24 hours after chemotherapy (153 of 189), compared to 69% of those treated with Ondansetron, treated patients (127 from 185)."</seg>
<seg id="2615">When compared with Dolasetron these values at 63% for Aloxi (119 of 189 patients) and 53% for Dolasetron (101 of 191 patients).</seg>
<seg id="2616">March 2005 shared the European Commission of the company Helsinki n Birex Pharmaceuticals Ltd. a permit for the transport of Aloxi in the entire European Union.</seg>
<seg id="2617">Aloxi is indexed: to prevent acute sickness and vomiting from strongly emetogenic chemotherapy due to cancer disease and the prevention of nausea and vomiting in moderately emetoed chemotherapy due to cancer.</seg>
<seg id="2618">The effectiveness of Aloxi for the prevention of nausea and vomiting that induces through a strongly emetogenic chemotherapy may be induced by adding one before chemotherapy given Corticosteroids.</seg>
<seg id="2619">"since Palonosetron can extend the colon track, patients should be monitored with anamnestischer Obstipation or signs of a subtle Ileus after the injection machine."</seg>
<seg id="2620">"however, as with other 5HT3 antagonists, caution is offered with drugs that extend the QT interval or in patients where QT interval is extended or that tend to be an extension of such an extension."</seg>
<seg id="2621">"besides, in connection with other chemotherapists, Aloxi should be employed neither for the prevention nor for the treatment of nausea and vomiting."</seg>
<seg id="2622">"in preclinical studies, Palonosetron was not intoxicated against tumors-oriented activity of the five examined chemotherapists, Cyclockers, Cyclocks, Cycloorin, Doxorubicin and Mitomycin C)."</seg>
<seg id="2623">"in a clinical study, no significant pharmacokinetic interaction between a unique intravenous dose of Palonotic tron and a steady state- concentration of oroclopramids, of a CYP2D6-Inhibitors."</seg>
<seg id="2624">"in a population based pharmacokinetic analysis, Celectrine, Doxorubicin, Doxorubicin, Doxorubicin, Chinidin, Chinidin, Chinidin, Knights, Sertrine and Terbinafin) did not have a significant impact on the clearing of Palonosetron."</seg>
<seg id="2625">"experiences for the application of Palonosetron on human pregnancies do not lie before, therefore, Palonosetron should not be applied for sangers unless it is necessary by the treating doctor."</seg>
<seg id="2626">"in clinical trials, the most common in a dose of 250 micrograms to observe side-effects (a total of 633 patients) who at least potentially were associated with Aloxi in connection, headaches (9%) and obstipation (5%)."</seg>
<seg id="2627">"very rare cases (&lt; 1 / 10,000) of hypersensitive reactions and reactions to the administration of the administration (burning, curing, discomfort and pain) were reported in post-marketing experiences."</seg>
<seg id="2628">"in the group with the highest dosage, similar frequencies of unwanted events appear as in the other dodom groups; there were no dose of active relationships."</seg>
<seg id="2629">"no dialysis studies were conducted, due to the large distribution of distribution, a dialysis probably does not have effective therapy in a aloxi- overdose."</seg>
<seg id="2630">"in two randomized double-flasks, carboplatin, Carboplatin, Carboplatin, Carboplatin, Carboplatin, Carboplatin, Carboplatin, Carboplatin, Carboplatin, with patients compared to the 32 mg Ondansetron (half-time 4 hours) or 100 mg Dolasetron (half-time 7,3 hours), which was given to day 1 without Dexamethasone intravenously."</seg>
<seg id="2631">"in a randomized double-blind study, a total of 667 patients who were heavily emetoed chemotherapy with ≥ 60 mg / macarbaine, as well as 250 or 750 microgram Palonosetron, with patients compared to 32 mg Ondansetron who were given to day 1 intravenously."</seg>
<seg id="2632">Findings of the studies with moderate chemotherapy and the study with strongly emetoed chemotherapy are summarised in the following tables.</seg>
<seg id="2633">"in clinical studies on the indications of chemotherapy-induced nausea and vomiting (CINV), the effects of Palonosetron was comparable to blood pressure, heart rate and EKG parameters, including the QTc Intervalls with the corresponding effects of Ondansetron and Dolasetron."</seg>
<seg id="2634">"according to the preclinical studies, Palonosetron has the ability to block the ionization and recpolarization involved in ventricular determinations and reproductive-polarization and duration of the action potential."</seg>
<seg id="2635">"the aim of the study carried out at 221 healthy Probanden study was the assessment of the EKG effects of i.V, by 0.25, 0.75 and 2,25 mg."</seg>
<seg id="2636">Resorption After intravenous treatment follows a initiating elimination of the plastic ccentrations a slow elimination out of the body with an average season half-time of about 40 hours.</seg>
<seg id="2637">The average maximum Plasmakonzentration (Cmax) and the area under the concentration time curve (AUC0- ∞) are generally in general in the entire dosage range of 0.3- 90 μ g / kg with gestures and cancer patients dosisproportional.</seg>
<seg id="2638">After intravenous gift from Palonosetron 0.25 mg every second day for a total of 3 doses was lower between day 1 and day 5 measured medium (± SD) increase of Palonosetron-Plasmakonzentration at 42 ± 34%.</seg>
<seg id="2639">"from pharmacoinetic simulation, the intravenous intravenous survey of 0.25 mg of Palonosetron was comparable with the intravenous intravenous administration of 0.75 mg. however, the Cmax was higher after the entry of 0.75 mg higher."</seg>
<seg id="2640">About 40% are eliminated over the kidneys and approximately further 50% are transformed into two primary metrics which have less than 1% of the antagonistic effect on 5HT3 receptor.</seg>
<seg id="2641">"in-vitro studies on Metabolization have shown that CYP2D6 and, in less dimensions, the Isoenzymes CYP3A4 and CYP1A2 am Metabolism of Palonosetron."</seg>
<seg id="2642">"Elimination After an intravenous single dose of 10 micrograms / kg [14C] -Palonosetron, approximately 80% of the dose were recovered within 144 hours in urine, Palonosetron as unchanging active ingredients made around 40% of the given dose."</seg>
<seg id="2643">After a unique intravenous stuusintimtion in gestures the total body of the body was 173 ± 73 ml / min and the renal Clearance 53 ± 29 ml / min.</seg>
<seg id="2644">"although patients with severe liver disorders are the terminale elimination of elimination and the average system of systemic exposure to Palonosetron, however, a reduction in the dose is therefore non-justified."</seg>
<seg id="2645">"in pre-clinical studies, effects were observed only by expeditions that are considered adequate over the maximum human therapeutic exposure, which indicates a low relevance to clinical use."</seg>
<seg id="2646">10 out of preclinical studies notice that Palonosetron can block only in very high concentrations of iterations that are involved in ventricular degeneration and repolarization and prolonging the duration of action.</seg>
<seg id="2647">"high doses Palonosetron (each dose spoke about 30 times the therapeutic exposure to the people), who were given daily about two years, endocrine Neoplasmen (in the thyroid, pituitary, Pancreas, secondary mark) and skin tumors in rats, but not with mice."</seg>
<seg id="2648">"the underlying mechanisms are not fully known, but because of the used high doses and since Aloxi is determined in humans for unique application, the relevance of this results will be low for the human being."</seg>
<seg id="2649">The owner of this approval for the goods shall be transferred to the European Commission on the information contained in this decision by means of approved drug as part of this decision.</seg>
<seg id="2650">"• If any of the listed side effects you have considerably affected or you notice side effects which are not specified in this usage information, please inform your doctor."</seg>
<seg id="2651">"• Aloxi is a clear, colorless injection solution for injecting in a vene. • This can block the effect of a serotonin which can cause nausea and vomiting. • Aloxi is used for the prevention of nausea and vomiting. • Aloxi is used for the prevention of nausea and vomiting, associated with chemotherapy due to cancer."</seg>
<seg id="2652">"21 For applying Aloxi with other medicines Please inform your doctor if you use other medicines / apply or have recently been taken / used, even if it is not prescription drugs."</seg>
<seg id="2653">"pregnancy If you are pregnant or believe, pregnant your doctor will not give Aloxi it unless, it is clearly required."</seg>
<seg id="2654">Ask your doctor or pharmacist for advice when you are pregnant or believing to have become pregnant.</seg>
<seg id="2655">"in some very rare cases, it came to allergic reactions to Aloxi or to burning or pain at the entrance place."</seg>
<seg id="2656">"like Aloxi looks and content of the Packung Aloxi injection solution is a clear, colourless solution and is available in a package of glass bottle that contains 5 ml of the solution."</seg>
<seg id="2657">"at the end of China's helix working together." "readers" "Mrągoose" "WiÄ ceedings" "1592, Princes' helpers'.: + 359 2 975 13 95 (6)"</seg>
<seg id="2658">"Latvija pharmacy of Street Riga, LV-1011 Tel: + 37167502185 Lietuva UAB Pharomymyniš kiosk."</seg>
<seg id="2659">United Kingdom IS Pharmaceuticals Ltd Office Chester Business Park Chester CH4 9QZ - UK Tel: + 44 1244 625 152</seg>
<seg id="2660">June 2006 passed a negative expert in which the approval of the approval of hepatitis C has been recommended for the treatment of hepatitis C by Alpheon 6 million IE / ml injecting solution.</seg>
<seg id="2661">"this means that Alpheon a biological medicine named Roferon-A would like to be similar to the same medical version, which has already been approved already in the EU (also" "reference practitioner" ")."</seg>
<seg id="2662">Alpheon should be used for treating adult patients with chronic (long lasting) hepatitis C (one by viral infection caused by viral infection).</seg>
<seg id="2663">"in a microscopic examination the liver tissue damages indicates, in addition, the values of the liver enzymes are increased in the blood standard (ALT) in the blood."</seg>
<seg id="2664">It is produced by a yeast into which a gene (DNA) introduced this to the formation of the substance.</seg>
<seg id="2665">"the manufacturer of Alpheon presented data, covering the comparison of Alpheon with Roferon-A (drug structure, composition and purity of the medicine, effect, safety and effectiveness of hepatitis C)."</seg>
<seg id="2666">"in the study of hepatitis C, the effectiveness of Alpheon was compared to the effectiveness of the reference fleet with 455 patients."</seg>
<seg id="2667">"in the study, measured how many patients after 12 of total 48 treatment weeks as well as 6 months after setting the treatment to the drug spoke (i.e. no sign of virus in the blood)."</seg>
<seg id="2668">"(44-20) 74 18 84 00 fax, / / www.emea.eu.int © EMEA 2006 Reproduction and / or distribution of this document for non business purposes only grant the EMEA-a.eu.int © EMEA 2006 Reproduction and / or distribution of this document for non business purposes only grant the CHMP on the recommendation to failure the approval for the goods?"</seg>
<seg id="2669">"furthermore, concerns were concerned that data is not sufficient for the stability of the substance of the drug and the market of drug."</seg>
<seg id="2670">"the number of patients with hepatitis C, which in the treatment with Alpheon and Roferon-A spoke, was similar in the clinical study."</seg>
<seg id="2671">"according to the treatment with Alpheon flammates the disease in more patients than with the reference practitioner, and in addition Alpheon had more side effects."</seg>
<seg id="2672">"apart from that, the test in the study was issued in the study to determine what extent the drug forms an immune response (i.e. the body forms antibodies - special proteins - against medicines), not sufficient validated."</seg>
<seg id="2673">"it can be applied to the treatment of Impetigo (one with crstenation associated skin infection) and small intracted intractions (rissor or cutting), disggled and sewn wounds may be applied."</seg>
<seg id="2674">Altargo should not be used for the treatment of infections that were detectable or probably caused by methicillinresistant sthylococcus aureus (MRSA) because Alargo against this type of infections may not affect.</seg>
<seg id="2675">"Altargo can be applied for patients from the age of nine months, but with patients under 18 years of age, the surface of the surface is no longer than 2% of the surface."</seg>
<seg id="2676">"if the patient is not talking to treatment after two or three days, the doctor should investigate the patient and consider alternative treatments."</seg>
<seg id="2677">It works by blocking the bacterial ribosoma (the parts of the bacterienzelle in which proteins are produced) and thus inhibits the growth of bacteria.</seg>
<seg id="2678">Main indeer of the effectiveness was in all five studies of the proportion of patients whose infection was sealed after the end of the treatment.</seg>
<seg id="2679">119 (85.6%) of the 139 patients under Altargo and 37 (52.1%) of the 71 patients under placebo spoke to treatment.</seg>
<seg id="2680">"in the treatment of infected Hautwunden Altargo and cefalexin, similar contact rates, if the results of both studies have been taken together with Hautwunden, they spoke about 90% of the patients of both groups on treatment."</seg>
<seg id="2681">"in these two studies, however, Altargo have been caused in the treatment of abscesses (recerased hollow rooms in the body tissue) or of infections which have been demonstrably or probably caused by MRSA, is not effective enough."</seg>
<seg id="2682">The most common side-effect with Altargo (which was observed from 1 to 10 of 100 patients) is a irritation at the order.</seg>
<seg id="2683">"in conclusion, the benefits of Altargo in the short-time treatment of the following superficial skin infections in case of short-time treatment of the following superficial skin infections in relation to the risks: • Impetigo, • infied small inpetitions, disgents or sewn wounds."</seg>
<seg id="2684">May 2007 the European Commission adopted the company Glaxo Group Ltd. a licence for the transport of Altargo in the entire European Union.</seg>
<seg id="2685">"the patients, which shows no improvement within two or three days, should be examined once again and be considered an alternative therapy (see Section 4.4)."</seg>
<seg id="2686">"in the event of raising awareness or serious local irritation through the application of reapamulin Salbe, the treatment has been interrupted, the Salve carefully checked and an adequate alternative therapy of the infection will be started."</seg>
<seg id="2687">Retapamulin is not supposed to be used to treat infections in which MRSA is known or suspected (see section 5.1).</seg>
<seg id="2688">In clinical trials at secondary studies the effectiveness of reapamulin in patients with infections caused by a methane-resistant pile hylococcus aureus (MRSA) were insufficient.</seg>
<seg id="2689">Alternative therapy is supposed to be considered if after a 2-day treatment no improvement or deterioration of the infected site occurs.</seg>
<seg id="2690">The impact of the simultaneous application of reapamulin and other topic means on the same skin surface is not examined and the simultaneous application of other topical drugs is not recommended.</seg>
<seg id="2691">"due to the low plasma centrations, which were reached by people after topic use on shielded skin or infected superficial wounds, is not to be expected in vivo (see Section 5.2)."</seg>
<seg id="2692">3 After more than 200 mg Ketoconazol increased the average reapamulin Auc (0-24) and Cmax after topan application of healthy adult men by 81%.</seg>
<seg id="2693">"due to the low system exposure to topical application in patients may not be necessary, if topical reapamulin is used during a systemic treatment with CYP3A4 Inhibitors."</seg>
<seg id="2694">Animal studies have shown a retinent xicity after orative intake and are inadequate regarding a statement on the birth and the federal / post / postnatal development (see Section 5.3).</seg>
<seg id="2695">Retapamulin Salbe should be used during pregnancy when a topic antibacterial therapy is clearly indebted and the application of reapamulin is preferable of a systemic antibiotic.</seg>
<seg id="2696">When deciding whether the stitching continued / terminated or the therapy with Altargo continues to be terminated between the benefit of breastfeeding for the infant and the benefit of Altargo therapy for the woman.</seg>
<seg id="2697">"in clinical trials at 2150 patients with superficial skin infections, the Altargo was the most common reported by-effect on the administration, which concerned about 1% of the patients."</seg>
<seg id="2698">"effect of reapamulin is a semi-synthetic derivatives of Plights mutilin, a substance that is isolated by Fermentation from Clitopilus (formerly Pleurotus passive seckery)."</seg>
<seg id="2699">The active mechanism of Retapamulin is based on selective inhibition of the bacterial protein synthesis by interaction at a particular binder of the bacterial Ribosoms which differ from the ties of other ribosomal interacting anti-bacterial substances.</seg>
<seg id="2700">Data is pointed out that the binary point ribosomales protein L3 is involved and lies in the region of the ribosomalen P-Binum point and the Peptidyltransferasecentre.</seg>
<seg id="2701">"by binding on this bonding point, Plights romutitutiline the Peptidyltransfer, block partial P-binder interactions and prevent normal formation of more active 50s ribosomaler subunits."</seg>
<seg id="2702">"should be focused on the basis of the local prevalence of the resistance to the application of reapamulin at least some infection forms, a consultation should be pursued by experts."</seg>
<seg id="2703">"there were no differences in the In-vitro activity of Retapamulin against S.aureus, regardless of whether the insulates is sensitive or resistant to methane."</seg>
<seg id="2704">"in the case of failure to treatment at S.aureus, the presence of tribes with additional viral factors (like PVL = Panton-Valentine Leucocidin) should be considered."</seg>
<seg id="2705">"Resorption In a study with healthy adults, 1% Retapamulin Salbe was recorded daily under occlusion, and placed on shielded skin for up to 7 days."</seg>
<seg id="2706">"of 516 patients (adults and children) of 516 patients (adults and children), the 1% Retapamulin Salbe twice daily for 5 days to the topical treatment of secondary ininfected trauma, individual plasma-consuming were obtained."</seg>
<seg id="2707">The sampling took place in the days 3 or 4 in adult patients before the medication and the children between 0-12 hours after the last application.</seg>
<seg id="2708">"however, the maximum individual system of systematic inclusion in the human being after topical application of 1% obe is reduced to 200 cm2 on 200 cm2; Auc (0-24) = 238 ng · h / ml) 660-times lower than the Retapamulin IC50 for the PGP inhibiting."</seg>
<seg id="2709">"Metabolism The in vitro oxidative Metabolism of Retapamulin by CYP3A4, under small participation of CYP2C8 and CYP2D6 (see Section 4.5)."</seg>
<seg id="2710">"in studies of orderity to rats (50, 150 or 450 mg / kg) that were conducted over 14 days, there were signs of adaptive liver and thyroid changes."</seg>
<seg id="2711">In-vitro-testing on genomation and / or chromosomale effects in mouse-lymphoma-testing or in cultures human peripheral blood cytes and in rats-microtest in the In-vivo investigation chromosomal effects.</seg>
<seg id="2712">"there was neither male nor female clumsy signs of 50, 150 or 450 mg / kg / day, thus reducing up to 5-times higher exposure to people (topical application on 200 cm2 of poor skin:"</seg>
<seg id="2713">"in an embryos study by ≥ 150 mg / kg / day (according to the ≥ 3-times the estimated human exposure (see above), development stoxicity (reduced body weight of the fetus and delayed Ossification) and maternale toxicity."</seg>
<seg id="2714">"the holder of the approval of the approval must make sure that a pharmaceutical company system, as described in the 1.8.1 of the authorisation application (Version 6.2) is available and works before the product is marketed, and as long as the market has been applied."</seg>
<seg id="2715">"the holder of the approval of the authorization is obliged to perform in detail more detailed studies and additional pharmaceutical drugs activities, as described in the version 1 of the Risk Management Plan (RMP) and posted all additional updates of the RMP, which will be agreed with the CHMP."</seg>
<seg id="2716">"as described in CHMP" Guideline on Risk Management Systems for Medicinal products for human use, "the updated RMP should be submitted at the same time with the next Periodic Safety Update Report."</seg>
<seg id="2717">"indicate irritation or other signs and symptoms at the treated point, you should end the use of Altargo and speak with your doctor."</seg>
<seg id="2718">"do not apply any other salabs, creams or lotions on the area, which is treated with Altargo if you are not expressly prescribed by your doctor."</seg>
<seg id="2719">"it must not be applied in the eyes, in the mouth or on the lips, in the nose or the female genital area."</seg>
<seg id="2720">"when the Saline is made out of one of these areas, wash the place with water and ask your doctor for advice, if complaints occur."</seg>
<seg id="2721">"after wearing the salbe, you can cover the affected area with a sterilen association or Gaza, unless your doctor has come to cover the area."</seg>
<seg id="2722">"it is offered in an aluminum tube with a plastic closure, which contains 5, 10 or 15 grams of Saline, or in an aluminum bag, which contains 0,5 g."</seg>
<seg id="2723">Ambirix is protected against hepatitis A and hepatitis B (diseases which affect the liver) in children between the ages of 15 and 15 that are not immute against these two diseases.</seg>
<seg id="2724">Ambirix is applied within one of two doses existing vaccines where protection against hepatitis B may only be reached after administration of the second dose.</seg>
<seg id="2725">"for this reason, Ambirix may only be used if the immunisation is a low risk of hepatitis B infection, and it is ensured that the two doses can be fought at the end of two doses."</seg>
<seg id="2726">"if a refresher-dose is desired against hepatitis A or B, Ambirix can be given at ambient or any other hepatitis or -B vaccine."</seg>
<seg id="2727">Vaccines have to affect vaccines by bringing the immune system (the natural resistance of the body) as it can defend itself against a disease.</seg>
<seg id="2728">"after a child has received the vaccine, the immune system recognises the viruses and surface antigens as" alien "and creates antibodies against it."</seg>
<seg id="2729">Ambirix contains the same ingredients that has been approved since 1996 approved vaccine Twinrix adults and who has been approved by 1997 Twinrix children.</seg>
<seg id="2730">"the three vaccines are applied to protection against the same diseases, but Twinrix will be assigned to Twinrix, and Twinrix children in the frame of one out of three doses existing vaccines."</seg>
<seg id="2731">"because Ambirix and Twinrix are identical to identical ingredients, some of the data, which support the application of Twinrix adults, also used as proof of the application of Ambirix."</seg>
<seg id="2732">The main indiator for the effectiveness was the proportion of vaccinated children who had developed a month after the last injection of antibodies.</seg>
<seg id="2733">"in an additional study with 208 children, the effectiveness of the vaccine was compared with a six month-month and a 12-month distance between the two injections."</seg>
<seg id="2734">Ambirix resulted in between 98 and 100% of vaccinated children one month after the last injection for the development of antibody antibody concentrations against hepatitis A and B.</seg>
<seg id="2735">The additional study showed that the degree of protection of Ambirix was similar to a seag- and a 12-month gap between the injections.</seg>
<seg id="2736">"the most common side effects of Ambirix (observed in more than 1 of 10 vaccines) are headache, appetite deficiency, pain at the injure place, redness, activity (fatigue) as well as irritation."</seg>
<seg id="2737">"Ambirix may react in patients who are possibly oversensitive (allergic) to the active ingredients, one of the other components or Neomycin (an antibiotic), will not be applied."</seg>
<seg id="2738">August 2002 shared the European Commission to the company GlaxoSmithKline Biologicals s.a. a permit for ingestion of Ambirix in the whole</seg>
<seg id="2739">"the Standardians for the Grundimminisation with Ambirix consists of two vaccinations, whereby the first dose is administered in the deadline for the first dose and the second dose is administered between six and twelve months after the first dose."</seg>
<seg id="2740">"if a refresher for hepatitis A is desired for hepatitis A as well as for hepatitis B, can be vaccinated with the appropriate monovalent vaccines or with a combination."</seg>
<seg id="2741">The prescribed anti-hepatitis surface (anti-HBsAg) and anti-hepatitis-A-virus (anti-HAV) - and anti-hepatitis-A-virus (anti-HAV) - and anti-hepatitis-A-virus (anti-HAV) - and anti-hepatitis (anti-HAV) - and anti-hepatitis (anti-HAV) - and anti-hepatitis (anti-HAV).</seg>
<seg id="2742">"it is not yet fully guaranteed whether immuncompetent persons addressed to a hepatitis A- vaccination, as they need no more detectable antibodies by the immunological memory."</seg>
<seg id="2743">"3 As with all injections, for the rare case of an anaphylactic reaction after the gift of the vaccine appropriate ways of medical treatment and monitoring are always available immediately."</seg>
<seg id="2744">"if a fast protection against hepatitis B is required, the Standardized dosage is recommended using the combination of material, the 360 ELISA units formalinine hepatitis-A virus and 10 µg recombinantes hepatitis B surface."</seg>
<seg id="2745">"at hemalyalysis and individuals with disorders of the immune system, no sufficient anti-HAV- and anti-hbs can be reached, so in these cases the gift of other vaccinations can be required."</seg>
<seg id="2746">Since an intradermal injection or intramuscular administration could lead in the gluteal muscle to a suboptimal impact success should these injectors should be avoided.</seg>
<seg id="2747">"at Thrombocytopenie or bloodstream disorder, Ambirix can be injected at present subcutters as it can occur in these cases according to intramuscular gift of bleeding."</seg>
<seg id="2748">"when Ambirix is administered in the second year in the form of a separate injection -, inactivated Poliomyelitis- and Haemophilus renenzae type b vaccine (DTPa-IPV / Hib) or with a combined masern- Mumps-Tubes vaccine was the immune response to all antigens (see section 5.1)."</seg>
<seg id="2749">"in patients suffering from immunosuppressive therapy or in patients with immunisation, it must be assumed that possibly no adequate immune response is achieved."</seg>
<seg id="2750">"in a clinical study, which was conducted with 3 vaccinations of this formulation in adults was the frequency of pain, redness, gastroenttis, headaches, and fever comparable to the frequency that has been observed in the former thioilage and preservative vaccines."</seg>
<seg id="2751">"in clinical trials, 2029 vaccines have been given a total of 1027 vaccines at the age of 1 to including 15 years."</seg>
<seg id="2752">"in a study with 300 participants at the age of 12 to 15 years, the tolerability of Ambirix was compared to that of the 3-doses combined."</seg>
<seg id="2753">"only exceptions were the higher frequency of pain and matiness on a computation base per vaccdosis Ambirix, but not on a calculation basis per person."</seg>
<seg id="2754">Pain has been observed after the gift of Ambirix at 50.7% of the probanden compared to 39.1% at the probanden after the gift of a dose of the 3-cans combination.</seg>
<seg id="2755">"after the complete cycle of cycle, 66.4% of the promoters received, over pain, compared to 63,8% at the probanden, which had been vaccinated with the 3-tin combination."</seg>
<seg id="2756">"however, the frequency of mating was comparable (i.e. over the entire vaccination cycle at 39.6% of the proportions that got the Ambirix compared to 36.2% on the probanden, which received the 3-cans combined.)"</seg>
<seg id="2757">The frequency was low and comparable to that which was observed after administration of the combination with the 3-cans vaccine.</seg>
<seg id="2758">"in a comparative study with 1- to 11-year-old vaccines, the occurrence of local reactions and general actions in the ambirixgroup was comparable to that in administration with the 3-doses combined with 360 ELISA units formatinactivated hepatitis-A virus and 10 µg recombinant hepatitis B surface."</seg>
<seg id="2759">"however, from the 6- to 11- Jolds, however, after vaccination with Ambirix was a common occurrence of pain (at the injections) per dose, not per speaker."</seg>
<seg id="2760">"the share of vaccinations, which reported about heavy side-effects during the 2-doses-vaccine with Ambirix or during the 3-cans vaccine schemas with a combination of 360 ELISA- units formal hepatitis-A virus and 10 µg recombinant hepatitis-B- surface, was not different."</seg>
<seg id="2761">"in clinical trials, conducted at vaccination between 1 and 15 years of age, Seroconversionrates for anti-HAV 99.1% were a month after the first dose and 100% a month after the second, month 6 administered dose (i.e. in month 7)."</seg>
<seg id="2762">Seroconversionrates for anti-hbs were 74.3% a month after the first dose and 100% a month after the second one month 6 (i.e. in month 7).</seg>
<seg id="2763">"7 In a comparative study conducted at 12- until including 15-year-old, 142 two doses ambirix and 147 the standard combined with three doses."</seg>
<seg id="2764">"at the 289 persons whose immunogenicity was more valuable, the Seroprotinfection rates were higher (SP in the table below) against hepatitis B in the table 2 and 6 after the 3-dosage imal higher than with Ambirix."</seg>
<seg id="2765">The immune response provided in a clinical case study at 1- to 11-year-olds one month after completion of the full vaccine series (i.e. in month 7) have been listed in the following table.</seg>
<seg id="2766">In both studies the vaccinations were either a 2-doses vaccine with Ambirix or a 3-cans vaccine scheme with a combination of 360 ELISA units formatininactivated hepatitis-A virus and 10µg recombinant hepatitis B surface.</seg>
<seg id="2767">Persons who were aged between 12 and 15 years old were able to substantiate the persistence of anti-HAV- and anti-hbs antibodies over at least 24 months after the immunisation at the 0-6-month-vaccine scheme.</seg>
<seg id="2768">"the immune response against both antigens was comparable to that which, according to vaccination of 3 cans, consisting of 360 ELISA units formatinactivated Hepatitis- A-virus and 10 µg recombinant hepatitis B surface in a dosage volume of 0.5 ml."</seg>
<seg id="2769">In a clinical study at 12- until including 15-year-old antibodies can be shown that the persistence of anti-HAV- and anti-hbs antibodies 24 months after immunisation in the 0-6- months-vaccine scheme is comparable to that in the 0-12-month-vaccine scheme.</seg>
<seg id="2770">"when the first dose of ambiente (DTPa-IPV / Hib) or with the first dose of a combined texture unit, inactivated poliomyelitis-, inactivated poliomyelitis-, inactivated poliomyelitis-, inactivated Poliomyelitis- and 8 Haemophilus, inactivated Poliomyelitis- and 8 Haemophilus."</seg>
<seg id="2771">"a clinical trial, which was conducted with 3 doses of the current formulation in adults showed for the current formulation similar seroprotinfection - and seroconversionrates, as for the previous formulation."</seg>
<seg id="2772">The vaccine is both before and after the resentment as well as to investigate the foreign particles and / or physical visible changes.</seg>
<seg id="2773">"in accordance with Article 114 of the Directive 2001 / 83 / EC, the state chargenation took place from a state laboratory or for this purpose authorized laboratory."</seg>
<seg id="2774">14 details AUTIGSPRITZE MIT Nadel 10 FERTIGSPRITZEN OHNE 50 FERTIGSPRITZEN OHNE needles</seg>
<seg id="2775">Suspension to injecting 1 ready-injection with needle 10 ready-splash with needle 10 ready-splash with needles 50 ready-splashing with no needles 1 dose (1 ml)</seg>
<seg id="2776">EU / 1 / 02 / 224 / 002 10 ready-splashing with Nadel EU / 1 / 02 / 224 / 004 10 ready-injection with needles to EU / 1 / 02 / 224 / 005 50 ready-splashing with no needles</seg>
<seg id="2777">"the hepatitis A virus is usually transmitted by viral foods and beverages, but can also be transmitted by other ways, such as through bathing in water dehydrated waters."</seg>
<seg id="2778">"you can feel very tired, have a dark urine, a pale face, yellow skin and / or eyes (yellowing) and other symptoms that may require a stationary treatment necessary."</seg>
<seg id="2779">"as with all vaccines, Ambirix can not be completely protected from an infection with hepatitis-A- or hepatitis B virus, even if the complete vaccine series has been completed with 2 doses."</seg>
<seg id="2780">If you / your child are infected with hepatitis-A- or hepatitis B virus in front of the administration of both vaccines or hepatitis B virus (although you / your child may not feel uncomfortable or ill / feels) a vaccine may not prevent a disease.</seg>
<seg id="2781">"protection against other infections, which cause the liver harmful or symptoms, which are similar to those according to a hepatitis or hepatitis B infection, cannot be conveyed."</seg>
<seg id="2782">• if you already have an allergic reaction to Ambirix or any part of this vaccine including Neomycin (an antibiotic).</seg>
<seg id="2783">An allergic reaction can sell through itching skin surcharges; respiratory or swelling of the face or tongue. • if you have an allergic reaction to a earlier vaccination against hepatitis A or hepatitis B. • if you / your child have had a serious infection with fever).</seg>
<seg id="2784">• If you want to quickly have protection against hepatitis B (i.e. within 6 months and prior to the designated administration of the second vaccine).</seg>
<seg id="2785">"with a possible risk of infection with hepatitis B between the first and second vaccination, the doctor will advise you / your child from a vaccine with Ambirix."</seg>
<seg id="2786">Instead he will recommend you / your child 3 injections of a combined hepatitis-A / hepatitis B vaccine with a decreased salary (360 ELISA units of a formalinine hepatitis-A virus and 10 micrograms of a recombinant hepatitis B surface area.</seg>
<seg id="2787">"the second vaccination dose of this vaccine with reduced salary to effective components is usually administered for a month after the first dose, and should give you / your child a vaccine protection against the termination of the vaccinations series."</seg>
<seg id="2788">"sometimes, Ambirix will suffer from people suffering from severe blood disorders, under the skin and not in the muscle. • If you / your child are weakened due to a disease or treatment in your / its body's body."</seg>
<seg id="2789">Ambirix can be given in these cases but the immune response of these persons to vaccination may not be sufficient so that a blood test can be necessary to see how strong the reaction to vaccination is.</seg>
<seg id="2790">"21 Sagen you take your doctor if you are taking other medications / eings (including those that you can receive no prescription) or if you / your child have recently been vaccinated / or immunoglobuline (antibodies) have been given, or has been planned in the near future."</seg>
<seg id="2791">"however, it may be that in this case the immune response to the vaccine is not sufficient and the person is not protected against one or both hepatitis A and B viruses."</seg>
<seg id="2792">"if another vaccine has to be given at the same time with Ambirix, should be vaccinated in separate places and as possible as possible."</seg>
<seg id="2793">"if Ambirix will be administered at the same time or shortly before or after an injection of immunoglobulins, it is likely that the response to the vaccine will nevertheless be sufficient."</seg>
<seg id="2794">"usually, ambient or nursing women is not administered, except it is urgent need to be vaccinated against hepatitis A as well as hepatitis B."</seg>
<seg id="2795">Important information about certain other ingredients of Ambirix Please inform your doctor if you already have an allergic reaction to Neomycin (antibiotic).</seg>
<seg id="2796">"if you miss the agreed appointment for the second vaccination, talk to your doctor and arrange a new date as soon as possible."</seg>
<seg id="2797">Very frequently (more than 1 case per 10 implated cans): • pain or discomfort at the vortex or redness • Mateness • friction • headaches of headaches • Appetitdeficiency</seg>
<seg id="2798">Frequently (up to 1 case per 10 implated doses): • swelling at the injection center • fever (over 38 ° C) • Inzzing • gastrointestinal symptoms</seg>
<seg id="2799">"other side-effects, days or weeks after vaccination with comparable combination of hepatitis A and hepatitis B (less than 1 case per 10,000 verted cans) are:"</seg>
<seg id="2800">"these encompass-limited limited or extended extracts, the itching can be or blows-shaped, swelling of the eyebrow and the face, scanned breathing or drocks, sudden blood pressure and conscielessness."</seg>
<seg id="2801">"flu-like symptoms, including chills, missemps like crime and" ants "," multiple sclerosis, diseases of the tentious body, loss of sensation or movement-ability manure body, strong headaches and stiffness of neck, interruption normal brain functions "</seg>
<seg id="2802">"impotence lighting inflammation, diarrhea blood vessels, diarrhea or disease-feeling, apologies, diarrhea, diarrhea, diarrhea, diarrhea, diarrhea, diarrhea, diarrhea, diarrhea blood, diarrhea, diarrhea, and abdominal pain, caused by waste of blood plets."</seg>
<seg id="2803">23 Informing your doctor or pharmacist if one of the listed side effects you / your child greatly affects or you notice side effects which are not specified in this package.</seg>
<seg id="2804">Ambirix is available in packages for 1 and 10 with or without any needles and in packs to 50 without needles.</seg>
<seg id="2805">"based on the data that have been announced since the initial approval of the distribution, the CHMP despised that the value risk ratio remains positive for Ambirix."</seg>
<seg id="2806">"however, since Ambirix was only placed in a member state (in the Netherlands since May 2003), the available security data for this drug is limited due to low patient exposure."</seg>
<seg id="2807">Ammonaps can also be used in patients at the age of more than one month with inexhaustive enzymeric or with hyperammonial endowdness (brain damage) in the pre-story.</seg>
<seg id="2808">"Ammonaps is divided - split by several single beds to meals - swallowed up, under the food or via a guest rostomieschlalso (through the abdomen in the stomach leading hose) or a nose-sonde (through the nose in the stomach of leading hose)."</seg>
<seg id="2809">"it was not a comparative study, as Ammonaut did not compare with any other treatment or with placebo (a hypocracy, i.e. without active ingredient)."</seg>
<seg id="2810">"in addition to Appetitloss, a aberration of loss, headaches, stimulant, headaches, glomability, headaches, fluid, constipation, nausea, stipation, rash, fainting, skin-smell or weight gain."</seg>
<seg id="2811">The Committee for Humanitarian Medicine (CHMP) reached the conclusion that in patients with disorders of the urinary cycle to high amoral levels are effective.</seg>
<seg id="2812">Ammonaps was approved under "exceptional circumstances because of the rarity of the disease at the time of authorisation only limited information on this medicine.</seg>
<seg id="2813">"the use has been indexed to all patients, in which a complete enzymous lack already manifests in the newborn (within the first 28 Living age)."</seg>
<seg id="2814">"in patients with a late-proof shape (incomplete duck defect, which manifests after the first life month) then there is an indicator of the use when in the Anamnese a hyperammonic Encephalopathy consists."</seg>
<seg id="2815">"for infants, for children who are not able to swallow tablets or for patients with lockdysfunctions, AMMONAPS is also available in granite form."</seg>
<seg id="2816">The daily dose will be individually calculated with respect for the balance and development necessary for the growth and development necessary daily protein intake.</seg>
<seg id="2817">"according to recent clinical experiences, the normal daily dose of sodium-phenylbutyrat: • 450 - 600 mg / kg / day with children with a body weight of less than 20 kg • 9.9 - 13.0 g / m ² / day with children with a body weight over 20 kg as well as for adolescents and adults."</seg>
<seg id="2818">"in patients suffering from a low-proof lack of carbamyl phosphates or oral disease transcarecase, is the substitution of Citrullin or arginine in a dosage of 0.17 g / kg / day or 3.8 g / m ² / day required."</seg>
<seg id="2819">Patients with a Argininosuccinatsynthetase deficiency must be arginine in a dosage of 0.4 - 0.7 g / kg / day or 8.8 - 15.4 g / m ² / day.</seg>
<seg id="2820">AMMONAPS tablets may not be administered as a risk to the emergence of Ösopthusulzera when the tablets can't get into the stomach immediately.</seg>
<seg id="2821">Each tablet AMMONAPS contains 62 mg (2,7 mmol) sodium (108 mmol) sodium per 20 g sodium-phenylbutyrat which corresponds to the maximum daily dose.</seg>
<seg id="2822">"AMMONAPS should therefore be used in patients with congestive heart failure or severe renal insufficiency, as well as in the sodium of intoxication and oil-related clinical conditions."</seg>
<seg id="2823">"as Metabolisation and excretion of sodium phenylbutyrat about the liver and the kidneys, AMMONAPS should be applied to patients with liver or kidney failure only with extreme caution."</seg>
<seg id="2824">The importance of these results in regards to pregnant women is not known; the use of AMMONAPS during pregnancy is therefore contraindicated (see 4.3).</seg>
<seg id="2825">At subcutters of phenylacetate at young deer in high dosage (190 - 474 mg / kg) it came to a slowing of the neuronal multiplication and an increased loss of neurons.</seg>
<seg id="2826">It also found a delayed curing of cerebral synapses and a diminished number of functioning neurons in the brain and thus a disability of brain growth.</seg>
<seg id="2827">"it could not be noticed whether phenylacetate is out at the mother's mother's milk, and for this reason, the use of AMMONAPS is contraindicated during the lactation period (see 4.3)."</seg>
<seg id="2828">"in clinical trials with AMMONAPS, at least 56% of patients came at least an unwanted event (AE) at least 78% of these undesirable events that they were not connected to AMMONAPS."</seg>
<seg id="2829">"the frequency is defined as follows: very common (≥ 1 / 10), commonly (≥ 1 / 100, &lt; 1 / 10) and occasionally (≥ 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="2830">"a probable toxic reaction to AMMONAPS (450 mg / kg / day) was reported by a 18 year old abnormal patient, severe hypokalemia, panzytopenie, periphery neuropathy and pancreatitis."</seg>
<seg id="2831">A case of overdose entered a 5 month old small child with a longed single dose of 10 g (1370 mg / kg).</seg>
<seg id="2832">These symptoms go on with the accumulation of phenylacetate which demonstrated in an intravenous administration of doses up to 400 mg / kg / day a dosages neurotoxicity showed.</seg>
<seg id="2833">Phenylacetate is a metabolic active connection that is controlled by acetylation with glutamine to phenylacetylglutamine that is out of the kidneys.</seg>
<seg id="2834">Stöchiometrisch is phenylacetylglutamine with urea comparable (both links included 2 nitrogen); phenylacetylglutamine is therefore suitable as an alternative carrier to excretion of excess nitrogen.</seg>
<seg id="2835">5 patients with malfunctions of the urinary cycle can be accepted that for any gram type of sodium phenylbutyrat between 0,12 and 0.15 g phenylacetylglutamine nitrogen.</seg>
<seg id="2836">"it is of importance that the diagnosis is made early, and the treatment will be immediately started to improve the survival chances and clinical outcome."</seg>
<seg id="2837">"the prognosis of the early symptoms of the first symptoms in the new born old, earlier was almost always infaught, and the disease himself led to treatment with peritoneal dialysis and essential amino acids, or with its stickling-free analoga within the first year of life to death."</seg>
<seg id="2838">"by hemalysis, the use of alternative pathology (sodium phenylbutyrat, sodium-zoat and sodium phenylic acid), proteinated cost and possibly substitution of essential amino acids, it was possible to increase the survival rates at postpartal (however within the first stage of life) diagnosed at 80%."</seg>
<seg id="2839">"in patients, whose disease was diagnosed in the course of pregnancy and the survival rate was 100%, but even in these patients it came with time with many to mental disabilities or other neurological deficits."</seg>
<seg id="2840">"in patients with a late manic shape of the disease (including female patients with the heterozygoten form of the Ornithinstryl acid waste, and then permanently treated with sodium phenylbutyrat and a proteinated diet, was the survival rate 98%."</seg>
<seg id="2841">Already existing neurological deficits are hardly reversible in the treatment and in some patients may occur further deterioration of the neurological state.</seg>
<seg id="2842">"it is known that phenylbutyrat is oxidized, which is oxidized in liver and kidney enzymatic with glutamine, whereby phenylacetylglutamine is created."</seg>
<seg id="2843">The concentrations of phenylbutyrat and of its metrology in plasma and urine have been determined according to gift of a single dose of 5 g sodium-phenylbutyrat in contested healthy adult and with liver cirrhosis of up to 20 g / day (not controlled studies).</seg>
<seg id="2844">The behaviour of phenylbutyrat and its Metabolites was also examined in cancer patients after intravenous treatment of sodium phenylbutyrat (up to 2 g / m ²) or phenylacetate.</seg>
<seg id="2845">After a oral single dose of 5 g sodium-phenylbutyrat in tablet form were determined 15 minutes after taking measurable plastic maconcentric by phenylbutyrat.</seg>
<seg id="2846">In the majority of patients with urinary tract or hemoglobinopathies was detectable by different doses phenylbutyrat (300-650 mg / kg / day up to 20 g / day) the next morning after nightly fasting no phenylacetate in the plasma.</seg>
<seg id="2847">"in three of six patients with liver cirrhosis, the middle phenylacetyrat (20 g / day orally in three single-ins) were treated, the middle phenylacetyrgyms (20 g / day orally in three single) were treated higher than according to the first gifts."</seg>
<seg id="2848">Excretion The drug is lowered within 24 hours to approximately 80 - 100% in the form of the conjuy product phenylacetylglutamine over the kidneys.</seg>
<seg id="2849">"according to the results of the Micronucleus testing, sodium phenylbutyrat with toxic and non-toxic doses treated have no clastogenic effects (investigation 24 and 48 h according to oral administration of a single dose of 878 to 2800 mg / kg)."</seg>
<seg id="2850">"AMMONAPS Granules is taken either oral (infant and children, who can swallow no tablets or patients with lockdysfunctions) or about a Gastrostomieschlor or a nose-sonde."</seg>
<seg id="2851">"according to recent clinical experiences, the normal daily dose of sodium-phenylbutyrat: • 450 - 600 mg / kg / day with a body weight of less than 20 kg • 9.9 - 13.0 g / m ² / day with children with a body weight over 20 kg as well as for adolescents and adults."</seg>
<seg id="2852">"the concentration of ammonia, arginine, essential amino acids (especially branched-chain amino acids), carnitin and serum proteins in the plasma should be kept within the normal range."</seg>
<seg id="2853">"in patients suffering from a low-proof lack of carbamyl phosphates or oral disease transcarecase, is the substitution of Citrullin or arginine in a dosage of 0.17 g / kg / day or 3.8 g / m ² / day required."</seg>
<seg id="2854">AMMONAPS Granules contains 124 mg (5.4 mmol) sodium per gram monylbutyrat, accordingly 2.5 g (108 mmol) sodium per 20 g sodium-phenylbutyrat which corresponds to the maximum daily dose.</seg>
<seg id="2855">If rat federated before the birth phenylacetate (active metabolit by phenylbutyrat) were exposed to lesions in the pyramid cells of the brain rinse.</seg>
<seg id="2856">"a probable toxic reaction to AMMONAPS (450 mg / kg / day) was reported by a 18 year old abnormal patient, severe hypokalemia, panzytopenie, periphery neuropathy and pancreatitis."</seg>
<seg id="2857">Stöchiometrisch is phenylacetylglutamine with urea comparable (both connections contain 2 nitrogen-atoms); phenylacetylglutamine is therefore suitable as an alternative carrier to excretion of excess weight</seg>
<seg id="2858">On the basis of investigations on the excretion of phenylacetylglutamine in patients with disorders of the urinary cycle can be assumed that for any gram type of sodium phenylbutyrat between 0,12 and 0.15 g phenylacetylglutamine nitrogen.</seg>
<seg id="2859">"already existing neurological deficits are hardly reversible, and in some patients may occur further deterioration of the neurological state."</seg>
<seg id="2860">After a oral single dose of 5 g sodium phenylbutyrat in granule form were determined 15 minutes after taking measurable plastic maconcentric by phenylbutyrat.</seg>
<seg id="2861">"during the duration of the durability, the patient can keep the finished product unique for a period of 3 months at a temperature of not more than 25 ° C."</seg>
<seg id="2862">"with this approach, the small Messlpoon contains 0.95 g, the middle measuring spoon 2.9 g and the large measurement-spoon 8,6 g sodium-phenylbutat."</seg>
<seg id="2863">"if a patient has to get the medication above a sonde, AMMONAPS can be dissolved in water (the solubility of sodium phenylbutyrat is up to 5 g in 10 ml of water)."</seg>
<seg id="2864">"in patients with these rare diseases, certain liver enzymes have been missing certain liver enzymes, so that they accumulate the insulating waste products that can not be eliminated after consuming proteins in the body."</seg>
<seg id="2865">"if you are working with laboratory studies, you must notify the doctor that you may use AMMONAPS, since sodium phenylbutyrat can influence the results of certain laboratory studies."</seg>
<seg id="2866">"when taking AMMONAPS with other medicines Please inform your doctor or pharmacist if you are taking other medicines or have recently taken, even if they are not prescription drugs."</seg>
<seg id="2867">"during the lactation period, you may not take AMMONAPS, since the drug can move into the mother's milk and harm your baby."</seg>
<seg id="2868">"in rare cases were also concreteness, headache, flavors, descendants of the secret, disoriented, memory disorders, and a deterioration of existing neurological states."</seg>
<seg id="2869">"if you find any of these symptoms in itself, get in touch immediately with your doctor or with the emergency of your hospital as introduction to appropriate treatment."</seg>
<seg id="2870">If you forget the intake of AMMONAPS take the appropriate dose as soon as possible with the next meal.</seg>
<seg id="2871">"alterations of the blood image (red blood cell, white blood cell, vomiting, vomiting, vomiting, vomiting, vomiting, vomiting, nausea, loss, kidney functional, weight-taking, weight-taking and anomale lab values."</seg>
<seg id="2872">Please inform your doctor or pharmacist if one of the listed side effects you have considerably affected or you notice side effects which are not stated in this usage information.</seg>
<seg id="2873">You are allowed to use AMMONAPS according to the umarton and the eldest after "useable up to" specified expiration date.</seg>
<seg id="2874">"like AMMONAPS, the contents of the AMMONAPS tablets are of white color and oval shape, and they are equipped with the precondition" UCY 500. ""</seg>
<seg id="2875">"30 If for you are conducted laboratory studies, you must notify the doctor that you may use AMMONAPS, since sodium phenylbutyrat can influence the results of certain laboratory studies."</seg>
<seg id="2876">"when taking AMMONAPS with other medicines Please inform your doctor or pharmacist if you are taking other medicines or have recently taken, even if they are not prescription drugs."</seg>
<seg id="2877">You should take AMMONAPS distributed to same individual dots or over a stomach fistula (hose who runs through the abdominal wall directly in the stomach) or a nose-sonde (hose run through the nose in the stomach).</seg>
<seg id="2878">"31 • can remove you from the container a spoon measuring of granules. • Stay a straight channel, for example a knife over the upper edge of the Messds to remove excess granules. • Get the recommended number of Messspoon Granules from the container."</seg>
<seg id="2879">"Angiox is applied to the treatment of adult patients with" acute Koronarsyndromes "(heart attack), for example, at instabiler Angina (a form of pain in the chest with different strength) or myocardinality."</seg>
<seg id="2880">"if Angiox is applied to prevent clots in patients suffering from one PCI, a higher dose is administered and the infusion can be continued up to four hours after the procedure."</seg>
<seg id="2881">This can help in patients with Angina or heart attack to maintain blood flow to the heart and increase the effectiveness of an PCI.</seg>
<seg id="2882">"nearly 14 000 patients participated in the main study of the treatment of ACS, with the effect of Angiox in alla-IIb / IIIA-Inhibitor (GPI, another medicine to prevent blood cells) with conventional combination treatment with heparin (another anticoagulans) and an GPI."</seg>
<seg id="2883">"during PCI, the patient often got a stent (a short tube that remains in the arteries to prevent a loss), and they added additionally other medicines to prevent blood clots, such as Abciximab and aspirin."</seg>
<seg id="2884">"in the treatment of ACS angiox - with or without the gift of GPI - in preventing new events (deaths, heart attack or revascularization) after 30 days or a year as effective as conventional treatment."</seg>
<seg id="2885">"with patients, subjected to PCI, Angiox was subject to all indicators as effective as Heparin, except for serious bleeding, in which it was significantly more effective than haparin."</seg>
<seg id="2886">"Angiox may not be used in patients who may be oversensitive (allergic) against bivalirudine, other Hirudine, or one of the other components."</seg>
<seg id="2887">"it may not be used in patients that have recently had a blood pressure, as well as people with strong high blood pressure or severe kidney problems or heart infection."</seg>
<seg id="2888">The Committee for Humanitarian Medicine (CHMP) reached the conclusion that Angiox is in the treatment of ACS and during a PCI an adequate replacement for Heparin.</seg>
<seg id="2889">September 2004 shared the European Commission to the company The Medicines Company UK Ltd. approval of Angiox in the entire European Union.</seg>
<seg id="2890">For the treatment of adult patients with acute Koronarsyndromes (instabile Angina / Non- ST-Hebrides (IA / NSTEMI) at an emergency attack or if an early intervention is planned.</seg>
<seg id="2891">The recommended initialdosis of Angiox in patients with ACS is an intravenous stud of 0.1 mg / kg followed by an infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"if a PCI is performed in another episode, an additional bolt of 0.5 mg / kg should be given and the infusion for the duration of the surgery to 1,75 mg / kg / h increases."</seg>
<seg id="2893">"after PCI, according to clinical requirements, the reduced infusion dose of 0.25 mg / kg / h may be recorded for 4 to 12 hours."</seg>
<seg id="2894">"immediately before the procedure, a Bolusgabe of 0,5 mg / kg is given, followed by an infusion of 1,75 mg / kg / h for the duration of the surgery."</seg>
<seg id="2895">The recommended Dosage of Angiox in patients with a PCI consists of an initials intravenous Bolusgabe of 0.75 mg / kg body weight and one directly subsequent intravenous infusion with a dose of 1.75 mg / kg body weight / h at least for the duration of the surgery.</seg>
<seg id="2896">The safety and efficacy of a certain Bolus Gift from Angiox was not investigated and is not recommended even if a short PCI procedure is planned.</seg>
<seg id="2897">"this value is shortened (ACT after 5 minutes) to under 225 seconds, should be a second bolt of 0,3 mg / kg / body weight."</seg>
<seg id="2898">"in order for possibility to decrease the lower ACT values, the reconstitued and diluted drug was carefully mixed before the application and the Bolusdosis quickly administered intravenously."</seg>
<seg id="2899">"as soon as the ACT value is more than 225 seconds, another monitoring is no longer required, provided the 1,75 mg / kg infusion dosage is administered properly."</seg>
<seg id="2900">"in patients with moderate kidney functional systems (GFR 30-59 ml / min), which are subjected to PCI (whether with Bivalirudine against ACS or not), should be used a lower infusion rate of 1,4 mg / kg / h."</seg>
<seg id="2901">"lies the ACT value under 225 seconds, a second Bolusdosis is administered from 0.3 mg / kg and reviewing the ACT 5 minutes after the second Bolusdosis."</seg>
<seg id="2902">"in patients with moderate kidney damage, included in the phase III- PCI study (Replace-2), which was included in the phase III- PCI study (Replace-2), which was included in the phase of the Bivalirudin-Bolus without dosage adjustment at an average 366 ± 89 seconds."</seg>
<seg id="2903">3 At patients with severe kidney damage (GFR &lt; 30 ml / min) and also in dialysis patients Angiox contraindications (see below Section 4.3).</seg>
<seg id="2904">The treatment with Angiox can end 30 minutes after termination of the intravenous Heparin or 8 hours after the cannon of the subcutaneous Gift from Lower-molecular Heparin.</seg>
<seg id="2905">• known hypersensitivity to the active ingredient or other components or against Hirudine • active bleeding and higher blood risk due to a disturbulation of the hemostal-system and / or missive tapping. • severe kidney damage (GFR &lt; 30 ml / min) and in dialysis patients</seg>
<seg id="2906">Patients are carefully monitored throughout the treatment with regard to symptoms and signs of a blood. especially if Bivalirudine is administered in combination with another antikoagulans (see Section 4.5).</seg>
<seg id="2907">"even if in PCI-patients under Bivalirudine, most of the bloodings occur at arterial score, can undergo in patients who occur at a percutaneous coron (PCI) while treating in principle everywhere bleeding occur."</seg>
<seg id="2908">"when they are treated with patients, warfarin and treated with bivalirudine, the value of treatment with Bivalirudin should again be achieved before the treatment existing level."</seg>
<seg id="2909">"starting from the knowledge about the active mechanism of anticoagulancia (Heparin, warfarin, thymbolwood or trombocylinders) can be presumed that these active ingredients increase the blood of blood."</seg>
<seg id="2910">"in combination of bivalirudine with Thrombocylinders or anticoagulum, the clinical and biological hemostal parameters are regularly inspected in any case."</seg>
<seg id="2911">"the experimental studies are inadequate regarding the pregnancy, the embryo / fetal development, the relationship or post-natal development (see below Section 5.3)."</seg>
<seg id="2912">4612 were randomized to Bivalirudine alone, 4604 were randomized to Bivalirudine plus GPIIb / IIIA Inhibitor and 4603 were randomized to either unfractionified Heparin or Enoxaparin plus GPIIb / IIIA Inhibitor.</seg>
<seg id="2913">"both in the Bivalirudin group as well as in the dormitory groups, it came more frequently in women as well as in patients over 65 years old than with male or younger patients."</seg>
<seg id="2914">Serious bleeding were defined according to ACUITY and TIMI measures for heavy blood flow as defined in table 2.</seg>
<seg id="2915">Both light and heavy blood vessels stood under Bivalirudine alone significantly less often than in the groups with piparin plus GPIIb / IIIA inhibitor and Bivalidrudin plus GPIIb / IIIa- Inhibitor (see table 2).</seg>
<seg id="2916">"an ACUITY heavy blood pressure was defined as one of the following events: invarietal, retroperitoneal, intraocular bleeding or bloodshed with diameter ≥ 5 g / dl with a well-known blood location, reoperation due to bleeding, use of blood products to transfusion."</seg>
<seg id="2917">"further, less often observed blood localities that appeared with more than 0.1% (occasionally) were" other "point of point, retroperitoneal, hospitable, ear, nose or neck."</seg>
<seg id="2918">The following information on side effects are based on the data of a clinical study with bivalirudine at 6,000 patients who are subjected to PCI.</seg>
<seg id="2919">"both in the bivalirudine group, as well as in the dormitory groups, it came more frequently in women as well as in patients over 65 years old than with male or younger patients."</seg>
<seg id="2920">Both light and heavy blood vessels used under Bivalirudin significantly less often than in the comparison group under Heparin plus GPIIb / IIIA-Inhibitor.</seg>
<seg id="2921">"the following side effects that are not listed above have been reported according to comprehensive application in practice, and are arranged according to system organic classes in table 6."</seg>
<seg id="2922">"in case of overdose, the treatment with Bivalirudine is immediately breaking away and the patient engmaschig can be monitored with regard to signs of a blood."</seg>
<seg id="2923">"Angiox contains Bivalirudine, a direct and specific trombinary, which is both in the catalytic centre as well as in the animating region of Thrombin, regardless of whether Thrombin is tied in the liquid phase or at Gerinnsel."</seg>
<seg id="2924">"the bond of bivalirudine in Thrombin, and thus its effect, is reversible, because Thrombin is slowly splitting the bond of bivalirudin-arg3-pro4, thus reducing the function of the active center of Thrombin."</seg>
<seg id="2925">"in addition, through Bivalirudine with Serum from patients, in which it was ininductive Thrombocytopenie / heparininduced Thrombosis syndrome (HIT / HITTS), do not induce Thrombolic Aggregational reaction."</seg>
<seg id="2926">"with healthy probands and in patients Bivalirudin shows a dosages and concentric anticoagulatory effect, which is occupied by the extension of ACT, aPTT, PT, INR and TT."</seg>
<seg id="2927">"if a PCI was performed in the following a PCI, an additional Bolus was given of 0.5mg / kg Bivalirudine, and the infusion for the duration of the surgery to 1.75mg / kg / h increases."</seg>
<seg id="2928">In the arm A of the ACUITY study was administered unfactional Heparin or Enoxaparin in accordance with relevant guidelines for the treatment of acute Koronarsyndrome (ACS) in patients with instabiler Angina / non-ST-Hebrides (IA / NSTEMI).</seg>
<seg id="2929">Patients in arm A and B were also randomized to obtain an GPIIb / IIIA Inhibitor either before the beginning of the angiography (at the time of Randomization) or during PCI.</seg>
<seg id="2930">"in the ACUITY study, the characteristics of high risks, which required an angiography within 72 hours required, evenly distributed over the 3 treatment arms."</seg>
<seg id="2931">"about 77% of patients had recurrent ischaemia, 70% had dynamic EKG- changes or increased cardiovascular, 28% had diabetes and about 99% of all patients are subjected within 72 hours of angiography."</seg>
<seg id="2932">"the primary analysis and the results from the ACUITY study for the total population (ITT) and the 1- Annual point for the total population (ITT) and the 1- Annual point for the total population (ITT) and for the patients, the aspirin and Clopidogrel according to protocol (before the angiography or before the PCI), are represented in tables 7 and 8."</seg>
<seg id="2933">ACUITY study; 30-day and 1-year risk difference for the combined-mix endpoint and its components for patients who received aspirin and Clopidogrel according to protocol *</seg>
<seg id="2934">Patients who received aspirin and Clopidogrel according to protocol A arm B arm C UFH / Enox Bival + GPIIb / IIIA + GPIIb / IIIA risk Diff.</seg>
<seg id="2935">"the frequency of blood vessels in ACUITY- as well as in the TIMI extent to day 30 for the total population (ITT) and for patients, the aspirin and Clopidogrel according to protocol, is represented in table 9."</seg>
<seg id="2936">Patients / IIIA Inhibitor Inhibitl / IIIA Inhibitor / IIIA Inhibitor (N = 2911) Inhibitor Inhibitor (N = 4624)% (N = 4604) (N = 2842)%%%</seg>
<seg id="2937">"* Clopidogrel in front of angiography or before PCI 1 A ACUITY has been defined as one of the following events: inhibition, retroperito-neal, intraocular bleeding or bloodshed with diameter ≥ 5 g / dl with a well-known blood location, reoperation due to bleeding, use of blood products to transfusion."</seg>
<seg id="2938">"the 30-day results, based on quadruple and triple-end points of a randomized double-blind study with more than 6,000 patients have been subjected to a PCI (Replace-2), are shown in table 10."</seg>
<seg id="2939">Clinical studies with a small number of patients provided limited information on the use of Angiox in patients with HIT / HITTS.</seg>
<seg id="2940">The pharmacoinetic properties of Bivalirudine were evaluated in patients who subjected to a percutaneous coron (PCI) as well as in patients with ACS.</seg>
<seg id="2941">It is expected that Bivalirudine as Peptid is expected to pass a catabolism into its amino acid components with subsequent revaluation of the amino acids in the body pool.</seg>
<seg id="2942">"the primary metabolit, which results from the split of the Arg3-Trial Sequence by Thrombin, is not effective due to the loss of its affinity to the catalytic center of Thrombin."</seg>
<seg id="2943">The Elimination takes place in patients with normal kidney function after a process of first order with an terminal half-time of 25 ± 12 minutes.</seg>
<seg id="2944">"based on conventional studies on safety harology, toxicity in repeated gift, Genotoxicity or Reproductive Toxicity, the preclinical data cannot recognize any particular dangers for the human being."</seg>
<seg id="2945">The toxicity in animals of repeated or continuous exposure (1 day to 4 weeks during exposure to 10-times of clinical steady state-state-plastics) are limited to over-going pharmacological effects.</seg>
<seg id="2946">"side-effects as a reaction to a non-homeostatic coagulation have been observed after short-term exposure comparable to those in clinical use, even with a lot of higher dosage, not observed."</seg>
<seg id="2947">"if the production of the ready-to-finished solution 17 is not under-controlled and validated aseptic conditions, this is no longer than 24 hours at 2 ° C to 8 ° C."</seg>
<seg id="2948">Angiox is a freeerdried powder in single dose of type-1 glass consisting of type-1 glass consisting of type-1 glass which is sealed with a butylrubbing closed and a cap from pressed aluminum sealed.</seg>
<seg id="2949">"5 ml sterile water for injection purposes are given into a bottle of angiox, and gently curved until all has been completely dissolved, and the solution is clear."</seg>
<seg id="2950">5 ml are extracted from a bottle of bottle or with 9% glucose solution for injection or with 9 mg / ml (0.9%) sodium chlorinated solution for injection in a total volume of 5mg / ml bivalirudine.</seg>
<seg id="2951">"the holder of the approval of the approval agrees, as described in version 4 of the risk management plan (RMP) and entered into module 1.8.2 of approval for ingestion, as well as any follow-up on the RMP, which was agreed by CHMP."</seg>
<seg id="2952">"according to CHMP Guideline to risk management systems for human medicines, the RMP should be submitted at the same time with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="2953">• patients with breast cancer due to a cardiac disease (acute Koronaroom - ACS) • Patients that are operated for the treatment of closures in blood vessels (angioplasty and / or percutaneous coronaranjoplasty - PCI).</seg>
<seg id="2954">• You are pregnant or suspect that you could be pregnant • You intend to get pregnant • You are currently breastfeeding.</seg>
<seg id="2955">"there were no investigations of the effects on the transport and the ability to serve machines, but one knows that the effects of this medicine are only short-term."</seg>
<seg id="2956">"if a blood flow should occur, treatment with angiox is broken. • before the beginning of injecting or infusion will inform you of your doctor about the possible characters of an allergic reaction."</seg>
<seg id="2957">Such reactions are rare (they occur in less than 1 of 1000 treated patients). • A particularly meticulous monitoring is carried out if you have a radiotherapy for the vessels that you get the heart with blood (this treatment is called Better or Gamma-Brachytherapy). • The dose which you will receive from your body weight and the type of therapy you will receive.</seg>
<seg id="2958">• 0.1 mg / kg body weight per hour (0.1 mg / kg body weight per hour (0.1 mg / kg body weight per hour means a quarter of a milligram of drug using for each kilogram body weight per hour).</seg>
<seg id="2959">Likely if Angiox is administered in combination with other inninnings or anti-thromous medications (see section 2 "In use of Angiox with other medicines).</seg>
<seg id="2960">These are occasional side-effects (for less than 1 of 100 treated patients). • Thrombosis (blood-innate) that could lead to severe complications like a heart attack.</seg>
<seg id="2961">"this is an occasional side effect (in less than 1 of 100 treated patients). pain, blood and blood flow at the point of point (after an PCI treatment)."</seg>
<seg id="2962">"please inform your doctor if any of the listed side effects you have considerably affected, or you notice side effects which are not indicated in this usage information."</seg>
<seg id="2963">Angiox may no longer be applied after on the label and the umarton after "used up."</seg>
<seg id="2964">Polska The Medicines Company UK Ltd.: + 800 61 564 1320 mackλ: + 30 210 5281700 e-mail:</seg>
<seg id="2965">Apidra is used for treatment of adults, young people and children from six years with diabetes who need a treatment with insulin.</seg>
<seg id="2966">"Apidra is subcutaneous (under the skin) in the abdominal wall, thighs or the upper arm, or as a continuous infusion with a insulin pump."</seg>
<seg id="2967">Diabetes is a disease in which the body does not produce enough insulin in regulating the glucose level (sugar) in the blood or can not process the insulin.</seg>
<seg id="2968">"insulin-lulisin is very different in humanities, and the change means that it is faster and a shorter active time has than a short-effective Humaninsulin."</seg>
<seg id="2969">Apidra has been studying in combination with a long-effective insulin in patients with type 1 diabetes where the body has no insulin in two studies in two studies with 572 children aged four to 17 years.</seg>
<seg id="2970">"in type 2 diabetes, in which the body insulin can not be effectively processed, Apidra was investigated in a study with 878 adults."</seg>
<seg id="2971">The main indication of the effectiveness was the modification of concentration of the substance glycosylated bunmoglobin (HbA1c) in the blood that shows how good the blood sugar is adjusted.</seg>
<seg id="2972">"in the first study of adults with type-1 diabetes, after six months a reduction of 0.14% (from 7.60% to 7.46%) compared to a reduction of 0.14% in insulin-lisper."</seg>
<seg id="2973">In adults with type 2 diabetes the reduction of HbA1c concentration 0.46% after six months with Apidra compared to 0.30% in human-normal normal.</seg>
<seg id="2974">Apidra may not be applied in patients who might be oversensitive (allergic) against insulin-ulisin or one of the other components or in patients who are already suffering from hypoglycaemia.</seg>
<seg id="2975">The cans of Apidra may have to be adapted if it is administered along with a number of other medicines that can affect the blood glucose level.</seg>
<seg id="2976">September 2004 shared the European Commission to the company Sanofi-Aventis Deutschland GmbH approved approval for Inpidra throughout the European Union.</seg>
<seg id="2977">Apidra is used as a subcutaneous injection either in the area of the abdominal blanket or delcutus to apply or subcutters due to continuous infusion into the area of the abdominal detachment.</seg>
<seg id="2978">"due to the reduced glucose capacity and diminishing insulin-change, the insulin can be fixed in patients with a limitation of the liver function."</seg>
<seg id="2979">"any change of the active strength, the trademark (Her- Steller), the type of insulin (normal, NPH, galvanizing, etc.), the type of insulin (animal insulin) and / or the manufacturing method can change a change in insulin."</seg>
<seg id="2980">"3 A insufficient dosage or the interruption of a treatment, in particular in patients with an insulated diabetes, can lead to a hyperglycaemia and a diabetic Ketoazide; these states are potentially life-threatening."</seg>
<seg id="2981">Changing a patient to another insulin or a insulin in another manufacturer should be under strict physician supervision and can make a change of dosage necessary.</seg>
<seg id="2982">The timing of hypoglycaemia depends on the drug profile of the used insulin and can therefore change in the conversion of the treatment schemas.</seg>
<seg id="2983">"to the substances that increase the bloodsugar activity and increase the inclination to hypoglycemics, fopic antidiabetics, Fibrooyllin, propoxyphen, saliases, and sulfonking antibiotics."</seg>
<seg id="2984">"in addition, under the effect of sympatholytika such as betweers, Clonidine, Guanethidine and Reserves may be the symptoms of inalienable counter regulation, or are absent."</seg>
<seg id="2985">"animal experimental studies on Reproductive Toxicity showed no differences between Insu- linglulisin and humaninsulin regarding pregnancy, the embryonic / fetal development, the birth or post-natal development (see Section 5.3)."</seg>
<seg id="2986">"it is not known whether insulin-lulisenters into human breast milk, but generally insulin occurs neither into the mother's milk nor is it resorted to orative application."</seg>
<seg id="2987">"following are the undesirable drugs known from clinical studies, grouped according to system organic classes, and ordered after decreasing the frequency of their occurrence (very common: ≥ 1 / 100; rare: ≥ 1 / 10,000; very rare: &lt; 1 / 10.000; very rare: &lt; 1 / 10,000; very rare: &lt; 1 / 10.000; very rare: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10.000; very rarely: &lt; 1 / 10.000; very rare: &lt; 1 / 10.000; very rare: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rare: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rarely: &lt; 1 / 10,000; very rare</seg>
<seg id="2988">"cold, gentle and pale skin, fatigue, nervousness or tremor, anxiety, uncommon, nervousness or tremor, confusion, tighter, changes of vision, headache, nausea and heartbeat."</seg>
<seg id="2989">Lipodstreamphie Dispensed to change the injection point within the injection range can occur in the episode a Lipodstreamphie at the injection point.</seg>
<seg id="2990">Heavy hypoglycemics with conscielessness can be given by an intramuscular or subcutaneous injection of glucose (0,5 to 1 mg) which is given by an appropriately trained person or treated by intravenous treatment of glucose by a doctor.</seg>
<seg id="2991">"after a glucose rate, the patient should be monitored in a hospital to determine the urch- thing for heavy hypoglycaemia and avoid similar episodes."</seg>
<seg id="2992">Insulin reduces the blood sugar levels by the stimulation of the peripheral glucose level (especially by skeletal muscles and fat) as well as by inhibiting the glucose production in the liver.</seg>
<seg id="2993">Studies with healthy volunteers and patients with diabetes have shown that at subcutters Ga- be carried out faster and the active time is shorter than with hu- manem standard.</seg>
<seg id="2994">"in a study with 18 male people at the age of 21 to 50 years with type-1 diabetes, insulin-lulisin in therapeutically relevant dosages of 0.075 to 0,15 E / kg saw a dose of disproportionate effect, and with 0,3 E / kg or more a lower increase in gluing joint effect, just like humaninsulin."</seg>
<seg id="2995">Insulin-ulisin has a twice as fast impact as normal Humaninsulin and achieves the complete gluing joint effect approximately 2 hours earlier than humaninsulin.</seg>
<seg id="2996">"from the data was intentionally that in an application of insulin lulisin 2 minutes before the meal, a comparable postprandiale control is achieved as with human normal standard, which will be given 30 minutes before the meal."</seg>
<seg id="2997">Insulin was reached in 2 minutes before the meal was insisting in 2 minutes before the meal - was achieved a better postpranous control than with human normal standard that was given 2 minutes before the meal.</seg>
<seg id="2998">"insulin is reached in 15 minutes after the meal at the start of the meal, a comparable glycaemic control is given in excess of human curinsulin, which is given 2 mixes before the meal (see figure 1)."</seg>
<seg id="2999">Insulin-ulisin at Gift 2 minutes (GLULISIN - before) before the meal was given (figure 1A) before the start of the meal (figure 1A) as well as compared to human normal normal standard (figure 1A) before the meal was given (figure 1A) before the meal was given (figure 1B) before the start of the meal (figure 1A).</seg>
<seg id="3000">Insulin-ulisin at Gift 15 minutes (GLULISIN - afterward) after the meal of the meal compared to human Nor- Maliulin which was given 2 minutes (normal - previously) before the meal (figure 1C) before the start of the meal (figure 1C).</seg>
</doc>
</tstset>
